access IDWeek™ 2018 abstracts via OFID

All conference abstracts have been published as a supplement to Open Forum Infectious Diseases (OFID), the online only, fully open access journal from IDSA and HIVMA. Oral, poster, and late-breaking abstracts are being permanently archived as part of the journal and are accessible to all journal readers, not only meeting attendees or society members.

To access the IDWeek™ abstracts published via OFID, download the IDSA Journals app from the iTunes app store or go to academic.oup.com/ofid.
Dear Colleagues,

As the IDWeek™ Program Chairs, it is our pleasure to welcome you to IDWeek 2018! We are excited to launch the program this year, as it is the first iteration of the IDWeek strategic vision developed to ensure IDWeek 2018 evolves and advances this critical education. Leveraging the experience of the Program Committee and past attendees, we implemented new programs, like the IDea Incubator, the new live forum in the exhibition hall on Thursday, October 4, at 5 p.m., and continued cornerstone events, like the IDBugBowl on Saturday, October 6 at 4:45 p.m.

IDWeek, now in its seventh year, strategically builds on the expertise of members from the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society to create a compelling educational program featuring the latest science and bench-to-bedside approaches.

There is no better forum than IDWeek to feature the impact and need of epidemiology, diagnosis, treatment, and prevention of infectious diseases across all ages and locations. IDWeek is designed to energize you and validate the important work you do EVERY DAY. Every attendee here has a role in improving patients’ lives. IDWeek is the opportunity to see this by learning from the best and the brightest in the field who are taking their work to the next level when it comes to managing current infectious diseases outbreaks; implementing the newest diagnostic and treatment modalities; practicing the latest prevention strategies; and applying state-of-the-art science to clinical care.

We hope you will take advantage of the opportunity to meet and network with your colleagues from around the world while you are here. One of the most important benefits of attending IDWeek 2018 is the chance to build strategic networks and share your passion with others who have similar passions and goals to form relationships that far outlast the conference!

IDWeek is constantly improving so if you have suggestions for topics or ideas you would like to see at IDWeek 2019, please tell a staff member.

We hope you enjoy the program as much as we enjoyed creating it. Enjoy San Francisco, and set your calendars for IDWeek 2019, scheduled for October 2 - 6, 2019, in Washington, DC.

With best regards,

Andrew T. Pavia, MD, FIDSA, FSHEA, FPIDS  
IDWeek Chair, IDSA

Ebbing Lautenbach, MD, FIDSA, FSHEA  
IDWeek Chair, SHEA

Jeanne M. Marrazzo, MD, MPH, FIDSA  
IDWeek Chair, HIVMA

Marsha S. Anderson, MD, FIDSA  
IDWeek Chair, PIDS
Acknowledgements

The IDWeek partners wish to extend a special Thank You to the following organizations who developed sessions in collaboration with the IDWeek Program Committee (see Allied Partners on page 13 for specific session details):

- American Society of Transplantation
- Centers for Disease Control and Prevention
- European Society of Clinical Microbiology and Infectious Diseases
- European Society for Paediatric Infectious Diseases
- IDSA Clinical Affairs Committee
- IDSA ID Training Program Directors’ Committee
- IDSA Medical Education Workgroup
- IDSA Education Committee

- IDSA Standards and Practice Guidelines Committee
- IDSA Telehealth Committee
- Johns Hopkins University School of Medicine Div. of Infectious Diseases
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National Network of STD Clinical Prevention Training Centers
- Pan-American Society of Infectious Diseases, Brazilian Society of Infectious Diseases

The IDWeek Program Committee would like to extend a special Thank You to the following individuals who generously donated their time and expertise to review abstracts for IDWeek 2018:

Paul Ambrose, PharmD, FIDSA, Institute for Clinical Pharmacodynamics, Inc., Schenectady, NY
Evan J. Anderson, MD, Emory University School of Medicine, Atlanta, GA
Senu Apekewokin, MD, University of Cincinnati College of Medicine, Cincinnati, OH
Kevin Ard, MD, Massachusetts General Hospital, Boston, MA
David Aronoff, MD, FIDSA, Vanderbilt University School of Medicine, Nashville, TN
Muhammad Salman Ashraf, MBBS, East Carolina University, Greenville, NC
Ritu Banerjee, MD, PhD, Vanderbilt University, Nashville, TN
Miriam Barshak, MD, FIDSA, Harvard Medical School, Boston, MA
Ingrid V. Bassett, MD, MPH, FIDSA, Massachusetts General Hospital, Boston, MA
Robert Bednarczyk, PhD, Rollins School of Public Health, Emory University, Atlanta, GA
Elle F. Berbari, MD, FIDSA, Mayo Clinic, Rochester, MN
Luiz Bermudez, MD, Oregon State University, Corvallis, OR
Anne J. Blaschke, MD, PhD, FIDSA, FPIDS, University of Utah School of Medicine, Salt Lake City, UT
Chloe Bryson-Cahn, MD, University of Washington School of Medicine, Seattle, WA
Angela P. Campbell, MD, MPH, FIDSA, FPIDS, Centers for Disease Control and Prevention, Atlanta, GA
Ann Chahroudi, MD, PhD, Emory University, Atlanta, GA
Archana Chatterjee, MD, PhD, FIDSA, FPIDS, University of South Dakota Sanford School of Medicine/Sanford Children's Specialty Clinic, Sioux Falls, SD
Natasha Chida, MD, Johns Hopkins University School of Medicine, Elkhridge, MD
Pearlie Chong, MD, MSCR, University of North Carolina at Chapel Hill, Chapel Hill, NC
Andrew Chou, MD, Michael E. Debakey Veterans Affairs Medical Center, Houston, TX
Cornelius J. Clancy, MD, University of Pittsburgh, Pittsburgh, PA
Christopher Crnich, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, WI
Louise Demby, MD, MS, MBA, FIDSA, FSHEA, Yale School of Medicine, New Haven, CT
Sarah B. Doernberg, MD, Yale University, New Haven, CT
Yohei Doi, MD, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA
Dimitri M. Drekonja, MD, MS, FIDSA, Minneapolis Veterans Affairs Health Care System, Minneapolis, MN
Jennifer Duchon, MD, MPH, Columbia Presbyterian Medical Center, New York, NY
Joseph Duncan, MD, PhD, FIDSA, University of North Carolina School of Medicine, Chapel Hill, NC
Marlene Durand, MD, FIDSA, Harvard Medical School, Boston, MA
Michael J Durkin, MD, MPH, Washington University School of Medicine, St. Louis, MO
Kathryn Edwards, MD, FIDSA, Vanderbilt University School of Medicine, Nashville, TN
Nathan Erdmann, MD, PhD, University of Alabama at Birmingham, Birmingham, AL
Claudia Espinosa, MD, MSc, University of Louisville, Louisville, KY
Andras Farkas, PharmD, Mount Sinai, New York, NY
Cynthia Fisher, MD, PhD, University of Washington School of Medicine, Seattle, WA
Michelle Floris-Moore, MD, MS, University of North Carolina School of Medicine, Chapel Hill, NC
Donald Forthal, MD, FIDSA, University of California Irvine School of Medicine, Orange, CA
Ricardo Franco, MD, University of Alabama at Birmingham, Alabama, AL
Bishara Freij, MD, FIDSA, Beaumont Hospital - Dearborn, Royal Oak, MI
Betina C. Fries, MD, FIDSA, Stony Brook University, Stony Brook, NY
Julia Garcia-Diaz, MD, FIDSA, Ochsner Clinic Foundation, New Orleans, LA
Kathleen Gensheimer, MD, MPH, FIDSA, US Food and Drug Administration, College Park, MD
Michael Glickman, MD, FIDSA, Memorial Sloan-Kettering Cancer Center, New York, NY
Rachel Gordon, MD, MPH, Columbia University College of Physicians and Surgeons, New York, NY
Rana Hamdy, MD, MPH, MSCE, Children’s National Health System, Washington, DC
Nada Harik, MD, Children’s National Health System, Washington, DC
Joshua Hartzell, MD, FIDSA, Walter Reed National Military Medical Center, Bethesda, MD
Mary K. Hayden, MD, FIDSA, FSHEA, Rush University Medical Center, Chicago, IL
Marisa Holubar, MD, FSHEA, Rush University Medical Center, Chicago, IL
Kengo Inagki, MD, University of Mississippi Medical Center, Jackson, MS
Michael G. Ison, MD, FIDSA, Northwestern University, Chicago, IL
Lisa Jackson, MD, MPH, FIDSA, Northwestern University, Chicago, IL
Seena Jain, MD, MPH, FIDSA, Centers for Disease Control and Prevention, Atlanta, GA
Vivek Jain, MD, MAS, University of California San Francisco, San Francisco, CA
Erica Johnson, MD, Johns Hopkins Medicine, Baltimore, MD
Melissa Johnson, PharmD, MHS, Duke University School of Medicine, Durham, NC
Acknowledgements (continued)

Ameeta Kalokhe, MD, Emory University School of Medicine, Atlanta, GA
Susana Keeshin, MD, University of Utah, Salt Lake City, UT
Jennie Kwon, DO, Washington University School of Medicine, St. Louis, MO
Maryrose Lago-Vila, MD, Rochester Regional Health, Rochester, NY
Francesca Lee, MD, University of Texas Southwestern Medical Center, Dallas, TX
Alexander Lepak, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI
Michael Y. Lin, MD, MPH, Rush University Medical Center, Chicago, IL
Matt Linam, MD, MS, Emory University School of Medicine, Atlanta, GA
Vera Luther, MD, Wake Forest School of Medicine, Winston-Salem, NC
Anurag Malani, MD, FIDSA, FSHEA, St. Joseph Mercy Health System, Ypsilanti, MI
Michael Mansour, MD, Massachusetts General Hospital, Boston, MA
Trini Mathew, MD, MPH, FIDSA, Conemaugh Health System, Johnstown, PA
Larissa May, MD, MSPH, FIDSA, University of California-Davis, Sacramento, CA
Dana Mazo, MD, Mount Sinai, New York, NY
Daniel McQuilken, MD, FIDSA, Lahey Hospital & Medical Center, Burlington, MA
Sanjay Mehta, MD, University of California, San Diego, La Jolla, CA
Asuncion Mejias, MD, PhD, MSCS, The Research Institute at Nationwide Children’s Hospital, Columbus, OH
Andre G. Melendez, MD, Emory University School of Medicine, Atlanta, GA
Michael T. Melia, MD, Johns Hopkins University School of Medicine, Baltimore, MD
Ian C. Michelow, MD, DTM&H, Rhode Island Hospital/Medical School of Brown University, Providence, RI
William Miller, MD, FIDSA, UTH Health McGeown Medical School, Houston, TX
Christopher Moore, MD, University of Virginia, Charlottesville, VA
David Mushatt, MD, MPH & TM, FIDSA, Tulane University School of Medicine, New Orleans, LA
Sandra Nelson, MD, FIDSA, Massachusetts General Hospital, Boston, MA
Priya Nori, MD, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY
Bianna L. Norton, DO, MPH, Duke University Medical Center, Durham, NC
Ann-Christine Nyquist, MD, MSPH, FPIDS, University of Colorado School of Medicine/Children’s Hospital Colorado, Aurora, CO
Christopher Ohl, MD, FIDSA, Wake Forest Baptist Health, Winston-Salem, NC
Nwora Lance Okeke, MD, MPH, Duke University Medical Center, Durham, NC
Luis Ostrosky-Zeichner, MD, FIDSA, FSHEA, McGovern Medical School, Houston, TX
April Palmer, MD, FPIDS, University of Mississippi Medical Center, Jackson, MS
Federico Perez, MD, MS, Louis Stokes Cleveland VA Medical Center, Cleveland, OH
Steven Pergam, MD, MPH, FIDSA, Fred Hutchinson Cancer Research Center, Seattle, WA
Varun Phadke, MD, Emory University, Atlanta, GA
Jason M. Pogue, PharmD, Detroit Medical Center, Detroit, MI
Kyle J Popovich, MD, MS, FIDSA, Rush University Medical Center, Chicago, IL
Paul S. Pottinger, MD, FIDSA, University of Washington, Seattle, WA
Jennifer S. Read, MD, MS, MPH, DTM&H, FIDSA, University of Vermont, Burlington, VT
Maria Rodriguez-Barradas, MD, FIDSA, Michael E. DeBakey VA Medical Center, Houston, TX
Nadine Rouphael, MD, Emory University, Atlanta, GA
Rafik Samuel, MD, FIDSA, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Maurizio Sanguinetti, Università Cattolica del Sacro Cuore, Milano, Italy
Patrice Savard, MD, FRCP, CHUM, Montreal, QC
Jennifer Schuster, MD, MSCI, Children’s Mercy Kansas City, Kansas City, MO
Brian Schwartz, MD, University of California, San Francisco, San Francisco, CA
Andi L. Shane, MD, MPH, MSc, FIDSA, FPIDS, Emory University School of Medicine, Atlanta, GA
Dawd Siraj, MD, FIDSA, University of Wisconsin-Madison, Madison, WI
Michael Smit, MD, MSPH, Rhode Island Hospital, Providence, RI
Becky Smith, MD, Duke University Medical Center, Durham, NC
Geeta Sood, MD, Johns Hopkins University School of Medicine, Baltimore, MD
Pranavi Sreeramoju, MD, MPH, FIDSA, University of Texas Southwestern Medical Center, Dallas, TX
Arjun Srinivasan, MD, FSHEA, Centers for Disease Control and Prevention, Washington, DC
R. Scott Stienecker, MD, Parkview Health, Fort Wayne, IN
Sankar Swaminathan, MD, FIDSA, University of Utah, Salt Lake City, UT
Tina Q. Tan, MD, FIDSA, Northwestern University Feinberg School of Medicine, Chicago, IL
Jesus Vallejo, MD, FIDSA, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX
Rebecca Wallihan, MD, The Research Institute at Nationwide Children’s Hospital, Columbus, OH
David J. Weber, MD, MPH, FIDSA, FSHEA, University of North Carolina, School of Public Health, Chapel Hill, NC
Zachary Willis, MD, MPH, University of North Carolina School of Medicine, Chapel Hill, NC
Joshua Wolf, MBBS, FRACP, St. Jude Children’s Research Hospital, Memphis, TN
Heather Yun, MD, FIDSA, Brooke Army Medical Center, JBOS Fort Sam Houston, TX
Gary Zeitlin, MD, White Plains Medical Associates, White Plains, NY
Annelies Zinkernagel, MD, PhD, MSc, University Hospital Zurich, Zurich, Switzerland
DOWNLOAD THE OFFICIAL
IDWeek 2018™ mobile application

Search the Apple App Store and Google Play for “IDWeek”.

- Join the Scavenger Hunt and Trivia activities for a chance to win prizes.
- Search for sessions
- Participate in audience response
- Create your schedule
- Read abstracts and view posters
- Browse the exhibitors
- Find helpful meeting information
- Connect with other attendees

*Use your registration email address to gain access.
Table of Contents

General Information ........................................... 8
  Headquarters Office........................................... 8
  Certificate of Attendance..................................... 8
  Childcare, Child Safety, and Nursing Mothers............... 8
  IDWeek Booth / Society Booths................................. 8
  IDSA-HIVMA-PIDS Advocacy Education Breakfast........... 8
  Newsroom ................................................................ 8
  Smoking Policy ...................................................... 8
  IDWeek Mobile App ................................................ 8
  IDWeek Digital Session Library................................ 8

IDWeek 2018 Program Committee ................................. 9

Program Information ............................................. 10
  IDWeek Description ................................................ 10
  Accreditation Statement for Physicians ....................... 10
  Accreditation Statement for Pharmacists ..................... 10
  ACCME Guidelines for Moderators ............................. 10
  Credit Designation Statement ................................... 10
  ABIM MOC Statement ............................................. 10
  ABP MOC Statement .............................................. 10
  Claim CME/CPE/MOC Credit .................................... 10
  Continuing Education Credit for Pharmacists ............... 10
  Faculty Disclosures ............................................... 11
  Commercial Support Statement ................................ 11
  Scientific Sessions and Room Capacity ....................... 11
  Opening Reception and “Posters in the Park” ............... 11
  IDWeek Partnering Societies Business Meetings ........... 11
  Abstracts ............................................................. 11
  Poster Discussion Rounds ....................................... 11
  Speaker Ready Room .............................................. 12
  IDWeek Supporters ................................................ 12
  Allied Partners ..................................................... 13

Plenaries ............................................................. 15
  Special Opening Plenary Session: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space .............................................. 15
  Closing Plenary Session: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections ............................................. 16
  Named Lectures .................................................... 18
  Awards Presentation Schedule .................................. 25
  IDSA Society Awards .............................................. 26
  IDSA Education and Research Foundation Awards.......... 34
  SHEA Society Awards ............................................ 35
  HIVMA Awards .................................................... 39
  PIDS Society Awards ............................................. 41
  Abstract Awards ................................................... 42

CME/CPE/MOC Credit Tracker .................................. 52

IDWeek 2018 Program Tracks .................................... 57

Scientific Sessions ................................................ 81

Oral Abstract Sessions .......................................... 119

Poster Abstract Sessions ....................................... 127
General Information

Headquarters Office
The IDWeek Headquarters Office will be located in Room N 21 in the North Building of the Moscone Center. On Sunday, October 7, please visit the IDWeek information desk in the lobby of Moscone West for headquarters services.

Certificate of Attendance
Attendees may obtain certificates of attendance at the designated IDWeek registration desk in the lobby of Moscone West or after the meeting at www.idweek.org/post-meeting-tools/

Childcare, Child Safety, and Nursing Mothers
For childcare services at the meeting, please contact your hotel concierge.

A nursing mothers’ lounge will be available during the meeting hours on the second floor of the West building of the Moscone Center. Only nursing mothers and their infants are permitted in this room. Water and temporary refrigeration for storage will be available for your convenience.

IDWeek Booth / Society Booths
All attendees are invited to stop by the IDWeek booth and individual societies’ booths in the registration area in the lobby of West Building to learn more about the meeting and membership in IDWeek’s partnering societies. At the society booths, learn more about what each society is doing to advocate for better federal policies on your behalf and how you can get more engaged. Please visit the individual booths to get the latest advocacy news from Washington, DC and sign up for each society’s Member Advocacy Program. You can also join and become a member on site or renew your membership for 2019. Stop by and say hello!

IDSA-HIVMA-PIDS Advocacy Education Breakfast
The Advocacy Education Breakfast session highlights the work of IDSA, HIVMA, and PIDS members to improve federal policy for ID and HIV physicians, scientists, and patients. IDSA, HIVMA, and PIDS members will discuss and demonstrate the key elements of effective advocacy. The session will feature testimonials from IDSA, HIVMA, and PIDS members about their experience participating in advocacy activities and information about current opportunities for members to get involved. IDSA, HIVMA, and PIDS policy staff will share the latest policy news from Washington, DC. The session is scheduled for Friday, October 5, from 7 - 9 a.m. in S 155 in the Moscone Center.

Newsroom
The Newsroom will be located in Room N 20 in the North Building of the Moscone Center. Press conferences will be held on selected abstracts. Interviews with authors can also be arranged for the media.

Smoking Policy
No smoking is allowed at IDWeek.

IDWeek Mobile App
- Browse for IDWeek 2018 in the Apple App Store or Google Play market to download.
- Registered attendees may download the IDWeek mobile application for their iPhone, iPad, or Android devices for free.
- Participate in the Interactive Sessions with the mobile app, which will be used as the audience response system.
- The mobile app helps you navigate event details, manage your personal meeting agenda, connect with other attendee colleagues on Facebook and Twitter, view full abstracts and posters, and search the list of exhibiting companies.
- Authenticate the app using the email address you used to register for IDWeek.

View the App for the following information:
- Moderator and Presenter Information
- Detailed Map of Sessions
- Attendees with Disabilities
- Badge Policies
- Baggage and Coat Check
- Lost and Found
- Financial Disclosures

IDWeek Digital Session Library
- View sessions in premier format from your Mac, PC, smartphone, or tablet.
- The recordings feature high-quality digital audio and visuals.
- All sessions will include synchronized speaker slides, animations, procedural videos, and pointer movements displayed at the event.
- Access the digital library through the IDWeek app or online at www.IDWeek.org.
- Access will be free for all scientific attendees.

IDWeek Booth / Society Booths
All attendees are invited to stop by the IDWeek booth and individual societies’ booths in the registration area in the lobby of West Building to learn more about the meeting and membership in IDWeek’s partnering societies. At the society booths, learn more about what each society is doing to advocate for better federal policies on your behalf and how you can get more engaged. Please visit the individual booths to get the latest advocacy news from Washington, DC and sign up for each society’s Member Advocacy Program. You can also join and become a member on site or renew your membership for 2019. Stop by and say hello!

IDSA-HIVMA-PIDS Advocacy Education Breakfast
The Advocacy Education Breakfast session highlights the work of IDSA, HIVMA, and PIDS members to improve federal policy for ID and HIV physicians, scientists, and patients. IDSA, HIVMA, and PIDS members will discuss and demonstrate the key elements of effective advocacy. The session will feature testimonials from IDSA, HIVMA, and PIDS members about their experience participating in advocacy activities and information about current opportunities for members to get involved. IDSA, HIVMA, and PIDS policy staff will share the latest policy news from Washington, DC. The session is scheduled for Friday, October 5, from 7 - 9 a.m. in S 155 in the Moscone Center.

Newsroom
The Newsroom will be located in Room N 20 in the North Building of the Moscone Center. Press conferences will be held on selected abstracts. Interviews with authors can also be arranged for the media.
**Program Information**

**Chairs:**
- Andrew T. Pavia, MD, FIDSA, FSHEA, FPIDS, Chair, IDSA, University of Utah, Salt Lake City, UT
- Ebbing Lautenbach, MD, FIDSA, FSHEA, Chair, SHEA, University of Pennsylvania School of Medicine, Philadelphia, PA
- Jeanne M. Marrazzo, MD, MPH, FIDSA, Chair, HIVMA, University of Alabama at Birmingham School of Medicine, Birmingham, AL
- Marsha S. Anderson, MD, FIDSA, Chair, PIDS, University of Colorado School of Medicine, Aurora, CO

**Vice-Chairs:**
- Cesar Arias, MD, PhD, FIDSA, Vice-Chair, IDSA, University of Texas Health Science Center at Houston, Houston, TX
- Kristina A. Bryant, MD, FPIDS, Vice-Chair, SHEA, University of Louisville, Louisville, KY
- Eric Daar, MD, Vice-Chair, HIVMA, Harbor-UCLA Medical Center, Torrance, CA
- Roberta L. DeBiasi, MD, MS, FIDSA, FPIDS, Vice-Chair, PIDS, Children's National Health System/George Washington University School of Medicine, Washington, DC

**Members:**
- David Andes, MD, FIDSA, University of Wisconsin School of Medicine and Public Health, Madison, WI
- Hilary Babcock, MD, MPH, Washington University in St. Louis, Saint Louis, MO
- Adarsh Bhimraj, MD, FIDSA, Cleveland Clinic, Cleveland, OH
- Robert Bonomo, MD, FIDSA, Louis Stokes Cleveland VA Medical Center, Cleveland, OH
- Karen C. Carroll, MD, FIDSA, Johns Hopkins University School of Medicine, Baltimore, MD
- Christina Coyle, MD, Albert Einstein College of Medicine, Bronx, NY
- Inger Damon, MD, PhD, FIDSA, Centers for Disease Control and Prevention, Atlanta, GA
- Jeff Duchin, MD, FIDSA, Public Health - Seattle & King County, Seattle, WA
- Hana M. El Sahly, MD, FIDSA, Baylor College of Medicine, Houston, TX
- Debra Goff, PharmD, Ohio State University, Columbus, OH
- Marcia Goldberg, MD, FIDSA, Massachusetts General Hospital, Boston, MA
- David Greenberg, MD, FIDSA, University of Texas Southwestern Medical Center, Dallas, TX
- Patricia Griffin, MD, FIDSA, Centers for Disease Control and Prevention, Atlanta, GA
- Natasha B. Halasa, MD, MPH, FIDSA, FPIDS, Vanderbilt University School of Medicine, Nashville, TN
- Randall Hayden, MD, St. Jude Children's Research Hospital, Memphis, TN
- Tobias M. Hohl, MD, PhD, FIDSA, Memorial Sloan Kettering Cancer Center, New York, NY
- John B. Lynch, MD, MPH, Harborview Medical Center, Seattle, WA
- Shelley Magill, MD, PhD, Centers for Disease Control and Prevention, Atlanta, GA
- Rachel Miller, MD, FIDSA, Duke University Medical Center, Durham, NC
- Susanna Naggie, MD, MHS, FIDSA, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC
- Joshua Nosanchuk, MD, FIDSA, Albert Einstein College of Medicine, Bronx, NY
- Tara Palmore, MD, National Institute of Allergy and Infectious Diseases, Bethesda, MD
- Mario Poljak, MD, University of Ljubljana, Ljubljana, Slovenia
- Raymund R. Razonable, MD, FIDSA, Mayo Clinic, Rochester, MN
- Samuel Shelburne, MD, PhD, FIDSA, The University of Texas MD Anderson Cancer Center, Houston, TX
- H. Keipp Talbot, MD, MPH, FIDSA, Vanderbilt University Medical Center, Nashville, TN
- Thomas Talbot, MD, MPH, FIDSA, FSHEA, Vanderbilt University, Nashville, TN
- Virginia Triant, MD, MPH, FIDSA, Massachusetts General Hospital, Boston, MA
- David Van Duin, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC
- Wesley Van Voorhis, MD, PhD, FIDSA, University of Washington, Seattle, WA
- Vincent B. Young, MD, PhD, FIDSA, University of Michigan, Ann Arbor, MI

**Ex-officio:**
- Paul G. Auwarter, MD, FIDSA, IDSA President, Johns Hopkins University School of Medicine, Baltimore, MD
- Cynthia Sears, MD, FIDSA, IDSA President-Elect, Johns Hopkins University School of Medicine, Baltimore, MD
- Chris Busky, CAE, Chief Executive Officer, IDSA, Arlington, VA
- Sandra Vura Harwood, CMP, Meeting Secretariat, IDWeek, Arlington, VA
- Eve Humphreys, MBA, CAE, Executive Director, SHEA, Arlington, VA
- Andrea Weddle, MSW, Executive Director, HIVMA, Arlington, VA
- Terri Christene Phillips, MSA, Executive Director, PIDS, Arlington, VA

**Infectious Diseases Society of America**
- www.idsociety.org

**The Society for Healthcare Epidemiology of America**
- www.shea-online.org

**HIV Medicine Association**
- www.hivma.org

**Pediatric Infectious Diseases Society**
- www.pids.org

**IDWeek 2018 Program Committee**

**Infectious Diseases Society of America**
- www.idsociety.org

**The Society for Healthcare Epidemiology of America**
- www.shea-online.org

**HIV Medicine Association**
- www.hivma.org

**Pediatric Infectious Diseases Society**
- www.pids.org

IDWeek 2018 1300 Wilson Blvd., Suite 300, Arlington, VA 22209, 703-740-4961
info@idweek.org • www.idweek.org
Program Information

IDWeek Description
IDWeek 2018 is a joint meeting of IDSA, SHEA, HIVMA, and PIDS, focusing on the theme—Advancing Science, Improving Care—and featuring the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek is geared toward healthcare professionals in infectious diseases and healthcare epidemiology and prevention, including researchers, clinicians, quality and patient safety practitioners, epidemiologists, and public health officials, including those who see HIV and pediatric patients. There are no prerequisites for attendance. The meeting will provide state-of-the-art science and clinical care updates on key topics and issues. It is a must-attend meeting.

IDWeek Objectives
• Update infectious diseases clinicians and investigators with state-of-the-art developments in the field, including timely reviews of recent advances in clinical care and research, and original reports of clinical, translational, and basic research.
• Bridge the widening gaps among the fields of infectious diseases clinical practice, clinical research, epidemiological and health services research, translational research, and basic research.
• Promote multi-disciplinary dialogue and collaboration among clinicians and investigators, thus facilitating advances in the prevention, diagnosis, and treatment of infectious diseases.

Accreditation Statement for Physicians
The Infectious Diseases Society of America (IDSA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Accreditation Statement for Pharmacists
The continuing education activities for pharmacists have been developed through a joint providership of ProCE, Inc. and the Infectious Diseases Society of America (IDSA). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-18-178-L01-P through 0221-9999-18-281-L04-P, and 0221-9999-18-301-L01-P through 0221-9999-18-316-L01-P have been assigned to these live knowledge-based and application-based sessions (initial release date October 2-7, 2018). This conference is acceptable for up to 32.85 contact hours (3.285 CEUs) in states that recognize ACPE providers. The registration fee covers the cost of CE credits. CE Statements will be issued by the Infectious Diseases Society of America (IDSA) at the conclusion of the conference. Participants must complete an evaluation for each session they attended to receive pharmacy CE credit. The deadline for completing the evaluations is Monday, November 26, 2018.

ACCME Guidelines for Moderators
In accordance with ACCME guidelines, and to ensure balanced presentations, at least one IDWeek Program Committee member will serve as a moderator of each session.

Credit Designation Statement
IDSA designates this live activity for a maximum of 35.5 AMA PRA Category 1 Credits™. The core IDWeek sessions are designated for 23.5 credit hours and premeeting workshops are an additional 12. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Statement
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 15 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

IDWeek 2018 physician participation information will be shared with ABIM through ACCME PARS.

ABP MOC Statement
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn up to 23.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

Claim CME/CPE/MOC Credit
Statements of credit must be claimed either at the CME Pavilion or online after the meeting. Attendees will be required to complete a short evaluation for every session for which credit is claimed. The deadline to claim credit is Monday, November 26, 2018. Attendees must attend each selected session in its entirety to receive CME/CPE/MOC credit. Partial credit is not available.

Continuing Education Credit for Pharmacists
Pharmacy credit will be available for select sessions at IDWeek 2018. Please refer to the CME/CPE/MOC Credit Tracker on pages 53 - 57 for a detailed list and ACPE number assigned to each applicable session. Pharmacists must attend each select session in its entirety to receive CPE credit.
Faculty Disclosures

In accordance with the ACCME Standards for Commercial Support, IDWeek must provide balance, objectivity, and scientific rigor in all sponsored educational activities accredited for CME. The intent of the disclosures is to provide the audience with information on which they can make their own independent judgments pertaining to program content. IDWeek requires all faculty to disclose relevant financial relationships that they or a spouse/partner have, or have had, within the past 12 months with companies or commercial supporters of any products/services that are related to the research being presented at IDWeek (for example, employee, grants, research support, speaker, sponsors, stockholder, etc.). In addition to verbal and written disclosures, faculty are required to provide on the first slide of PowerPoint presentations any significant financial interest(s) / relationship(s) or note that there is “Nothing to disclose.” These disclosures can be found on the IDWeek App.

Commercial Support Statement

IDWeek and ProCE, Inc. follow and support the ACCME/ACPE guidelines for commercial support.

Scientific Sessions and Room Capacity

Scientific sessions will be held at the Moscone Center. For floor plans and maps please check the meeting app. IDWeek has made every effort to assign sessions to the appropriate room. Attendance is on a first-come, first-served basis and we ask that attendees use all available seating before standing. We apologize in advance if attendance exceeds available seating.

Opening Reception and “Posters in the Park”

The IDWeek Opening Reception and the “Posters in the Park” event will be held together on Wednesday, October 3, from 5:30 - 6:30 p.m. in the North Hall D Opening Reception Area, immediately following the Opening Plenary Session. Mingle with colleagues and talk to poster presenters whose research has been specially selected by each of the partner societies. This event is open to all registered attendees.

IDWeek Partnering Societies Business Meetings

Cocktails and Conversation with CDC Director Robert Redfield, MD, and an IDSA/HIVMA update: “Reflecting the New Face of ID”

Join IDSA and HIVMA leadership for a special session with CDC Director Robert Redfield, MD, on Friday, October 5, from 5 - 6 p.m. in North Hall D in the Moscone Center. Hear Dr. Redfield’s perspective as a public leader actively engaged in clinical research and clinical care of chronic human viral infections and infectious diseases, especially HIV, for more than 30 years. In addition, hear an update from IDSA and HIVMA leadership on key projects in the works and successful accomplishments over the past year. Please join us for cocktails and to catch up with friends!

PIDS Business Meeting

Join PIDS Leadership for the PIDS Business Meeting on Thursday, October 4 from 6 - 6:45 p.m. in the Moscone Center, North 23. Several PIDS Society Awards will be presented along with a wrap up from the year and a look forward at the year to come.

SHEA President’s Reception & Business Meeting

Join SHEA Leadership for SHEA President’s Reception & Business Meeting on Thursday, October 4 from 6 - 7:30 p.m. in the Embarcadero Room at the Parc 55 Hotel. SHEA’s newly elected leadership will be announced along with a wrap up of SHEA’s activities for the past year. SHEA will present the NEW SHEA Research Scholar Grant and the top fundraisers of the Race Against Resistance. Please join us for light refreshments as we discuss SHEA’s successful year!

Abstracts

Abstracts are available online through the Interactive Program Planner at www.IDWeek.org. You can also access them on the IDWeek app. See IDWeek Mobile App for details.

IDWeek 2018 abstracts will be published as an online supplement to Open Forum Infectious Diseases (OFID), the open access journal from IDSA. They will be permanently archived as part of the journal and will be accessible to all journal readers, not only meeting attendees or society members.

Poster Discussion Rounds

These sessions emphasize poster presentations of highlighted abstracts chosen through peer review. For each session, an expert in the field will summarize the research findings in context and participants will have the opportunity to ask questions of the authors. The group leader will determine the objectives and scope of discussion.

Pre-registration is not required. Participants are asked to meet in the Poster Discussion area 10 minutes prior to the beginning of the session. All of these will be held in the South Poster Hall of the Moscone Center during the time below.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, October 4</td>
<td>12:30 - 1:45 p.m.</td>
</tr>
<tr>
<td>Friday, October 5</td>
<td>12:30 - 1:45 p.m.</td>
</tr>
<tr>
<td>Saturday, October 6</td>
<td>12:30 - 1:45 p.m.</td>
</tr>
</tbody>
</table>

continued on next page
Speaker Ready Room
Check-in is required for all speakers. All speakers must use PowerPoint presentations. Speakers should check in at the onsite Speaker Ready Room at least 24 hours prior to presentation time. Please bring an electronic copy of your presentation. The Speaker Ready Room will be located in the lobby of the South Hall of the Moscone Center. For those speaking in the West Building of the Moscone Center, there will be a smaller Speaker Ready Room located near registration in the Lobby of West. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual consultants and IDWeek staff will be available for assistance. Computers in the Speaker Ready Room will be configured with hardware and software exactly like the ones in the meeting rooms and will allow you to preview your presentation, identify problems, and make corrections as necessary before your presentation.
All speakers are requested to leave a version of their PowerPoint presentation in the Speaker Ready Room for posting in the IDWeek digital library after the meeting.

Speaker Ready Room Hours of Operation:

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, October 1</td>
<td>2 - 6 p.m.</td>
</tr>
<tr>
<td>Tuesday, October 2</td>
<td>7 a.m. - 6 p.m.</td>
</tr>
<tr>
<td>Wednesday, October 3</td>
<td>6:30 a.m. - 6 p.m.</td>
</tr>
<tr>
<td>Thursday, October 4</td>
<td>6:30 a.m. - 6 p.m.</td>
</tr>
<tr>
<td>Friday, October 5</td>
<td>6:30 a.m. - 6 p.m.</td>
</tr>
<tr>
<td>Saturday, October 6</td>
<td>6:30 a.m. - 6 p.m.</td>
</tr>
<tr>
<td>*Sunday, October 7</td>
<td>7 - 9 a.m.</td>
</tr>
</tbody>
</table>

*Speaker Ready Room will be in the Lobby of the West Building

IDWeek Supporters
IDWeek gratefully acknowledges the support of the following companies:

**DIAMOND**
Gilead Sciences, Inc.

**PLATINUM**
ViiV Healthcare

**GOLD**
Astellas
BioFire Diagnostics, LLC
Genentech

**SILVER**
Merck

**BRONZE**
Healix
Leadiant Biosciences, Inc.
Medical Device Business Services, Inc.
Roche Diagnostics Corporation

Supported by a grant from Pfizer Inc.
Supported by Shire through an educational grant
Allied Partners

- **American Society of Transplantation**
  INTERACTIVE SESSION
  Friday, October 5, 2 - 3:15 p.m.

- **Centers for Disease Control and Prevention**
  MEET-THE-PROFESSOR SESSION
  Antimicrobial and Diagnostic Stewardship
  Thursday, October 4, 7:15 - 8:30 a.m.
  Combating Antimicrobial Resistance: Relevance of the One Health Concept
  Thursday, October 4, 8:45 - 10 a.m.

- **European Society of Clinical Microbiology and Infectious Diseases**
  INTERACTIVE SESSION
  Challenging Cases in Infectious Diseases
  Friday, October 5, 10:30 - 11:45 a.m.

- **European Society for Paediatric Infectious Diseases**
  SYMPOSIUM
  Pediatric Immunization: Perspectives from Both Sides of the Pond
  Friday, October 5, 2 - 3:15 p.m.

- **IDSA Clinical Affairs Committee**
  SYMPOSIUM
  ID Physicians in the Age of Value-Based Healthcare
  Friday, October 5, 3:30 - 4:45 p.m.
  SYMPOSIUM
  ID Physicians and Addiction Medicine
  Saturday, October 6, 8:45 - 10 a.m.
  SYMPOSIUM
  I’m Better than You and I Can Prove It: Quality Metrics for Clinical ID
  Saturday, October 6, 10:30 - 11:45 a.m.

- **IDSA ID Training Program Directors’ Committee**
  PREMEETING WORKSHOP
  Fellows’ Day Workshop ($)
  Wednesday, October 3, 8 a.m. - Noon

- **IDSA Medical Education Workgroup, IDSA Education Committee**
  SYMPOSIUM
  Hot Topics in Medical Education 2018
  Thursday, October 4, 10:30 - 11:45 a.m.

**MEET-THE-PROFESSOR SESSION**
Educating Trainees about Stewardship
Saturday, October 6, 7:15 - 8:15 a.m.

**MEET-THE-PROFESSOR SESSION**
Clinical Teaching for the ID Provider
Saturday, October 6, 7:15 - 8:15 a.m.

- **IDSA Standards and Practice Guidelines Committee and Johns Hopkins University School of Medicine Div. of Infectious Diseases**
  SYMPOSIUM
  New and Updated Guidelines
  Thursday, October 4, 10:30 - 11:45 a.m.

- **IDSA Telehealth Committee**
  SYMPOSIUM
  Can You Hear and See Me Now? ID Telehealth
  Thursday, October 4, 8:45 - 10 a.m.

- **National Institute of Allergy and Infectious Diseases**
  PREMEETING WORKSHOP
  NIH Initiatives / Grant Writing Workshop
  Tuesday, October 2, 1 - 5 p.m.
  SYMPOSIUM
  Migration and Immigration: Global Diseases at Your Doorstep
  Thursday, October 4, 2 - 3:15 p.m.
  SYMPOSIUM
  Novel Clinical Risks for Fungal Disease
  Thursday, October 4, 2 - 3:15 p.m.

- **National Institutes of Health**
  INTERACTIVE SESSION
  Controversies in Infection Prevention
  Thursday, October 4, 2 - 3:15 p.m.
  MEET-THE-PROFESSOR SESSION
  Designing a QI Project You Can Publish
  Friday, October 5, 7:15 - 8:15 a.m.

- **National Network of STD Clinical Prevention Training Centers**
  INTERACTIVE SESSION
  STIs in the HIV Care Setting
  Thursday, October 4, 10:30 - 11:45 a.m.

- **Pan-American Society of Infectious Diseases, Brazilian Society of Infectious Diseases**
  SYMPOSIUM
  Non-Zika Arboviruses in the Americas
  Saturday, October 6, 8:45 - 10 a.m.
Kathleen “Kate” Rubins, PhD, was selected by the National Aeronautics and Space Administration (NASA) in 2009. Dr. Rubins completed her first spaceflight on Expedition 48/49, where she became the first person to sequence DNA in space. She spent 115 days in space and conducted two spacewalks. She holds a Bachelor of Science in Molecular Biology from the University of California and a PhD in Cancer Biology from Stanford University Medical School Biochemistry Department and Microbiology and Immunology Department.

Dr. Rubins conducted her undergraduate research on HIV-1 integration in the Infectious Diseases Laboratory at the Salk Institute for Biological Studies. She worked as a Fellow/Principal Investigator at the Whitehead Institute for Biomedical Research and headed 14 researchers studying viral diseases that primarily affect Central and West Africa.

Dr. Rubins’ talk, “Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space,” will focus on improving the microbiome research.

---

Special Opening Plenary Session:

Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space

*Wednesday, October 3, 2018*

3:45 - 5:15 p.m.

Moscone Center: North Hall D
Steffanie Strathdee, PhD, is an infectious disease epidemiologist who is renowned for her research on the intersection of HIV and drug use, having generated over 500 scholarly publications. She is Associate Dean of Global Health Sciences and Harold Simon Professor of Medicine at the University of California San Diego, where she directs a campus-wide Global Health Institute. She is married to Thomas L. Patterson, Professor of Psychiatry at UC San Diego, where they co-direct a research and training program on the Mexico-U.S. border.

Dr. Strathdee is credited with saving her husband’s life from a deadly superbug infection using bacteriophage therapy. The case, which involved cooperation from three universities, the U.S. Navy, and researchers across the globe, shows how phage therapy is a future weapon against multidrug-resistant bacterial infections, which are expected to kill 10 million people per year by 2050.

Tom Patterson, PhD, is distinguished professor of Psychiatry at the University of California San Diego. Dr. Patterson’s HIV research has focused primarily on counseling interventions for high-risk individuals to increase condom use and reduce HIV transmission risk. He has published over 500 peer reviewed journal articles and numerous book chapters.

Together, Drs. Strathdee and Patterson are working on a book which chronicles how phages were used to save Dr. Patterson’s life and why they have been largely ignored by clinicians. Their presentation will focus on this experience in a talk titled “Turning the Phage on Antibiotics.”
From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections

Robert T. “Chip” Schooley, MD, FIDSA, is a Professor of Medicine in the Department of Medicine, Division of Infectious Diseases and Global Public Health, at the University of California San Diego. Dr. Schooley received his medical degree from the Johns Hopkins University School of Medicine in 1974 and completed his medical house staff training at the Johns Hopkins Hospital in 1976. He completed fellowships in infectious diseases at the National Institute of Allergy and Infectious Diseases and at the Massachusetts General Hospital before joining the faculty of Harvard Medical School in 1981.

Dr. Schooley began his research career studying the immunopathogenesis of herpesvirus infections in immunocompromised patients but shifted his focus to AIDS in 1981 when the first cases of this syndrome began to appear in Boston. His research group was among the first to delineate the humoral and cellular immune responses to HIV infection. Over the next 15 years he became increasingly involved in the discovery and development of antiretroviral chemotherapeutic agents, including reverse transcriptase inhibitors, protease inhibitors, and entry inhibitors.

His current research interests include HIV and HCV pathogenesis and therapy and infections that cause morbidity and mortality in resource limited settings.

We are pleased to welcome Dr. Schooley to discuss his experience on the use of phage to treat antibiotic-resistant infections in his talk titled “From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections.”

Using Phage Lysins to Treat Antibiotic-Resistant Infections

Vincent A. Fischetti, PhD, is Professor and Head of the Laboratory of Bacterial Pathogenesis and Immunology at the Rockefeller University, in New York. He has over 40 years of experience in the anti-infectives field. Over those years his laboratory has been involved in understanding the earliest events in gram-positive bacterial infection, so that strategies may be devised to prevent infection. His laboratory was the first to identify lytic enzymes as novel therapeutics to decolonize human mucous membranes of bacterial pathogens and treat systemic infections caused by antibiotic-resistant organisms. His laboratory also identified the mechanism by which gram-positive bacteria attach their surface proteins in the cell, a target for antibiotic development. He has published over 230 primary research articles and over 70 textbook chapters and is a co-editor of two major books on gram-positive pathogens. He is an inventor of over 40 issued patents dealing with the control of infectious diseases. Dr. Fischetti received a PhD in Microbiology with honors from New York University.

Dr. Fischetti’s presentation will focus on “Using Phage Lysins to Treat Antibiotic-Resistant Infections.”
Rochelle Walensky, MD, MPH, FIDSA, is the Chief of Infectious Diseases and Co-Director of the Medical Practice Evaluation Center at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Walensky has been a member of the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) team since 1998. Her research interests have focused on HIV/AIDS policy and cost-effective strategies of HIV care in the U.S. and in resource-limited settings. She is internationally recognized for motivating U.S. policy toward the promotion of routine HIV screening and for her work on effective and efficient strategies of HIV care in South Africa. She is a member of the American Society for Clinical Investigation (ASCI), the American Association of Physicians (AAP), and the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and she is past Chair of the NIH Office of AIDS Research Advisory Council. She has also been an advisor to the World Health Organization and UNAIDS. Dr. Walensky received her BA from Washington University in St. Louis (1991), her MD from the Johns Hopkins School of Medicine (1995), and her MPH from the Harvard School of Public Health (2001). She trained in Internal Medicine at the Johns Hopkins Hospital (1995-1998) and in Infectious Disease at the MGH/BWH combined fellowship program (1998-2001).

Dr. Walensky’s presentation, “The Cost of Our Drugs: Branded, Generics and Why We Should Care,” will review healthcare costs and physician’s contributions to these costs and discuss issues and challenges in the use of some generic antimicrobial therapy. She will also discuss the question of whether use of generic antiretroviral therapy in the U.S. will help curb overall HIV costs.

Past Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
<th>Year</th>
<th>Lecturer</th>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>Connie Celum</td>
<td>2009</td>
<td>Stanley M. Lemon</td>
<td>2001</td>
<td>Lawrence Corey</td>
</tr>
<tr>
<td>2016</td>
<td>Judith Currier</td>
<td>2008</td>
<td>Bruce Walker</td>
<td>2000</td>
<td>Richard J. Whitley</td>
</tr>
<tr>
<td>2015</td>
<td>Lynne Mofenson</td>
<td>2007</td>
<td>Thomas C. Quinn</td>
<td>1999</td>
<td>Samuel L. Katz</td>
</tr>
<tr>
<td>2013</td>
<td>Nancy J. Cox</td>
<td>2005</td>
<td>Stephen E. Straus</td>
<td>1997</td>
<td>Diane Griffin</td>
</tr>
<tr>
<td>2011</td>
<td>Angela M. Caliendo</td>
<td>2003</td>
<td>Catherine M. Wilpert</td>
<td>1995</td>
<td>Ciro De Quadros</td>
</tr>
<tr>
<td>2009</td>
<td>Lawrence Corey</td>
<td>2000</td>
<td>Richard J. Whitley</td>
<td>1999</td>
<td>Samuel L. Katz</td>
</tr>
<tr>
<td>2007</td>
<td>Thomas C. Quinn</td>
<td>2006</td>
<td>Frederick G. Hayden</td>
<td>1997</td>
<td>Diane Griffin</td>
</tr>
<tr>
<td>2006</td>
<td>Frederick G. Hayden</td>
<td>2005</td>
<td>Stephen E. Straus</td>
<td>1996</td>
<td>Anne Gershon</td>
</tr>
</tbody>
</table>
MAXWELL FINLAND, MD, DSci, served as the first president of IDSA. His prestigious medical career spanned more than 50 years at Harvard University and Boston City Hospital. He was internationally recognized for his study of the incidence and character of infectious diseases and their specific treatments. Dr. Finland's unbiased judgment on the role of antimicrobial agents in medical treatment was universally respected.

He is credited with influencing pioneering studies of antibiotic therapy and the treatment for pneumonia and respiratory injuries linked to exposure to noxious gases. He was noted as establishing early identification of new infectious hazards and the emergence of dangerous new infections in hospitalized patients. The Maxwell Finland Lecture, which bears his name, was first given in 1972 by Theodore E. Woodward, MD.

Antibiotic Stewardship: Looking Back and Moving Forward

Arjun Srinivasan, MD (CAPT, USPHS), FSHEA, is associate director for healthcare-associated infection prevention programs in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention’s National Center for Emerging and Zoonotic Infectious Diseases. Dr. Srinivasan is also a captain in the U.S. Public Health Service. An infectious disease doctor, Dr. Srinivasan oversees several CDC programs aimed at eliminating healthcare-associated infections and improving antibiotic use. For much of his CDC career, Dr. Srinivasan ran the healthcare outbreak investigation unit, helping hospitals and other healthcare facilities track down bacteria and stop them from infecting other patients. Today, Dr. Srinivasan leads CDC’s work to improve antibiotic prescribing and works with a team of CDC experts researching new strategies to eliminate healthcare-associated infections.

As assistant professor of medicine in the Infectious Diseases Division at the Johns Hopkins School of Medicine and a staff physician, Dr. Srinivasan founded the Johns Hopkins Antibiotic Management Program. A graduate of the Vanderbilt University School of Medicine, Dr. Srinivasan is a member of Alpha Omega Alpha medical honor society. He completed an internal medicine residency and infectious disease fellowship at Johns Hopkins University Hospital. Dr. Srinivasan is an adjunct assistant professor of medicine at Emory University Medical Center and sees patients at the Atlanta Veteran’s Affairs Medical Center.

Dr. Srinivasan’s presentation, “Antibiotic Stewardship: Looking Back and Moving Forward,” will cover the past, present, and future of antibiotic stewardship from a U.S. nationwide perspective. He will summarize some of the key next steps for antibiotic stewardship in hospitals to move into the future.

Past Lecturers

2017 Steven Holland
2016 Robert C. Read
2015 Henry “Chip” Chambers
2014 Lise-Anne Pirofski
2013 Victoria J. Fraser
2012 George McCracken
2011 Julie Parsonnet
2010 Gerald Friedland
2009 Cynthia L. Sears
2008 Anthony Fauci
2007 Louis B. Rice

2006 W. Michael Scheld
2005 William Dismukes
2004 King Holmes
2003 Robert C. Moellering, Jr.
2002 Jerome Klein
2001 Margaret K. Hostetter
2000 P. Frederick Sparling
1999 Frederick S. Southwick
1998 Elaine Toumanen
1997 Gerald Keusch
1996 Barbara Murray
1995 Theodore Eickhoff
1994 Carol J. Baker
1993 Stanley Falkow
1992 John E. Bennett
1991 Michael Blaese
1990 Robert Gallo
1989 John Robbins
1988 Thomas Merigan
1987 R. Palmer Beasley
1986 Alexander D. Langmuir
1985 Harry F. Dowling
1984 Albert B. Sabin
1983 Paul G. Quie
1982 Jack S. Remington
1981 Abraham I. Braude
1980 Maclyn McCarty
1979 Harry A. Feldman
1978 Dorothy M. Horstmann
1977 George G. Jackson
1976 Edward H. Kass
1975 George Meiklejohn
1974 Robert Austrian
1973 Louis Weinstein
1972 Theodore E. Woodward

continued on next page
Ruth A. Karron, MD, FIDSA, is a Professor in the Department of International Health, Johns Hopkins Bloomberg School of Public Health, Director of the Center for Immunization Research, and Founding Director of the Johns Hopkins Vaccine Initiative.

Dr. Karron is a pediatrician, trained in infectious diseases, who has extensive experience in the evaluation of respiratory virus vaccines (including vaccines for respiratory syncytial virus, parainfluenza viruses, avian influenza, and pandemic influenza) in adult and pediatric populations. Dr. Karron’s research interests also include the pathogenesis of enhanced RSV disease, the development of immune responses to respiratory viral infections in early life, the epidemiology of RSV and other respiratory viral diseases in resource-poor settings, and public policy issues related to vaccine development and distribution. She has served on a number of national and international vaccine advisory committees and panels, and chaired the FDA’s Vaccine and Related Biological Products Advisory Committee from 2006-2008.

Dr. Karron’s talk, titled “RSV Vaccines: Where Do We Go From Here?” will focus on her experience and thoughts on the future for respiratory syncytial virus vaccination across all settings.
The SHEA Lectureship award is given annually to recognize the career contributions of a senior investigator in healthcare epidemiology and infection prevention and control. Awardees have shown leadership through notable contributions to the science of healthcare epidemiology, demonstration of ongoing dedication to advancing the field, demonstration of mentorship, and dedication to SHEA and its mission to prevent healthcare-associated infections.

A Wrinkle in Time: Reflections on Advances and Unmet Needs in Healthcare Epidemiology

Jan E. Patterson, MD, MS, FIDSA, FSHEA, is currently Professor and Associate Dean for Quality and Lifelong Learning and also directs the Center for Patient Safety and Health Policy at the University of Texas Health Science Center at San Antonio. Dr. Patterson served as the president of the Society for Healthcare Epidemiology in 2012. She graduated from the University of Texas Medical School at Houston and completed her Internal Medicine residency at Vanderbilt University Medical Center. She completed her postdoctoral fellowship in Infectious Diseases at Yale University School of Medicine where she trained in healthcare epidemiology with Dr. Walter J. Hierholzer, Jr., a former SHEA President. She received a Master of Science in Health Care Management from Harvard School of Public Health in May 2010.

Dr. Patterson’s presentation, titled “Reflections on Advances and Unmet Needs in Healthcare Epidemiology,” will focus on the gaps in knowledge and research related to infection prevention.

Past Lecturers

2017  Neil Fishman
2016  Daniel Sexton
2015  Richard Platt
2014  Lisa Saiman
2013  Denise Cardo
2012  William Rutala
2011  Victoria Fraser
2010  David Henderson
2009  Elaine Larson
2008  Didier Pittet
2007  Dale Gerding
2006  C. Glen Mayhall
2005  Robert Weinstein
2004  Lindsay Nicole
2003  William Jarvis
2001  William Scheckler
2000  Walter Hierholzer
1999  Dennis Maki
1998  John E. McGowan
1997  Richard Wenzel
1996  William Schaffner
1995  Philip S. Brachman
1993  John V. Benett
The Stanley A. Plotkin Lecture in Vaccinology is presented annually to an individual who has made significant contributions to the field of vaccinology or areas of related science that have impacted the lives of children and the specific area of pediatric infectious diseases.

2018 Stanley A. Plotkin Lectureship in Vaccinology
Friday, October 5, 2018: 3:45 - 4:45 p.m.
Moscone Center: Room N 25

Vaccine Hesitancy, History and Human Nature

Gary S. Marshall, MD, is a professor of pediatrics at the University of Louisville School of Medicine and is chief of the Division of Pediatric Infectious Diseases, director of the Pediatric Clinical Trials Unit, and author of The Vaccine Handbook: A Practical Guide for Clinicians (The Purple Book).

Dr. Marshall received his medical degree from Vanderbilt University School of Medicine and completed his residency in Pediatrics at Vanderbilt University Hospital. Dr. Marshall completed his fellowship in Pediatric Infectious Diseases at the Children’s Hospital of Philadelphia.

Dr. Marshall's presentation will focus on vaccine hesitancy in the broader context of human thought patterns and belief systems and discuss how to engage stakeholders in developing strategies to improve immunization rates despite pervasive anti-vaccinationism.

Past Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Lecturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>Peter F. Wright</td>
</tr>
<tr>
<td>2016</td>
<td>Carol J. Baker</td>
</tr>
<tr>
<td>2016</td>
<td>Larry K. Pickering</td>
</tr>
<tr>
<td>2015</td>
<td>Neal A. Halsey</td>
</tr>
<tr>
<td>2014</td>
<td>Eugene D. Shapiro</td>
</tr>
<tr>
<td>2013</td>
<td>Anne A. Gershon</td>
</tr>
<tr>
<td>2012</td>
<td>John B. Robbins</td>
</tr>
<tr>
<td>2011</td>
<td>David I. Bernstein</td>
</tr>
<tr>
<td>2010</td>
<td>Dan Granoff</td>
</tr>
<tr>
<td>2009</td>
<td>James A. Cherry</td>
</tr>
<tr>
<td>2008</td>
<td>Paul A. Offit</td>
</tr>
<tr>
<td>2007</td>
<td>Kathryn M. Edwards</td>
</tr>
<tr>
<td>2006</td>
<td>Walter A. Orenstein</td>
</tr>
<tr>
<td>2005</td>
<td>Samuel L. Katz</td>
</tr>
<tr>
<td>2004</td>
<td>Stanley A. Plotkin</td>
</tr>
</tbody>
</table>
Joseph E. Smadel, MD, was a physician and investigator who created a bridge between basic laboratory science and the clinician, making significant contributions to the knowledge of psittacosis, vaccinia, variola, myxomatosis, and viral encephalitis. During World War II, Dr. Smadel lead a study of control measures of typhus fever in Egypt and southern Italy. Dr. Smadel served at the Department of Virus and Rickettsial Diseases of the Army Medical School, Walter Reed Army Institute of Research and National Institutes of Health (NIH). He held the position of chief of virology and rickettsiology in the Division of Biologic Standards at NIH until his death. The Joseph E. Smadel Lecture is intended to honor someone who has made a significant impact in public health.

2018 Joseph E. Smadel Lecture
Saturday, October 6, 2018: 3:30 - 3:55 p.m.
Moscone Center: North Hall D

Joseph E. Smadel, MD, MA, DSci, 1907-1963

2018 Featured Lecturer

Academic Partnership with Public Health: Infectious Diseases at the Population-Level

Monica M. Farley, MD, FIDSA, is the Jonas A. Shulman Professor of Medicine and the Director of the Division of Infectious Diseases at Emory University School of Medicine and a Staff Physician at the Atlanta VA Medical Center. She is past-President of the American Federation for Medical Research and a longstanding council member and past-President of the Southern Society for Clinical Investigation. She has served on the Women’s Committee, the Program Planning Committee, and the Public Health Committee in IDSA. Dr. Farley leads a large infectious diseases division at Emory made up of nearly 70 faculty members with a large research portfolio. She serves as the academic Principal Investigator for the Georgia Emerging Infections Program (EIP), a CDC-funded surveillance network conducting applied epidemiologic and laboratory research focused on invasive bacterial pathogens, influenza, foodborne diseases, and healthcare-associated infections. She is a past member of the U.S. Food and Drug Administration (FDA) Advisory Committee on Vaccines and Related Biological Products, and she currently serves on the Pneumococcal Vaccine Working Group for CDC’s Advisory Committee on Immunization Practices (ACIP). The collaborative EIP research program has been highly productive, providing population-based assessment of the epidemiology and risk factors for a number of important bacterial infections, including adult and pediatric Group B Streptococcal infections, pneumococcal disease and community-associated MRSA, and performing post-licensure vaccine effectiveness studies.

Dr. Farley’s presentation on “Academic Partnership with Public Health: Infectious Diseases at the Population-Level” gives a broad look at how academic institutions and public health can partner for the benefit of the communities they serve.

Past Lecturers

2017 Ruth Lynfield
2016 Patricia Griffin
2015 Bruno Moonen* (in honor of Alan Magill)
2014 Robert Weinstein
2013 Myron S. Cohen
2012 Diane Havlir
2011 William Schaffner
2010 Kathleen Neuzil
2009 Myron Levine
2008 Jane E. Koehler
2007 Kathryn M. Edwards
2006 Allan R. Ronald
2005 Lyle Peterson
2004 Eric Otteson
2003 Didier Raoult
2002 Donald A. Henderson
2001 Karl M. Johnson
2000 Anne Schuchat
1999 Lou H. Miller
1998 Thomas Wellem
1997 Brett Finlay
1996 Scott B. Halstead
1995 David T. Dennis
1994 Roy Anderson
1993 Richard Guerrant
1992 Alfred Sommer
1991 Charles Carpenter
1990 Zenvil Cohen
1989 Thomas Grayston
1988 P. Frederick Sparling
1987 Jack M. Gwaltney
1986 Richard T. Johnson
1985 Franklin A. Neva
1984 Maurice R. Hilleman
1983 Garrison Rapmund
1982 Richard B. Horlick
1981 Baruj Benacerraf
1980 Robert M. Chanock
1979 Philip K. Russell
1978 Philip Y. Paterson
1977 D. Carleton Gajdusek

continued on next page
2018 Edward H. Kass Lecture
Saturday, October 6, 2018: 4:20 - 4:45 p.m.
Moscone Center: North Hall D

Edward H. Kass, MD, was one of the founding leaders of IDSA. He served as the Society’s seventh president in 1970 as well as the Society’s secretary from 1964 to 1967. He helped to create not only IDSA, but also the Channing Memorial Laboratory and the International Congress on Infectious Diseases. Dr. Kass was instrumental in securing IDSA’s role in publishing The Journal of Infectious Diseases, and he developed the concept for Reviews of Infectious Diseases – now Clinical Infectious Diseases. Not only was he a pioneer in the study of infection, he was an advocate for social justice and passionate about addressing poverty, racism, and discrimination. Dr. Kass held the positions of William Ellery Channing Professor of Medicine at Harvard Medical School and director of the Channing Laboratory at Harvard Medical School and Brigham and Women’s Hospital. In his memory, IDSA maintains the annual Edward H. Kass Lectureship in the History of Medicine and the Kass Awards, which assist medical students and residents with travel expenses to IDWeek. The first Kass Lectureship was given in 1991 by Theodore E. Woodward, MD.

Henry Masur, MD, FIDSA, trained in internal medicine at the New York Hospital-Cornell Medical Center and Johns Hopkins Medical Center. At Cornell Medical Center, he trained in infectious diseases with a focus on pneumocystis. While serving on the faculty at Cornell, he saw some of the earliest cases of AIDS. In 1982 he was recruited to the National Institutes of Health as Assistant Chief of Critical Care Medicine, a logical fit in an era when most AIDS patients ultimately spent time in the ICU, and when formal training in critical care was just being developed.

He became the Chief of the Critical Care Medicine Department at the NIH Clinical Center in 1989. At NIH, Dr. Masur was active in defining AIDS related opportunistic infections, and focused on developing new diagnostics, new therapeutics, and new prevention strategies for a wide range of pathogens. He initiated the first HIV related clinical guideline in 1989, which has evolved into the “IDSA-NIH-CDC Guideline for Management of HIV Related Opportunistic Infections in Adults and Adolescents.” Dr. Masur has also taken leadership roles in developing the IDSA-AASLD Guidance on HCV Management, and the IDSA-SCCM Guideline in Prevention of Catheter Related Infections, and had an active role on the Surviving Sepsis Guidelines. In addition to continuing to serve as Chief of the Critical Care Medicine Department at the NIH Clinical Center, Dr. Masur is the co-director of the District of Columbia Partnership for AIDS Progress, a joint program between NIH, academic and community partners, and the DC Department of Health to create a model for how urban areas can reduce the impact that HIV has on their communities. Dr. Masur is a past president of the Infectious Diseases Society of America.

Past Lecturers

2017  James M. Hughes
2016  John Perfect
2015  Karen C. Carroll
2014  Janet Gilshorff
2013  Peter Hotez
2012  Elaine Larson
2011  Larry Pickering
2010  Richard Wenzel
2009  Paul A. Volberding
2008  Arturo Casadevall
2007  David Relman
2006  Wafaa El-Sadr
2005  Constance Benson
2004  Lucy Tompkins
2003  Seymour J. Klebanoff
2002  Stanley A. Plotkin
2001  John G. Bartlett
2000  Walter E. Stamm
1999  Sharon L. Hillier
1998  Martin J. Blaser
1997  Judith Wasserheit
1996  Charles S. Bryan
1995  Alfred Evans
1994  Jay Sanford
1993  Floyd Denny
1992  Allan Brandt
1991  Theodore E. Woodward
## Awards Presentation Schedule

### IDSA Society Awards

<table>
<thead>
<tr>
<th>Award</th>
<th>Recipient</th>
<th>Date and Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IDSA Alexander Fleming Award for Lifetime Achievement</strong></td>
<td>Richard Whitley, MD, FIDSA</td>
<td>Wednesday, October 3, at 3:45 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>IDSA Society Citation</strong></td>
<td>Louis Saravolatz, MD, FIDSA</td>
<td>Thursday, October 4, at 4 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>IDSA Watanakunakorn Clinician Award</strong></td>
<td>Barry Hartman, MD, FIDSA</td>
<td>Thursday, October 4, at 4 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>IDSA D.A. Henderson Award</strong></td>
<td>William Schaffner, MD, FIDSA, FSHEA</td>
<td>Thursday, October 4, at 4 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>IDSA Clinical Teacher Award</strong></td>
<td>Allan R. Tunkel, MD, FIDSA, Frank Berkowitz, MD</td>
<td>Saturday, October 6, at 4 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>IDSA Oswald Avery Award for Early Achievement</strong></td>
<td>Susanna Naggie, MD, FIDSA</td>
<td>Saturday, October 6, at 4 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>IDSA Walter E. Stamm Mentor Award</strong></td>
<td>Carol Kauffman, MD, FIDSA, FSHEA</td>
<td>Saturday, October 6, at 4 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>IDSA Clinical Practice Innovation Award</strong></td>
<td>Javeed Siddiqui, MD, MPH</td>
<td>Saturday, October 6, at 4 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
</tbody>
</table>

### SHEA Society Awards

<table>
<thead>
<tr>
<th>Award</th>
<th>Recipient</th>
<th>Date and Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SHEA Senior Scholar Award</strong></td>
<td>David J. Weber, MD, MPH, FIDSA, FSHEA</td>
<td>Wednesday, October 3, at 3:45 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>SHEA Advanced Practice Infection Preventionist Award</strong></td>
<td>Joan Hebden, RN, MS, CIC</td>
<td>Friday, October 5, at 4:30 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
</tbody>
</table>

### HIVMA Leadership Awards

<table>
<thead>
<tr>
<th>Award</th>
<th>Recipient</th>
<th>Date and Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIVMA Clinical Educator Award</strong></td>
<td>Rajesh T. Gandhi, MD, FIDSA</td>
<td>Wednesday, October 3, at 3:45 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
<tr>
<td><strong>HIVMA Research Award</strong></td>
<td>Lisa B. Hightow-Weidman, MD, MPH</td>
<td>Thursday, October 4, at 4 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
</tbody>
</table>

### PIDS Society Awards

<table>
<thead>
<tr>
<th>Award</th>
<th>Recipient</th>
<th>Date and Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PIDS Distinguished Research Award</strong></td>
<td>Carol J. Baker, MD, FIDSA, FPIDS</td>
<td>Wednesday, October 3, at 3:45 p.m.</td>
<td>North Hall D, Moscone Center</td>
</tr>
</tbody>
</table>
Alexander Fleming Award for Lifetime Achievement

Presented on Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center

Richard J. Whitley, MD, FIDSA, a pioneer in the development of antiviral therapies for infections in children and adults, is the recipient of IDSA's 2018 Alexander Fleming Award for Lifetime Achievement. This award recognizes a career that reflects major contributions to the acquisition and dissemination of knowledge about infectious diseases.

Dr. Whitley's work over more than 40 years has spanned from fundamental drug discovery through complex clinical trials that established the safety and efficacy of novel therapies for many previously untreatable viral infections. These include herpes simplex encephalitis, neonatal herpes, congenital cytomegalovirus, West Nile encephalitis, and influenza, among others. His efforts to define the pharmacokinetics of antiviral drugs for herpesvirus infections and their safety and efficacy in children, pregnant women, the immunocompromised, and older adults have enabled all patients to benefit from these therapies. Dr. Whitley was instrumental in the development of recommendations for the treatment of cytomegalovirus with ganciclovir and its derivatives, and following the 2009 H1N1 influenza outbreak, guidelines for the emergency use of oseltamivir in infants. His ongoing laboratory research focused on genetically engineered herpes viruses as oncolytic agents also holds promise for patients with otherwise fatal brain tumors.

A sought-after authority on viruses, biodefense, and emerging infections, Dr. Whitley has served on major national and international committees, including the Board of Scientific Counselors at the National Institute of Allergy and Infectious Diseases, among many others. The author of more than 400 publications, he is also responsible for the Collaborative Antiviral Study Group, based at the University of Alabama at Birmingham (UAB) and funded by the National Institutes of Health. This group has led multicenter trials of antiviral therapies for medically important diseases since the 1970s.

Dr. Whitley is a Distinguished Professor of Pediatrics, vice chair of the Department of Pediatrics, co-director of the Division of Pediatric Infectious Diseases, the Loeb Eminent Scholar Chair in Pediatrics, and professor of microbiology, medicine, and neurosurgery at UAB. After receiving his medical degree at George Washington University School of Medicine, he completed his pediatric internship, residency, and fellowship training at UAB before joining the faculty. An IDSA John F. Enders Lecturer in 2000, Dr. Whitley was president of IDSA from 2009 to 2010 and has been a strong supporter of the Society’s mission for many years. The recipient of numerous honors and awards, he has served as an associate editor of *The Journal of Infectious Diseases* since 2004 and is a member of several other journal editorial boards.

Dr. Whitley's practice-changing work over four-plus decades has greatly improved how physicians diagnose and care for children and adults with once untreatable viral infections. The Society is proud to honor him with the 2018 Alexander Fleming Award for Lifetime Achievement.
IDSA Society Awards (continued)

IDSA Society Citation

Presented on Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center

Louis D. Saravolatz, MD, FIDSA, a widely respected clinician and researcher with a strong commitment to IDSA, is the recipient of the 2018 IDSA Society Citation. First awarded in 1977, this is a discretionary award given in recognition of exemplary contribution to IDSA, an outstanding discovery in the field of infectious diseases, or a lifetime of outstanding achievement.

Dr. Saravolatz is chair of the Department of Medicine at St. John Hospital and Medical Center in Grosse Pointe Woods, Michigan, and a professor of medicine at Wayne State University School of Medicine in Detroit. He developed an extensive background in bacterial infections early in his career, including descriptions of early outbreaks of *Legionella*. In the early 1980s, he was among the first to document the emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) infection in the community. A decade later, Dr. Saravolatz was actively involved in National Institutes of Health committees that developed treatment strategies for HIV before modern antiretroviral therapy became available. The author of more than 200 publications and book chapters, he has continued to actively pursue research interests in infection control and novel antimicrobial agents for Gram-positive bacteria, including MRSA, vancomycin-intermediate *S. aureus*, vancomycin-resistant *S. aureus*, and daptomycin-resistant isolates.

One of the most respected ID physicians in the Detroit metropolitan area, Dr. Saravolatz has made substantial contributions to IDSA through his dedicated service on multiple committees. A member of the Publications Committee for more than five years (2010-2016), he served as its chair from 2013 to 2016, leading the committee’s efforts to oversee the publication of the Society’s scientific journals. In 2015, he was chair of the search committee for the editor-in-chief of *Clinical Infectious Diseases*. A former chair of the Society’s Committee on Antimicrobial Usage and Clinical Trials (2000-2003) and chair of the ad hoc committee that reviewed the Joint Commission’s sepsis guidelines in 2005, he has also been a member of the Fellows In-Training Examination Writing Committee (2006-2007) and the Regional Representative National Committee (2010-2012).

Dr. Saravolatz received his medical degree from the University of Michigan Medical School, followed by an internship and residency training at Henry Ford Hospital in Detroit, where he also completed his ID fellowship. Invited frequently to speak at regional, national, and international meetings and conferences, Dr. Saravolatz has served on numerous hospital, regional, and state committees. An active member of the Infectious Diseases Division who regularly rounds with house staff, he continues to attend on the consult service and mentors fellows and young faculty in their own research.

An accomplished physician and researcher, Dr. Saravolatz has contributed significantly to IDSA’s mission, including through his extensive service on the Society’s Publications Committee. IDSA is delighted to add the 2018 Society Citation to his long list of achievements.

continued on next page
HONORS, AWARDS, AND GRANTS

IDSA Watanakunakorn Clinician Award

Presented on Thursday, October 4, at 4 p.m. in North Hall D, Moscone Center

Barry J. Hartman, MD, FIDSA, a renowned clinician and teacher with a long history of service locally and nationally, is the recipient of IDSA’s 2018 Watanakunakorn Clinician Award. Named to honor the memory of Chatrchai Watanakunakorn, this award is presented by the IDSA Foundation to recognize an IDSA member for outstanding achievement in the clinical practice of infectious diseases.

Dr. Hartman has earned the respect and admiration of several generations of students, residents, ID fellows, colleagues, and faculty throughout his career. Having transitioned to private practice in the late 1980s, he has remained closely affiliated with Weill Medical College of Cornell in New York City, where he is a clinical professor of medicine. He has delivered annual lectures to medical students on the clinical use of antibiotics, bacteremia, and sepsis for the past 20 years, in addition to presentations at various specialty and subspecialty conferences and ID continuing medical education courses. He has been a member of 30 different medical school committees, including search committees for the school’s dean, the faculty promotions committee, and the general faculty council, which he also led as chair, all while maintaining his own private clinical practice.

Recognized by his institution’s house staff in a survey identifying the most respected attending physicians, Dr. Hartman has repeatedly been named among the Best Doctors in America and in New York. Sought after for his advice on the most challenging clinical cases, he is the ID physician that many colleagues would choose as their own. The author of more than 40 peer-reviewed publications and 12 book chapters, Dr. Hartman served on the panel that developed IDSA’s 2004 practice guidelines for the management of bacterial meningitis and the 2008 management of encephalitis guidelines. He was a member of the IDSA Finance Committee and served as its chair. Active with the American Board of Internal Medicine, he has been a member of the self-evaluation program in infectious diseases and the subspecialty board. He has also served as a councilor of the Infectious Diseases Society of New York.

After obtaining his medical degree from M.S. Hershey Medical Center/Pennsylvania State University and completing his internship, residency, and ID fellowship training at New York Hospital (now New York Presbyterian Hospital-Weill Cornell Medical Center), Dr. Hartman joined the faculty at Cornell University Medical College. He also trained in the laboratory of Dr. Alexander Tomasz at Rockefeller University, where he conducted research on mechanisms of S. aureus resistance.

Truly a “doctor’s doctor,” Dr. Hartman is an esteemed clinician with an impressive record of dedicated service to patients, students, colleagues, and the ID specialty throughout his career. The Society is proud to recognize him with the 2018 Watanakunakorn Award.
IDSA D.A. Henderson Award

Presented on Thursday, October 5, at 4 p.m. in North Hall D, Moscone Center

William Schaffner, MD, FIDSA, FSHEA, a peerless communicator and committed proponent of adult immunization, is the recipient of IDSA’s 2018 D.A. Henderson Award for Outstanding Contributions to Public Health. Named to honor the memory of Dr. Henderson, who led the successful eradication of smallpox, this award recognizes a lifetime of achievement in public health.

Highly effective at melding curative and preventive medicine, Dr. Schaffner has advanced epidemiologic science, translated that science into national health policy, and eloquently communicated these developments and countless other infectious disease-related topics to the public throughout his career. He has served on the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices since 1982. During this unmatched length of service, he has provided an important and respected voice as the influential group has made recommendations about vaccine products and their use across the U.S. As a member of several organizations focused on immunization, he has been a tireless advocate for science-based evidence in debates fueled by vaccine skepticism, persistently providing both facts and reassurance.

Among Dr. Schaffner’s more than 300 peer-reviewed publications are several with a significant impact on public health, including the first demonstration that vaccination could eliminate measles from a state and an investigation of Pseudomonas and Serratia infections associated with defective bronchoscopes, which prompted a worldwide recall. Because of his unparalleled ability to distill topics like these and others to their essential points and convey them simply, he is the “go to” ID expert for many media outlets. Through these interactions, he has brought a greater understanding of infectious diseases and public health to the general public.

A graduate of Cornell University Medical College, Dr. Schaffner completed his internship, residency, and ID fellowship training at Vanderbilt University School of Medicine, where he is currently a professor of preventive medicine in the Department of Health Policy and a professor of medicine in the Division of Infectious Diseases. He joined the faculty there after serving as an Epidemic Intelligence Service officer with CDC. A past president of SHEA, he has served on the IDSA Board of Directors, including as secretary; received the IDSA Walter E. Stamm Mentor Award in 2011; and has been an IDSA Joseph E. Smadel Lecturer. An associate editor of The Journal of Infectious Diseases since 2003, he is also a past president of the National Foundation for Infectious Diseases, for which he currently serves as medical director.

Recognized as a premier ambassador for the field of ID and a dedicated advocate for adult immunization and evidence-based policies, Dr. Schaffner has advanced the nation’s health through his research, teaching, mentorship, practice, and service. IDSA is pleased to recognize his outstanding contributions to public health with the 2018 D.A. Henderson Award.
IDSA Clinical Teacher Award

Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center

Allan R. Tunkel, MD, PhD, FIDSA, is one of two recipients of IDSA’s 2018 Clinical Teacher Award. This award honors a career dedicated to teaching clinical infectious diseases to fellows, residents, and medical students and recognizes excellence as a clinician and motivation to teach the next generation of physicians.

An international expert in bacterial meningitis and other central nervous system infections, Dr. Tunkel has an extensive background in medical education, administration, clinical care, and research. Currently a professor of medicine and medical science and associate dean for medical education at Brown University’s Warren Alpert Medical School, he also held significant academic leadership positions at Drexel University College of Medicine and Monmouth Medical Center. Passionate about physician training and mentorship, he has received numerous honors and awards for teaching throughout his career, including six Golden Apple Awards, four Dean’s Awards for Excellence in Clinical Teaching, the Christian R. and Mary F. Lindback Foundation Award for Distinguished Teaching at Drexel University, the Laureate Award from the Pennsylvania chapter of the American College of Physicians (ACP), and several awards for teaching excellence from internal medicine residents.

A leader in the development of unique and innovative medical education programs, Dr. Tunkel has authored more than 100 peer-reviewed publications and more than 150 book chapters, including for prominent textbooks in the field. He is often asked by clinicians from around the world for advice on how to manage complex patients with central nervous system infections. A prominent authority in this area, he was the chair of three different panels that developed IDSA practice guidelines for bacterial meningitis, encephalitis, and healthcare-associated ventriculitis and meningitis. Listed as one of the Best Doctors in America, he has served multiple times on the writing committee for ACP’s Medical Knowledge Self-Assessment Program, a highly regarded resource for internal medicine residents preparing for the board certification exam. A sought-after speaker, he has given several invited presentations at national and international conferences.

Dr. Tunkel earned a PhD in experimental pathology followed by a medical degree from the University of Medicine and Dentistry of New Jersey - New Jersey Medical School. He completed his residency and chief residency in internal medicine at the Hospital of the Medical College of Pennsylvania and a fellowship in infectious diseases at the University of Virginia Health Sciences Center. He has served on several IDSA committees, including the Society Awards Committee, the Nominations Committee, and the Education Committee.

Over the last three decades, Dr. Tunkel has contributed greatly to the education and training of medical students, residents, and fellows through his excellent teaching, clinical expertise, effective administrative leadership, and respected scholarship. IDSA is pleased to add the 2018 Clinical Teacher Award to his impressive record of achievements.
IDSA Clinical Teacher Award

Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center

Frank E. Berkowitz, MD, MPH, is one of two recipients of IDSA's 2018 Clinical Teacher Award. This award honors a career dedicated to teaching clinical infectious diseases to fellows, residents, and medical students and recognizes excellence as a clinician and motivation to teach the next generation of physicians.

Dr. Berkowitz has served on the faculty of Emory University School of Medicine, where he is currently a professor of pediatrics, since 1988. Heavily involved in the education of hundreds of pediatricians and specialists during his tenure at Emory, he is widely regarded by students, residents, fellows, and colleagues for his astute clinical reasoning, the clarity of his teaching, and his unparalleled physical exam skills. Over the past three decades, these attributes have enriched pediatric grand rounds, ID educational seminars, pediatric infectious diseases case conferences, inpatient clinical service weeks, pediatric continuity clinics, and countless patient encounters at his institution. With specialty training not only in pediatric infectious diseases but also neurology and ophthalmology, Dr. Berkowitz brings these to bear in his clinical teaching as well.

The recipient of multiple honors for his teaching, Dr. Berkowitz has received the senior pediatric residents' annual teaching award 12 times while at Emory. In 2017, he was recognized as one of 41 top faculty educators from across his institution for Emory’s Educator Appreciation Day. His effective teaching styles range from bedside instruction to didactic lectures, including case studies and images collected from his own vast clinical experience, and even medically relevant poetry. No student leaves his team without having performed a Gram stain, and days on service with him often start in the microbiology lab. A supervisor of ID fellows on service and preceptor for the pediatric residency clinic, he also excels at educating patients and their families, using a series of diagrams he has created to help explain various infections.

Dr. Berkowitz earned his medical degree at the University of the Witwatersrand in Johannesburg, South Africa, followed by additional training in microbiology, neurology, pediatrics, and ophthalmology in South Africa. He completed his pediatric ID fellowship at the University of Colorado Health Sciences Center in Denver and also earned a master of public health degree from Emory. His publications include more than 50 articles, case reports, reviews, and case studies, in addition to two textbooks, Practical Medical Microbiology for Clinicians, which he co-authored, and Case Studies in Pediatric Infectious Diseases, both invaluable resources for clinicians. He has also contributed to the American Academy of Pediatrics’ Red Book.

A master clinical educator and a consummate physician, Dr. Berkowitz has greatly impacted the careers of countless students, residents, and fellows with his passion for teaching. IDSA is pleased to recognize his achievements with the 2018 Clinical Teacher Award.
HONORS, AWARDS, AND GRANTS

IDSA Society Awards (continued)

**IDSA Oswald Avery Award for Early Achievement**

*Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center*

Susanna Naggie, MD, MHS, FIDSA, whose novel research on the treatment of patients co-infected with HIV and hepatitis C virus (HCV) has advanced the field, is the recipient of IDSA's 2018 Oswald Avery Award for Early Achievement. This honor recognizes members of IDSA age 45 or younger who have demonstrated outstanding achievements in an area of infectious diseases.

Currently an associate professor of medicine at Duke University School of Medicine, where she has been a member of the faculty since 2009, Dr. Naggie is medical director of the Department of Medicine's Clinical Research Unit and director of infectious diseases research at the Duke Clinical Research Institute. In addition to her own prolific research, she has served as the primary mentor for many trainees, including interns, residents, fellows, and junior faculty. She has demonstrated a strong interest in developing young trainees to pursue their own careers in research and academics by helping them gain important exposure to clinical trial design, operations, and leadership.

Dr. Naggie has served as a member and co-chair of the IDSA and American Association for the Study of Liver Diseases HCV guidance panel, as a member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and as a member or leader of several other notable national committees and groups. She has also served on the IDSA Clinical Affairs Committee, the IDWeek Program Committee, and the IDSA HCV Maintenance of Certification Development Panel. A graduate of Johns Hopkins University School of Medicine, Dr. Naggie completed her internship, residency, chief residency, and ID fellowship training at Duke, where she also earned a master of health sciences degree in clinical research.

For her important contributions to our understanding of the care of patients living with HIV and HCV, IDSA is proud to honor Dr. Naggie with the 2018 Oswald Avery Award for Early Achievement.

Strongly committed to the care of patients living with HIV and viral hepatitis, Dr. Naggie’s research has been dedicated to understanding the mechanisms of accelerated liver fibrogenesis in this population. Her impressive work has helped define the role of pharmacogenomics and mechanistic studies of HCV treatment response in these patients, including studies of single nucleotide polymorphisms in HCV therapy and associated liver disease. This research identified 16 genes that were expressed at higher levels in the unfavorable CT/TT genotype versus the favorable CC genotypes and biologically implicated innate immunity functions. Her group was the first to report that black patients who carried the favorable CC genotype had more immune dysregulation than non-black patients without the favorable genotype. This research has laid an important foundation for understanding the disparity in HCV treatment response in co-infected African Americans.
IDSA Society Awards (continued)

IDSA Walter E. Stamm Mentor Award

Presented on Saturday, October 6, at 4 p.m. in North Hall D, Moscone Center

Carol A. Kauffman, MD, FIDSA, FSHEA, a dedicated mentor to countless trainees and colleagues during her career, is the recipient of IDSA’s 2018 Walter E. Stamm Mentor Award. Named to honor the memory of a former IDSA president who was renowned for nurturing the careers of others, this award recognizes individuals who have served as exemplary mentors and who have been exceptional in guiding the professional growth of infectious diseases professionals.

Committed to equity and diversity, Dr. Kauffman has been an inspirational role model for trainees through her excellent patient care, inspirational teaching, innovative research, and participatory leadership. Professor of internal medicine at the University of Michigan Medical School since 1981 and chief of the Infectious Diseases Section of the Veterans Affairs Ann Arbor Healthcare System since 1977, she fosters an energetic, productive, close-knit team and has created a culture of support and encouragement that provides trainees with strong and enduring mentorship. A champion of inclusion, she has made mentoring a priority with a commitment to fostering the careers of women and encouraging them to seek and excel in leadership roles.

Bringing out the best in trainees and helping them maximize their potential, Dr. Kauffman maintains lifelong mentoring relationships, celebrating former trainees’ successes, providing support during adversity and disappointments, and serving as a valued sounding board. On a recent birthday, more than 80 of Dr. Kauffman’s former colleagues and trainees travelled to San Diego to show their appreciation for the great impact she has had on their lives and to share stories of her ongoing mentorship throughout their careers, her advice on major career decisions, and her help with difficult cases. Many strive to emulate her mentorship style, seeking to be as kind, open, available, and influential in the lives of their trainees as Dr. Kauffman has been in their own.

An exceptional researcher whose interests include the diagnosis and treatment of fungal infections and infections in immunocompromised patients, Dr. Kauffman has published more than 300 peer-reviewed publications. The recipient of multiple awards for her teaching, including an IDSA Clinical Teacher Award in 2012, she has served on the IDSA Board of Directors, several Society committees and task forces, and multiple IDSA practice guideline panels. She earned her medical degree from the University of Michigan Medical School, completed an internship and residency at University of Michigan Medical Center, and completed fellowship training in infectious diseases at the University of Cincinnati Medical Center.

A tireless leader, physician, teacher, researcher, and role model with an immense capacity to mentor, Dr. Kauffman has had a tremendous and ongoing impact on the lives and careers of her mentees. IDSA is delighted to recognize her with the 2018 Walter E. Stamm Mentor Award.
The Robert C. Moellering Trainee Travel Award supports attendance at IDWeek for fellows-in-training who submit excellent research in the field of antibiotic resistance. Applicants must be IDSA members-in-training for 2018 and have an accepted abstract to IDWeek. Member donations to the IDSA Foundation directly support these awards.

**Award Winners:**
- Thomas McConville, MD, Columbia University Medical Center
- Michael Woodworth, MD, MSc, Emory University School of Medicine
- Teppei Shimasaki, MD, MS, Rush University Medical Center
SHEA Society Awards

SHEA Senior Scholar Award

Presented on Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center

David Jay Weber, MD, MPH, FSHEA, is the recipient of the 2018 SHEA Senior Scholar Award recognizing his work as a senior investigator in infection prevention and healthcare epidemiology over the course of his career. Dr. Weber received his Bachelor of Arts degree from Wesleyan University in 1973, his Medical Degree from the University of California San Diego in 1977, a master of public health degree from Harvard University in 1985, and completed his medicine residency and infectious disease fellowship at the Massachusetts General Hospital in 1985. He is Board Certified in Internal Medicine, Infectious Disease, Critical Care Medicine, and Preventive Medicine.

Dr. Weber has been on the faculty of the University of North Carolina at Chapel Hill since 1985, where he is currently a Professor of Medicine and Pediatrics in the School of Medicine, and a Professor of Epidemiology in the Gillings School of Global Public Health. Dr. Weber serves as an Associate Chief Medical Officer for UNC Hospitals. He also serves as the Medical Director of the Departments of Hospital Epidemiology (Infection Prevention) and Occupational Health for UNC Hospitals.

He is the Medical Director of the North Carolina Statewide Infection Control Program (SPICE), a co-chair of UNC Biomedical IRB, and serves as the UNC Principle Investigator on the CDC sponsored Duke-UNC Epicenter. Dr. Weber is an Associate Editor of Infection Control Hospital Epidemiology, the SHEA liaison to the Advisory Committee on Immunization Practices (ACIP), and is a member of the SHEA Board of Trustees. Dr. Weber has published more than 380 scientific papers in the peer-reviewed literature. His research interests include the epidemiology of healthcare-associated infections, disinfection and sterilization, new and emerging infectious diseases (novel influenza, SARS-coV, MERS-coV, Ebola), response to biothreats, nontuberculous mycobacteria, control of drug resistant pathogens, immunization practices (especially of healthcare personnel), zoonotic diseases, and epidemiology of tuberculosis.

SHEA is pleased to present Dr. Weber with the 2018 SHEA Senior Scholar Award for his ongoing career contributions to healthcare epidemiology and infection prevention.

SHEA Advanced Practice Infection Preventionist Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

Joan Hebden, RN, MS, CIC, is the recipient of the 2018 SHEA Advanced Practice Infection Preventionist Award based on her career achievements in infection prevention. Ms. Hebden received her baccalaureate and master degrees from the University of Maryland School of Nursing. She is currently an independent infection prevention consultant and research coordinator. She served as the Director of Infection Prevention and Control for 28 years at the University of Maryland Medical Center in Baltimore, Maryland. An accomplished practitioner, Ms. Hebden has presented at national epidemiology conferences, participated in research regarding the transmission of multidrug-resistant bacteria, contributed chapters on infection control to nursing resource texts, and published in medical and infection control journals.

She is certified in infection control through the Certification Board of Infection Control and Epidemiology, is an active member of the Society for Healthcare Epidemiologists of America and the Association for Professionals in Infection Control, serves as a section editor and reviewer for the American Journal of Infection Control, and is a fellow of APIC.

For her years of dedication and overall contributions and commitment to excellence, SHEA is pleased to award Joan Hebden the 2018 Advanced Practice Infection Preventionist Award.

continued on next page
SHEA Society Awards (continued)

SHEA Antibiotic Stewardship Scholar Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

SHEA is pleased to award Deverick (“Dev”) J. Anderson, MD, MPH, FIDSA, FSHEA, the 2018 SHEA Antibiotic Stewardship Scholar Award for his contributions as an investigator and practitioner to antibiotic stewardship program and research. Dr. Anderson is an Associate Professor with tenure in the Division of Infectious Diseases and Department of Medicine at Duke University. He is currently Director of the Duke Center for Antimicrobial Stewardship and Infection Prevention.

With training in internal medicine, infectious diseases, and epidemiology, Dr. Anderson assesses medical problems at both the population and individual patient levels. Over the past decade, Dr. Anderson’s work has led to improvements in the quality and safety of care in multiple areas of healthcare, including Duke University Hospital and more than 45 community hospitals in the southeastern U.S. through the Center’s outreach networks, the Duke Infection Control Outreach Network (DICON), and the Duke Antimicrobial Stewardship Outreach Network (DASON).

Dr. Anderson is recognized as an international expert in healthcare epidemiology and multidrug-resistant pathogens. He is currently a Fellow of the Infectious Diseases Society of America (IDSA) and a Fellow of the Society for Healthcare Epidemiology of America (SHEA). He is the Director of the Duke Program for Infection Prevention for the National Football League (NFL). Dr. Anderson has authored over 160 peer-reviewed articles related to quality of care, patient safety, healthcare epidemiology, antimicrobial stewardship, and multidrug-resistant pathogens. Dr. Anderson has received research funding from the NIH, AHRQ, and CDC and is currently the Principal Investigator of the Duke-UNC Prevention Epicenter Program. In addition, he is a member of the Steering Committee for the NIH’s Antibacterial Resistance Leadership Group.

SHEA is pleased to recognize Dr. Anderson for his commitment to Antibiotic Stewardship with the 2018 SHEA Antibiotic Stewardship Scholar Award.

SHEA Mentor Scholar Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

Aaron M. Milstone, MD, MHS, FIDSA, FSHEA, FPIDS, is this year’s recipient for the 2018 SHEA Mentor Scholar Award for his commitment to mentoring fellows and junior faculty. Dr. Milstone is an Associate Professor of Pediatric Infectious Diseases and Epidemiology at Johns Hopkins University. He is Associate Hospital Epidemiologist at Johns Hopkins Hospital and the Pediatric Lead for Infection Prevention for Johns Hopkins Health System. He serves on multiple national committees and writing groups guiding practices to prevent healthcare associated infections (HAIs) and emergence of antibiotic resistance. For more than 10 years, he has been working to advance the science of infection control through studies of the prevalence and transmission of multidrug-resistant organisms (MDRO) and interventions to reduce MDRO spread and prevent healthcare-associated infections.

Dr. Milstone’s research program is funded by NIH, CDC, and AHRQ. Recently, he has expanded his work in these areas to include low and middle-income countries in response to heightened need for and awareness of MRDO and HAI prevention in these locations. As a pediatrician, he advocates for unique approaches to infection prevention in children, to balance infection control and family-centered care. He has been an active member of SHEA advocating to advance science in infection control in a changing healthcare environment.

SHEA is pleased to recognize the achievements of Dr. Milstone with the 2018 SHEA Mentor Scholar Award.
SHEA Mid-Career Scholar Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

Anucha Apisarnthanarak, MD, is this year’s recipient of the 2018 SHEA Mid-Career Scholar Award for his contributions during his career in infection prevention and healthcare epidemiology science and practice. Dr. Apisarnthanarak finished his Infectious Diseases fellowship training from Washington University School of Medicine, under the supervision of Professor Victoria Fraser, MD. He is currently the Professor in Infectious Diseases at Thammasat University Hospital and also serves as Adjunct Visiting Professor at Washington University School of Medicine.

Over the past 15 years, he has been a strong contributor to the knowledge of Infection Prevention in resource-limited settings. He has co-authored over 240 peer-review publications and more than 20 book chapters and become one of the internationally renowned speakers from Asia for infection prevention and healthcare epidemiology. His major contributions include the characterization of human avian influenza (H5N1) including atypical avian influenza (H5N1), the control and prevention of the spread of healthcare associated infections in resource-limited settings, the emergence and control of drug-resistant bacterial and viral infections, outbreaks and hospital preparedness after major Thai 2011 floods, and most recently studies on the epidemiology and practice to prevent nosocomial infections on the national scale. Several of these efforts have contributed to many landmark studies for Asia Pacific and globally.

He was the recipient of the SHEA William Jarvis Award for a 2009 publication in *Infection Control and Hospital Epidemiology* which reported an association between an infection control bundle and reduced transmission of influenza-like illnesses in pre-school children. With continuous contribution in the field, Dr. Apisarnthanarak received the 2015 SHEA International Scholar Award and 2016 Distinguished Thai Academician Award from the Royal College of Physicians of Thailand. Dr. Apisarnthanarak also serves on the editorial board for key infectious diseases and infection control journals including *Clinical Infectious Diseases*, *Infection Control and Hospital Epidemiology*, *Journal of Hospital Infection* and *American Journal of Infection Control*. Recently, Dr. Apisarnthanarak served as a guest editor for *Clinical Infectious Diseases* Supplementary issue in 2017 titled “Advance in Infection Prevention in Asia Pacific,” which represented the top-quality works on infection prevention in Asia Pacific.

SHEA is pleased to present Dr. Apisarnthanarak with this award for his career achievements to date and looks forward to his ongoing contributions to the global field.

SHEA Pediatric Scholar Award

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

Kristina A. Bryant, MD, FPIDS, was selected as the 2018 SHEA Pediatric Scholar Award Recipient recognizing her contributions to the fields of pediatric infection prevention. Dr. Bryant is Professor of Pediatrics at the University of Louisville, Director of the Kosair Charities Fellowship in Pediatric Infectious Diseases, and Hospital Epidemiologist at Norton Children’s Hospital. The majority of her professional activity is devoted to clinical service, education of fellows and residents, and oversight of infection control and hospital epidemiology at Norton Children’s Hospital. Dr. Bryant’s research interests include vaccine clinical trials and prevention of healthcare-acquired infections. She is an active participant in national research collaboratives to study the epidemiology and prevention of HAIs and MDROs in children. Since December 2016, she has served as a member of the Healthcare Infection Control Practices Advisory Committee (HICPAC).

Dr. Bryant has served on the PIDS Training Programs Committee since 2004 (and was chair or co-chair 2008-2017). She also served as the moderator or co-moderator of the annual Pediatric Fellows’ Day Program held during IDWeek from 2008 to 2016. She is the President-elect of PIDS and currently serves as the PIDS liaison to the SHEA Board of Trustees. Actively involved in SHEA since 2000, Dr. Bryant has served as chair of the SHEA Guidelines Committee and SHEA External Affairs Committee, a member of the SHEA Pediatric Leadership Council steering committee, and is the Vice Chair representing SHEA on the IDWeek Planning Committee.

For her contributions to SHEA and pediatrics, we are pleased to present Dr. Bryant with the 2018 SHEA Pediatric Scholar Award.
SHEA Society Awards (continued)

**SHEA Barry Farr Award**

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

The editors of *Infection Control and Hospital Epidemiology* (ICHE) selected the following manuscript to receive the Barry Farr Award for most outstanding domestic clinical study published in ICHE in 2017: “A Multicenter Randomized Trial to Determine the Effect of an Environmental Disinfection Intervention on the Incidence of Healthcare-Associated *Clostridium difficile* Infection.” ICHE (2017), 38(7): 777-783.

The study conducted a 12-month randomized trial in 7 intervention hospitals and 8 control hospitals to compare standard cleaning to enhanced cleaning that included monitoring of environmental services (EVS) personnel performance with feedback to EVS and infection control staff. The study assessed the thoroughness of cleaning based on fluorescent marker removal from high-touch surfaces and the effectiveness of disinfection based on environmental cultures for *C. difficile*. Overall, the intervention resulted in significantly increased fluorescent marker removal in CDI and non-CDI rooms and decreased recovery of *C. difficile* from high-touch surfaces in CDI rooms. An environmental disinfection intervention improved the thoroughness and effectiveness of cleaning but did not reduce the incidence of healthcare-associated CDI. Thus, interventions that focus only on improving cleaning may not be sufficient to control healthcare-associated CDI.

Lead author Amy J. Ray, MD, MPH, has a dual appointment at both the Department of Medicine, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, both in Cleveland, Ohio. Additional authors include Abhishek Deshpande, Dennis Fertelli, Brett M. Sitzlar, Priyaleela Thota, Thriven Sankar, Annette L. Jencson, Jennifer L. Cadnum, Robert A. Salata, Richard R. Watkins, Ajay K. Sethi, Philip C. Carling, Brigid M. Wilson, and Curtis J. Donskey.

**SHEA William Jarvis Award**

Presented on Friday, October 5, at 4:30 p.m. in North Hall D, Moscone Center

The editors of *Infection Control and Hospital Epidemiology* (ICHE) selected the following manuscript to receive the William Jarvis Award for most outstanding international clinical study published in ICHE in 2017: “Reduction of Environmental Contamination With Multidrug-Resistant Bacteria by Copper-Alloy Coating of Surfaces in a Highly Endemic Setting.” ICHE (2017), 38(7): 765-771.

The study looked to evaluate the efficacy of copper-coating in reducing environmental colonization in an intensive-care unit (ICU) with multidrug-resistant-organism (MDRO) endemicity. The results showed that copper coating significantly reduced the percentage of colonized surfaces (55.6% vs 72.5%; P<.0001), the percentage of surfaces colonized by MDR gram-negative bacteria (13.8% vs 22.7%; P=.003) or by enterococci (4% vs 17%; P=.014), the total bioburden (2,858 vs 7,631 cfu/100 cm2; P=.008), and the bioburden of gram-negative isolates, specifically (261 vs 1,266 cfu/100 cm2; P=.049). This effect was more pronounced when the ratio of coated surfaces around the patient was increased (phase 2b). Copper-coated items in an ICU setting with endemic high antimicrobial resistance reduced environmental colonization by MDROs.

The lead author was Maria Souli, MD, PhD, who practices in the 4th Department of Internal Medicine at the National and Kapodistrian University of Athens, School of Medicine, University General Hospital Attikon in Athens, Greece. Other authors were Anastasia Antoniadou, Ioannis Katsarolis, Irini Mavrou, Elisabeth Paramythiotou, Evangelos Papadomichelakis, Maria Drogari-Apiranthitou, Theofano Panagea, Helen Giamarellou, George Petrikos, and Apostolos Armaganidis. SHEA is presenting the authors of this manuscript the 2018 William Jarvis Award based on the strength of the research performed. SHEA and ICHE do not endorse or recommend any commercial organizations, products, processes, or services. The views and opinions expressed in this paper do not necessarily state or reflect those of SHEA and may not be used for advertising or product endorsement purposes.
HIVMA Awards

HIVMA Clinical Educator Award

Presented on Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center

Rajesh T. Gandhi, MD, FIDSA, is a Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital (MGH). Dr. Gandhi is the site leader of the MGH AIDS Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit and chair of the AIDS Clinical Trials Group (ACTG) HIV Reservoirs and Eradication Transformative Science Group. He is also the Director of the Harvard University Center for AIDS Research Clinical Core (CFAR). Dr. Gandhi is the editor of Partners ID Images, an educational infectious diseases website, and organizer of the HIV Online Provider Education (HOPE) program, an internet-based educational conference series for physicians and nurses caring for HIV-infected patients in resource-limited settings. He is also a Deputy Editor of *NEJM Journal Watch Infectious Diseases* and *NEJM Journal Watch HIV/AIDS*. Dr. Gandhi is a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and the International Antiviral Society-USA Panel on Antiretroviral Drugs for Treatment and Prevention of HIV in Adults. Dr. Gandhi graduated from Harvard Medical School, completed his medical residency and chief residency at Brigham and Women’s Hospital, and his infectious diseases fellowship training at Johns Hopkins Hospital.

Lisa B. Hightow-Weidman, MD, MPH, is an Associate Professor of Medicine in the Departments of Infectious Diseases and Health Behavior, University of North Carolina-Chapel Hill. Dr. Hightow-Weidman completed her medical school training at the University of Virginia and became board certified in Internal Medicine in 2001 after completing three years residency training at Stanford University. She completed three years of fellowship training in Infectious Diseases at UNC-Chapel Hill. In 2004, she earned a Master’s in Public Health in Epidemiology from the UNC-Chapel Hill School of Public Health. She has been directly involved with the management of HIV-infected and at-risk adolescents and adults at UNC-Chapel Hill since 2001. Dr. Hightow-Weidman is an expert on mhealth, social media and utilization and evaluation of technology-based interventions to address the HIV Care Continuum for youth and young adults, particularly among young men who have sex with men (YMSM). She has published over 90 peer-reviewed articles on these topics. Her research interests include HIV prevention for YMSM using both the Internet and other mobile technologies, and interventions that incorporate game-based elements and social networking to change behaviors. She has developed technology-based interventions to address uptake and adherence to biomedical HIV prevention and treatment, as well as to increase HIV diagnosis, linkage, and retention in care for YMSM. She is the PI of iTech, The UNC/Emory Center for Innovative Technology Across the Prevention and Care Continuum. This grant, part of the Adolescent Trials Network for HIV Interventions (ATN), seeks to develop a technology center to address the domestic epidemic of HIV among at risk and HIV-infected youth. She has a proven track record of successful funding from the National Institutes of Health, HIV/AIDS Bureau, and the Centers for Disease Control and Prevention.
Amy Baca, MD, earned her medical degree at the University of New Mexico in 2015. She completed her residency in Internal Medicine-Primary Care at Highland Hospital in Oakland, California, in 2018. During residency she had a second continuity clinic in HIV primary care for vulnerable patients living with HIV. Working with a population that was disproportionately affected by complications of HIV/AIDS inspired Dr. Baca to pursue training in HIV primary care under the guidance of mentors committed to working with underserved patients. Her primary clinical training site will be UCSF School of Medicine at San Francisco General Hospital and Susa Coffey, MD, will serve as her mentor.

Growing up in a low-income, single parent home, motivated Dr. Baca to work with underserved patients. During her childhood her uncle was diagnosed with HIV. He was a member of ACT-UP, and she watched the early AIDS epidemic unfold in his living room. Watching her beloved uncle live and ultimately succumb to the disease inspired her to pursue a career in HIV medicine. Witnessing the deleterious effects of stigma and poor access to care inspired her to be a patient advocate, and she was awarded the Woo Award for Patient Advocacy by her residency program.

“I was born and raised in northern New Mexico and my goal is to return home to practice outpatient HIV medicine. Many barriers make HIV care in New Mexico very challenging,” Dr. Baca said. “HIV care is complicated by high rates of IV opiate abuse, poverty, minimal access to PrEP, and a shortage of qualified providers. As a person of Hispanic and Native American descent who grew up in a low-income family, I feel I am in a unique position to relate to this patient population and help overcome these barriers to care.”

Upon completion of her fellowship, Dr. Baca intends to practice outpatient HIV medicine in an underserved community and integrate hepatitis C treatment, addiction medicine, and transgender care into her practice.

Meghan Fibbi, DO, MPH, received her medical degree from the Philadelphia College of Osteopathic Medicine in 2015, and completed her residency in Family Medicine and Community Health at the University of Pennsylvania in 2018. Dr. Fibbi is eager to further her training in HIV care this year through the HIVMA Clinical Fellowship at the University of Pennsylvania Department of Family Medicine and Community Health. Her work will focus on the provision of comprehensive HIV and PrEP services, embedded in the primary care setting, to transgender/gender non-binary individuals and black MSM who have been most affected by the epidemic in Philadelphia.

“Since being identified as a transgender-competent provider in my health system, I have provided care for approximately two dozen transgender patients in my continuity clinic. A significant number of these patients are young adults living with HIV who have transitioned their care from the Children’s Hospital of Philadelphia to my Family Medicine resident clinic,” Dr. Fibbi said. “I believe that the HIVMA fellowship will add another layer of expertise to my training that would allow my clinic to function as a medical home for this population, eliminating the need for multiple sites of care that too often results in care lapses for those already struggling with housing insecurity, poverty, and a mistrust in the medical system.”

After her fellowship, Dr. Fibbi plans to use her skillset to continue to serve medically underserved urban populations including providing HIV primary care and to train Family Medicine residents with the goal of developing a primary care HIV fellowship at the University of Pennsylvania.
PIDS Distinguished Research Award

Presented on Wednesday, October 3, at 3:45 p.m. in North Hall D, Moscone Center

Carol J. Baker, MD, FIDSA, FPIDS, a Professor of Pediatrics at the University of Texas McGovern Medical School, has been selected as the 2018 recipient of the PIDS Distinguished Research Award. This award recognizes the outstanding investigative efforts of a Society member who, throughout his or her career, has made outstanding contributions to research with significant impact on the field of pediatric infectious diseases.

Dr. Baker’s work has focused on all aspects of Group B streptococcal (GBS) infections, from the first description of early- and late-onset sepsis and meningitis in neonates and young infants to the discovery of critical epitopes in the capsular polysaccharides necessary for development of candidate conjugate vaccine candidates. Her policy work in the early 1990s led to the development of the first CDC recommendations for intrapartum chemoprophylaxis to prevent early-onset group B streptococcal disease in neonates, a policy currently preventing more than 80% of infections. Her current research includes efforts to prevent infections in pregnant women and their young infants through maternal immunization.

Among numerous honors, Dr. Baker has received the Mentor Award (2008), Society Citation for outstanding achievements in the field of Infectious Disease (2011) and the Alexander Fleming Award for Lifetime Achievement (2016), each from the Infectious Diseases Society of America, and the Schneerson-Robbins Prize in Vaccinology (2018). Dr. Baker is a past secretary of PIDS, past president of IDSA, and a former chair of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, 2009-2012.

Carol Baker’s contributions to our understanding, management, and prevention of Group B Streptococcal disease are unparalleled and are an inspiration to all our members. PIDS is proud to honor Dr. Baker with the Distinguished Research Award.

PIDS Society Awards

PIDS presents several Society Awards during their business meeting.

Antimicrobial Stewardship Fellowship Award
Maria de Lourdes Eguiguren Jimenez, MD
Sophie Katz, MD
Rebecca G. Same, MD

PIDS-St. Jude Children’s Research Hospital Fellowship Award in Basic and Translational Science
Megan Culler Freeman, MD, PhD

PIDS Fellowship Award
Funded by the PIDS Foundation and the Quidel Corporation
Karen Ocwieja, MD, PhD

Stanley & Susan Plotkin and Sanofi Pasteur Fellowship Award
Jennifer Rathe, MD, PhD

PIDS Distinguished Physician Award, Young Investigator Award and other Society Awards will also be presented during the PIDS Business Meeting.
Abstract Awards

IDWeek Program Committee Choice Awards

This $2,500 award recognizes up to four of the best abstracts overall. IDWeek’s Program Committee selected the following recipients based on outstanding scientific research:

Alejandro Diaz, MD, Nationwide Children’s Hospital, Columbus, OH - Presentation #118: “Nasopharyngeal (NP) Bacterial Detection in Infants with Respiratory Syncytial Virus (RSV) Infection: Impact on Clinical Outcomes” Session 31: Infant Viral Infections, Thursday, October 4, 2018, 8:45 - 10 a.m.

Kevin Kamis, MPH, Denver Public Health, Denver, CO - Presentation #859: “Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-In STD Clinic Appointments is a Safe, Feasible, and Effective Method to Engage Patients at Risk for HIV in PrEP Care” Session 85: Preventing and Identifying New HIV Infections, Thursday, October 4, 2018, 2 - 3:15 p.m.

Jennifer Manne-Goehler, MD, DSc, MSc, Beth Israel Deaconess Medical Center, Boston, MA - Presentation #875: “Sex Differences in Academic Achievement and Faculty Rank in Academic Infectious Diseases” Session 90: Featured Oral Abstract, Thursday, October 4, 2018, 4:05 - 4:20 p.m.

Chanu Rhee, MD, MPH, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA - Presentation #1659: “Variation in Identifying Sepsis and Organ Dysfunction Using Administrative versus Clinical Data and Impact on Hospital Outcome Comparisons” Session 174: SHEA Featured Oral Abstract, Friday, October 5, 2018, 3:55 - 4:10 p.m.

IDWeek Diagnostic Awards

The IDWeek Award for top abstracts submitted in diagnostics is intended to recognize the best abstract in the category of diagnostics. The IDWeek Program Committee selected the recipients based on outstanding scientific research in the field of diagnostics.

Tristan Clark, BM, MRCP, DTM&H, MD, University of Southampton, Southampton, United Kingdom - Presentation #1717: “The impact of routine molecular point-of-care testing for gastrointestinal pathogens in adults hospitalised with suspected gastroenteritis: results of a pragmatic randomised controlled trial (GastroPOC)” Session 199: Clinical Trials that May Change Your Practice, Saturday, October 6, 2018, 8:45 - 10 a.m.

Martin Hoenigl, MD, Medical University of Graz, Graz, Austria - Presentation #2567: “Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients receiving Mold-active Antifungals: Performance of Interleukins 6 and 8, Asp LFD, and Aspergillus PCR in Same Day Blood and Bronchoalveolar Lavage Fluid Samples” Session 271: Novel Diagnostics for Fungi, Parasites, and CNS Infection, Saturday, October 6, 2018, 2 - 3:15 p.m.

Anne Piantadosi, MD, PhD, Massachusetts General Hospital, Boston, MA - Presentation #868: “Prospective pathogen detection in patients with central nervous system inflammation using metagenomic sequencing” Session 86: Pushing the Envelope in CNS Infections, Thursday, October 4, 2018, 2 - 3:15 p.m.
Abstract Awards (continued)

**IDWeek Investigator Awards**

The Investigator Awards are intended to recognize the work of investigators in practice for less than 15 years, whose submitted abstracts are accepted for presentation at IDWeek. The award consists of $1,250, and selection was based on the quality of the scientific merit of the nominee’s accepted abstract. Each IDWeek sponsoring society has chosen one outstanding abstract from a member in their specialty to highlight. Following are the awardees for IDWeek 2018:

**SHEA Awardee:** Robin Jump, MD, PhD, Case Western Reserve University School of Medicine, Cleveland, Ohio – Presentation 857: “A Tele-Antibiotic Stewardship Program Influences Antibiotic Use at 2 Rural Veterans Affairs Medical Centers” Session 84: Antimicrobial Stewardship: Better Prescribing, Better Outcomes, Thursday, October 4, 2018, 2 - 3:15 p.m.

**PIDS Awardee:** Larry Kocielek, MD, MSCI, Northwestern University Feinberg School of Medicine, Chicago, IL - Presentation #976: “Clostridium difficile colonization molecular epidemiology and anti-toxin serological responses in healthy infants: A prospective cohort study” Session 126: Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting, Friday, October 5, 2018, 10:30 - 11:45 a.m.

**HIVMA Awardee:** Sarah M. Labuda, MD, MPH, Tulane University School of Medicine, New Orleans, LA - Presentation #2571: “Higher Rates of Hospitalization and Infection-Related Hospitalization among HIV-Exposed Uninfected Infants Compared to HIV Unexposed Uninfected Infants in the U.S.” Session 272: Pediatric Viral Infections, Saturday, October 6, 2018, 2 - 3:15 p.m.

**IDSA Awardee:** Kyle J Popovich, MD, MS, FIDSA, Rush University Medical Center, Chicago, IL - Presentation #159: “Genomic Epidemiology of MRSA at Intake to a Large Inner-City Jail—Evidence for Community Transmission Networks?” Session 46: Healthcare Epidemiology: Special Populations, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

The Investigator Awards are intended to recognize the work of investigators in practice for less than 15 years, whose submitted abstracts are accepted for presentation at IDWeek. The award consists of $1,250, and selection was based on the quality of the scientific merit of the nominee’s accepted abstract. Each IDWeek sponsoring society has chosen one outstanding abstract from a member in their specialty to highlight. Following are the awardees for IDWeek 2018:

**SHEA Awardee:** Robin Jump, MD, PhD, Case Western Reserve University School of Medicine, Cleveland, Ohio – Presentation 857: “A Tele-Antibiotic Stewardship Program Influences Antibiotic Use at 2 Rural Veterans Affairs Medical Centers” Session 84: Antimicrobial Stewardship: Better Prescribing, Better Outcomes, Thursday, October 4, 2018, 2 - 3:15 p.m.

**PIDS Awardee:** Larry Kocielek, MD, MSCI, Northwestern University Feinberg School of Medicine, Chicago, IL - Presentation #976: “Clostridium difficile colonization molecular epidemiology and anti-toxin serological responses in healthy infants: A prospective cohort study” Session 126: Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting, Friday, October 5, 2018, 10:30 - 11:45 a.m.

**HIVMA Awardee:** Sarah M. Labuda, MD, MPH, Tulane University School of Medicine, New Orleans, LA - Presentation #2571: “Higher Rates of Hospitalization and Infection-Related Hospitalization among HIV-Exposed Uninfected Infants Compared to HIV Unexposed Uninfected Infants in the U.S.” Session 272: Pediatric Viral Infections, Saturday, October 6, 2018, 2 - 3:15 p.m.

**IDSA Awardee:** Kyle J Popovich, MD, MS, FIDSA, Rush University Medical Center, Chicago, IL - Presentation #159: “Genomic Epidemiology of MRSA at Intake to a Large Inner-City Jail—Evidence for Community Transmission Networks?” Session 46: Healthcare Epidemiology: Special Populations, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

*continued on next page*
## IDWeek International Investigator Awards

The IDWeek International Investigator Awards are intended to recognize and support the work of individuals outside the United States and Canada who are either currently in training or who have been in practice for five years or less, and have an abstract accepted for presentation at IDWeek. The grant selection was based on scientific merit of the submitted abstract, and presenting authors receive $1,500. Following are the awardees for IDWeek 2018:

### Carlos Correa-Martinez, MD
Institute of Medical Microbiology, University Hospital Münster, Münster, Germany - Presentation #1987: “Validation of a MALDI-TOF MS-based direct-on-target microdroplet growth assay (DOT-MGA) for rapid detection of extended-spectrum beta-lactamase (ESBL) and AmpC in clinical Enterobacteriaceae isolates” Session 228: Diagnostics: Bacteria and Mycobacteria, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

### Hans De Graaf, BM
University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, NH, United Kingdom - Presentation #167: “A Bordetella perfrussis Human Challenge Model Induces Immunizing Colonization in the Absence of Symptoms” Session 47: Science Relevant to ID, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

### Michal Meir, MD
The Ruth Rappaport Children’s Hospital, Rambam Health Care Campus, Haifa, Israel - Presentation #787: “The addition of avibactam augments the activity of piperacillin against Mycobacterium abscessus in vitro, and is effective in treating M. abscessus infection in a Galleria mellonella in vivo model” Session 70: Tuberculosis and Other Mycobacterial Infections, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

### Divyashree S, MD
MGM New Bombay Hospital, Navi Mumbai, India - Presentation #646: “Therapeutic Immunosuppression to Treat Rabies Encephalitis” Session 86: Pushing the Envelope in CNS Infections, Thursday, October 4, 2018, 2 - 3:15 p.m.

### Okko Savonius, MD
Children’s Hospital, Helsinki University Hospital, and the University of Helsinki, Helsinki, Finland - Presentation #667: “Upregulated Matrix Metalloproteinase-2 Relates to Milder Hearing Impairment in Bacterial Meningitis” Session 86: Pushing the Envelope in CNS Infections, Thursday, October 4, 2018, 2 - 3:15 p.m.

### Robert Van De Peppel, MD
Leiden University Medical Center, Leiden, Netherlands - Presentation #968: “Managing Invasive Aspergillosis in the Era of Diagnostic PCR and Increasing Triazole Resistance: a Modelling Study of Different Strategies.” Session 125: Fungal Infections, Friday, October 5, 2018, 10:30 - 11:45 a.m.

### IDSA Awardee: Lucia Gallo Vaulet, Biochemist/PhD
Universidad de Buenos Aires, INFIBIOC. Instituto de Fisiopatología y Bioquímica Clínica, Buenos Aires, Argentina - Presentation #2056: “Trypanosama cruzi DNA Detection by PCR in Dried Blood Spots Preserved in Filter Paper” Session 231: Diagnostics: Parasitology, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

### PIDS Awardee: Nilson N. Mendes Neto, MD
University of California, Davis, CA - Presentation #693: “Congenital Zika Syndrome: Assessing the Fatality Rate Since the 2015 Zika Outbreak” Session 66: Public Health: Epidemiology and Outbreaks, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

### SHEA Awardee: Olivia Smibert, Bachelor of Medicine, Bachelor of Surgery
Peter MacCallum Cancer Center, Melbourne, Australia - Presentation #1787: “The safety and efficacy of an oral penicillin rechallenge program in cancer patients – A pilot multicentre study” Session 217: Antimicrobial Stewardship: Impact of Allergy, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

### HIVMA Awardee: Melanie Stecher, MSc. Public Health
University Hospital of Cologne, Cologne, Germany - Presentation #1767: “Structured Treatment Interruptions in HIV-infected Patients Receiving Antiretroviral Therapy – Implications for Future HIV Cure Trials: a systematic review and meta-analysis” Session 214: Optimizing HIV Treatment, Saturday, October 6, 2018, 10:30 - 11:45 a.m.
Guerrant International Travel Grants

The Guerrant International Travel Grants are awarded to fund travel to IDWeek from low- and lower-middle income countries (based on the World Bank’s definition). A limited number of grants up to $1,600 are available to participants whose abstracts are accepted. The following are the recipients who have received this award for 2018:

Abera Balcha Bulti, MD, DTM&H, University of Gondar, College of Medicine and Health Sciences, Gondar, Ethiopia - Presentation #1776: “Establishing an Antimicrobial Stewardship Program in a Resource Limited Setting: Experience of an Ethiopian Hospital” Session 216: Antimicrobial Stewardship: Global Perspectives, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Iris Cazali, MD, Hospital Roosevelt, Guatemala, Guatemala - Presentation #2104: “Impact of a supervision and education directed bundle in Ventilator Associated Pneumonia (VAP) on a pediatric critical care unit of a teaching hospital.” Session 234: Healthcare Epidemiology: Device-associated HAIs, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Arwa El Manakhly, PharmD, Dar Al Fouad Hospital, Cairo, Egypt - Presentation #2300: “Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Causing Central Line-Associated Bloodstream Infections (CLABSI) in 3 ICU Units in Egypt” Session 245: Molecular & Sequence Based Diagnostics, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Debdeep Mitra, MD, Dermatology, Army Hospital New Delhi, New Delhi, India - Presentation #811: “A Randomized Controlled Trial of Prednisolone vs Interleukin 17 A Inhibitor Secuinumab in the Management of Type 1 Lepra Reaction in Leprosy Patients” Session 70: Tuberculosis and Other Mycobacterial Infections, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

Husain Poonawala, MBBS, National Institute for Research in Tuberculosis, Chennai, India - Presentation #760: “The Diversity of Mycobacterium tuberculosis in India is Underestimated and Underreported” Session 70: Tuberculosis and Other Mycobacterial Infections, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

Ubald Tamoufe, MPH, MS, Metabiota Cameroon, Yaoundé, Cameroon - Presentation #687: “Modeling the impact of introduction of influenza vaccination on ILI cumulative case count in Cameroon” Session 66: Public Health: Epidemiology and Outbreaks, Thursday, October 4, 2018, 12:30 - 1:45 p.m.

Abstract Awards (continued)
The Kass Awards were established to honor the achievements of Edward H. Kass, a past IDSA president and leader in infectious diseases research. Grants in the amount of $750 are awarded to medical students, residents, or house officers who have demonstrated excellence in research in infectious diseases and allied fields. Following are the recipients of this award for 2018:

Sarah Baker, BSPH, MSc, Tulane University School of Medicine, New Orleans, LA - Presentation #168: “Intradermal immunization drives humoral and cellular immunity to the lung and protects against acute P. aeruginosa pneumonia” Session 47: Science Relevant to ID, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

Shahla Bari, MD, Morehouse School of Medicine, Atlanta, GA - Presentation #2241: “Outcomes of Program cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitor therapy in HIV patients with advanced cancer” Session 240: HIV: Malignancy, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

James Cheaveau, MBBS, MRCP, DTMH, University of Calgary, Calgary, AB, Canada - Presentation #2564: “Clinical validation of a commercial LAMP test for ruling out malaria in returning travelers: A prospective diagnostic trial” Session 271: Novel Diagnostics for Fungi, Parasites, and CNS Infection, Saturday, October 6, 2018, 2 - 3:15 p.m.

Edward Cuaresma, MD, Columbia University Medical Center, New York, NY - Presentation #1772: “Vancomycin-Resistant Enterococcus Alters the Gastrointestinal Microbiome in Critically Ill Patients” Session 215: Translating Microbiome Science into Practice, Saturday, October 6, 2018, 10:30 - 11:45 a.m.


Yosefa Hefter, MD, Westchester Medical Center, Valhalla, NY - Presentation #1760: “Interferon Gamma Release Assay for Diagnosis of Lyme Disease” Session 211: Diagnostics Making a Difference, Saturday, October 6, 2018, 10:30 - 11:45 a.m.

Colm Kerr, MB, BCh, BAO, MRCP, BSc, Microbiology, St. James’ Hospital, Dublin, Ireland - Presentation #1903: “Cost Minimisation Analysis of a Preferred ARV Prescribing Pathway for Treatment-Naïve HIV-Positive Patients” Session 225: Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis, Saturday, October 6, 2018, 12:30 - 1:45 p.m.

Thomas McHale, MD, MSc, University of Nebraska Medical Center, Omaha, NE - Presentation #158: “The Effect of Insurance Coverage on Appropriate Selection of Hospital Discharge Antibiotics for Staphylococcus aureus Bacteremia” Session 45: Cool Findings in Bacteremia and Endocarditis, Thursday, October 4, 2018, 10:30 - 11:45 a.m.

Rebecca Slotkin, MD, Yale University, New Haven, CT - Presentation #2566: “Diagnosis of Pneumocystis jiroveci pneumonia in HIV-negative immunocompromised patients: Is the Gomori-methenamine silver stain of bronchoalveolar lavage fluid the gold standard or sub-standard?” Session 271: Novel Diagnostics for Fungi, Parasites, and CNS Infection, Saturday, October 6, 2018, 2 - 3:15 p.m.
## Abstract Awards (continued)

### IDWeek Trainee Awards

Each IDWeek partnering society has chosen one outstanding abstract from a member in their specialty. These abstracts are recognized as the top submissions from trainees, and the presenting author has received an award in the amount of $1,250. Following are the awardees for IDWeek 2018:

**PIDS Trainee**: Rachel L. Epstein, MD, MA, Boston Medical Center, Boston, MA  
**HIVMA Trainee**: Allison Glaser, MD, Icahn School of Medicine at Mount Sinai Hospital, New York, NY  
**SHEA Trainee**: Michael Yarrington, MD, Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC  
**IDSA Trainee**: Yingda Xie, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

In addition to the above awards to trainees, IDWeek Trainee Awards are awarded to trainees who submitted excellent research. The IDWeek 2018 recipients are listed below:

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmed Babiker, MBBS</td>
<td>University of Pittsburgh Medical Center</td>
</tr>
<tr>
<td>Javier Baez Presser, MD</td>
<td>University of Miami/Jackson Memorial Hospital</td>
</tr>
<tr>
<td>Archana Balamohan, MD, FAAP</td>
<td>Cohen Children’s Medical Center</td>
</tr>
<tr>
<td>Marjorie Batista, MD, PhD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Nika Bejou, PharmD</td>
<td>Yale New Haven Hospital</td>
</tr>
<tr>
<td>Ilan Berlinrut, MD</td>
<td>Northwell Health, North Shore University Hospital</td>
</tr>
<tr>
<td>Mahesh Bhatt, MBBS</td>
<td>University of Kentucky</td>
</tr>
<tr>
<td>Mark Biagi, PharmD</td>
<td>University of Illinois at Chicago, College of Pharmacy</td>
</tr>
<tr>
<td>Paul Blair, MD, MSPH</td>
<td>Johns Hopkins University School of Medicine</td>
</tr>
<tr>
<td>Ana C. Blanchard, MDCM, FRCP</td>
<td>The Hospital for Sick Children</td>
</tr>
<tr>
<td>Jessica Boettcher, DO</td>
<td>University of Minnesota</td>
</tr>
<tr>
<td>Juri Boguniewicz, MD</td>
<td>Baylor College of Medicine and Texas Children’s Hospital</td>
</tr>
<tr>
<td>Brian Bohn, PharmD</td>
<td>Cleveland Clinic</td>
</tr>
<tr>
<td>Tyler D. Bold, MD, PhD</td>
<td>Brigham and Women’s Hospital/ Harvard School of Public Health</td>
</tr>
<tr>
<td>Jeannette Bouchard, PharmD</td>
<td>UPMC Presbyterian Shadyside</td>
</tr>
<tr>
<td>Rachel S. Britt, PharmD</td>
<td>Beth Israel Deaconess Medical Center</td>
</tr>
<tr>
<td>Robert Brunner, DO</td>
<td>Allegheny Health Network</td>
</tr>
<tr>
<td>Gregory Buchek, MD</td>
<td>Brooke Army Medical Center</td>
</tr>
<tr>
<td>Maria X Bueno Rios, MD</td>
<td>Cleveland Clinic</td>
</tr>
<tr>
<td>Juan Calix, MD, PhD</td>
<td>Washington University School of Medicine</td>
</tr>
<tr>
<td>Chase Cannon, MD</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Travis Carlson, PharmD</td>
<td>CHI St. Luke’s Health - Baylor St. Luke’s Medical Center</td>
</tr>
<tr>
<td>Amanda Casto, MD, PhD</td>
<td>Department of Medicine, University of Washington</td>
</tr>
<tr>
<td>Gaud Catho, MD</td>
<td>CHU Sainte-Justine, Université de Montréal</td>
</tr>
<tr>
<td>Kieran Chacko, BA, BS</td>
<td>Icahn School of Medicine at Mount Sinai</td>
</tr>
</tbody>
</table>

*continued on next page*
**IDWeek Trainee Awards (continued)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zohra Chaudhry, MD</td>
<td>Henry Ford Hospital</td>
</tr>
<tr>
<td>Matthew P. Cheng, MD</td>
<td>Brigham and Women's Hospital</td>
</tr>
<tr>
<td>Nicholas Cheronis, MD, MPH</td>
<td>Allegheny Health Network</td>
</tr>
<tr>
<td>Edna Cheung, PharmD</td>
<td>Michigan Medicine</td>
</tr>
<tr>
<td>Justine Choe, PharmD</td>
<td>University of Chicago Medicine</td>
</tr>
<tr>
<td>Emily Ciccone, MD, MHS</td>
<td>University of North Carolina</td>
</tr>
<tr>
<td>Erik Clarke, PhD</td>
<td>University of Pennsylvania School of Medicine</td>
</tr>
<tr>
<td>Meredith Clement, MD</td>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td>Jennifer P. Collins, MD, MSc</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Allison Cormier, MD</td>
<td>University of Wisconsin School of Medicine and Public Health</td>
</tr>
<tr>
<td>Gabriela Corsi, MD</td>
<td>University of Texas</td>
</tr>
<tr>
<td>Ryan L. Crass, PharmD</td>
<td>University of Michigan</td>
</tr>
<tr>
<td>Caroline Cruce, PharmD</td>
<td>Midwestern University Chicago College of Pharmacy</td>
</tr>
<tr>
<td>Jaclyn Cusumano, PharmD</td>
<td>University of Rhode Island</td>
</tr>
<tr>
<td>Laura N. Cwengros, PharmD</td>
<td>Detroit Medical Center</td>
</tr>
<tr>
<td>Adam Dale, MBChB, BSc, MRCP, FRCPath</td>
<td>University of Southampton</td>
</tr>
<tr>
<td>Dima Dandachi, MD</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Shom Dasgupta-Tsinikas, MD</td>
<td>Harbor-UCLA Medical Center</td>
</tr>
<tr>
<td>Rupak Datta, MD, PhD</td>
<td>Yale School of Medicine</td>
</tr>
<tr>
<td>David De Gijsel, MD, MSc</td>
<td>Dartmouth-Hitchcock Medical Center</td>
</tr>
<tr>
<td>Coralee Del Valle Mojica, MD, MPH</td>
<td>Stanford University</td>
</tr>
<tr>
<td>Martha DesBiens, MD</td>
<td>Dartmouth Hitchcock Medical Center</td>
</tr>
<tr>
<td>Emma Dishner, MD, MPH</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>David Dobrzynski, MD</td>
<td>Vanderbilt University Medical Center</td>
</tr>
<tr>
<td>Megan Donahue, MD</td>
<td>Walter Reed National Military Medical Center</td>
</tr>
<tr>
<td>Khalid M. Dousa, MD, FACP, CABIM</td>
<td>University Hospitals, Case Western Reserve University</td>
</tr>
<tr>
<td>Joshua Doyle, MD, PhD</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Kevin Dufour, MD</td>
<td>Université de Sherbrooke</td>
</tr>
<tr>
<td>Leona Ebara, MD</td>
<td>University of Chicago Medicine</td>
</tr>
<tr>
<td>Michael Edzards, MD</td>
<td>Children's National Medical Center</td>
</tr>
<tr>
<td>Lynn El Haddad, PhD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Abdulrahman Elabor, MD</td>
<td>Temple University Hospital</td>
</tr>
<tr>
<td>Zerelda Esquer Garrigos, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Evan Ewers, MD</td>
<td>Walter Reed National Military Medical Center</td>
</tr>
<tr>
<td>Farhan Fazal, MBBS, MD</td>
<td>All India Institute of Medical Science (AIIMS)</td>
</tr>
<tr>
<td>Priyanka Fernandes, MBBS, MPH</td>
<td>University of California Los Angeles</td>
</tr>
<tr>
<td>Madiha Fida, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Sean Fitzwater, MD, MHS</td>
<td>University of California, Los Angeles</td>
</tr>
<tr>
<td>Molly Fleece, MD</td>
<td>University of Virginia</td>
</tr>
<tr>
<td>Kap Sum Foong, MD</td>
<td>Washington University in St. Louis</td>
</tr>
<tr>
<td>Catherine Foster, MD</td>
<td>Baylor College of Medicine and Texas Children's Hospital</td>
</tr>
<tr>
<td>Dustin Freshwater, PharmD</td>
<td>Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Northeast Ohio VA Healthcare System (NOVAHS)</td>
</tr>
<tr>
<td>Gennifer Garmon, MD</td>
<td>Baylor Scott &amp; White Memorial Hospital</td>
</tr>
<tr>
<td>Benjamin Gern, MD</td>
<td>Center for Infectious Disease Research</td>
</tr>
<tr>
<td>Jean Gibb, MD</td>
<td>University of California, Los Angeles</td>
</tr>
<tr>
<td>Christian Gill, PharmD</td>
<td>Henry Ford Hospital</td>
</tr>
<tr>
<td>Philip Goldstein, MD</td>
<td>The Ohio State University Wexner Medical Center</td>
</tr>
<tr>
<td>Robert Goldstein, MD, PhD</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>David Goodman-Meza, MD, MAS</td>
<td>University of California, Los Angeles</td>
</tr>
<tr>
<td>Ronnie Matthew Gravett, MD</td>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>Megan Gray, MD</td>
<td>University of Virginia</td>
</tr>
<tr>
<td>Hind Hadid, MD</td>
<td>Henry Ford Health System</td>
</tr>
<tr>
<td>Manuela Haiduc, PharmD</td>
<td>Allegheny Health Network</td>
</tr>
<tr>
<td>Zeina Hajar, MD</td>
<td>Case Western Reserve University - University Hospitals Cleveland Medical Center</td>
</tr>
<tr>
<td>Ahmed Hamdi, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Richard Hankins, MD</td>
<td>University of Nebraska Medical Center</td>
</tr>
<tr>
<td>Edwin Hayes, MD</td>
<td>University of South Carolina</td>
</tr>
<tr>
<td>Justin F Hayes, MD</td>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>Shaina Hecht, MD</td>
<td>The Ohio State University and Nationwide Children's Hospital</td>
</tr>
<tr>
<td>Todd E. Hershberger, PharmD</td>
<td>Michigan Medicine</td>
</tr>
<tr>
<td>Matthew Hevey, MD</td>
<td>Washington University in St. Louis</td>
</tr>
<tr>
<td>Matthew Hitchcock, MD, MPH</td>
<td>Stanford University School of Medicine</td>
</tr>
<tr>
<td>Name</td>
<td>Institution/Location</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>Hayley Hodgson, PharmD</td>
<td>Midwestern University, Chicago College of Pharmacy</td>
</tr>
<tr>
<td>Catherine Hogan, MD, MSc</td>
<td>Stanford University School of Medicine</td>
</tr>
<tr>
<td>Babak Hooshmand, MD</td>
<td>Saint John Hospital and Medical Center, Ascension</td>
</tr>
<tr>
<td>Courtney Horvat, PharmD</td>
<td>Aurora Health Care</td>
</tr>
<tr>
<td>Jeff Hosry, MD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Joel Howard, MD</td>
<td>University of Utah</td>
</tr>
<tr>
<td>Michelle M. Hughes, PhD, MHS</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Ashley Husebye, MD</td>
<td>University of Minnesota</td>
</tr>
<tr>
<td>Claudia Ihm, MD</td>
<td>University of Utah</td>
</tr>
<tr>
<td>Hannah Imlay, MD</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Marinela Ingilizova, MD</td>
<td>Drexel University College of Medicine</td>
</tr>
<tr>
<td>Sisham Ingnam, MD</td>
<td>The Ohio State University Wexner Medical Center</td>
</tr>
<tr>
<td>Ra’Ed Jabr, MBChB</td>
<td>University of Kansas Medical Center</td>
</tr>
<tr>
<td>Paul Jacob, MD, MPH</td>
<td>Vanderbilt University</td>
</tr>
<tr>
<td>Niyati Jakharia, MD</td>
<td>University of Maryland Medical Center</td>
</tr>
<tr>
<td>Deeksha Jandhyala, MD</td>
<td>Mayo Clinic, Department of Infectious Diseases</td>
</tr>
<tr>
<td>Nathan Jansen, DO</td>
<td>San Antonio Military Medical Center</td>
</tr>
<tr>
<td>Tenny Mathew John, MD</td>
<td>Cleveland Clinic</td>
</tr>
<tr>
<td>Milissa Jones, MD</td>
<td>Walter Reed National Military Medical Center</td>
</tr>
<tr>
<td>Su Jin Joo, MD</td>
<td>Emory University School of Medicine</td>
</tr>
<tr>
<td>Sarah Jorgensen, PharmD, BCPS, AAHIVP</td>
<td>Wayne State University, Eugene Applebaum College of Pharmacy &amp; Health Sciences</td>
</tr>
<tr>
<td>Christopher Kandel, MD</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Anubhav Kanwar, MD</td>
<td>Louis Stokes Cleveland VA Medical Center</td>
</tr>
<tr>
<td>Olga Kaplun, MD</td>
<td>Stony Brook University Hospital</td>
</tr>
<tr>
<td>Anthony Karabanow, MD</td>
<td>Tufts Medical Center</td>
</tr>
<tr>
<td>Manjiree Karandikar, MD, MBS</td>
<td>Boston Children’s Hospital</td>
</tr>
<tr>
<td>Aspasia Katragkou, MD, PhD</td>
<td>Nationwide Children’s Hospital</td>
</tr>
<tr>
<td>Sophie Katz, MD</td>
<td>Vanderbilt University Medical Center</td>
</tr>
<tr>
<td>Razieh Kebrinaei, PhD</td>
<td>Wayne State University</td>
</tr>
<tr>
<td>Fareed Khawaja, MD</td>
<td>The University of Texas Health Science Center at Houston</td>
</tr>
<tr>
<td>Lilian Kibathi, PharmD</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>James M. Kidd, PharmD, BCPS</td>
<td>Hartford Hospital</td>
</tr>
<tr>
<td>John Kiley, MD</td>
<td>San Antonio Military Medical Center</td>
</tr>
<tr>
<td>Maiko Kondo, MD</td>
<td>New York-Presbyterian Weill Cornell Medical Center</td>
</tr>
<tr>
<td>Angelica Kottkamp, MD</td>
<td>New York University School of Medicine</td>
</tr>
<tr>
<td>Natan Kraitman, MD</td>
<td>University of South Florida</td>
</tr>
<tr>
<td>Brandon Kulengowski, PharmD, MS</td>
<td>University of Kentucky, College of Pharmacy</td>
</tr>
<tr>
<td>Prathit Kulkarni, MD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Bakri Kulla, MD</td>
<td>Eastern Virginia Medical School</td>
</tr>
<tr>
<td>Madan Kumar, DO</td>
<td>Childrens National Medical Center</td>
</tr>
<tr>
<td>Kevin Kurikose, MD</td>
<td>Vanderbilt University Medical Center</td>
</tr>
<tr>
<td>Kathryn Lago, DO</td>
<td>San Antonio Military Medical Center</td>
</tr>
<tr>
<td>John Lam, MD, University of Calgary</td>
<td></td>
</tr>
<tr>
<td>Tyler Lambing, MD</td>
<td>University of Maryland</td>
</tr>
<tr>
<td>Mariana Lanata Piazzon, MD</td>
<td>Nationwide Children’s Hospital</td>
</tr>
<tr>
<td>Derek Larson, DO</td>
<td>Naval Medical Center San Diego</td>
</tr>
<tr>
<td>Laurel Legenza, PharmD, MS</td>
<td>University of Wisconsin School of Pharmacy</td>
</tr>
<tr>
<td>Bethany Lehman, DO</td>
<td>Cleveland Clinic</td>
</tr>
<tr>
<td>Arnaud G L’Huillier, MD</td>
<td>University Health Network</td>
</tr>
<tr>
<td>Jiajun Liu, PharmD</td>
<td>Midwestern University/Northwestern Memorial Hospital</td>
</tr>
<tr>
<td>Santiago Lopez, MD</td>
<td>Children’s Hospital of Pittsburgh of UPMC</td>
</tr>
<tr>
<td>Jessica Lum, MD</td>
<td>University of Colorado Hospital</td>
</tr>
<tr>
<td>Megan Luther, PharmD</td>
<td>University of Rhode Island</td>
</tr>
<tr>
<td>Derek MacFadden, MD</td>
<td>University of Toronto</td>
</tr>
<tr>
<td>Gregory Madden, MD</td>
<td>University of Virginia</td>
</tr>
<tr>
<td>Theresa Madigan, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Stacey A. Maskarinec, MD, PhD</td>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td>Michelle Matheu, MD</td>
<td>University of Texas Health at San Antonio</td>
</tr>
<tr>
<td>Susannah McKay, PhD, MPH</td>
<td>Center for Surveillance, Epidemiology and Laboratory Services, Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Megan McKenna, MD</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Nathan McLeod, MD</td>
<td>West Virginia University School of Medicine</td>
</tr>
</tbody>
</table>

continued on next page
### IDWeek Trainee Awards (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tristan McPherson, MD</td>
<td>Columbia University Medical Center</td>
</tr>
<tr>
<td>Sonia Mehr, MD</td>
<td>University of Utah School of Medicine</td>
</tr>
<tr>
<td>Carlos Mejia, MD</td>
<td>Washington University School of Medicine</td>
</tr>
<tr>
<td>Nicholas J Mercuro, PharmD</td>
<td>Wayne State University</td>
</tr>
<tr>
<td>Jaime Eduardo Mogollon, MD</td>
<td>Montefiore Medical Center/Albert Einstein College of Medicine</td>
</tr>
<tr>
<td>Elizabeth A Moulton, MD</td>
<td>Boston Children’s Hospital</td>
</tr>
<tr>
<td>Mark Murphy, DO</td>
<td>Cincinnati Children’s Hospital Medical Center</td>
</tr>
<tr>
<td>Maria Nagori, MD</td>
<td>Cooper University Hospital</td>
</tr>
<tr>
<td>Julie Nahar, MD</td>
<td>University of Missouri Kansas City School of Medicine</td>
</tr>
<tr>
<td>Nancy Nashid, MD</td>
<td>FRCP, FAAP, The Hospital for Sick Children</td>
</tr>
<tr>
<td>Margaret E. Newman, MD</td>
<td>The University of Chicago School of Medicine</td>
</tr>
<tr>
<td>Jennifer O. Spicer, MD</td>
<td>Emory University School of Medicine</td>
</tr>
<tr>
<td>Brigid O’Brien, DO, MS</td>
<td>Tulane University</td>
</tr>
<tr>
<td>Chikara Ogimi, MD</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Jane O’Halloran, MD, PhD</td>
<td>Washington University School of Medicine, Division of Infectious Diseases</td>
</tr>
<tr>
<td>Ana Paim, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Ann Palmer, MD</td>
<td>University of Connecticut</td>
</tr>
<tr>
<td>Leo Parsons, DO</td>
<td>Detroit Medical Center</td>
</tr>
<tr>
<td>Ami Patel, MD, MPH</td>
<td>New York University School of Medicine/NYU Langone Health</td>
</tr>
<tr>
<td>Corey Peak, ScD, MS</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Dana Pepe, MD, MPH</td>
<td>Yale School of Medicine</td>
</tr>
<tr>
<td>Nitipong Permpalung, MD, MPH</td>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td>Whitney Perry, MD</td>
<td>Tufts Medical Center</td>
</tr>
<tr>
<td>Robert Pitts, MD</td>
<td>New York University</td>
</tr>
<tr>
<td>Heather Pomerantz, MD</td>
<td>San Antonio Military Medical Center</td>
</tr>
<tr>
<td>Haley Pritchard, MD</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Varvara Probst, MD</td>
<td>Vanderbilt University Medical Center</td>
</tr>
<tr>
<td>Laura Quilter, MD, MPH</td>
<td>Centers for Disease Control and Prevention, Division of STD Prevention</td>
</tr>
<tr>
<td>Mohammad Ali Rai, MD, PhD</td>
<td>University of Cincinnati Medical Center</td>
</tr>
<tr>
<td>Mohammed Raja, MD</td>
<td>University of Miami/Jackson Memorial Hospital</td>
</tr>
<tr>
<td>Talha Riaz, MD</td>
<td>Medical University of South Carolina</td>
</tr>
<tr>
<td>Katherine Richardson, MD</td>
<td>Children’s Mercy Hospital</td>
</tr>
<tr>
<td>Steven Richardson, PharmD</td>
<td>Cleveland Clinic</td>
</tr>
<tr>
<td>Alaina Ritter, MD</td>
<td>Massachusetts General Hospital</td>
</tr>
<tr>
<td>Makeda L. Robinson, MD</td>
<td>Stanford University</td>
</tr>
<tr>
<td>Ralph Rogers, MD</td>
<td>Warren Alpert Medical School of Brown University</td>
</tr>
<tr>
<td>Frances Saccoccio, MD, PhD</td>
<td>Duke University Hospital</td>
</tr>
<tr>
<td>Najmus Sahar, MBBS</td>
<td>Wright State University Boonsight School of Medicine</td>
</tr>
<tr>
<td>Aki Sakurai, MD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Mohammed Samannodi, MD</td>
<td>University of Texas Health Science Center at Houston, McGovern Medical School</td>
</tr>
<tr>
<td>Mindy Sampson, DO</td>
<td>University of South Florida</td>
</tr>
<tr>
<td>Terrel Sanders, MD</td>
<td>Naval Medical Center San Diego</td>
</tr>
<tr>
<td>Avnish Sandhu, DO</td>
<td>Wayne State University</td>
</tr>
<tr>
<td>Sarah Sansom, DO</td>
<td>Rush University Medical Center</td>
</tr>
<tr>
<td>Felicia Scaggs Huang, MD</td>
<td>Cincinnati Children’s Hospital Medical Center</td>
</tr>
<tr>
<td>Asher Schranz, MD</td>
<td>University of North Carolina</td>
</tr>
<tr>
<td>Jessica Seidelman, MD</td>
<td>Duke Center for Antimicrobial Stewardship and Infection Prevention</td>
</tr>
<tr>
<td>David P. Serota, MD</td>
<td>Emory University School of Medicine</td>
</tr>
<tr>
<td>Aditya Shah, MBBS</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Jacqueline Sherbuk, MD</td>
<td>University of Virginia</td>
</tr>
<tr>
<td>Hannah Shull, MD</td>
<td>David Geffen School of Medicine/University of California, Los Angeles</td>
</tr>
<tr>
<td>Anna Sick-Samuels, MD, MPH</td>
<td>Johns Hopkins University School of Medicine</td>
</tr>
<tr>
<td>Erik Skoglund, PharmD</td>
<td>University of Houston College of Pharmacy</td>
</tr>
<tr>
<td>Jessica Smith, PharmD</td>
<td>Wake Forest Baptist Health</td>
</tr>
<tr>
<td>Matthew A. Spinelli, MD</td>
<td>University of California, San Francisco</td>
</tr>
<tr>
<td>Erica Stohs, MD, MPH</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Nathan Summers, MD</td>
<td>Emory University School of Medicine</td>
</tr>
<tr>
<td>Zarchi Sumon, MD</td>
<td>University of Buffalo</td>
</tr>
<tr>
<td>Hiroyuki Suzuki, MD</td>
<td>University of Iowa Carver College of Medicine</td>
</tr>
</tbody>
</table>
### IDWeek Trainee Awards (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sadia Syed, MBBS</td>
<td>Mayo Clinic Rochester</td>
</tr>
<tr>
<td>Eugene M. Tan, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Beth Thielen, MD, PhD</td>
<td>University of Minnesota</td>
</tr>
<tr>
<td>Melissa Tiyouh, MD</td>
<td>Drexel University College of Medicine</td>
</tr>
<tr>
<td>Mitsuru Toda, PhD</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>Maria-Stephanie Tolg, PharmD</td>
<td>Providence Veterans Affairs Medical Center</td>
</tr>
<tr>
<td>Nicholas Turner, MD</td>
<td>Duke University Medical Center</td>
</tr>
<tr>
<td>Erlinda Rose Ulloa, MD, MSc</td>
<td>The Children's Hospital of Philadelphia</td>
</tr>
<tr>
<td>Robert Ulrich, MD</td>
<td>New York University School of Medicine</td>
</tr>
<tr>
<td>Amit Vahia, MD, MPH</td>
<td>Henry Ford Health System</td>
</tr>
<tr>
<td>Jose Carlo Valencia, MD</td>
<td>Division of Infectious Diseases, Mayo Clinic</td>
</tr>
<tr>
<td>Neethi Venkatappa, MD</td>
<td>Beaumont Hospital Royal Oak</td>
</tr>
<tr>
<td>Prakhar Vijayvargiya, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Elizabeth Wang, MD</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Rachel Weihe, MD</td>
<td>University of Kansas Medical Center</td>
</tr>
<tr>
<td>Wesley Willeford, MD</td>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>William R. Wilson, PharmD</td>
<td>University of Pittsburgh Medical Center</td>
</tr>
<tr>
<td>Rita Wilson Dib, MD</td>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Daniel Winetsky, MD, MS</td>
<td>Columbia University Medical Center</td>
</tr>
<tr>
<td>Rebeca Witherell, MD</td>
<td>Saint John Hospital and Medical Center; Ascension</td>
</tr>
<tr>
<td>Jacqueline Wong, MD, FRCPC, FAAP</td>
<td>The Hospital for Sick Children</td>
</tr>
<tr>
<td>Adrienne Workman, MD</td>
<td>University of Texas Southwestern</td>
</tr>
<tr>
<td>Joseph Yabes, MD</td>
<td>San Antonio Military Medical Center</td>
</tr>
<tr>
<td>Sanjay Yadava, MD</td>
<td>SUNY Upstate Medical Center</td>
</tr>
<tr>
<td>Masaki Yamada, MD</td>
<td>Children's Hospital of Pittsburgh of UPMC</td>
</tr>
<tr>
<td>Mohamad Yasmin, MD</td>
<td>Case Western Reserve University</td>
</tr>
<tr>
<td>Alexandra Yonts, MD</td>
<td>Children's National Medical Center</td>
</tr>
<tr>
<td>HoJoon You, MD</td>
<td>Albert Einstein Medical Center</td>
</tr>
<tr>
<td>Nabil Zeineddine, MD</td>
<td>Drexel University College of Medicine</td>
</tr>
<tr>
<td>Yanping Zhao, PhD</td>
<td>The University of Hong Kong</td>
</tr>
<tr>
<td>Shiwei Zhou, MD</td>
<td>University of Michigan</td>
</tr>
<tr>
<td>Matthew Ziegler, MD</td>
<td>Perelman School of Medicine, University of Pennsylvania</td>
</tr>
<tr>
<td>Jason Zucker, MD</td>
<td>Columbia University Medical Center</td>
</tr>
<tr>
<td>Attended</td>
<td>Session #</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td></td>
<td>PW01</td>
</tr>
<tr>
<td></td>
<td>PW02</td>
</tr>
<tr>
<td></td>
<td>PW03</td>
</tr>
<tr>
<td></td>
<td>PW06</td>
</tr>
<tr>
<td></td>
<td>PW07</td>
</tr>
<tr>
<td></td>
<td>PW08</td>
</tr>
<tr>
<td></td>
<td>PW09</td>
</tr>
<tr>
<td></td>
<td>PW10</td>
</tr>
<tr>
<td></td>
<td>PW11</td>
</tr>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>22</td>
</tr>
<tr>
<td>Attended</td>
<td>Session #</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
</tr>
<tr>
<td>✓</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>31</td>
</tr>
<tr>
<td></td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>45</td>
</tr>
<tr>
<td></td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>47</td>
</tr>
<tr>
<td></td>
<td>48</td>
</tr>
<tr>
<td></td>
<td>49</td>
</tr>
<tr>
<td></td>
<td>50</td>
</tr>
<tr>
<td></td>
<td>51</td>
</tr>
<tr>
<td></td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>54</td>
</tr>
<tr>
<td></td>
<td>55</td>
</tr>
</tbody>
</table>
CME/CPE/MOC Credit Tracker (continued)

<table>
<thead>
<tr>
<th>Attended</th>
<th>Session #</th>
<th>Session Title</th>
<th>CME/MOC Credits</th>
<th>Universal Program Number (for CPE credit)</th>
</tr>
</thead>
<tbody>
<tr>
<td>99</td>
<td></td>
<td>Microbiome Therapeutics</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-217-L01-P</td>
</tr>
<tr>
<td>100</td>
<td></td>
<td>Mid-Career Challenges and Opportunities</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-311-L04-P</td>
</tr>
<tr>
<td>101</td>
<td></td>
<td>Tropical Dermatology: Are You Ready for Jeopardy?</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-218-L01-P</td>
</tr>
<tr>
<td>102</td>
<td></td>
<td>Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems</td>
<td>Maximum of 1 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-219-L04-P</td>
</tr>
<tr>
<td>103</td>
<td></td>
<td>&quot;Achy Breaky Heart&quot;: Challenging Cases in Cardiovascular Infections</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-220-L01-P</td>
</tr>
<tr>
<td>104</td>
<td></td>
<td>A Day with the Hospital Epidemiologist’s Beeper: Challenging Cases in Infection Prevention</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-221-L01-P</td>
</tr>
<tr>
<td>105</td>
<td></td>
<td>Advances in RSV Prevention</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-222-L01-P</td>
</tr>
<tr>
<td>106</td>
<td></td>
<td>Fungal MDR Outbreak: Candida auris</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-223-L02-P</td>
</tr>
<tr>
<td>107</td>
<td></td>
<td>HIV State of the Art</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-224-L04-P</td>
</tr>
<tr>
<td>108</td>
<td></td>
<td>Metagenomic-Based Infectious Disease Diagnostics</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-312-L01-P</td>
</tr>
<tr>
<td>109</td>
<td></td>
<td>Pandemic Influenza</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-225-L04-P</td>
</tr>
<tr>
<td>110</td>
<td></td>
<td>Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-226-L04-P</td>
</tr>
<tr>
<td>111</td>
<td></td>
<td>Stewardship in Challenging Populations</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-227-L01-P</td>
</tr>
<tr>
<td>112</td>
<td></td>
<td>Challenging Cases in Infectious Diseases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-228-L04-P</td>
</tr>
<tr>
<td>113</td>
<td></td>
<td>Big Beasts I</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-229-L01-P</td>
</tr>
<tr>
<td>114</td>
<td></td>
<td>How to Treat Resistant Gram-Positive Infections</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-230-L01-P</td>
</tr>
<tr>
<td>115</td>
<td></td>
<td>Infection Control and Antimicrobial Stewardship in Dialysis Facilities</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-231-L04-P</td>
</tr>
<tr>
<td>116</td>
<td></td>
<td>Late Breaker Foodborne Illnesses</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-232-L01-P</td>
</tr>
<tr>
<td>117</td>
<td></td>
<td>Pathogen Interactions with the Microbiota</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-233-L02-P</td>
</tr>
<tr>
<td>118</td>
<td></td>
<td>Strategies to Achieve HIV Remission</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-234-L04-P</td>
</tr>
<tr>
<td>119</td>
<td></td>
<td>Time 101: Optimizing Meetings</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-235-L01-P</td>
</tr>
<tr>
<td>120</td>
<td></td>
<td>Caroline B. Hall Lectureship</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-236-L01-P</td>
</tr>
<tr>
<td>122</td>
<td></td>
<td>Challenging HIV Cases</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-238-L01-P</td>
</tr>
<tr>
<td>123</td>
<td></td>
<td>Beyond the Big Beasts of Healthcare Epidemiology</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-239-L04-P</td>
</tr>
<tr>
<td>124</td>
<td></td>
<td>Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuirinng Challenges</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-240-L01-P</td>
</tr>
<tr>
<td>125</td>
<td></td>
<td>Leading Change</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-241-L04-P</td>
</tr>
<tr>
<td>126</td>
<td></td>
<td>Pediatric Immunization: Perspectives From Both Sides of the Pond</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-242-L01-P</td>
</tr>
<tr>
<td>127</td>
<td></td>
<td>T-Cell Biology: What the ID Physician Needs to Know</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-243-L01-P</td>
</tr>
<tr>
<td>128</td>
<td></td>
<td>The ID Specialist and the Opioid Epidemic: What You Need to Know Now</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-244-L01-P</td>
</tr>
<tr>
<td>129</td>
<td></td>
<td>Vaccines Against Herpesviruses</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-245-L01-P</td>
</tr>
<tr>
<td>130</td>
<td></td>
<td>Diagnostic Updates: Clinical Mycology Update</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-246-L01-P</td>
</tr>
<tr>
<td>131</td>
<td></td>
<td>ID Physicians in the Age of Value-Based Healthcare</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-247-L01-P</td>
</tr>
<tr>
<td>132</td>
<td></td>
<td>My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits</td>
<td>0221-9999-18-248-L01-P</td>
</tr>
</tbody>
</table>

Only sessions with this symbol are available for ABP MOC Points.
<table>
<thead>
<tr>
<th>Attended</th>
<th>Session #</th>
<th>Session Title</th>
<th>CME/MOC Credits</th>
<th>Universal Program Number (for CPE Credit)</th>
</tr>
</thead>
<tbody>
<tr>
<td>✔️ 173</td>
<td></td>
<td>SHEA Lecture: A Wrinkle in Time: Reflections on Advances and Unmet Needs in Healthcare Epidemiology</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td></td>
</tr>
<tr>
<td>✔️ 176</td>
<td></td>
<td>Influential Publications in Antimicrobial Stewardship from the Past Year</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-244-L04-P</td>
</tr>
<tr>
<td>✔️ 177</td>
<td></td>
<td>Stanley A. Plotkin Lectureship in Vaccinology</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-247-L04-P</td>
</tr>
<tr>
<td>✔️ 179</td>
<td></td>
<td>β-lactam / β-lactamase Inhibitor Combinations: Which one?</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-248-L01-P</td>
</tr>
<tr>
<td>✔️ 180</td>
<td></td>
<td>Clinical Teaching for the ID Provider</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td></td>
</tr>
<tr>
<td>✔️ 181</td>
<td></td>
<td>Creepy, Dreadful, Wonderful Parasites and Other Creatures</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-252-L01-P</td>
</tr>
<tr>
<td>✔️ 182</td>
<td></td>
<td>Diagnosing &amp; Preventing Urinary Tract Infection: Science, Behavior Change, &amp; “Aha” Moments</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-249-L01-P</td>
</tr>
<tr>
<td>✔️ 183</td>
<td></td>
<td>Diagnosis of Toxoplasmosis in Special Populations</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td></td>
</tr>
<tr>
<td>✔️ 184</td>
<td></td>
<td>Dollar Dollar Bills Y’All: Billing and Coding in ID</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td></td>
</tr>
<tr>
<td>✔️ 185</td>
<td></td>
<td>Educating Trainees about Stewardship</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-250-L04-P</td>
</tr>
<tr>
<td>✔️ 186</td>
<td></td>
<td>Emerging Drug Resistance in STIs</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-251-L01-P</td>
</tr>
<tr>
<td>✔️ 187</td>
<td></td>
<td>NHSN Update</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td></td>
</tr>
<tr>
<td>✔️ 188</td>
<td></td>
<td>Rapid Fire: Curbsides in Transplant ID</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-253-L01-P</td>
</tr>
<tr>
<td>✔️ 189</td>
<td></td>
<td>Updates from the Antibacterial Resistance Leadership Group</td>
<td>Maximum of 1 AMA PRA Category 1 Credits™</td>
<td></td>
</tr>
<tr>
<td>✔️ 190</td>
<td></td>
<td>Shots Across the Bow: Debates in Vaccinology</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-261-L01-P</td>
</tr>
<tr>
<td>✔️ 191</td>
<td></td>
<td>Big Beasts II</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-254-L01-P</td>
</tr>
<tr>
<td>✔️ 192</td>
<td></td>
<td>Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-255-L01-P</td>
</tr>
<tr>
<td>✔️ 193</td>
<td></td>
<td>ID Physicians and Addiction Medicine</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-256-L01-P</td>
</tr>
<tr>
<td>✔️ 194</td>
<td></td>
<td>Malignancies in Patients with HIV</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-257-L02-P</td>
</tr>
<tr>
<td>✔️ 195</td>
<td></td>
<td>Neonatal Infectious Disease: Chagas, Zika, and LCMV</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-258-L01-P</td>
</tr>
<tr>
<td>✔️ 196</td>
<td></td>
<td>Non-Zika Arboviruses in the Americas</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-259-L01-P</td>
</tr>
<tr>
<td>✔️ 197</td>
<td></td>
<td>Pediatric Infection Prevention: Small Patients, Big Challenges</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-260-L01-P</td>
</tr>
<tr>
<td>✔️ 198</td>
<td></td>
<td>The Future of Transplant ID: Novel Diagnostics and Therapeutics</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-262-L01-P</td>
</tr>
<tr>
<td>✔️ 203</td>
<td></td>
<td>Tropical Medicine Cases: Conundrums and Case Management</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-270-L01-P</td>
</tr>
<tr>
<td>✔️ 204</td>
<td></td>
<td>Advances in Transplantation for Patients with HIV</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-263-L02-P</td>
</tr>
<tr>
<td>✔️ 205</td>
<td></td>
<td>Changing Landscape of Rapid Diagnostic Tests and Their Impact</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-264-L04-P</td>
</tr>
<tr>
<td>✔️ 206</td>
<td></td>
<td>Controlling Antimicrobial Resistance Across Borders</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-265-L04-P</td>
</tr>
<tr>
<td>✔️ 207</td>
<td></td>
<td>Cool Ways to Discover Antibiotics</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-266-L04-P</td>
</tr>
<tr>
<td>✔️ 208</td>
<td></td>
<td>I’m Better than You and I Can Prove It: Quality Metrics for Clinical ID</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-267-L04-P</td>
</tr>
<tr>
<td>✔️ 209</td>
<td></td>
<td>Infections in Immunocompromised Hosts</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td></td>
</tr>
<tr>
<td>✔️ 210</td>
<td></td>
<td>Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-268-L01-P</td>
</tr>
<tr>
<td>✔️ 260</td>
<td></td>
<td>Advances in Epidemiology Research Methods</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-271-L04-P</td>
</tr>
<tr>
<td>✔️ 261</td>
<td></td>
<td>Infection Prevention in Post-Acute Care: Controverses and Challenges</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-272-L01-P</td>
</tr>
<tr>
<td>✔️ 262</td>
<td></td>
<td>Intersection of Surgery and Pediatric Infectious Disease</td>
<td>Maximum of 1.25 AMA PRA Category 1 Credits™</td>
<td>0221-9999-18-314-L01-P</td>
</tr>
<tr>
<td>Attended</td>
<td>Session #</td>
<td>Session Title</td>
<td>CME/MOC Credits</td>
<td>Universal Program Number (for CPE credit)</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>✓</td>
<td>263</td>
<td>Old Foes and Emerging Threats: Multidrug-Resistant Bacterial Infections in Children</td>
<td>Maximum of 1.25 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-273-L01-P</td>
</tr>
<tr>
<td></td>
<td>264</td>
<td>Pain Management and Mental Health in Patients with HIV</td>
<td>Maximum of 1.25 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-274-L02-P</td>
</tr>
<tr>
<td></td>
<td>265</td>
<td>Strategy Trials: A New Paradigm in Infectious Diseases Research</td>
<td>Maximum of 1.25 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-275-L04-P</td>
</tr>
<tr>
<td></td>
<td>266</td>
<td>Syphilis in the 21st Century</td>
<td>Maximum of 1.25 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-276-L01-P</td>
</tr>
<tr>
<td></td>
<td>267</td>
<td>When Does PKPD Matter for Patient Care?</td>
<td>Maximum of 1.25 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-277-L04-P</td>
</tr>
<tr>
<td></td>
<td>268</td>
<td>When Transplant Tours the World</td>
<td>Maximum of 1.25 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-278-L01-P</td>
</tr>
<tr>
<td></td>
<td>273</td>
<td>Joseph E. Smadel Lecture</td>
<td>Maximum of 0.25 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-279-L04-P</td>
</tr>
<tr>
<td></td>
<td>276</td>
<td>Edward H. Kass Lecture</td>
<td>Maximum of 0.25 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-280-L02-P</td>
</tr>
<tr>
<td></td>
<td>277</td>
<td>ID BugBowl</td>
<td>Maximum of 1.0 AMA PRA Category 1 CreditsTM</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>278</td>
<td>Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics</td>
<td>Maximum of 1.0 AMA PRA Category 1 CreditsTM</td>
<td>No CPE Credit</td>
</tr>
<tr>
<td></td>
<td>279</td>
<td>Red Book Update</td>
<td>Maximum of 1.0 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-281-L04-P</td>
</tr>
<tr>
<td></td>
<td>280</td>
<td>Tele-Antimicrobial Stewardship</td>
<td>Maximum of 1.0 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-315-L04-P</td>
</tr>
<tr>
<td></td>
<td>281</td>
<td>Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections</td>
<td>Maximum of 1.5 AMA PRA Category 1 CreditsTM</td>
<td>0221-9999-18-316-L01-P</td>
</tr>
</tbody>
</table>
### ID Week 2018 Program Tracks

**Tuesday, October 2**

- **8 a.m. - 5 p.m.**  
  Pre-meeting Workshops
  - PW01. The Vincent T. Andrioite ID Board Review Course ($)  
  - PW02. Best Practices for Antimicrobial Stewardship Programs ($)  

- **1 - 5:30 p.m.**  
  - PW11. Medication Assisted Treatment Waiver Course ($)  
  - PW10. Infectious Diseases ABIM Recertification; Self-Evaluation of Medical Knowledge, IDSA MOC Modules: General ID ($) - S 158

**Wednesday, October 3**

- **8 a.m. - 12 p.m.**  
  Pre-meeting Workshops
  - PW04. Fellows’ Day Workshop ($) - W 2006-2008  
  - PW07. Hepatitis C Workshop ($) - S 156

- **8 a.m. - 12:30 p.m.**  
  Pre-meeting Workshop
  - PW09. How to Use EBM/GRADE to Develop Guidelines - S 157

- **12:30 - 1:45 p.m.**  
  Poster Abstract Sessions

- **10:30 - 11:45 a.m.**  
  Symposia

- **1:30 - 3:15 p.m.**  
  Interactive Session

- **3:45 - 5:15 p.m.**  
  Plenary Session

**Thursday, October 4**

- **7:15 - 8:15 a.m.**  
  Meet-the-Professor Sessions
  - 12. Disease Eradication Progress: Polio and Guinea Worm - S 151-153

- **7:15 - 8:30 a.m.**  
  Meet-the-Professor Session
  - 92. Antimicrobial and Diagnostic Stewardship - S 206-208

- **8:45 - 10 a.m.**  
  Interactive Sessions
  - 22. Case-Based Problems in Vaccines: Beyond the Guidelines - N 25  
  - 23. Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium - N Hall D

**W = West Hall  
N = North Hall  
S = South Hall**

---

**Symposia**

- 27. Predict, Prevent, and Protect: Optimizing Transplant Outcomes - S 214-216

**Oral Abstract Sessions**

- 32. Tuberculosis and other Mycobacterial Infections - W 2002
- 33. What’s Hot in UTIs and STIs - S 158

**Interactive Session**

- 34. Diagnostic Clinical Cases - W 2005-2024
- 36. Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship - N 24
- 37. Hepatitis B: Current and Future Challenges in Treatment and Prevention - N 25
- 38. Hot Topics in Medical Education 2018 - W 2014-2016
- 41. New and Updated Guidelines - S 305-314
- 42. The Microbiome and Multidrug-Resistant Organisms - S 206-208

**Plenary Session**


**Posters in the Park**

- Opening Reception and Posters in the Park - N Hall D Opening Reception Area

---

**W = West Hall  
N = North Hall  
S = South Hall**
IDWeek 2018 Program Tracks (continued)

- 59. Healthcare Epidemiology: Updates in C. difficile - S Poster Hall
- 60. HIV: Antiretroviral Therapy - S Poster Hall
- 61. HIV: Linkage to Care and Viral Suppression in the Care Cascade - S Poster Hall
- 62. HIV: Management and Clinical Outcomes - S Poster Hall
- 63. Maternal-Child Infections - S Poster Hall
- 64. Microbiome and Beyond - S Poster Hall
- 65. Pathogenesis and Immune Response - S Poster Hall
- 66. Public Health: Epidemiology and Outbreaks - S Poster Hall
- 68. Resistance Mechanisms: Gram-Positive - S Poster Hall
- 69. Respiratory Infections: Viral - S Poster Hall
- 70. Tuberculosis and Other Mycobacterial Infections - S Poster Hall

**8:45 - 10 a.m.**
Interactive Sessions
- 104. A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention - W 2006-2008

**Symposia**
- 105. Advances in RSV Prevention - N 24
- 106. Fungal MDR Outbreak: *Candida auris* - N 25
- 108. Metagenomic-Based Infectious Disease Diagnostics - S 214-216
- 109. Pandemic Influenza - S 305-314
- 111. Stewardship in Challenging Populations - S 206-208

**Oral Abstract Sessions**
- 112. Bacterial Infections and Antimicrobial Stewardship - S 156
- 113. Healthcare Epidemiology: Outbreaks! - S 158
- 114. Hepatitis C: Epidemiology and Elimination - W 2002
- 115. HIV-Related Comorbidities and Complications - S 157

**10:30 - 11:45 a.m.**
Interactive Session
- 116. Challenging Cases in Infectious Diseases - N Hall D

**Symposia**
- 117. Big Beasts I - W 2005-2024
- 118. How to Treat Resistant Gram-Positive Infections - N 24
- 120. Late Breaker Foodborne Illnesses - S 305-314
- 121. Pathogen Interactions with the Microbiota - S 206-208
- 122. Strategies to Achieve HIV Remission - N 25
- 123. Time 101: Optimizing Meetings - S 155

**Oral Abstract Sessions**
- 124. Adventures with Globally Acquired Infections - S 158
- 125. Fungal Infections - W 2002
- 126. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting - S 156
- 127. Medical Education - S 157

**10:45 - 11:45 a.m.**
Named Lecture
- 129. Caroline B. Hall Lectureship - S 214-216

**12:30 - 1:45 p.m.**
Poster Abstract Sessions
- 130. Adult and Pediatric Influenza Vaccine - S Poster Hall
- 131. Bacteremia and Endocarditis - S Poster Hall
- 132. Diarrhea Diagnostic Dilemmas - S Poster Hall
- 133. Enteric Infections - S Poster Hall
- 134. Fungi and Parasites in Immunocompromised Patients - S Poster Hall
- 135. Healthcare Epidemiology: Environmental and Occupational Health - S Poster Hall

---

**Friday, October 5**

**7 - 9 a.m.**
Meet-the-Professor Session
- 92b. Advocacy Session - S 155

**7:15 - 8:15 a.m.**
Meet-the-Professor Sessions
- 100. Mid-Career Challenges and Opportunities - S 158
- 95. Controversies in Sepsis (but not SIRS) - S 206-208
- 96. Designing a QI Project You Can Publish - S 157
### Saturday, October 6

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 - 8:15 a.m.</td>
<td>Meet-the-Professor Sessions</td>
</tr>
<tr>
<td></td>
<td>179. B-lactam/ B-lactamase Inhibitor Combinations: Which one?</td>
</tr>
<tr>
<td></td>
<td>-S 214-216</td>
</tr>
<tr>
<td></td>
<td>180. Clinical Teaching for the ID Provider -S 155</td>
</tr>
<tr>
<td></td>
<td>181. Creepy, Dreadful, Wonderful Parasites and Other Creatures</td>
</tr>
<tr>
<td></td>
<td>-S 151-153</td>
</tr>
<tr>
<td></td>
<td>182. Diagnosing &amp; Preventing Urinary Tract Infection: Science, Behavior</td>
</tr>
<tr>
<td></td>
<td>Change, &amp; &quot;Aha&quot; Moments -W 2014-2016</td>
</tr>
<tr>
<td></td>
<td>183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208</td>
</tr>
<tr>
<td></td>
<td>184. Dollar Dollar Bills Y’ALL: Billing and Coding in ID - S 158</td>
</tr>
<tr>
<td></td>
<td>185. Educating Trainees about Stewardship -W 2001-2003</td>
</tr>
<tr>
<td></td>
<td>186. Emerging Drug Resistance in STIs -S 157</td>
</tr>
<tr>
<td></td>
<td>187. NHSN Update -S 156</td>
</tr>
<tr>
<td></td>
<td>188. Rapid Fire: Curbsides in Transplant ID -S 152-154</td>
</tr>
<tr>
<td></td>
<td>189. Updates from the Antibacterial Resistance Leadership Group -W 2002</td>
</tr>
<tr>
<td>8:45 - 10 a.m.</td>
<td>Interactive Session</td>
</tr>
<tr>
<td>10:30 - 11:45 a.m.</td>
<td>Interactive Session</td>
</tr>
</tbody>
</table>

### 2 - 3:15 p.m.

**Interactive Session**


### 3:30 - 4:45 p.m.

**Oral Abstract Sessions**

- 158. Beyond the Big Beasts of Healthcare Epidemiology -N 25
- 160. Leading Change - S 155
- 162. T-Cell Biology: What the ID Physician Needs to Know -N 24
- 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now -W 2005-2024
- 164. Vaccines Against Herpesviruses - S 305-314

### 3:30 - 3:45 p.m.

**Oral Abstract Session**

- 178. PIDS Featured Oral Abstract -N 25

### 3:30 - 4:45 p.m.

**Symposia**

- 170. Diagnostic Updates: Clinical Mycology Update - N 24
- 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections -S 305-314

### 4:35 - 4:45 p.m.

**Named Lecture**

- 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

### 3:55 - 4:10 p.m.

**Oral Abstract Session**

- 174. SHEA Featured Oral Abstract -N Hall D

### 4:10 - 4:20 p.m.

**Awards Session**

- 175. Awards Session -N Hall D

### 4:20 - 4:45 p.m.

**Symposium**

- 176. Influential Publications in Antimicrobial Stewardship from the Past Year -N Hall D

---

**W = West Hall  N = North Hall  S = South Hall**
IDWeek 2018 Program Tracks (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session AID</th>
<th>Track Details</th>
<th>Hall</th>
</tr>
</thead>
</table>
| 12:30 - 1:45 p.m. | Poster Abstract Sessions | 216. Antimicrobial Stewardship: Global Perspectives  -S Poster Hall  
217. Antimicrobial Stewardship: Impact of Allergy  -S Poster Hall  
218. Antimicrobial Stewardship: Impact of New Diagnostics  -S Poster Hall  
219. Antimicrobial Stewardship: New Methods and Metrics  -S Poster Hall  
220. Antimicrobial Stewardship: Non-hospital Settings  -S Poster Hall  
221. Antimicrobial Stewardship: Outpatient Settings  -S Poster Hall  
222. Antimicrobial Stewardship: Potpourri  -S Poster Hall  
223. Antimicrobial Stewardship: Qualitative Research  -S Poster Hall  
224. Antiviral Therapies  -S Poster Hall  
225. Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis  -S Poster Hall  
226. Clinical Practice Issues: OPAT  -S Poster Hall  
227. Clinical Trials  -S Poster Hall  
228. Diagnostics: Bacteria and Mycobacteria  -S Poster Hall  
229. Diagnostics: Biomarkers and Novel Approaches  -S Poster Hall  
230. Diagnostics: Mycology  -S Poster Hall  
231. Diagnostics: Parasitology  -S Poster Hall  
232. Diagnostics: Resistance Testing  -S Poster Hall  
233. Diagnostics: Virology  -S Poster Hall  
234. Healthcare Epidemiology: Device-associated HAIs  -S Poster Hall  
235. Healthcare Epidemiology: Surgical Site Infections  -S Poster Hall  
236. Healthcare Epidemiology: Epidemiologic Methods  -S Poster Hall  
237. Healthcare Epidemiology: HAI Surveillance  -S Poster Hall  
238. Hepatitis A, B, and C  -S Poster Hall  
239. HIV and Viral Hepatitis Co-Infection  -S Poster Hall  
240. HIV: Malignancy  -S Poster Hall  
241. HIV: Metabolic, Cardiovascular, and Renal Complications  -S Poster Hall  
242. HIV: Opportunistic Infections and other Infectious Complications  -S Poster Hall  
243. HIV: Sexually Transmitted Infections  -S Poster Hall  
244. Miscellaneous Vaccines  -S Poster Hall  
245. Molecular & Sequence Based Diagnostics  -S Poster Hall  
249. Skin and Skin Structure Infection  -S Poster Hall  
250. Treatment of AMR Infections  -S Poster Hall  
251. Adolescent Vaccines  -S Poster Hall  
252. Vaccine Policy and Hesitancy  -S Poster Hall  
253. Vaccines for Herpes Zoster Virus  -S Poster Hall  
254. Vaccines for the Elderly and Immune Compromised  -S Poster Hall  
255. Virology Potpourri  -S Poster Hall  |

| 2 - 3:15 p.m. | Symposia              | 260. Advances in Epidemiology Research Methods  -N 24  
261. Infection Prevention in Post-Acute Care: Controversies and Challenges  -S 206-208  
266. Syphilis in the 21st Century  -N Hall D  
267. When Does PK/PD Matter for Patient Care?  -S 305-314  
268. When Transplant Tours the World  -N 25  
| Oral Abstract Sessions | 269. Flu and other Vaccines in Children  -W 2002  
270. Genomics and Susceptibility of Superbugs  -S 157  
271. Novel Diagnostics for Fungi, Parasites, and CNS Infection  -S 158  |

| 3:30 - 3:55 p.m. | Named Lecture | 273. Joseph E. Smadel Lecture  -N Hall D  
| Awards Session | 274. Awards Session  -N Hall D  |

| 4:05 - 4:45 p.m. | Named Lecture | 277. ID BugBowl  -N Hall D  |

| 5 - 6 p.m. | Interactive Session | 278. Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics  -W 2001-2003  
| 9:15 - 10:45 a.m. | Plenary Session | 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections  -W 2005-2024  |

Sunday, October 7

<table>
<thead>
<tr>
<th>Time</th>
<th>Session AID</th>
<th>Track Details</th>
<th>Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:15 - 10:45 a.m.</td>
<td>Plenary Session</td>
<td>281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections  -W 2005-2024</td>
<td></td>
</tr>
</tbody>
</table>
**ID Week 2018 Program Tracks (continued)**

**Tuesday, October 2**

_8 a.m. - 5 p.m._

Pre-meeting Workshop
- PW02. Best Practices for Antimicrobial Stewardship Programs ($)
  -W 2009-2024

**Wednesday, October 3**

_8 a.m. - 12 p.m._

Pre-meeting Workshops
- PW06. TB Workshop ($) - W 2001-2003
- PW08. A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship ($) - S 152-154
- PW09. How to Use EBM GRADE to Develop Guidelines - S 157

_1:30 - 3:15 p.m._

Symposia
- PW. Late Breaker Ebola Update - S 305-314
- PW. Machine Learning and Modeling in Infectious Diseases - S 214-216
- PW. What's Hot in ID + HIV - N Hall D

_3:45 - 5:15 p.m._

Plenary Session
- PW. Opening Plenary: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space - N Hall D

_5:30 - 6:30 p.m._

Posters in the Park
- Opening Reception and Posters in the Park - N Hall D Opening Reception Area

**Thursday, October 4**

_7:15 - 8:15 a.m._

Meet-the-Professor Sessions
- PW. Are You Ready? Outbreak Response Training - S 152-154
- PW. Disease Eradication Progress: Polio and Guinea Worm - S 151-153
- PW. Emerging Issues in the Diagnosis of STIs - S 214-216
- PW. How to Build Allergy Testing into Your Stewardship Program - S 157

_7:15 - 8:30 a.m._

Meet-the-Professor Session
- PW. Antimicrobial and Diagnostic Stewardship - S 206-208

_8:45 - 10 a.m._

Interactive Session
- PW. Case-Based Problems in Vaccines: Beyond the Guidelines - N 25
- PW. Predict, Prevent, and Protect: Optimizing Transplant Outcomes - S 214-216
- PW. What Are You Talking About? Communication Strategies for Stewardship Programs - N 24
  - Oral Abstract Session
- PW. Healthcare Epidemiology: Hot Topics - S 157

_10:30 - 11:45 a.m._

Interactive Session
- PW. Diagnostic Clinical Cases - W 2005-2024
- PW. Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship - N 24
- PW. Hot Topics in Medical Education 2018 - W 2014-2016
- PW. Hot Topics in Pediatric Infectious Diseases - W 2001-2003
- PW. The Microbiome and Multidrug-Resistant Organisms - S 206-208
- PW. Tuberculosis: What's New in Diagnosis and Management - S 214-216

**Oral Abstract Session**
- PW. Healthcare Epidemiology: Special Populations - S 156

_12:30 - 1:45 p.m._

Poster Abstract Sessions
- PW. Antimicrobial Stewardship: Interventions in Pediatric Populations - S Poster Hall
- PW. Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record - S Poster Hall
- PW. Antimicrobial Stewardship: Interventions to Improve Outcomes - S Poster Hall
- PW. Pediatric Antimicrobial and Diagnostic Stewardship - S Poster Hall
- PW. Fungal Disease: Management and Outcomes - S Poster Hall
- PW. Global Health and Travel Medicine - S Poster Hall
- PW. Healthcare Epidemiology: Advances in Hand Hygiene - S Poster Hall
- PW. Healthcare Epidemiology: Updates in C. difficile - S Poster Hall
- PW. Respiratory Infections: Viral - S Poster Hall
- PW. Tuberculosis and Other Mycobacterial Infections - S Poster Hall

_2 - 3:15 p.m._

Interactive Sessions
- PW. Clinical Controversies - W 2005-2024
- PW. Controversies in Infection Prevention - N 24
- PW. "Mano-a-Mano III": Controversies in Pediatric ID - S 206-208
  - Symposium
- PW. Novel Clinical Risks for Fungal Disease - W 2014-2016
  - Oral Abstract Session
- PW. Antimicrobial Stewardship: Better Prescribing, Better Outcomes - S 156

_3:30 - 3:55 p.m._

Named Lecture
- PW. John F. Enders Lecture - N Hall D

_3:55 - 4:05 p.m._

Awards Session
- PW. Awards Session - N Hall D

_4:05 - 4:20 p.m._

Oral Abstract Session
- PW. Featured Oral Abstract - N Hall D

_4:20 - 4:45 p.m._

Named Lecture
- PW. Maxwell Finland Lecture - N Hall D
ID Week 2018 Program Tracks (continued)

Friday, October 5

7 - 9 a.m.
Meet-the-Professor Session
92b. Advocacy Session - S 155

7:15 - 8:15 a.m.
Meet-the-Professor Sessions
100. Mid-Career Challenges and Opportunities - S 158
96. Designing a QI Project You Can Publish - S 157
98. ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs - S 151-153

8:45 - 10 a.m.
Interactive Session
104. A Day with the Hospital Epidemiologist’s Beeper: Challenging Cases in Infection Prevention - W 2006-2008
Symposia
106. Fungal MDR Outbreak: Candida auris - N 25
109. Pandemic Influenza - S 305-314
111. Stewardship in Challenging Populations - S 206-208
112. Bacterial Infections and Antimicrobial Stewardship - S 156
113. Healthcare Epidemiology: Outbreaks! - S 158
114. Hepatitis C: Epidemiology and Elimination - W 2002
115. HIV-Related Comorbidities and Complications - S 157

10:30 - 11:45 a.m.
Symposia
120. Late Breaker Foodborne Illnesses - S 305-314
123. Time 101: Optimizing Meetings - S 155
124. Adventures with Globally Acquired Infections - S 158
125. Fungal Infections - W 2002
126. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting - S 156

10:45 - 11:45 a.m.
Named Lecture
129. Caroline B. Hall Lectureship - S 214-216

12:30 - 1:45 p.m.
Poster Abstract Sessions
132. Diarrhea Diagnostic Dilemmas - S Poster Hall
133. Enteric Infections - S Poster Hall
135. Healthcare Epidemiology: Environmental and Occupational Health - S Poster Hall
136. Healthcare Epidemiology: MDR-Gram-Negative Infections - S Poster Hall
137. Healthcare Epidemiology: MSSA, MRSA and Other Gram-Positive Infections - S Poster Hall
138. Healthcare Epidemiology: Non-acute Care Settings - S Poster Hall

139. Healthcare Epidemiology: Outbreaks - S Poster Hall
140. HIV: Diagnosis and Screening - S Poster Hall
141. HIV: Molecular Epidemiology - S Poster Hall
142. HIV: Prevention - S Poster Hall
143. Medical Education - S Poster Hall
145. PK/PD Studies - S Poster Hall
146. Pneumococcal Vaccines - S Poster Hall
147. Respiratory Infections: CAP - S Poster Hall
148. Respiratory Infections: Miscellaneous - S Poster Hall
150. Urinary Tract Infection - S Poster Hall
151. Viruses and Bacteria in Immunocompromised Patients - S Poster Hall

2 - 3:15 p.m.
Symposia
158. Beyond the Big Beasts of Healthcare Epidemiology - N 25
160. Leading Change - S 155
163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now - W 2005-2024

Oral Abstract Sessions
167. Late Breaker Oral Abstracts - S 152-154
168. Novel Therapies for Superbugs - S 158
169. Respiratory and Gastroenteritis Viruses - W 2002

3:30 - 3:45 p.m.
Oral Abstract Session
178. PIDS Featured Oral Abstract - N 25

3:30 - 3:55 p.m.
Named Lecture

3:30 - 4:45 p.m.
Symposia
170. Diagnostic Updates: Clinical Mycology Update - N 24
172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections - S 305-314

3:45 - 4:45 p.m.
Named Lecture
177. Stanley A. Plotkin Lectureship in Vaccinology - N 25

3:55 - 4:10 p.m.
Oral Abstract Session
174. SHEA Featured Oral Abstract - N Hall D

4:10 - 4:20 p.m.
Awards Session
175. Awards Session - N Hall D

4:20 - 4:45 p.m.
Symposium
176. Influential Publications in Antimicrobial Stewardship from the Past Year - N Hall D

W = West Hall          N = North Hall         S = South Hall

EPI Track
### Saturday, October 6

**7:15 - 8:15 a.m.**
Meet-the-Professor Sessions
- 183. Diagnosis of Toxoplasmosis in Special Populations - S 206-208
- 187. NHSN Update - S 156
- 189. Updates from the Antibacterial Resistance Leadership Group - W 2002

**8:45 - 10 a.m.**
**Symposia**
- 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs - S 305-314
- 193. ID Physicians and Addiction Medicine - N Hall D

**Oral Abstract Sessions**
- 201. The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment - S 156

**10:30 - 11:45 a.m.**
**Symposia**
- 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact - S 206-208

**Oral Abstract Sessions**
- 211. Diagnostics Making a Difference - S 158
- 212. Healthcare Epidemiology: You Can Try This at Home - Innovative Epi Abstracts - S 157
- 213. Late Breaker Oral Abstracts - S 152-154

**12:30 - 1:45 p.m.**
**Poster Abstract Sessions**
- 216. Antimicrobial Stewardship: Global Perspectives - S Poster Hall
- 218. Antimicrobial Stewardship: Impact of New Diagnostics - S Poster Hall
- 222. Antimicrobial Stewardship: Potpourri - S Poster Hall
- 224. Antiviral Therapies - S Poster Hall
- 229. Diagnostics: Biomarkers and Novel Approaches - S Poster Hall
- 230. Diagnostics: Mycology - S Poster Hall
- 233. Diagnostics: Virology - S Poster Hall
- 234. Healthcare Epidemiology: Device-associated HAIs - S Poster Hall
- 235. Healthcare Epidemiology: Surgical Site Infections - S Poster Hall
- 236. Healthcare Epidemiology: Epidemiologic Methods - S Poster Hall
- 238. Hepatitis A, B, and C - S Poster Hall
- 242. HIV: Opportunistic Infections and other Infectious Complications - S Poster Hall
- 243. HIV: Sexually Transmitted Infections - S Poster Hall
- 245. Molecular & Sequence Based Diagnostics - S Poster Hall
- 246. Pediatric Healthcare Associated Infections - S Poster Hall
- 247. Pediatric Bacterial Infections - S Poster Hall
- 248. Pediatric Viral Infections - S Poster Hall
- 249. Skin and Skin Structure Infection - S Poster Hall
- 250. Treatment of AMR Infections - S Poster Hall

**2 - 3:15 p.m.**
**Symposia**
- 260. Advances in Epidemiology Research Methods - N 24
- 261. Infection Prevention in Post-Acute Care: Controversies and Challenges - S 206-208

**Oral Abstract Sessions**
- 269. Flu and other Vaccines in Children - W 2002
- 271. Novel Diagnostics for Fungi, Parasites, and CNS Infection - S 158

**3:30 - 3:55 p.m.**
**Named Lecture**
- 273. Joseph E. Smadel Lecture - N Hall D

**3:55 - 4:05 p.m.**
**Awards Session**
- 274. Awards Session - N Hall D

**4:05 - 4:20 p.m.**
**Oral Abstract Session**
- 275. Featured Oral Abstract - N Hall D

**4:20 - 4:45 p.m.**
**Named Lecture**
- 276. Edward H. Kass Lecture - N Hall D

**5 - 6 p.m.**
**Interactive Session**
- 277. ID BugBowl - N Hall D

### Sunday, October 7

**8 - 9 a.m.**
**Mini-Symposia**

**9:15 - 10:45 a.m.**
**Plenary Session**
- 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections - W 2005-2024

---

W = West Hall  
N = North Hall  
S = South Hall
### Wednesday, October 3

**8 a.m. - 12 p.m.**
Pre-meeting Workshops
- PW06. TB Workshop ($)-W 2001-2003
- PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

**1:30 - 3:15 p.m.**
Symposia
- 2. Late Breaker Ebola Update -S 305-314
- 7. What’s Hot in ID + HIV -N Hall D

**3:45 - 5:15 p.m.**
Plenary Session

**5:30 - 6:30 p.m.**
Posters in the Park
- Opening Reception and Posters in the Park -N Hall D Opening Reception Area

### Thursday, October 4

**7:15 - 8:15 a.m.**
Meet-the-Professor Sessions
- 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153
- 13. Emerging Issues in the Diagnosis of STIs -S 214-216

**8:45 - 10 a.m.**
Interactive Session
- 23. Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium -N Hall D

**10:30 - 11:45 a.m.**
Symposia
- 106. Fungal MDR Outbreak: *Candida auris* -N 25
- 109. Pandemic Influenza -S 305-314

**10:45 - 11:45 a.m.**
Named Lecture
- 129. Caroline B. Hall Lectureship -S 214-216

### Friday, October 5

**7 - 9 a.m.**
Meet-the-Professor Session
- 92b. Advocacy Session -S 155

**7:15 - 8:15 a.m.**
Meet-the-Professor Sessions
- 100. Mid-Career Challenges and Opportunities -S 158
- 97. Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era -S 214-216

**8:45 - 10 a.m.**
Symposia
- 106. Fungal MDR Outbreak: *Candida auris* -N 25
- 109. Pandemic Influenza -S 305-314

**10:30 - 11:45 a.m.**
Symposia
- 118. How to Treat Resistant Gram-Positive Infections -N 24
- 120. Late Breaker Foodborne Illnesses -S 305-314
- 123. Time 101: Optimizing Meetings -S 155
- 124. Adventures with Globally Acquired Infections -S 158

**10:45 - 11:45 a.m.**
Named Lecture
- 129. Caroline B. Hall Lectureship -S 214-216

**12:30 - 1:45 p.m.**
Poster Abstract Sessions
- 143. Medical Education -S Poster Hall
- 148. Respiratory Infections: Miscellaneous -S Poster Hall

**2 - 3:15 p.m.**
Symposia
- 160. Leading Change -S 155
- 161. Pediatric Immunization: Perspectives From Both Sides of the Pond -S 214-216
- 164. Vaccines Against Herpesviruses -S 305-314

**3:30 - 3:45 p.m.**
Oral Abstract Session
- 178. PIDS Featured Oral Abstract -N 25
IDWeek 2018 Program Tracks (continued)

3:30 - 4:45 p.m.
Symposia
- 170. Diagnostic Updates: Clinical Mycology Update - N 24
- 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections - S 305-314

3:45 - 4:45 p.m.
Named Lecture
- 177. Stanley A. Plotkin Lectureship in Vaccinology - N 25

4:10 - 4:20 p.m.
Awards Session
- 175. Awards Session - N Hall D

Saturday, October 6
7:15 - 8:15 a.m.
Meet-the-Professor Sessions
- 181. Creepy, Dreadful, Wonderful Parasites and Other Creatures - S 151-153
- 183. Diagnosis of Toxoplasmosis in Special Populations - S 206-208
- 189. Updates from the Antibacterial Resistance Leadership Group - W 2002

8:45 - 10 a.m.
Symposia
- 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs - S 305-314
- 196. Non-Zika Arboviruses in the Americas - N 25

10:30 - 11:45 a.m.
Interactive Session
- 203. Tropical Medicine Cases: Conundrums and Case Management - S 305-314

12:30 - 1:45 p.m.
Poster Abstract Sessions
- 216. Antimicrobial Stewardship: Global Perspectives - S Poster Hall
- 238. Hepatitis A, B, and C - S Poster Hall
- 246. Pediatric Healthcare Associated Infections - S Poster Hall
- 247. Pediatric Bacterial Infections - S Poster Hall
- 248. Pediatric Viral Infections - S Poster Hall

2 - 3:15 p.m.
Symposium
- 268. When Transplant Tours the World - N 25

3:30 - 3:55 p.m.
Named Lecture
- 273. Joseph E. Smadel Lecture - N Hall D

3:55 - 4:05 p.m.
Awards Session
- 274. Awards Session - N Hall D

4:05 - 4:20 p.m.
Oral Abstract Session
- 275. Featured Oral Abstract - N Hall D

Sunday, October 7
8 - 9 a.m.
Mini-Symposium

9:15 - 10:45 a.m.
Plenary Session
- 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections - W 2005-2024
IDWeek 2018 Program Tracks (continued)

**Tuesday, October 2**

**8 a.m. - 5 p.m.**
Pre-meeting Workshop
- PW01. The Vincent T. Andriole ID Board Review Course ($)
  -W 2005-2020
1 - 5:30 p.m.
- PW11. Medication Assisted Treatment Waiver Course ($)
  -W 2014-2016

**Wednesday, October 3**

**8 a.m. - 12 p.m.**
Pre-meeting Workshops
- PW06. TB Workshop ($)  -W 2001-2003
- PW07. Hepatitis C Workshop ($) -S 156
- PW09. How to Use EBM/GRADE to Develop Guidelines  -S 157
1:30 - 3:15 p.m.
Symposia
- 2. Late Breaker Ebola Update  -S 305-314
- 7. What's Hot in ID + HIV  -N Hall D
3:45 - 5:15 p.m.
Plenary Session

**Thursday, October 4**

7:15 - 8:15 a.m.
Meet-the-Professor Sessions
- 13. Emerging Issues in the Diagnosis of STIs  -S 214-216
- 16. Our Most Difficult HIV Cases (other than STIs)  -S 156
8:45 - 10 a.m.
Symposium
10:30 - 11:45 a.m.
Interactive Sessions
- 34. Diagnostic Clinical Cases  -W 2005-2024
- 35. STIs in the HIV Care Setting  -N Hall D
Symposia
- 37. Hepatitis B: Current and Future Challenges in Treatment and Prevention  -N 25
- 38. Hot Topics in Medical Education 2018  -W 2014-2016
- 43. Tuberculosis: What's New in Diagnosis and Management  -S 214-216
12:30 - 1:45 p.m.
Poster Abstract Sessions
- 56. Fungal Disease: Management and Outcomes  -S Poster Hall
- 57. Global Health and Travel Medicine  -S Poster Hall
- 58. Healthcare Epidemiology: Advances in Hand Hygiene  -S Poster Hall
- 60. HIV: Antiretroviral Therapy  -S Poster Hall
- 61. HIV: Linkage to Care and Viral Suppression in the Care Cascade  -S Poster Hall
- 62. HIV: Management and Clinical Outcomes  -S Poster Hall
- 63. Maternal-Child Infections  -S Poster Hall
- 70. Tuberculosis and Other Mycobacterial Infections  -S Poster Hall
- 2 - 3:15 p.m.
Symposium
- 83. The Human Microbiome in HIV  -S 305-314
Oral Abstract Session
- 85. Preventing and Identifying New HIV Infections  -S 157
3:30 - 3:55 p.m.
Named Lecture
- 88. John F. Enders Lecture  -N Hall D
3:55 - 4:05 p.m.
Awards Session
- 89. Awards Session  -N Hall D
4:05 - 4:45 p.m.
Named Lecture
- 91. Maxwell Finland Lecture  -N Hall D

**Friday, October 5**

7 - 9 a.m.
Meet-the-Professor Session
- 92b. Advocacy Session  -S 155
7:15 - 8:15 a.m.
Meet-the-Professor Sessions
- 100. Mid-Career Challenges and Opportunities  -S 158
- 94. Challenging STIs in the HIV Infected Patient  -S 156
- 97. Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era  -S 214-216
8:45 - 10 a.m.
Symposium
- 107. HIV State of the Art  -N Hall D
10:30 - 11:45 a.m.
Symposia
- 120. Late Breaker Foodborne Illnesses  -S 305-314
- 122. Strategies to Achieve HIV Remission  -N 25
- 123. Time 101: Optimizing Meetings  -S 155
Oral Abstract Sessions
- 124. Adventures with Globally Acquired Infections  -S 158
- 125. Fungal Infections  -W 2002
10:45 - 11:45 a.m.
Named Lecture
- 129. Caroline B. Hall Lectureship  -S 214-216
12:30 - 1:45 p.m.
Poster Abstract Sessions
- 140. HIV: Diagnosis and Screening  -S Poster Hall
- 141. HIV: Molecular Epidemiology  -S Poster Hall
- 142. HIV: Prevention  -S Poster Hall
- 143. Medical Education  -S Poster Hall
- 149. Sexually Transmitted Infections  -S Poster Hall

W = West Hall          N = North Hall         S = South Hall
**IDWeek 2018 Program Tracks (continued)**

### Saturday, October 6

- **7:15 - 8:15 a.m.**  
  Meet-the-Professor Sessions
  - 180. Clinical Teaching for the ID Provider - S 155
  - 183. Diagnosis of Toxoplasmosis in Special Populations - S 206-208
  - 186. Emerging Drug Resistance in STIs - S 157
- **8:45 - 10 a.m.**  
  Symposium
  - 194. Malignancies in Patients with HIV - S 206-208
- **10:30 - 11:45 a.m.**  
  Symposium
  - 204. Advances in Transplantation for Patients with HIV - W 2014-2016
  - 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact - S 206-208
- **12:30 - 1:45 p.m.**  
  Poster Abstract Sessions
  - 225. Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis - S Poster Hall
  - 238. Hepatitis A, B, and C - S Poster Hall
  - 239. HIV and Viral Hepatitis Co-Infection - S Poster Hall
  - 240. HIV: Malignancy - S Poster Hall
  - 241. HIV: Metabolic, Cardiovascular, and Renal Complications - S Poster Hall
  - 242. HIV: Opportunistic Infections and other Infectious Complications - S Poster Hall
  - 243. HIV: Sexually Transmitted Infections - S Poster Hall
  - 248. Pediatric Viral Infections - S Poster Hall

### 2 - 3:15 p.m.

**Interactive Session**
- 157. Challenging HIV Cases - N Hall D
- 160. Leading Change - S 155
- 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now - W 2005-2024

### Oral Abstract Session
- 167. Late Breaker Oral Abstracts - S 152-154

### 3:30 - 4:45 p.m.

**Symposium**
- 170. Diagnostic Updates: Clinical Mycology Update - N 24

### 3:45 - 4:45 p.m.

**Named Lecture**
- 177. Stanley A. Plotkin Lectureship in Vaccinology - N 25

### 4:10 - 4:20 p.m.

**Awards Session**
- 175. Awards Session - N Hall D

### Sunday, October 7

- **8 - 9 a.m.**  
  Mini-Symposium
- **9:15 - 10:45 a.m.**  
  Plenary Session
  - 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections - W 2005-2024
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 a.m. - 12 p.m.</td>
<td>Pre-meeting Workshop</td>
</tr>
<tr>
<td>1:30 - 3:15 p.m.</td>
<td>Symposia</td>
</tr>
<tr>
<td>3:45 - 5:15 p.m.</td>
<td>Plenary Session</td>
</tr>
<tr>
<td>5:30 - 6:30 p.m.</td>
<td>Posters in the Park</td>
</tr>
<tr>
<td>7:15 - 8:15 a.m.</td>
<td>Meet-the-Professor Session</td>
</tr>
<tr>
<td>7:15 - 8:30 a.m.</td>
<td>Meet-the-Professor Session</td>
</tr>
<tr>
<td>8:45 - 10 a.m.</td>
<td>Oral Abstract Sessions</td>
</tr>
<tr>
<td>10:30 - 11:45 a.m.</td>
<td>Symposia</td>
</tr>
<tr>
<td>12:30 - 1:45 p.m.</td>
<td>Poster Abstract Sessions</td>
</tr>
<tr>
<td>7 - 9 a.m.</td>
<td>Meet-the-Professor Session</td>
</tr>
<tr>
<td>7:15 - 8:15 a.m.</td>
<td>Meet-the-Professor Session</td>
</tr>
<tr>
<td>8:45 - 10 a.m.</td>
<td>Interactive Session</td>
</tr>
<tr>
<td>12:30 - 1:45 p.m.</td>
<td>Poster Abstract Sessions</td>
</tr>
</tbody>
</table>

**Wednesday, October 3**

- PW09. How to Use EBM/GRADE to Develop Guidelines - S 157
- 2. Late Breaker Ebola Update - S 305-314
- 3. Machine Learning and Modeling in Infectious Diseases - S 214-216
- 7. What's Hot in ID + HIV - N Hall D

**Thursday, October 4**

- 12. Disease Eradication Progress: Polio and Guinea Worm - S 151-153
- 92. Antimicrobial and Diagnostic Stewardship - S 206-208
- 31. Infant Viral Infections - S 156

**Friday, October 5**

- 92b. Advocacy Session - S 155
- 100. Mid-Career Challenges and Opportunities - S 158

**Symposia**

- Investigative ID Track
- Healthcare Epidemiology: Advances in Hand Hygiene - S Poster Hall
- Healthcare Epidemiology: Updates in C. difficile - S Poster Hall
- HIV: Linkage to Care and Viral Suppression in the Care Cascade - S Poster Hall
- Maternal-Child Infections - S Poster Hall
- Microbiome and Beyond - S Poster Hall
- Pathogenesis and Immune Response - S Poster Hall
- Public Health: Epidemiology and Outbreaks - S Poster Hall
- Resistance Mechanisms: Gram-Negative - S Poster Hall
- Resistance Mechanisms: Gram-Positive - S Poster Hall
- Tuberculosis and Other Mycobacterial Infections - S Poster Hall

**Poster Abstract Sessions**

- Antimicrobial Stewardship: Interventions in Pediatric Populations - S Poster Hall
- Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record - S Poster Hall
- Antimicrobial Stewardship: Interventions to Improve Outcomes - S Poster Hall
- Antimicrobial Stewardship: Special Populations - S Poster Hall
- Pediatric Antimicrobial and Diagnostic Stewardship - S Poster Hall
- Fungal Disease: Management and Outcomes - S Poster Hall
- Global Health and Travel Medicine - S Poster Hall

**Named Lecture**

- John F. Enders Lecture - N Hall D
- Awards Session - N Hall D
- Awards Session - N Hall D
- Featured Oral Abstract - N Hall D

**Interactive Session**

- A Day with the Hospital Epidemiologist’s Beeper: Challenging Cases in Infection Prevention - W 2006-2008
- Fungal MDR Outbreak: Candida auris - N 25
- Hepatitis C: Epidemiology and Elimination - W 2002
- HIV-Related Comorbidities and Complications - S 157

**W = West Hall   N = North Hall   S = South Hall**
### IDWeek 2018 Program Tracks (continued)

#### Saturday, October 6

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:15 - 8:15 a.m.</td>
<td>Meet-the-Professor Session</td>
</tr>
<tr>
<td>8:45 - 10 a.m.</td>
<td>Oral Abstract Sessions</td>
</tr>
<tr>
<td>10:30 - 11:45 a.m.</td>
<td>Symposium</td>
</tr>
<tr>
<td>10:45 - 11:45 a.m.</td>
<td>Named Lecture</td>
</tr>
<tr>
<td>12:30 - 1:45 p.m.</td>
<td>Poster Abstract Sessions</td>
</tr>
<tr>
<td>3:30 - 4:45 p.m.</td>
<td>Oral Abstract Session</td>
</tr>
<tr>
<td>3:45 - 4:45 p.m.</td>
<td>Named Lecture</td>
</tr>
<tr>
<td>4:10 - 4:20 p.m.</td>
<td>Awards Session</td>
</tr>
</tbody>
</table>

#### Saturday, October 6 - 10 a.m.

- 189. Updates from the Antibacterial Resistance Leadership Group -W 2002
- 199. Clinical Trials that May Change Your Practice -S 158
- 200. Public Health: Epidemiology and Outbreaks -S 157

#### Saturday, October 6 - 10:30 a.m.

- 118. How to Treat Resistant Gram-Positive Infections -N 24
- 120. Late Breaker Foodborne Illnesses -S 305-314
- 121. Pathogen Interactions with the Microbiota -S 206-208
- 123. Time 101: Optimizing Meetings -S 155

#### Saturday, October 6 - 10:45 a.m.

- 129. Caroline B. Hall Lectureship -S 214-216

#### Saturday, October 6 - 12:30 p.m.

- 131. Bacteremia and Endocarditis -S Poster Hall
- 137. Healthcare Epidemiology: MSSA, MRSA, and Other Gram-Positive Infections -S Poster Hall
- 138. Healthcare Epidemiology: Non-acute Care Settings -S Poster Hall
- 139. Healthcare Epidemiology: Outbreaks -S Poster Hall
- 141. HIV: Molecular Epidemiology -S Poster Hall
- 142. HIV: Prevention -S Poster Hall
- 143. Medical Education -S Poster Hall
- 144. Novel Agents -S Poster Hall
- 145. PK/PD Studies -S Poster Hall
- 146. Pneumococcal Vaccines -S Poster Hall
- 147. Respiratory Infections: CAP -S Poster Hall
- 150. Urinary Tract Infection -S Poster Hall
- 151. Viruses and Bacteria in Immunocompromised Patients -S Poster Hall

#### Saturday, October 6 - 2:00 p.m.

- 158. Beyond the Big Beasts of Healthcare Epidemiology -N 25
- 160. Leading Change -S 155
- 162. T-Cell Biology: What the ID Physician Needs to Know -N 24
- 165. Antibiotic Stewardship: Developing and Implementing Effective Programs -S 156
- 167. Late Breaker Oral Abstracts -S 152-154
- 168. Novel Therapies for Superbugs -S 158
- 169. Respiratory and Gastroenteritis Viruses -W 2002

#### Saturday, October 6 - 3:30 p.m.

- 178. PIDS Featured Oral Abstract -N 25

#### Saturday, October 6 - 3:45 p.m.

- 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

#### Saturday, October 6 - 4:10 p.m.

- 175. Awards Session -N Hall D

---

**Note:**

- **W** = West Hall
- **N** = North Hall
- **S** = South Hall
IDWeek 2018 Program Tracks (continued)

**2 - 3:15 p.m.**
- Symposia
  - 260. Advances in Epidemiology Research Methods -N 24
  - 266. Syphilis in the 21st Century -N Hall D
  - 267. When Does PK/PD Matter for Patient Care? -S 305-314
- Oral Abstract Sessions
  - 269. Flu and other Vaccines in Children -W 2002
  - 270. Genomics and Susceptibility of Superbugs -S 157
  - 271. Novel Diagnostics for Fungi, Parasites, and CNS Infection -S 158

**3:30 - 3:55 p.m.**
- Named Lecture
  - 273. Joseph E. Smadel Lecture -N Hall D

**3:55 - 4:05 p.m.**
- Awards Session
  - 274. Awards Session -N Hall D

**4:05 - 4:20 p.m.**
- Oral Abstract Session
  - 275. Featured Oral Abstract -N Hall D

**4:20 - 4:45 p.m.**
- Named Lecture
  - 276. Edward H. Kass Lecture -N Hall D

**5 - 6 p.m.**
- Interactive Session
  - 277. ID BugBowl -N Hall D

---

**Sunday, October 7**

**9:15 - 10:45 a.m.**
- Plenary Session
  - 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections -W 2005-2024
### Tuesday, October 2

**8 a.m. - 5 p.m.**
- Pre-meeting Workshop I
  - PW02. Best Practices for Antimicrobial Stewardship Programs ($) -W 2009-2024

---

### Wednesday, October 3

**7:45 a.m. - 12 p.m.**
- Pre-meeting Workshops
  - PW05. Pediatric Fellows' Day ($) -W 2002
  - PW06. TB Workshop ($) -W 2001-2003
  - PW07. Hepatitis C Workshop ($) -S 156
  - PW08. A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship ($) -S 152-154
  - PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

**8 a.m.-12:30 p.m.**
- Pre-meeting Workshop
  - PW10. Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Modules: General ID ($) -S 158

**1:30 - 3:15 p.m.**
- Interactive Session
  - 1. Challenging Cases in Pediatric Infectious Diseases -W 2005-2024
  - Symposia
  - 2. Late Breaker Ebola Update -S 305-314
  - 3. Machine Learning and Modeling in Infectious Diseases -S 214-216
  - 4. RCT That Will Change Your Practice -N 25
  - 7. What's Hot in ID + HIV -N Hall D
  - Interactive Session
  - 5. Stewardship: Best Drivers of Change Debate -N 24

**3:45 - 5:15 p.m.**
- Plenary Session

---

### Thursday, October 4

**7:15 - 8:15 a.m.**
- Meet-the-Professor Sessions
  - 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153
  - 13. Emerging Issues in the Diagnosis of STIs -S 214-216
  - 14. How to Build Allergy Testing into Your Stewardship Program -S 157
  - 15. NTM Infections: Challenges in Diagnosis and Management -W 2001-2003
  - 17. Questions in Bacteremia -W 2006-2008
  - 18. Respiratory Infections in Pregnant Women -S 158

---

**8:45 - 10 a.m.**
- Interactive Sessions
  - 22. Case-Based Problems in Vaccines: Beyond the Guidelines -N 25
  - 23. Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium -N Hall D
  - Symposia
  - 27. Predict, Prevent, and Protect: Optimizing Transplant Outcomes -S 214-216

**10:30 - 11:45 a.m.**
- Interactive Session
  - 34. Diagnostic Clinical Cases -W 2005-2024
  - Symposia
  - 36. Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship -N 24
  - 37. Hepatitis B: Current and Future Challenges in Treatment and Prevention -N 25
  - 38. Hot Topics in Medical Education 2018 -W 2014-2016
  - 41. New and Updated Guidelines -S 305-314
  - 42. The Microbiome and Multidrug-Resistant Organisms -S 206-208
  - 43. Tuberculosis: What's New in Diagnosis and Management -S 214-216

---

**12:30 - 1:45 p.m.**
- Poster Abstract Sessions
  - 49. Antimicrobial Stewardship: Interventions in Pediatric Populations -S Poster Hall
  - 50. Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record -S Poster Hall
  - 51. Antimicrobial Stewardship: Interventions to Improve Outcomes -S Poster Hall
  - 52. Antimicrobial Stewardship: Special Populations -S Poster Hall
  - 53. Pediatric Antimicrobial and Diagnostic Stewardship -S Poster Hall
  - 54. Bone and Joint Infections -S Poster Hall
  - 55. CNS Infections -S Poster Hall
  - 56. Fungal Disease: Management and Outcomes -S Poster Hall
  - 57. Global Health and Travel Medicine -S Poster Hall
IDWeek 2018 Program Tracks (continued)

68. Healthcare Epidemiology: Advances in Hand Hygiene  -S Poster Hall
69. Healthcare Epidemiology: Updates in C. difficile  -S Poster Hall
70. HIV: Antiretroviral Therapy  -S Poster Hall
71. HIV: Linkage to Care and Viral Suppression in the Care Cascade  -S Poster Hall
72. HIV: Management and Clinical Outcomes  -S Poster Hall
73. Maternal-Child Infections  -S Poster Hall
74. Public Health: Epidemiology and Outbreaks  -S Poster Hall
75. Tuberculosis and Other Mycobacterial Infections  -S Poster Hall

2 - 3:15 p.m.
Interactive Sessions
76. Clinical Controversies  -W 2005-2024
77. Controversies in Infection Prevention  -N 24
78. "Mano-a-Mano III": Controversies in Pediatric ID  -S 206-208
79. Bread and Butter Transplant ID  -N 25
80. Exploring the Antibiotic Pipeline 2018  -N Hall D
82. New Developments on Picornaviruses  -S 214-216
84. The Human Microbiome in HIV  -S 305-314
85. Antimicrobial Stewardship: Better Prescribing, Better Outcomes  -S 156
86. Pushing the Envelope in CNS Infections  -S 158
87. Respiratory Infections: An Update  -W 2002

3:30 - 3:55 p.m.
Named Lecture
88. John F. Enders Lecture  -N Hall D

3:55 - 4:05 p.m.
Awards Session
89. Awards Session  -N Hall D

4:05 - 4:20 p.m.
Oral Abstract Session
90. Featured Oral Abstract  -N Hall D

4:20 - 4:45 p.m.
Named Lecture
91. Maxwell Finland Lecture  -N Hall D

Friday, October 5
7 - 9 a.m.
Meet-the-Professor Session
92b. Advocacy Session  -S 155

7:15 - 8:15 a.m.
Meet-the-Professor Sessions
90. Mid-Career Challenges and Opportunities  -S 158
93. Controversies in Sepsis (but not SIRS)  -S 206-208
94. Designing a QI Project You Can Publish  -S 157
95. Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era  -S 214-216
96. ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs  -S 151-153
97. Microbiome Therapeutics  -S 152-154
98. Microbiome Therapeutics  -S 152-154
99. Microbiome Therapeutics  -S 152-154
8:45 - 10 a.m.
Interactive Sessions
100. "Achy Breaky Heart": Challenging Cases in Cardiovascular Infections  -W 2005-2024
101. A Day with the Hospital Epidemiologist’s Beeper: Challenging Cases in Infection Prevention  -W 2006-2008

Symposia
102. Advances in RSV Prevention  -N 24
103. Fungal MDR Outbreak: Candida auris  -S 25
104. HIV State of the Art  -N Hall D
105. Metagenomic-Based Infectious Disease Diagnostics  -S 214-216
106. Pandemic Influenza  -S 305-314
108. Stewardship in Challenging Populations  -S 206-208

Oral Abstract Sessions
109. Bacterial Infections and Antimicrobial Stewardship  -S 156
110. Healthcare Epidemiology: Outbreaks!  -S 158
111. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting  -S 156

10:30 - 10:45 a.m.
Oral Abstract Session
112. PIDS Featured Oral Abstract Caroline B. Hall Lectureship  -S 214-216

10:30 - 11:45 a.m.
Interactive Session
113. Challenging Cases in Infectious Diseases  -N Hall D

Symposia
114. How to Treat Resistant Gram-Positive Infections  -N 24
115. A Day with the Hospital Epidemiologist’s Beeper: Challenging Cases in Infection Prevention  -W 2006-2008
116. Late Breaker Foodborne Illnesses  -S 305-314
117. Pathogen Interactions with the Microbiota  -S 206-208
118. Strategies to Achieve HIV Remission  -N 25
119. Time 101: Optimizing Meetings  -S 155

Oral Abstract Sessions
120. Adventures with Globally Acquired Infections  -S 158
121. Fungal Infections  -W 2002
122. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting  -S 156

10:45 - 11:45 a.m.
Named Lecture
123. Caroline B. Hall Lectureship  -S 214-216

12:30 - 1:45 p.m.
Poster Abstract Sessions
124. Adult and Pediatric Influenza Vaccine  -S Poster Hall
125. Bacteremia and Endocarditis  -S Poster Hall
126. Diarrhea Diagnostic Dilemmas  -S Poster Hall
127. Enteric Infections  -S Poster Hall
128. Fungi and Parasites in Immunocompromised Patients  -S Poster Hall
129. Healthcare Epidemiology: Environmental and Occupational Health  -S Poster Hall
130. Healthcare Epidemiology: MDR-Gram-Negative Infections  -S Poster Hall
131. Healthcare Epidemiology: MSSA, MRSA, and Other Gram-Positive Infections  -S Poster Hall
132. Healthcare Epidemiology: Non-acute Care Settings  -S Poster Hall
133. Healthcare Epidemiology: Outbreaks!  -S 158
134. Healthcare Epidemiology: Positive Infections  -S Poster Hall
135. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting  -S 156
136. Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting  -S 156

W = West Hall          N = North Hall         S = South Hall
IDWeek 2018 Program Tracks (continued)

- 141. HIV: Molecular Epidemiology -S Poster Hall
- 142. HIV: Prevention -S Poster Hall
- 143. Medical Education -S Poster Hall
- 145. PK/PD Studies -S Poster Hall
- 146. Pneumococcal Vaccines -S Poster Hall
- 147. Respiratory Infections: CAP -S Poster Hall
- 148. Respiratory Infections: Miscellaneous -S Poster Hall
- 149. Sexually Transmitted Infections -S Poster Hall
- 150. Urinary Tract Infection -S Poster Hall
- 151. Viruses and Bacteria in Immunocompromised Patients -S Poster Hall

2 - 3:15 p.m.
Interactive Sessions
- 157. Challenging HIV Cases -N Hall D
- 158. Beyond the Big Beasts of Healthcare Epidemiology -N 25
- 160. Leading Change -S 155
- 161. Pediatric Immunization: Perspectives From Both Sides of the Pond -S 214-216
- 162. T-Cell Biology: What the ID Physician Needs to Know -N 24
- 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now -W 2005-2024
- 164. Vaccines Against Herpesviruses -S 305-314

Symposia
- 166. Changing Clinical Practice for Changing Times -S 157
- 167. Late Breaker Oral Abstracts -S 152-154
- 168. Novel Therapies for Superbugs -S 158
- 169. Respiratory and Gastroenteritis Viruses -W 2002

3:30 - 4:45 p.m.
Symposia
- 170. Diagnostic Updates: Clinical Mycology Update -N 24
- 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections -S 305-314

3:45 - 4:45 p.m.
Named Lecture
- 177. Stanley A. Plotkin Lectureship in Vaccinology -N 25

4:10 - 4:20 p.m.
Awards Session
- 175. Awards Session -N Hall D

Saturday, October 6

7:15 - 8:15 a.m.
Meet-the-Professor Sessions
- 180. Clinical Teaching for the ID Provider -S 155
- 181. Creepy, Dreadful, Wonderful Parasites and Other Creatures -S 151-153
- 183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208
- 184. Dollar Dollar Bills Y’All: Billing and Coding in ID -S 158
- 186. Emerging Drug Resistance in STIs -S 157
- 187. NHSN Update -S 156
- 188. Rapid Fire: Curbsides in Transplant ID -S 152-154
- 189. Updates from the Antibacterial Resistance Leadership Group -W 2002

8:45 - 10 a.m.
Interactive Session
- 190. Shots Across the Bow: Debates in Vaccinology -N 24
Symposia
- 191. Big Beasts II -W 2005-2024
- 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs -S 305-314
- 193. ID Physicians and Addiction Medicine -N Hall D
- 196. Non-Zika Arboviruses in the Americas -N 25
- 198. The Future of Transplant ID: Novel Diagnostics and Therapeutics -S 214-216

Oral Abstract Sessions
- 199. Clinical Trials that May Change Your Practice -S 158
- 200. Public Health: Epidemiology and Outbreaks -S 157
- 201. The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment -S 156

10:30 - 11:45 a.m.
Interactive Session
- 203. Tropical Medicine Cases: Conundrums and Case Management -S 305-314
Symposia
- 204. Advances in Transplantation for Patients with HIV -W 2014-2016
- 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact -S 206-208
- 207. Cool Ways to Discover Antibiotics -N 25
- 209. Infections in Immunocompromised Hosts -S 214-216
- 210. Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future -N 24

Oral Abstract Sessions
- 211. Diagnostics Making a Difference -S 158
- 212. Healthcare Epidemiology: You Can Try This at Home -N 25
- 214. Optimizing HIV Treatment -S 156

12:30 - 1:45 p.m.
Poster Abstract Sessions
- 217. Antimicrobial Stewardship: Impact of Allergy -S Poster Hall
- 218. Antimicrobial Stewardship: Impact of New Diagnostics -S Poster Hall
- 219. Antimicrobial Stewardship: New Methods and Metrics -S Poster Hall
- 220. Antimicrobial Stewardship: Non-hospital Settings -S Poster Hall
- 221. Antimicrobial Stewardship: Outpatient Settings -S Poster Hall
- 222. Antimicrobial Stewardship: Potpourri -S Poster Hall
- 224. Antiviral Therapies -S Poster Hall

Poster Abstract Sessions
- 224. Antiviral Therapies -S Poster Hall

W = West Hall          N = North Hall         S = South Hall
# IDWeek 2018 Program Tracks (continued)

- 225. Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis - S Poster Hall
- 226. Clinical Practice Issues: OPAT - S Poster Hall
- 227. Clinical Trials - S Poster Hall
- 228. Diagnostics: Bacteria and Mycobacteria - S Poster Hall
- 229. Diagnostics: Biomarkers and Novel Approaches - S Poster Hall
- 230. Diagnostics: Mycology - S Poster Hall
- 231. Diagnostics: Parasitology - S Poster Hall
- 233. Diagnostics: Virology - S Poster Hall
- 234. Healthcare Epidemiology: Device-associated HAIs - S Poster Hall
- 235. Healthcare Epidemiology: Surgical Site Infections - S Poster Hall
- 236. Healthcare Epidemiology: Epidemiologic Methods - S Poster Hall
- 238. Hepatitis A, B, and C - S Poster Hall
- 239. HIV and Viral Hepatitis Co-Infection - S Poster Hall
- 240. HIV: Malignancy - S Poster Hall
- 241. HIV: Metabolic, Cardiovascular, and Renal Complications - S Poster Hall
- 242. HIV: Opportunistic Infections and other Infectious Complications - S Poster Hall
- 243. HIV: Sexually Transmitted Infections - S Poster Hall
- 244. Miscellaneous Vaccines - S Poster Hall
- 245. Molecular & Sequence Based Diagnostics - S Poster Hall
- 246. Pediatric Healthcare Associated Infections - S Poster Hall
- 247. Pediatric Bacterial Infections - S Poster Hall
- 248. Pediatric Viral Infections - S Poster Hall
- 249. Skin and Skin Structure Infection - S Poster Hall
- 250. Treatment of AMR Infections - S Poster Hall
- 251. Adolescent Vaccines - S Poster Hall
- 252. Vaccine Policy and Hesitancy - S Poster Hall

## 2 - 3:15 p.m.

### Symposia

- 260. Advances in Epidemiology Research Methods - N 24
- 261. Infection Prevention in Post-Acute Care: Controversies and Challenges - S 206-208
- 262. Intersection of Surgery and Pediatric Infectious Disease - S 214-216
- 267. When Does PK/PD Matter for Patient Care? - S 305-314
- 268. When Transplant Tours the World - N 25

## 3:30 - 3:55 p.m.

### Named Lecture

- 273. Joseph E. Smadel Lecture - N Hall D

## 3:55 - 4:05 p.m.

### Awards Session

- 274. Awards Session - N Hall D

## 4:05 - 4:20 p.m.

### Oral Abstract Session

- 275. Featured Oral Abstract - N Hall D

## 4:20 - 4:45 p.m.

### Named Lecture

- 276. Edward H. Kass Lecture - N Hall D

## 5 - 6 p.m.

### Interactive Session

- 277. ID BugBowl - N Hall D

### Sunday, October 7

#### 8 - 9 a.m.

**Mini-Symposia**


#### 9:15 - 10:45 a.m.

**Plenary Session**

- 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections - W 2005-2024
### IDWeek 2018 Program Tracks (continued)

#### Tuesday, October 2

**1 - 5 p.m.**

- Pre-meeting Workshop
  - PW03. NIH Initiatives/Grant Writing Workshop ($) -W 2001-2003

**Wednesday, October 3**

**8 a.m.-12 p.m.**

- Pre-meeting Workshops
  - PW04. Fellows' Day Workshop ($) -W 2006-2008
  - PW05. Pediatric Fellows' Day ($) -W 2002
  - PW09. How to Use EBM/GRADE to Develop Guidelines -S 157

**1:30 - 3:15 p.m.**

- Interactive Session
  - 1. Challenging Cases in Pediatric Infectious Diseases -W 2005-2024
  - 2. Late Breaker Ebola Update -S 305-314
  - 3. Machine Learning and Modeling in Infectious Diseases -S 214-216
  - 4. RCT That Will Change Your Practice -N 25
  - 5. Stewardship: Best Drivers of Change Debate -N 24
  - 7. What's Hot in ID + HIV -N Hall D

**3:45 - 5:15 p.m.**

- Plenary Session

**Thursday, October 4**

**7:15 - 8:15 a.m.**

- Meet-the-Professor Sessions
  - 12. Disease Eradication Progress: Polio and Guinea Worm -S 151-153
  - 13. Emerging Issues in the Diagnosis of STIs -S 214-216
  - 14. How to Build Allergy Testing into Your Stewardship Program -S 157
  - 15. NTM Infections: Challenges in Diagnosis and Management -W 2001-2003
  - 16. Our Most Difficult HIV Cases (other than STIs) -S 156
  - 17. Questions in Bacteremia -W 2006-2008
  - 18. Respiratory Infections in Pregnant Women -S 158
  - 20. Women in ID -S 155

**8:45 - 10 a.m.**

- Interactive Sessions
  - 22. Navigating the Phenotype vs. Genotype Conundrum in Resistance: A Case-Based Symposium -N Hall D

---

**W = West Hall  N = North Hall  S = South Hall**
## IDWeek 2018 Program Tracks (continued)

### Friday, October 5

**7 - 9 a.m.**  
Meet-the-Professor Session  
- 92b. Advocacy Session - S 155

**7:15 - 8:15 a.m.**  
Meet-the-Professor Sessions  
- 94. Challenging STIs in the HIV Infected Patient - S 156  
- 95. Controversies in Sepsis (but not SIRS) - S 206-208  
- 96. Designing a QI Project You Can Publish - S 157  
- 98. ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs - S 151-153  
- 99. Microbiome Therapeutics - S 152-154

**8:45 - 10 a.m.**  
Interactive Sessions  
- 104. A Day with the Hospital Epidemiologist's Beeper: Challenging Cases in Infection Prevention - W 2006-2008

Symposia  
- 105. Advances in RSV Prevention - N 24  
- 106. Fungal MDR Outbreak: Candida auris - N 25  
- 107. HIV State of the Art - N Hall D  
- 108. Metagenomic-Based Infectious Disease Diagnostics - S 214-216  
- 111. Stewardship in Challenging Populations - S 206-208

**10:30 - 11:45 a.m.**  
Interactive Session  
- 116. Challenging Cases in Infectious Diseases - N Hall D

Symposia  
- 117. Big Beasts I - W 2005-2024  
- 118. How to Treat Resistant Gram-Positive Infections - N 24  
- 120. Late Breaker Foodborne Illnesses - S 305-314  
- 121. Pathogen Interactions with the Microbiota - S 206-208  
- 122. Strategies to Achieve HIV Remission - N 25  
- 123. Time 101: Optimizing Meetings - S 155

**10:45 - 11:45 a.m.**  
Named Lecture  
- 129. Caroline B. Hall Lectureship - S 214-216

**12:30 - 1:45 p.m.**  
Poster Abstract Session

**2 - 3:15 p.m.**  
Interactive Sessions  
- 157. Challenging HIV Cases - N Hall D

**Symposia**  
- 158. Beyond the Big Beasts of Healthcare Epidemiology - N 25  
- 160. Leading Change - S 155  
- 161. Pediatric Immunization: Perspectives From Both Sides of the Pond - S 214-216  
- 162. T-Cell Biology: What the ID Physician Needs to Know - N 24  
- 163. The ID Specialist and the Opioid Epidemic: What You Need to Know Now - W 2005-2024

**Oral Abstract Sessions**  
- 167. Late Breaker Oral Abstracts - S 152-154  
- 169. Respiratory and Gastroenteritis Viruses - W 2002

**3:30 - 4:45 p.m.**  
Symposia  
- 170. Diagnostic Updates: Clinical Mycology Update - N 24  
- 172. My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections - S 305-314

**3:45 - 4:45 p.m.**  
Named Lecture  
- 177. Stanley A. Plotkin Lectureship in Vaccinology - N 25

**4:10 - 4:20 p.m.**  
Awards Session  
- 175. Awards Session - N Hall D

**4:20 - 4:45 p.m.**  
Symposium  
- 176. Influential Publications in Antimicrobial Stewardship from the Past Year - N Hall D

### Saturday, October 6

**7:15 - 8:15 a.m.**  
Meet-the-Professor Sessions  
- 181. Creepy, Dreadful, Wonderful Parasites and Other Creatures - S 151-153  
- 183. Diagnosis of Toxoplasmosis in Special Populations - S 206-208  
- 184. Dollar Dollar Bills Y’All: Billing and Coding in ID - S 158  
- 185. Educating Trainees about Stewardship - W 2002-2003  
- 186. Emerging Drug Resistance in STIs - S 157  
- 187. NHSN Update - S 156  
- 188. Rapid Fire: Curbsides in Transplant ID - S 152-154  
- 189. Updates from the Antibacterial Resistance Leadership Group - W 2002

**8:45 - 10 a.m.**  
Symposia  
- 191. Big Beasts II - W 2005-2024  
- 192. Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs - S 305-314  
- 193. ID Physicians and Addiction Medicine - N Hall D  
- 194. Malignancies in Patients with HIV - S 206-208  
- 197. T-Cell Biology: What the ID Physician Needs to Know - N 24  
- 198. The Future of Transplant ID: Novel Diagnostics and Therapeutics - S 214-216

---

W = West Hall  
N = North Hall  
S = South Hall
IDWeek 2018 Program Tracks (continued)

Oral Abstract Sessions
- 199. Clinical Trials that May Change Your Practice - S 158
- 200. Public Health: Epidemiology and Outbreaks - S 157
- 201. The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment - S 156

10:30 - 11:45 a.m.
Interactive Session
- 203. Tropical Medicine Cases: Conundrums and Case Management - S 305-314
Symposia
- 204. Advances in Transplantation for Patients with HIV - W 2014-2016
- 205. Changing Landscape of Rapid Diagnostic Tests and Their Impact - S 206-208
- 207. Cool Ways to Discover Antibiotics - N 25
- 209. Infections in Immunocompromised Hosts - S 214-216
- 210. Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future - N 24

Oral Abstract Sessions
- 211. Diagnostics Making a Difference - S 158
- 212. Healthcare Epidemiology: You Can Try This at Home - Innovative Epi Abstracts - S 157
- 213. Late Breaker Oral Abstracts - S 152-154
- 214. Optimizing HIV Treatment - S 156

12:30 - 1:45 p.m.
Poster Abstract Session
- 248. Pediatric Viral Infections - S Poster Hall

2 - 3:15 p.m.
Symposia
- 260. Advances in Epidemiology Research Methods - N 24
- 261. Infection Prevention in Post-Acute Care: Controversies and Challenges - S 206-208
- 262. Intersection of Surgery and Pediatric Infectious Disease - S 214-216
- 266. Syphilis in the 21st Century - N Hall D
- 267. When Does PK/PD Matter for Patient Care? - S 305-314
- 268. When Transplant Tours the World - N 25

Oral Abstract Sessions
- 269. Flu and other Vaccines in Children - W 2002
- 271. Novel Diagnostics for Fungi, Parasites, and CNS Infection - S 158
- 272. Pediatric Viral Infections - S 156

3:30 - 3:55 p.m.
Named Lecture
- 273. Joseph E. Smadel Lecture - N Hall D

3:55 - 4:05 p.m.
Awards Session
- 274. Awards Session - N Hall D

4:05 - 4:20 p.m.
Oral Abstract Session
- 275. Featured Oral Abstract - N Hall D

4:20 - 4:45 p.m.
Named Lecture
- 276. Edward H. Kass Lecture - N Hall D

5 - 6 p.m.
Interactive Session
- 277. ID BugBowl - N Hall D

Sunday, October 7

8 - 9 a.m.
Mini-Symposia

9:15 - 10:45 a.m.
Plenary Session
- 281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections - W 2005-2024

W = West Hall   N = North Hall   S = South Hall
### Tuesday, October 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8 a.m. - 5 p.m. | Pre-meeting Workshop  
PW01. The Vincent T. Andriole ID Board Review Course ($) -W 2005-2020 |

### Wednesday, October 3

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8 a.m. - 12 p.m. | Pre-meeting Workshop  
PW09. How to Use EBM/GRADE to Develop Guidelines -S 157 |
| 1:30 - 3:15 p.m. | Symposia  
2. Late Breaker Ebola Update -S 305-314  
7. What’s Hot in ID + HIV -N Hall D |
| 3:45 - 5:15 p.m. | Plenary Session  
| 5:30 - 6:30 p.m. | Posters in the Park  
Opening Reception and Posters in the Park -N Hall D Opening Reception Area |

### Thursday, October 4

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:45 - 10 a.m. | Symposium  
27. Predict, Prevent, and Protect: Optimizing Transplant Outcomes -S 214-216 |
| 10:30 - 11:45 a.m. | Symposium  
42. The Microbiome and Multidrug-Resistant Organisms -S 206-208 |
| 12:30 - 1:45 p.m. | Poster Abstract Sessions  
57. Global Health and Travel Medicine -S Poster Hall  
58. Healthcare Epidemiology: Advances in Hand Hygiene -S Poster Hall  
63. Maternal-Child Infections -S Poster Hall  
70. Tuberculosis and Other Mycobacterial Infections -S Poster Hall  
2 - 3:15 p.m. | Symposia  
78. Bread and Butter Transplant ID -N 25  
| 3:30 - 3:55 p.m. | Named Lecture  
88. John F. Enders Lecture -N Hall D |
| 3:55 - 4:05 p.m. | Awards Session  
89. Awards Session -N Hall D |
| 4:05 - 4:20 p.m. | Oral Abstract Session  
90. Featured Oral Abstract -N Hall D  
4:20 - 4:45 p.m. | Named Lecture  
91. Maxwell Finland Lecture -N Hall D |

### Friday, October 5

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 7 - 9 a.m. | Meet-the-Professor Session  
92b. Advocacy Session -S 155 |
| 7:15 - 8:15 a.m. | Meet-the-Professor Session  
| 8:45 - 10 a.m. | Symposium  
106. Fungal MDR Outbreak: *Candida auris* -N 25 |
| 10:30 - 11:45 a.m. | Symposium  
120. Late Breaker Foodborne Illnesses -S 305-314  
10:45 - 11:45 a.m. | Named Lecture  
129. Caroline B. Hall Lectureship -S 214-216 |
| 12:30 - 1:45 p.m. | Poster Abstract Sessions  
134. Fungi and Parasites in Immunocompromised Patients -S Poster Hall  
143. Medical Education -S Poster Hall  
2 - 3:15 p.m. | Interactive Session  
Oral Abstract Session  
167. Late Breaker Oral Abstracts -S 152-154 |
| 3:45 - 4:45 p.m. | Named Lecture  
177. Stanley A. Plotkin Lectureship in Vaccinology -N 25  
4:10 - 4:20 p.m. | Awards Session  
175. Awards Session -N Hall D |

### Saturday, October 6

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 7:15 - 8:15 a.m. | Meet-the-Professor Sessions  
183. Diagnosis of Toxoplasmosis in Special Populations -S 206-208  
188. Rapid Fire: Curbsides in Transplant ID -S 152-154  
189. Updates from the Antibacterial Resistance Leadership Group -W 2002 |
| 8:45 - 10 a.m. | Symposium  
198. The Future of Transplant ID: Novel Diagnostics and Therapeutics -S 214-216  
Oral Abstract Session  
| 10:30 - 11:45 a.m. | Symposium  
204. Advances in Transplantation for Patients with HIV -W 2014-2016  
Oral Abstract Session  
213. Late Breaker Oral Abstracts -S 152-154 |
IDWeek 2018 Program Tracks (continued)

12:30 - 1:45 p.m.  
Poster Abstract Session  
248. Pediatric Viral Infections - S Poster Hall
2 - 3:15 p.m.  
Symposium  
268. When Transplant Tours the World - N 25
3:30 - 3:55 p.m.  
Named Lecture  
273. Joseph E. Smadel Lecture - N Hall D
3:55 - 4:05 p.m.  
Awards Session  
274. Awards Session - N Hall D
4:05 - 4:20 p.m.  
Oral Abstract Session  
275. Featured Oral Abstract - N Hall D
4:20 - 4:45 p.m.  
Named Lecture  
276. Edward H. Kass Lecture - N Hall D
5 - 6 p.m.  
Interactive Session  
277. ID BugBowl - N Hall D

Sunday, October 7

8 - 9 a.m.  
Mini-Symposium  
9:15 - 10:45 a.m.  
Plenary Session  
281. Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections - W 2005-2024
PW01. Pre-meeting Workshop
The Vincent T. Andriole ID Board Review Course ($)
Tuesday, 8 a.m. - 5 p.m.  W 2005-2020

Objectives: At the conclusion of this session, participants will be able to:
• discuss and apply updated information on diagnosis and treatment of sexually transmitted infections
• assess and apply current trends in diagnosis and treatment of tuberculosis and other mycobacteria
• discuss and apply updated information on diagnosis and treatment of non-HIV/non-transplant viral syndromes
• discuss common parasitic disease infections including their diagnosis and treatment
• recognize and apply in diagnostic and therapeutic ways the epidemiologic, tempo, and sign/symptom features of important bacterial infections
• assess and apply components of effective infection control/prevention programs
• discuss the most common non-infectious causes of elevated temperature
• discuss the diagnosis and treatment of Rickettsial and other tick-borne diseases
• discuss and apply updated information on vaccination
• assess and apply current trends in HIV care
• assess and apply current trends in the diagnosis and treatment of transplant-associated infections
• identify and apply characteristic pharmacologic and clinical features of antimicrobial agents used in treating the spectrum of clinical infections

Intended Audience: clinicians, infectious diseases physicians

Maximum of 7.50 hours of AMA PRA Category 1 Credit™
ACPE 7.5 application-based contact hours of pharmacy CE; 0221-9999-18-178-L01-P

PW02. Pre-meeting Workshop
Best Practices for Antimicrobial Stewardship Programs ($)
Tuesday, 8 a.m. - 5 p.m.  W 2009-2024

Objectives: At the conclusion of this activity, participants should be able to:
• evaluate components of effective antimicrobial stewardship programs and implement interventions in their healthcare setting
• describe the strategies for the implementation process and the outcome measures
• apply antimicrobial stewardship interventions for unique populations and across healthcare settings
• critically assess available data, including pharmacy and microbiology data, needed to support antimicrobial stewardship in their institution

Intended Audience: clinicians, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, microbiologists, other: healthcare providers who wish to create, implement, or improve an antimicrobial stewardship program for their healthcare institution, pharmacists

Maximum of 4.00 hours of AMA PRA Category 1 Credit™
ACPE 4.0 knowledge-based contact hours of pharmacy CE; 0221-9999-18-178-101-P

PW03. Pre-meeting Workshop
NIH Initiatives/Grant Writing Workshop ($)
Tuesday, 1 - 5 p.m.  W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:
• review NIH research training funding opportunities and identify how an applicant can decide which opportunity is best for them
• discuss the categories of grant mechanisms (what they are and which career stages they are intended to support) and test successful grantsmanship strategies
• determine how to set the best trajectory for a successful ID physician-scientist career and build best practices by refining career pathways and aligning training goals with those pathways

Intended Audience: fellows, medical students and residents, members-in-training

Maximum of 4.00 hours of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

PW11. Pre-meeting Workshop
Medication Assisted Treatment Waiver Course ($)
Tuesday, 1 - 5:30 p.m.  W 2014-2016

Objectives: Upon completion of the first 4 hours of training in-person and the second 4 hours of training online, the participants will be able to:
• have the training required to apply for a waiver to prescribe buprenorphine to their patients with opioid dependence (addiction)
• identify and assess patients who are appropriate for treatment with buprenorphine
• have the specific knowledge concerning the use of buprenorphine to manage opioid dependence in the outpatient setting
• discuss the psychiatric and medical comorbidities associated with opioid addiction

Intended Audience: clinicians, healthcare workers, HIV clinicians, HIV specialists, infection preventionists, infectious diseases physicians

Maximum of 4.00 hours of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.
### PW04. Pre-meeting Workshop
**Fellows’ Day Workshop ($)**
*Co-organized with the IDSA ID Training Program Directors*

**Wednesday, 8 a.m. - 12 p.m.**  
W 2006-2008

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss challenging infectious disease cases and approaches to differential diagnosis
- describe career pathways in at least two different infectious disease fields
- develop an initial action plan in pursuit of a post-fellowship position

**Intended Audience:** fellows, medical students and residents, members-in-training

No CME credit is offered for this session.

No CPE credit is offered for this session.

### PW05. Pre-meeting Workshop
**Pediatric Fellows’ Day ($)**
*Co-organized with the PIDS Training Programs Committee*

**Wednesday, 7:45 a.m. - 12 p.m.**  
W 2002

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss challenging infectious disease cases and approaches to patient management
- summarize career opportunities and pathways to achieve professional goals
- review common questions and best practices for interviewing for your first job

**Intended Audience:** fellows, medical students and residents, members-in-training

No CME credit is offered for this session.

No CPE credit is offered for this session.

### PW06. Pre-meeting Workshop
**TB Workshop ($)**

**Wednesday, 8 a.m. - 12 p.m.**  
W 2001-2003

**Objectives:** At the conclusion of this session, participants will be able to:
- explain how a comprehensive approach using whole-genome sequencing can be developed, validated, and approved as a CLIA-compliant test for *Mycobacterium tuberculosis*
- evaluate psychosocial approaches to improve adherence to TB treatment
- translate such approaches into tangible changes in medical practice

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 4.00 hours of **AMA PRA Category 1 Credit™**  
ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-179-L01-P

### PW07. Pre-meeting Workshop
**Hepatitis C Workshop ($)**

**Wednesday, 8 a.m. - 12 p.m.**  
S 156

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss how to design the treatment options for HCV patients according to their RAVS, treatment experience, HCV genotype, and disease stage
- compare methods for staging liver disease
- distinguish steatosis from steatohepatitis
- explain how to diagnose common liver diseases

**Intended Audience:** clinicians, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, pharmacists

Maximum of 4.00 hours of **AMA PRA Category 1 Credit™**  
ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-302-L01-P

### PW08. Pre-meeting Workshop
**A Sociobehavioral Approach to Infection Prevention and Antimicrobial Stewardship ($)**

**Wednesday, 8 a.m. - 12 p.m.**  
S 152-154

**Objectives:** At the conclusion of this session, participants will be able to:
- describe a conceptual framework informed by the social sciences that can be applied to the work of improving patient safety and quality
- discuss an overview of the fields of medical sociology, behavioral economics and implementation science as they apply to antimicrobial stewardship and infection prevention
- describe a practical example of an antimicrobial stewardship intervention that utilizes evidence-based communication training
- explain what a social driver diagram is and how it can be practically applied to the everyday work of managing social barriers to change in implementing antimicrobial stewardship and infection prevention interventions

**Intended Audience:** clinicians, epidemiologists, hospital epidemiologists, infection preventionists, infectious diseases physicians, pharmacists
PW09. Pre-meeting Workshop
How to Use EBM/GRADE to Develop Guidelines
Wednesday, 8 a.m. - 12 p.m.  S 157

Objectives: At the conclusion of this session, participants will be able to:
- explain the guideline development process utilized by IDSA including: initiation of guidelines, scope, question formulation, searching for evidence, evidence synthesis, and recommendation development using Grading of Recommendation Assessment, Development and Evaluation framework (GRADE) methods
- discuss GRADE methods as a means to rate the quality/certainty of the underlying evidence and the grading of the strength and direction of recommendation

Intended Audience: clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, researchers, scientists, vaccinologists

Maximum of 4.00 hours of AMA PRA Category 1 Credit™
ACPE 4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-303-L01-P

PW10. Pre-meeting Workshop
Infectious Diseases ABIM Recertification: Self-Evaluation of Medical Knowledge, IDSA MOC Module: General ID 2018 ($)
Wednesday, 8 a.m. - 12:30 p.m.  S 158

Objectives: At the conclusion of this activity, the learner will be able to:
- identify gaps in infectious diseases medical knowledge where further study is needed for board preparation and patient management
- improve competence in the area of infectious diseases medicine regarding diagnosis, treatments, and other aspects of patient management
- evaluate and revise patient management strategies
- improve clinical decision-making skills in infectious diseases medicine

Intended Audience: clinicians, infectious diseases pediatricians, infectious diseases physicians

Maximum of 1.75 hours of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

Scientific Sessions (continued)

1. Interactive Session
Challenging Cases in Pediatric Infectious Diseases
Wednesday, 1:30 - 3:15 p.m.  W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:
- discuss the clinical presentation and diagnostics of challenging cases in infectious diseases
- describe atypical presentations of certain infectious diseases
- discuss clinical presentations mimicking infectious diseases

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, medical students and residents, pharmacists

Maximum of 1.75 hours of AMA PRA Category 1 Credit™
ACPE 1.75 application-based contact hours of pharmacy CE; 0221-9999-18-180-L01-P

2. Symposium
Late Breaker Ebola Update
Wednesday, 1:30 - 3:15 p.m.  S 305-314

Objectives: At the conclusion of this session, participants will be able to:
- TBD

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.75 hours of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

3. Symposium
Machine Learning and Modeling in Infectious Diseases
Wednesday, 1:30 - 3:15 p.m.  S 214-216

Objectives: At the conclusion of this session, participants will be able to:
- review the data on how the electronic medical record can be used to generate models that predict risk of healthcare-associated infections
- apply machine learning approaches to stratify patients who present with clinical manifestations of sepsis
Scientific Sessions (continued)

- discuss the impact data-driven approaches can have in the management of patients in the intensive care unit

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists

[ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-181-L01-P]

**4. Symposium**

**RCT That Will Change Your Practice**

Wednesday, 1:30 - 3:15 p.m.  N 25

**Objectives:** At the conclusion of this session, participants will be able to:

- discuss recent data from randomized controlled trials in the area of antifungals
- discuss recent data from randomized controlled trials in the area of antivirals
- discuss recent data from randomized controlled trials in the area of antibacterials

**Intended Audience:** clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians

[ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-182-L01-P]

**5. Interactive Session**

**Stewardship: Best Drivers of Change Debate**

Wednesday, 1:30 - 3:15 p.m.  N 24

**Objectives:** At the conclusion of this session, participants will be able to:

- discuss the controversy surrounding the inclusion of the "end of life population" in antimicrobial stewardship programs
- debate the best outcome measures for antimicrobial stewardship programs: clinical outcomes vs. antibiotic use data
- discuss the advantages and disadvantages of including antifungals in an antimicrobial stewardship program

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, pharmacists, public health practitioners, researchers, scientists, vaccinologists

[ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-183-L01-P]

**6. Symposium**

**Update on Biofilm-Related Infections**

Wednesday, 1:30 - 3:15 p.m.  W 2014-2016

**Objectives:** At the conclusion of this session, participants will be able to:

- explain the role that biofilm plays in infectious diseases and certain hosts
- describe the impact that biofilm has on lung disease, particularly in cystic fibrosis
- discuss the challenges in diagnosing and assessing the impact of biofilm in implant related infections

**Intended Audience:** academicians, clinicians, fellows, infection preventionists, infectious diseases physicians, investigators, lab personnel, members-in-training, microbiologists, pharmacists, researchers, scientists

[ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-304-L01-P]

**7. Symposium**

**What’s Hot in ID + HIV**

Wednesday, 1:30 - 3:15 p.m.  N Hall D

**Objectives:** At the conclusion of this session, participants will be able to:

- review what is new in the field of infectious diseases using basic and clinical science
- describe what is new in the field of clinical and epidemiological sciences in HIV
- review what is new in the field of basic science and pathogenesis of HIV infection

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

[ACPE 1.75 knowledge-based contact hours of pharmacy CE; 0221-9999-18-184-L02-P]
8. Plenary Session

**Opening Plenary Session: Reaching for the Stars, Improving Science on Earth: Microbiome Research in Space**

*Wednesday, 3:45 - 5:15 p.m.*

**N Hall D**

**Objectives:** At the conclusion of this session, participants will be able to:
- TBD

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

*Maximum of 1.50 hours of AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

**Posters in the Park**

**Opening Reception and Posters in the Park**

*Wednesday, 5:30 - 6:30 p.m.*

**N Hall D Opening Reception Area**

No CME credit is offered for this session.

No CPE credit is offered for this session.

11. Meet-the-Professor Session

**Are You Ready? Outbreak Response Training**

*Thursday, 7:15 - 8:15 a.m.*

**S 152-154**

**Objectives:** At the conclusion of this session, participants will be able to:
- utilize tools developed as part of the SHEA/CDC Outbreak Response Training Program to respond to outbreaks in adult and pediatric healthcare facilities

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

*Maximum of 1.00 hour of AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

13. Meet-the-Professor Session

**Emerging Issues in the Diagnosis of STIs**

*Thursday, 7:15 - 8:15 a.m.*

**S 214-216**

**Objectives:** At the conclusion of this session, attendees will be able to:
- discuss the prevalence and risks to health of bacterial vaginosis
- explain the clinical significance of *M. genitalium*
- list diagnostic testing approaches for bacterial vaginosis and *M. genitalium*

**Intended Audience:** clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

*Maximum of 1.00 hour of AMA PRA Category 1 Credit™*

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-185-L01-P

14. Meet-the-Professor Session

**How to Build Allergy Testing into Your Stewardship Program**

*Thursday, 7:15 - 8:15 a.m.*

**S 157**

**Objectives:** At the conclusion of this session, participants will be able to:
- identify challenges in incorporating allergy testing into an antimicrobial stewardship program
- discuss practical examples of allergy testing in stewardship

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital
Scientific Sessions (continued)

epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, pharmacists, researchers

Maximum of 1.00 hour of AMA PRA Category 1 Credit™

ACPE 1 application-based contact hours of pharmacy CE; 0221-9999-18-187-L04-P

Trainee / Pediatric ID / Adult ID

15. Meet-the-Professor Session

NTM Infections: Challenges in Diagnosis and Management
Thursday, 7:15 - 8:15 a.m. W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:
• review the epidemiology of NTM infections
• discuss challenges in diagnosing clinical NTM infections
• review current management strategies and challenges in treating NTM infections

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, pharmacists, researchers

Maximum of 1.00 hour of AMA PRA Category 1 Credit™

ACPE 1 application-based contact hours of pharmacy CE; 0221-9999-18-187-L04-P

16. Meet-the-Professor Session

Our Most Difficult HIV Cases (other than STIs)
Thursday, 7:15 - 8:15 a.m. S 156

Objectives: At the conclusion of this session, participants will be able to:
• identify key aspects of managing antiretroviral therapy in HIV-infected patients who are treatment experienced and/or have co-occurring conditions
• evaluate different strategies and options in selecting an antiretroviral treatment regimen for HIV-infected patients

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-188-L01-P

HIV-STD-TB / Trainee

17. Meet-the-Professor Session

Questions in Bacteremia
Thursday, 7:15 - 8:15 a.m. W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:
• discuss the current management of bacteremia
• explain recent advances in the diagnosis of bacteremia
• list outcomes in patients with bacteremia

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, researchers, scientists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-190-L01-P

Trainee / Pediatric ID / Trainee

18. Meet-the-Professor Session

Respiratory Infections in Pregnant Women
Thursday, 7:15 - 8:15 a.m. S 158

Objectives: At the conclusion of this session, participants will be able to:
• review the epidemiology, clinical presentation, and prevention of prevalent respiratory infections in pregnant women

Intended Audience: academicians, investigators, medical students and residents, members-in-training, vaccinologists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-191-L01-P

Trainee / Pediatric ID

19. Meet-the-Professor Session

Shall We Agree to Disagree: Management of Pediatric Acute Hematogenous Osteomyelitis
Thursday, 7:15 - 8:15 a.m. W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:
• explain the transition to oral antimicrobial therapy, including the criteria and whether the criteria differ for bacteremic patients
• discuss data for oral antimicrobial dosing, including the choice of agent and dosing intervals
• review intravenous therapy for bacteremic patients with MSSA
• describe the utility/yield and timing of bone aspirates for culture
• explain the use of inflammatory markers to guide management and therapy

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-186-L01-P

Trainee / Pediatric ID
20. Meet-the-Professor Session
Women in ID
Thursday, 7:15 - 8:15 a.m.  S 155

Objectives: At the conclusion of this session, participants will be able to:
- discuss compensation disparities across gender in ID
- describe barriers to career enhancement across gender in ID
- identify strategies to enhance career success and satisfaction

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-305-L04-P

21. Interactive Session
“Brain on Fire:” Challenging Cases in Infectious and Inflammatory Encephalitis
Thursday, 8:45 - 10 a.m.  W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:
- list the common and rare causes of encephalitis
- describe the difference between infectious and autoimmune encephalitis
- interpret an MRI brain in the approach to encephalitis

Objectives: At the conclusion of this session, participants will be able to:
- address the current challenges posed by the diagnosis of antimicrobial-resistant organisms in clinical settings
- review mechanisms of resistance and treatment options for carbapenem-resistant Enterobacteriaceae and multidrug-resistant Pseudomonas aeruginosa
- discuss the most important issues in the diagnosis and treatment of mold infections

Intended Audience: academicians, clinicians, fellows, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-192-L01-P
and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-194-L01-P

Pediatric ID / Global ID / Adult ID / Trainee

24. Symposium
Can You Hear and See Me Now? ID Telehealth
IDSA Telehealth Committee
Thursday, 8:45 - 10 a.m.  S 206-208

Objectives: At the conclusion of this session, participants will be able to:
• describe the current state of telemedicine in infectious disease practice
• discuss opportunities to improve patient care and programmatic interventions

Intended Audience: clinicians, hospital administrators, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses

Maximum of 1.25 hours of AMA PRA Category 1 Credit™

No CPE credit is offered for this session.

25. Symposium
Combating Antimicrobial Resistance: Relevance of the One Health Concept
Thursday, 8:45 - 10 a.m.  W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:
• explain the importance of the work of the President’s Advisory Council on Combating Antibiotic-Resistant Bacteria
• describe a gap in the U.S. system that can lead to the development of antibiotic-resistant bacteria
• discuss how a resistant organism or gene can spread through the environment

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-195-L01-P

Transplant ID / Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID

27. Symposium
Predict, Prevent, and Protect: Optimizing Transplant Outcomes
Thursday, 8:45 - 10 a.m.  S 214-216

Objectives: At the conclusion of this session, participants will be able to:
• construct an infectious diseases approach to evaluating and readying the transplant candidate for transplantation
• discuss the complexities of infection control practices in the transplant population
• illustrate the importance and challenges of practicing antimicrobial stewardship in the transplant setting

Intended Audience: clinicians, epidemiologists, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, vaccinologists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-306-L01-P

HIV-STD-TB / Trainee

28. Symposium
Still at Highest Risk: Innovative Approaches & Urgent Needs for Prevention and Care
Thursday, 8:45 - 10 a.m.  S 305-314

Objectives: At the conclusion of this session, participants will be able to:
• apply strategies to improve HIV prevention and care for MSM and young African women
• assess the health care needs of transgender patients living with HIV
• describe approaches to improving health outcomes for adolescent patients at risk or living with HIV

Intended Audience: clinicians, fellows, HIV clinicians, HIV

Trainee / Pediatric ID
specialists, infectious diseases physicians, members-in-training, pharmacists, public health practitioners

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-196-L01-P

29. Symposium
What Are You Talking About? Communication Strategies for Stewardship Programs
Thursday, 8:45 - 10 a.m.  N 24

Objectives: At the conclusion of this session, participants will be able to:
• discuss strategies for communication in stewardship initiatives in the hospital setting
• assess stewardship communication practices in the emergency department and outpatient settings
• identify the role of social media-based communication strategies

Intended Audience: clinicians, epidemiologists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, public health practitioners

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-197-L04-P

30. Oral Abstract Session
Healthcare Epidemiology: Hot Topics
Thursday, 8:45 - 10 a.m.  S 157

Objectives for all IDWeek Oral Abstract Sessions: ALL IDWeek Oral Abstract Session objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Oral Abstract Sessions: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.
No CPE credit is offered for this session.

31. Oral Abstract Session
Infant Viral Infections
Thursday, 8:45 - 10 a.m.  S 156

No CME credit is offered for this session.
No CPE credit is offered for this session.

32. Oral Abstract Session
Tuberculosis and other Mycobacterial Infections
Thursday, 8:45 - 10 a.m.  W 2002
No CME credit is offered for this session.
No CPE credit is offered for this session.

33. Oral Abstract Session
What's Hot in UTIs and STIs
Thursday, 8:45 - 10 a.m.  S 158
No CME credit is offered for this session.
No CPE credit is offered for this session.

34. Interactive Session
Diagnostic Clinical Cases
Thursday, 10:30 - 11:45 a.m.  W 2005-2024
Objectives: At the conclusion of this session, participants will be able to:
• explain the selection and interpretation of microbiologic testing to solve case-based diagnostic dilemmas in clinical infectious diseases
• describe the results of various tests to solve case-based diagnostic dilemmas in infectious diseases

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, public health practitioners, researchers

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-198-L04-P

35. Interactive Session
STIs in the HIV Care Setting
Co-organized with the National Network of STD Clinical Prevention Training Centers
Thursday, 10:30 - 11:45 a.m.  N Hall D

Objectives: At the conclusion of the session, participants will be able to:
• outline strategies for preventing, diagnosing, and managing common sexually transmitted infections in HIV care settings
• develop therapeutic approaches to managing syphilis, gonorrhea, nongonococcal urethritis trichomoniasis, and other infections in an era of increasing drug resistance and in the setting of drug allergies
Scientific Sessions (continued)

- review evidence-based treatment guidelines for managing STIs in HIV-infected persons

**Intended Audience:** fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, nurses, pharmacists, public health practitioners

**Maximum of 1.25 hours of AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-203-L02-P

**Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID**

### 36. Symposium

**Diagnostic Stewardship: Partner and Ally of Antimicrobial Stewardship**

**Thursday, 10:30 - 11:45 a.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- Describe concrete ways in which clinicians and antimicrobial stewardship teams can collaborate with microbiology laboratories to optimize test utilization and antimicrobial administration
- Identify outcome measures that are appropriate for stewardship of laboratory tests
- Define overuse, overdiagnosis, and overtreatment and apply these concepts to infectious diseases tests

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, public health practitioners, researchers

**Maximum of 1.25 hours of AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-199-L04-P

**Pediatric ID / Adult ID / HIV-STD-TB**

### 37. Symposium

**Hepatitis B: Current and Future Challenges in Treatment and Prevention**

**Thursday, 10:30 - 11:45 a.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- Discuss current standard of care management and treatment of HBV infection
- Review challenges of current HBV vaccine, approach to waning immunity and immunocompromised hosts, and investigational vaccines on the horizon
- Discuss new approaches to HBV treatment and most recent developments in drug discovery

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists

**Maximum of 1.25 hours of AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-200-L01-P

**Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID**

### 38. Symposium

**Hot Topics in Medical Education 2018**

**Co-organized with the IDSA Education Committee and Medical Education Workgroup**

**Thursday, 10:30 - 11:45 a.m.**

**Objectives:** At the end of this session, participants will be able to:
- Describe the ways in which the three domains of physician well-being—culture of wellness, efficiency of practice, and personal resilience—reciprocally influence one another
- Name at least two strategies for enhancing trainee resilience
- Describe strategies for supporting the development of skills associated with the promotion of trainee well-being
- Identify at least one strategy to bring back to teaching and learning environments to enhance learner wellness
- Define equity pedagogy and describe its principles
- Describe the successes and failures of efforts to try to recruit a more diversified work force
- Name existing challenges and barriers to the establishment of equity pedagogy
- Describe at least one way to reduce disparities and incorporate principles of equity into teaching

**Intended Audience:** academicians, clinicians, fellows, HIV clinicians, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, public health practitioners, researchers, scientists

**Maximum of 1.25 hours of AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-201-L03-P

**No CPE credit is offered for this session.**

**Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID**

### 39. Symposium

**Hot Topics in Pediatric Infectious Diseases**

**Thursday, 10:30 - 11:45 a.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- Discuss the year’s important clinical advances and biomedical discoveries that have the potential to impact clinical care
- Describe the content of new scientific findings from experts in the field
- Discuss strategies to apply new data to further discovery or clinical practices

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection control practitioners, pediatricians, pediatric infectious diseases physicians, public health practitioners, researchers, scientists

**Maximum of 1.25 hours of AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-202-L02-P
Scientific Sessions (continued)

Researchers, microbiologists, pharmacists, public health practitioners, infectious diseases physicians, medical students and residents, workers, infection preventionists, infectious diseases pediatricians.

Objectives: At the end of this session, participants will be able to:
- review the data on the role the indigenous microbiota can play in resistance to colonization and disease to multidrug-resistant organisms
- analyze the evidence that analysis of the microbiome in an individual patient can provide guidance with formulating specific therapies
- discuss the impact that therapies that intentionally or unintentionally modify the microbiota can influence susceptibility to infection with MDRs

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

At the end of this session, participants will be able to:
- review the data on the role the indigenous microbiota can play in resistance to colonization and disease to multidrug-resistant organisms
- analyze the evidence that analysis of the microbiome in an individual patient can provide guidance with formulating specific therapies
- discuss the impact that therapies that intentionally or unintentionally modify the microbiota can influence susceptibility to infection with MDRs

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Objectives: At the conclusion of this session, participants will be able to:
- discuss diagnostic approaches to Lyme disease and evidence-based therapeutics
- discriminate asymptomatic bacteriuria from other genitourinary infections and learn to facilitate indications for treatment and prevention of unnecessary treatment
- recognize appropriate patients for OPAT and employ effective programmatic strategies to achieve successful treatment and best safety measures

Intended Audience: academicians, clinicians, fellows, healthcare workers, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, pharmacists, public health practitioners, researchers

Objectives: At the conclusion of this session, participants will be able to:
- discuss the management of both HIV+ and HIV- persons with tuberculosis
- discuss the complications of tuberculosis therapy and drivers of multidrug-resistant Mycobacterium tuberculosis
- explain diagnostic modalities for tuberculosis, both latent and active forms

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, hospital epidemiologists, infection preventionists, infectious diseases fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Objectives: At the conclusion of this session, participants will be able to:
- discuss the management of both HIV+ and HIV- persons with tuberculosis
- discuss the complications of tuberculosis therapy and drivers of multidrug-resistant Mycobacterium tuberculosis
- explain diagnostic modalities for tuberculosis, both latent and active forms

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, hospital epidemiologists, infection preventionists, infectious diseases fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Objectives: At the conclusion of this session, participants will be able to:
- discuss the management of both HIV+ and HIV- persons with tuberculosis
- discuss the complications of tuberculosis therapy and drivers of multidrug-resistant Mycobacterium tuberculosis
- explain diagnostic modalities for tuberculosis, both latent and active forms

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, hospital epidemiologists, infection preventionists, infectious diseases fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-202-L04-P

Trainee / Pediatric ID / Investigative ID / Pediatric ID / Epidemiology and Infection Control / Adult ID

Trainee / Pediatric ID / Investigative ID / Pediatric ID / Epidemiology and Infection Control / Adult ID
training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-205-L01-P

44. Oral Abstract Session
Adult and Adolescent Vaccines
Thursday, 10:30 - 11:45 a.m.  S 158

No CME credit is offered for this session.
No CPE credit is offered for this session.

45. Oral Abstract Session
Cool Findings in Bacteremia and Endocarditis
Thursday, 10:30 - 11:45 a.m.  W 2002

No CME credit is offered for this session.
No CPE credit is offered for this session.

46. Oral Abstract Session
Healthcare Epidemiology: Special Populations
Thursday, 10:30 - 11:45 a.m.  S 156

No CME credit is offered for this session.
No CPE credit is offered for this session.

47. Oral Abstract Session
Science Relevant to ID
Thursday, 10:30 - 11:45 a.m.  S 157

No CME credit is offered for this session.
No CPE credit is offered for this session.

48. Oral Abstract Session
Late Breaker Oral Abstracts
Thursday, 10:30 - 11:45 a.m.  S 151-153

No CME credit is offered for this session.
No CPE credit is offered for this session.

49. Antimicrobial Stewardship: Interventions in Pediatric Populations

50. Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record

51. Antimicrobial Stewardship: Interventions to Improve Outcomes

52. Antimicrobial Stewardship: Special Populations

53. Pediatric Antimicrobial and Diagnostic Stewardship

54. Bone and Joint Infections

55. CNS Infections

56. Fungal Disease: Management and Outcomes

57. Global Health and Travel Medicine

58. Healthcare Epidemiology: Advances in Hand Hygiene

59. Healthcare Epidemiology: Updates in C. difficile

60. HIV: Antiretroviral Therapy

61. HIV: Linkage to Care and Viral Suppression in the Care Cascade

62. HIV: Management and Clinical Outcomes

63. Maternal-Child Infections

64. Microbiome and Beyond

65. Pathogenesis and Immune Response

66. Public Health: Epidemiology and Outbreaks

67. Resistance Mechanisms: Gram-Negative

68. Resistance Mechanisms: Gram-Positive

69. Respiratory Infections: Viral

70. Tuberculosis and Other Mycobacterial Infections

71. Poster Discussion Round
Clostridium difficile
Thursday, 12:30 - 1:45 p.m.  S Poster Hall

Objectives for all IDWeek Poster Discussion Rounds: ALL IDWeek Poster Discussion Rounds objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Poster Discussion Rounds: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.
No CPE credit is offered for this session.
72. Poster Discussion Round
Antiretroviral Therapy and Management
Thursday, 12:30 - 1:45 p.m.  S Poster Hall
No CME credit is offered for this session.
No CPE credit is offered for this session.

73. Poster Discussion Round
Antimicrobial Resistance
Thursday, 12:30 - 1:45 p.m.  S Poster Hall
No CME credit is offered for this session.
No CPE credit is offered for this session.

74. Interactive Session
Clinical Controversies
Thursday, 2 - 3:15 p.m.  W 2005-2024
Objectives: At the conclusion of this session, participants will be able to:
• contrast the advantages and disadvantages of prescribing probiotics for all hospitalized patients who are taking antibiotics
• critically analyze available data suggesting that HIV persons with an undetectable viral load are not infectious to others
• define the risks and benefits of maintaining IV access after hospital discharge in persons known to use illicit IV drugs

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, medical students and residents, members-in-training

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-308-L01-P

75. Interactive Session
Controversies in Infection Prevention
Thursday, 2 - 3:15 p.m.  N 24
Objectives: At the conclusion of this session, participants will be able to:
• identify potential benefits and pitfalls of public reporting of healthcare-associated infections
• review different approaches to monitoring hand hygiene compliance

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-207-L04-P

76. Interactive Session
“Mano-a-Mano III”: Controversies in Pediatric ID
Thursday, 2 - 3:15 p.m.  S 206-208
Objectives: At the conclusion of this session, participants will be able to:
• explain the differences between tuberculin skin test vs. IGRA in the initial evaluation of children for TB
• discuss the benefits of vancomycin for empiric therapy for meningitis
• describe associated benefits of respiratory viral panel testing

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-308-L01-P

77. Interactive Session
Exploring the Antibiotic Pipeline 2018
Thursday, 2 - 3:15 p.m.  N Hall D
Objectives: At the conclusion of this session, participants will be able to:
• review novel antibiotics in the pipeline including mechanism of action and clinical applications
• discuss the possible niche of novel therapies against antibiotic-resistant organisms

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-206-L04-P

78. Symposium
Bread and Butter Transplant ID
Thursday, 2 - 3:15 p.m.  N 25
Objectives: At the conclusion of this session, participants will be able to:
• review the importance of CMV infections in transplantation, providing an update on diagnosis and management
• discuss the implications of common respiratory viral infections in transplant recipients and management options
• explain how to generate a differential diagnosis for diarrhea in the transplant recipient and a thoughtful diagnostic and management approach

Intended Audience: clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-206-L04-P

79. Symposium
Exploring the Antibiotic Pipeline 2018
Thursday, 2 - 3:15 p.m.  N Hall D
Objectives: At the conclusion of this session, participants will be able to:
• review novel antibiotics in the pipeline including mechanism of action and clinical applications
• discuss the possible niche of novel therapies against antibiotic-resistant organisms

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-206-L04-P
Scientific Sessions (continued)

- evaluate clinical and price-clinic data of new antimicrobial molecules that are being developed

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, researchers, scientists

No CME credit is offered for this session.
No CPE credit is offered for this session.

80. Symposium
**Migration and Immigration: Global Diseases at Your Doorstep**
Thursday, 2 - 3:15 p.m. W 2006-2008

**Objectives:** At the conclusion of this session, participants will be able to:
- identify diagnostic methods, clinical manifestations, and complications of Strongyloidiasis
- describe staging, treatment, and complications of echinococcal disease
- discuss diagnostic methods and treatment approaches to malaria in the U.S.

**Intended Audience:** clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, public health practitioners

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

81. Symposium
**New Developments on Picornaviruses**
Thursday, 2 - 3:15 p.m. S 214-216

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss updates in the epidemiology of picornaviruses
- review updates in laboratory methods for picornavirus infection
- describe childhood picornavirus illness

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, microbiologists, public health practitioners, scientists

Maximum of 1.50 hours of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.

82. Symposium
**Novel Clinical Risks for Fungal Disease**
Thursday, 2 - 3:15 p.m. W 2014-2016

**Objectives:** At the conclusion of this session, participants will be able to:
- evaluate clinical risk for fungal disease with small molecule kinase inhibitors
- discuss the clinical risk for fungal disease with chimeric antigen receptor T cell therapy
- discuss fungal prophylaxis in high-risk groups
- explain the epidemiology of invasive fungal infections

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, investigators, members-in-training, microbiologists, pharmacists, researchers, scientists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-209-L01-P

83. Symposium
**The Human Microbiome in HIV**
Thursday, 2 - 3:15 p.m. S 305-314

**Objectives:** At the conclusion of this session, participants will be able to:
- review the metabolic effects of gut and immune modifications
- describe how the microbiome of the female genital tract interacts with HIV
- summarize the latest scientific findings on immunology in the rectal environment

**Intended Audience:** fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners, researchers

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-210-L02-P

84. Oral Abstract Session
**Antimicrobial Stewardship: Better Prescribing, Better Outcomes**
Thursday, 2 - 3:15 p.m. S 156

**Objectives:** At the conclusion of this session, participants will be able to:
- review the metabolic effects of gut and immune modifications
- describe how the microbiome of the female genital tract interacts with HIV
- summarize the latest scientific findings on immunology in the rectal environment

No CME credit is offered for this session.
No CPE credit is offered for this session.
<table>
<thead>
<tr>
<th>Session Number</th>
<th>Session Title</th>
<th>Date &amp; Time</th>
<th>Location</th>
<th>Credit Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>85.</td>
<td>Oral Abstract Session</td>
<td>Preventing and Identifying New HIV Infections</td>
<td>Thursday, 2 - 3:15 p.m.</td>
<td>S 157 No CME credit is offered for this session. No CPE credit is offered for this session.</td>
</tr>
<tr>
<td>86.</td>
<td>Oral Abstract Session</td>
<td>Pushing the Envelope in CNS Infections</td>
<td>Thursday, 2 - 3:15 p.m.</td>
<td>S 158 No CME credit is offered for this session. No CPE credit is offered for this session.</td>
</tr>
<tr>
<td>87.</td>
<td>Oral Abstract Session</td>
<td>Respiratory Infections: An Update</td>
<td>Thursday, 2 - 3:15 p.m.</td>
<td>W 2002 No CME credit is offered for this session. No CPE credit is offered for this session.</td>
</tr>
<tr>
<td>88.</td>
<td>Named Lecture</td>
<td>John F. Enders Lecture</td>
<td>Thursday, 3:30 - 3:55 p.m.</td>
<td>N Hall D Objectives: At the conclusion of this session, participants will be able to: • review the data on healthcare costs and physician's contributions to these costs • provide a brief description of generic drugs and discuss issues and challenges in the use of some generic antimicrobial therapy • discuss the question of whether use of generic antiretroviral therapy in the U.S. will help curb overall HIV costs Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists Maximum of 0.25 hours of AMA PRA Category 1 Credit™ ACPE .4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-310-L04-P</td>
</tr>
<tr>
<td>89.</td>
<td>Awards Session</td>
<td>Awards Session</td>
<td>Thursday, 3:55 - 4:05 p.m.</td>
<td>N Hall D Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists No CME credit is offered for this session. No CPE credit is offered for this session.</td>
</tr>
<tr>
<td>90.</td>
<td>Oral Abstract Session</td>
<td>Featured Oral Abstract</td>
<td>Thursday, 4:05 - 4:20 p.m.</td>
<td>N Hall D No CME credit is offered for this session. No CPE credit is offered for this session.</td>
</tr>
<tr>
<td>91.</td>
<td>Named Lecture</td>
<td>Maxwell Finland Lecture</td>
<td>Thursday, 4:20 - 4:45 p.m.</td>
<td>N Hall D Objectives: At the conclusion of this session, participants will be able to: • list reasons why antibiotic stewardship has become a national priority • describe some of the factors that are promoting the uptake of antibiotic stewardship in hospitals • summarize some of the key next steps for antibiotic stewardship in hospitals Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists Maximum of 0.25 hours of AMA PRA Category 1 Credit™ ACPE .4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-211-L04-P</td>
</tr>
</tbody>
</table>
Scientific Sessions (continued)

Business Meetings
SHEA's President's Reception & Business Meeting
Thursday, 6 - 7:30 p.m. Embarcadero Room, Parc 55 Hotel

No CME credit is offered for this session.
No CPE credit is offered for this session.

Business Meetings
PIDS Business Meeting
Thursday, 6 - 6:45 p.m. N 23

No CME credit is offered for this session.
No CPE credit is offered for this session.

92b. Meet-the-Professor Session
Advancing ID and HIV Priorities: Making the Case to Policymakers
Friday, 7 - 9 a.m. S 155

Objectives: At the conclusion of this session, participants will be able to:
• identify opportunities for educating members of Congress and advocating for infectious disease and HIV policy priorities
• describe strategies for effectively communicating with policymakers to develop relationships with policymaker and their staff and to advance policy priorities
• describe the guidelines regarding advocacy and policy education by individuals who receive federal grant funding or work for a local or state health department or other agencies

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.
No CPE credit is offered for this session.

93. Meet-the-Professor Session
Ask the Expert: Managing Invasive Fungal Infections
Friday, 7:15 - 8:15 a.m. W 2001-2003

Objectives: At the conclusion of this session, participants will be able to:
• discuss the management of invasive yeast and mold infections in transplant patients
• discuss contemporary anti-fungal agents and the use of diagnostic tests for fungal infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training

Maximum of 1.00 hour of AAMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-212-L01-P

HIV-STD-TB / Trainee

94. Meet-the-Professor Session
Challenging STIs in the HIV Infected Patient
Friday, 7:15 - 8:15 a.m. S 156

Objectives: At the conclusion of this session, participants will be able to:
• identify key aspects of the medical evaluation, diagnosis, and treatment of STIs in patients with HIV
• evaluate different strategies and options in managing complicated STIs in patients with HIV

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, nurses, pharmacists, public health practitioners

Maximum of 1.00 hour of AAMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-213-L02-P

Pediatric ID / Trainee / Adult ID

95. Meet-the-Professor Session
Controversies in Sepsis (but not SIRS)
Friday, 7:15 - 8:15 a.m. S 206-208

Objectives: At the conclusion of this session, participants will be able to:
• describe the current use of sepsis criteria
• discuss the pros and cons of the sepsis definitions
• describe how the sepsis definition affects antimicrobial use

Intended Audience: clinicians, epidemiologists, fellows, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

Maximum of 1.00 hour of AAMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-214-L04-P

Pediatric ID / Trainee / Adult ID

96. Meet-the-Professor Session
Designing a QI Project You Can Publish
Friday, 7:15 - 8:15 a.m. S 157

Objectives: At the conclusion of this session, participants will be able to:
• explain how to design a quality improvement project
Scientific Sessions (continued)

- describe steps to plan for publication of a quality improvement project

**Intended Audience:** clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists

Maximum of 1.00 hour of **AMA PRA Category 1 Credit™**

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-215-L04-P

**97. Meet-the-Professor Session**

**Hepatitis C: Case-Based Discussion of HCV Treatment in the DAA Era**
Friday, 7:15 - 8:15 a.m.  S 214-216

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the recommendations for treatment of HCV using direct acting antiviral therapy
- describe the approach to treatment of HCV for special populations including patients with HIV-infection
- discuss testing required prior to HCV therapy

**Intended Audience:** academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners

Maximum of 1.00 hour of **AMA PRA Category 1 Credit™**

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-216-L01-P

**Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID**

**98. Meet-the-Professor Session**

**ID Physician New to Infection Prevention and Antimicrobial Stewardship Programs**
Friday, 7:15 - 8:15 a.m.  S 151-153

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the various responsibilities for physicians entering into a role as medical director of infection prevention or an antibiotic stewardship program
- understand common challenges facing such physicians as they enter these roles and strategies to successfully overcome these barriers

**Intended Audience:** clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training

Maximum of 1.00 hour of **AMA PRA Category 1 Credit™**

No CPE credit is offered for this session.

**99. Meet-the-Professor Session**

**Microbiome Therapeutics**
Friday, 7:15 - 8:15 a.m.  S 152-154

**Objectives:** At the conclusion of this session, participants will be able to:
- review the data on the use of fecal microbiota transplants in patients with infectious diseases
- discuss the development of novel therapies designed to modify the microbiome to improve human health

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.00 hour of **AMA PRA Category 1 Credit™**

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-217-L01-P

**Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID**

**100. Meet-the-Professor Session**

**Mid-Career Challenges and Opportunities**
Friday, 7:15 - 8:15 a.m.  S 158

**Objectives:** At the conclusion of this session, participants will be able to:
- identify at least 3 challenges experienced in mid-career
- describe opportunities for mid-career physicians and pharmacists

**Intended Audience:** academicians, clinicians, epidemiologists, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, researchers, scientists, vaccinologists

Maximum of 1.00 hour of **AMA PRA Category 1 Credit™**

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-311-L04-P

**Trainee / Pediatric ID / Global ID / Adult ID**

**101. Meet-the-Professor Session**

**Tropical Dermatology: Are You Ready for Jeopardy?**
Friday, 7:15 - 8:15 a.m.  W 2014-2016

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss differential diagnosis of skin lesions acquired during travel and residence in tropical areas
- identify and manage skin infections acquired in tropical regions

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists,
hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-218-L01-P

102. Meet-the-Professor Session
Using Mathematical Modeling to Inform HAI Prevention: Fresh Perspectives on Old Problems
Friday, 7:15 - 8:15 a.m.  W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:
- describe how mathematical modeling can help inform the design and interpretation of studies to evaluate pathogen spread and strategies to prevent transmission
- discuss specific examples of how mathematical modeling can help guide concrete prevention strategies

Intended Audience: academicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-219-L04-P

103. Interactive Session
“Achy Breaky Heart”: Challenging Cases in Cardiovascular Infections
Friday, 8:45 - 10 a.m.  W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:
- describe the use of molecular diagnostic tests in endocarditis
- discuss the role of diagnostic imaging in endocarditis
- evaluate the role of surgical management in patients with endocarditis

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-221-L01-P

104. Interactive Session
A Day with the Hospital Epidemiologist’s Beep: Challenging Cases in Infection Prevention
Friday, 8:45 - 10 a.m.  W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:
- using case-based learning, understand the challenges with resolving infection control issues where guidance and prevention evidence may be lacking
- describe various approaches to complicated operational infection prevention problems

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

105. Symposium
Advances in RSV Prevention
Friday, 8:45 - 10 a.m.  N 24

Objectives: At the conclusion of this session, participants will be able to:
- describe advances in RSV molecular virology
- describe advances in applications of RSV vaccines
- discuss approaches to RSV immunoprophylaxis

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, pharmacists, scientists, vaccinologists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-221-L01-P

106. Symposium
Fungal MDR Outbreak: Candida auris
Friday, 8:45 - 10 a.m.  N 25

Objectives: At the conclusion of this session, participants will be able to:
- describe the epidemiology of the emerging yeast C. auris
- describe and compare the virulence characteristics of C. auris and other Candida
- identify opportunities for scientific and clinical studies on C. auris
• describe the therapeutic challenges of managing patients with C. auris
• identify opportunities and challenges in infection control for fungi

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-222-L01-P

107. Symposium
**HIV State of the Art**
Friday, 8:45 - 10 a.m.  
N Hall D

**Objectives:** At the conclusion of this session, participants will be able to:
• review the status of long-acting antiretrovirals in HIV prevention and care
• identify new treatment approaches for highly treatment-experienced patients with HIV
• evaluate strategies for reducing inflammation in patients with HIV

**Intended Audience:** fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, pharmacists, public health practitioners

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-223-L02-P

108. Symposium
**Metagenomic-Based Infectious Disease Diagnostics**
Friday, 8:45 - 10 a.m.  
S 214-216

**Objectives:** At the conclusion of this session, participants will be able to:
• describe the principles, advantages, and limitations of metagenomic sequencing for the detection of infectious pathogens
• explain how next-generation sequencing (NGS) can be used to predict phenotypic bacterial resistance to antimicrobials
• describe the application of whole genome sequencing to the investigation and characterization of clinical bacterial outbreaks

**Intended Audience:** clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-312-L01-P

**109. Symposium**
**Pandemic Influenza**
Friday, 8:45 - 10 a.m.  
S 305-314

**Objectives:** At the conclusion of this session, participants will be able to:
• describe characteristics of an emerging novel influenza virus with pandemic potential
• identify treatment options for pandemic influenza
• describe two ways the global community can prepare for the next flu pandemic

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-224-L04-P

**110. Symposium**
**Secret Sauce for Effective Vaccines: Adjuvants and Effective Immune Responses**
Friday, 8:45 - 10 a.m.  
W 2014-2016

**Objectives:** At the conclusion of this session, participants will be able to:
• describe the mechanism of adjuvants
• explain the risks and benefits of adjuvants
• identify which adjuvants are currently in use or will be used soon

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-225-L04-P
Scientific Sessions (continued)

111. Symposium
Stewardship in Challenging Populations
Friday, 8:45 - 10 a.m.  S 206-208

Objectives: At the conclusion of this session, participants will be able to:
• describe the use of antimicrobials in the neonatal, dental, and emergency department populations
• discuss antimicrobial stewardship interventions in these settings

Intended Audience: clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-226-L04-P

112. Oral Abstract Session
Bacterial Infections and Antimicrobial Stewardship
Friday, 8:45 - 10 a.m.  S 156

Objectives for all IDWeek Oral Abstract Sessions: ALL IDWeek Oral Abstract Session objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Oral Abstract Sessions: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.
No CPE credit is offered for this session.

113. Oral Abstract Session
Healthcare Epidemiology: Outbreaks!
Friday, 8:45 - 10 a.m.  S 158

No CME credit is offered for this session.
No CPE credit is offered for this session.

114. Oral Abstract Session
Hepatitis C: Epidemiology and Elimination
Friday, 8:45 - 10 a.m.  W 2002

No CME credit is offered for this session.
No CPE credit is offered for this session.

115. Oral Abstract Session
HIV-Related Comorbidities and Complications
Friday, 8:45 - 10 a.m.  S 157

No CME credit is offered for this session.
No CPE credit is offered for this session.

116. Interactive Session
Challenging Cases in Infectious Diseases
Friday, 10:30 - 11:45 a.m.  N Hall D

Objectives: At the conclusion of this session, participants will be able to:
• discuss the clinical presentation and diagnostics of challenging cases in infectious diseases
• describe atypical presentations of certain infectious diseases
• discuss clinical presentations mimicking infectious diseases

Intended Audience: academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, members-in-training, nurses, pharmacists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-229-L01-P

117. Symposium
Big Beasts I
Friday, 10:30 - 11:45 a.m.  W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:
• discuss the current clinical update on sino-facial infections
• discuss the current clinical update on infectious hepatitis
• discuss the current clinical update on intra-abdominal infections

Intended Audience: academicians, clinicians, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-227-L01-P
Scientific Sessions (continued)

118. Symposium

**How to Treat Resistant Gram-Positive Infections**
Friday, 10:30 - 11:45 a.m.\(^{N 24}\)

**Objectives:** At the conclusion of this session, participants will be able to:
- identify the most current approaches for the treatment of severe infections caused by multidrug-resistant *S. aureus*
- review the mechanisms of resistance and therapeutic options for vancomycin-resistant enterococci
- discuss the impact of resistance in the treatment of pneumococcal infections

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-230-L01-P

119. Symposium

**Infection Control and Antimicrobial Stewardship in Dialysis Facilities**
Friday, 10:30 - 11:45 a.m.\(^{W 2006-2008}\)

**Objectives:**
- describe current approaches to antimicrobial stewardship in the dialysis population
- discuss the goals and accomplishments of the “Nephrologists Transforming Dialysis Safety” project
- identify HAI surveillance challenges in dialysis facilities and describe how surveillance can drive prevention

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-231-L01-P

120. Symposium

**Late Breaker Foodborne Illnesses**
Friday, 10:30 - 11:45 a.m.\(^{S 305-314}\)

**Objectives:** At the conclusion of this session, participants will be able to:
- TBD

**Intended Audience:** TBD

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

121. Symposium

**Pathogen Interactions with the Microbiota**
Friday, 10:30 - 11:45 a.m.\(^{S 206-208}\)

**Objectives:** At the conclusion of this session, participants will be able to:
- list new research findings on how pathogens are modulated by the microbiota
- discuss how microbiota alter disease pathogenesis

**Intended Audience:** academicians, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, microbiologists, pharmacists, researchers, scientists

No CME credit is offered for this session.

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-232-L01-P

122. Symposium

**Strategies to Achieve HIV Remission**
Friday, 10:30 - 11:45 a.m.\(^{N 25}\)

**Objectives:** At the conclusion of this session, participants will be able to:
- review the relationship of acute HIV infection to developing an HIV cure
- describe bone marrow transplantation and other strategies to achieve a sterilizing cure for HIV
- summarize the state of research on HIV vaccine therapy to achieve HIV remission

**Intended Audience:** fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacist, public health practitioners

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-233-L02-P
123. Symposium
**Time 101: Optimizing Meetings**
*Co-organized by the IDSA Education Committee and IDSA Medical Education Workgroup*

Friday, 10:30 - 11:45 a.m.  

**Objectives:** At the end of this session, participants will be able to:
- describe appropriate reasons for setting up a meeting
- state key steps to effectively prepare for a meeting
- describe components of effectively running a meeting
- state key steps to effectively close and follow-up from a meeting
- apply skills to effectively run interactive, transformational events

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*  
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-234-L04-P

124. Oral Abstract Session
**Adventures with Globally Acquired Infections**

Friday, 10:30 - 11:45 a.m.  

No CME credit is offered for this session.  
No CPE credit is offered for this session.

125. Oral Abstract Session
**Fungal Infections**

Friday, 10:30 - 11:45 a.m.  

No CME credit is offered for this session.  
No CPE credit is offered for this session.

126. Oral Abstract Session
**Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on *C. difficile* in the Healthcare Setting**

Friday, 10:30 - 11:45 a.m.  

No CME credit is offered for this session.  
No CPE credit is offered for this session.

127. Oral Abstract Session
**Medical Education**

Friday, 10:30 - 11:45 a.m.  

No CME credit is offered for this session.  
No CPE credit is offered for this session.

128. Oral Abstract Session
**PIDS Featured Oral Abstract Caroline B. Hall Lecture**

Friday, 10:30 - 10:45 a.m.  

No CME credit is offered for this session.  
No CPE credit is offered for this session.

129. Named Lecture
**Caroline B. Hall Lectureship**

Friday, 10:45 - 11:45 a.m.  

**Objectives:** At the conclusion of the session, participants will be able to:
- describe challenges in the development of RSV vaccines
- identify types of RSV vaccines and mAbs currently in development and target populations for each product

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*  
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-228-L01-P

130. Adult and Pediatric Influenza Vaccine
131. Bacteremia and Endocarditis
132. Diarrhea Diagnostic Dilemmas
133. Enteric Infections
134. Fungi and Parasites in Immunocompromised Patients
135. Healthcare Epidemiology: Environmental and Occupational Health
136. Healthcare Epidemiology: MDR-Gram-Negative Infections
137. Healthcare Epidemiology: MSSA, MRSA, and Other Gram-Positive Infections
138. Healthcare Epidemiology: Non-acute Care Settings
139. Healthcare Epidemiology: Outbreaks
140. HIV: Diagnosis and Screening
141. HIV: Molecular Epidemiology
142. HIV: Prevention
143. Medical Education
144. Novel Agents
145. PK/PD Studies
146. Pneumococcal Vaccines
147. Respiratory Infections: CAP
148. Respiratory Infections: Miscellaneous
149. Sexually Transmitted Infections
150. Urinary Tract Infection
151. Viruses and Bacteria in Immunocompromised Patients

152. Poster Discussion Round
Healthcare Epidemiology
Friday, 12:30 - 1:45 p.m. S Poster Hall

Objectives for all IDWeek Poster Discussion Rounds: ALL IDWeek Poster Discussion Rounds objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

Intended Audience for all IDWeek Poster Discussion Rounds: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.
No CPE credit is offered for this session.

153. Poster Discussion Round
PrEP
Friday, 12:30 - 1:45 p.m. S Poster Hall

No CME credit is offered for this session.
No CPE credit is offered for this session.

154. Poster Discussion Round
Novel Agents
Friday, 12:30 - 1:45 p.m. S Poster Hall

No CME credit is offered for this session.
No CPE credit is offered for this session.

Transplant ID / Trainee / Pediatric ID / Adult ID

155. Interactive Session
Co-organized with the American Society of Transplantation
Friday, 2 - 3:15 p.m.  S 206-208

Objectives: At the conclusion of this session, participants will be able to:
• construct an approach to diagnosing and managing challenging infectious disease syndromes occurring in organ and stem cell transplant recipients

Intended Audience: academicians, clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-235-L01-P

156. Interactive Session
Challenging HIV Cases
Friday, 2018: 2 - 3:15 p.m. N Hall D

Objectives: At the conclusion of this session, participants will be able to:
• identify complicating factors in HIV-infected patients
• apply strategies to address treatment complications in HIV-infected patients
• choose between different treatment strategies for managing HIV-infected patients

Intended Audience: clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-237-L02-P

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

157. Symposium
Beyond the Big Beasts of Healthcare Epidemiology
Friday, 2 - 3:15 p.m. N 25

Objectives: At the conclusion of this session, participants will be able to:
• discuss the epidemiology and burden of several under-recognized healthcare-associated infections
• identify differences in surveillance definitions for these infections compared with those traditionally under infection prevention program surveillance
• describe potential interventions to prevent these infections

Intended Audience: clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, public health practitioners

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-235-L01-P
159. Symposium
Laboratory Diagnosis of Bloodstream Infections: New Technologies and Continuing Challenges
Friday, 2 - 3:15 p.m.

**Objectives:** At the conclusion of this session, participants will be able to:
- explain the principles for optimizing current blood culture technology
- describe the challenges and progress with direct from whole blood testing for detection of bacteremia
- discuss the clinical use and utility of sepsis biomarkers

**Intended Audience:** clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

Acpe 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-238-L01-P

160. Symposium
Leading Change
Co-organized by the IDSA Education Committee and IDSA Medical Education Workgroup
Friday, 2 - 3:15 p.m.

**Objectives:** At the conclusion of this session, participants will be able to:
- identify initiatives that would significantly benefit from a thoughtful and deliberate change management process
- state the definition of change management
- describe Kotter’s 8 stages of change
- apply Kotter’s model to a change initiative
- explain how to facilitate change

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

Acpe 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-240-L01-P

161. Symposium
Pediatric Immunization: Perspectives From Both Sides of the Pond
Co-organized with the European Society for Pediatric Infectious Diseases
Friday, 2 - 3:15 p.m.

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the differing recommendations for universal pediatric influenza immunization and selection of vaccination product in Europe and North America
- describe the North American and European perspectives on and experiences with effectiveness and safety of pediatric vaccine adjuvants
- outline strategies to increase uptake of pediatric immunization, especially influenza immunizations

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

Acpe 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-241-L04-P

162. Symposium
T-Cell Biology: What the ID Physician Needs to Know
Friday, 2 - 3:15 p.m.

**Objectives:** At the conclusion of this session, participants will be able to:
- review aspects of T-cell biology that increase understanding of immune responses to infection
- describe the current state of engineering of T cells for therapeutic use

**Intended Audience:** academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, pharmacists, researchers, scientists

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

Acpe 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-241-L04-P
Scientific Sessions (continued)

<table>
<thead>
<tr>
<th>Trainee / Pediatric ID / HIV-STD-TB / Epidemiology and Infection Control / Adult ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>163. Symposium</strong></td>
</tr>
<tr>
<td><strong>The ID Specialist and the Opioid Epidemic: What You Need to Know Now</strong></td>
</tr>
<tr>
<td>Friday, 2 - 3:15 p.m.</td>
</tr>
<tr>
<td>W 2005-2024</td>
</tr>
<tr>
<td><strong>Objectives:</strong> At the conclusion of this session, participants will be able to:</td>
</tr>
<tr>
<td>• review strategies for successful treatment of chronic HCV among IDU in the context of elimination of HCV as a public health problem</td>
</tr>
<tr>
<td>• explain the key elements of a clinical practice-based model for delivering medication-assisted treatment for opiate use disorder by infectious disease specialists</td>
</tr>
<tr>
<td>• discuss the evidence base for supervised injection facilities for persons who inject drugs, including preventing infectious complications of IDU</td>
</tr>
<tr>
<td><strong>Intended Audience:</strong> academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners</td>
</tr>
<tr>
<td>ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-242-L01-P</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Global ID / Pediatric ID / Adult ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>164. Symposium</strong></td>
</tr>
<tr>
<td><strong>Vaccines Against Herpesviruses</strong></td>
</tr>
<tr>
<td>Friday, 2 - 3:15 p.m.</td>
</tr>
<tr>
<td>S 305-314</td>
</tr>
<tr>
<td><strong>Objectives:</strong> At the conclusion of this session, participants will be able to:</td>
</tr>
<tr>
<td>• discuss progress in herpes simplex vaccines</td>
</tr>
<tr>
<td>• describe progress in cytomegalovirus vaccines</td>
</tr>
<tr>
<td>• discuss progress in varicella vaccines</td>
</tr>
<tr>
<td><strong>Intended Audience:</strong> academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, vaccinologists</td>
</tr>
<tr>
<td>ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-243-L01-P</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adult ID / Pediatric ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>165. Oral Abstract Session</strong></td>
</tr>
<tr>
<td><strong>Antibiotic Stewardship: Developing and Implementing Effective Programs</strong></td>
</tr>
<tr>
<td>Friday, 2 - 3:15 p.m.</td>
</tr>
<tr>
<td>S 156</td>
</tr>
</tbody>
</table>

No CME credit is offered for this session.
No CPE credit is offered for this session.

<table>
<thead>
<tr>
<th>Adult ID / Pediatric ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>166. Oral Abstract Session</strong></td>
</tr>
<tr>
<td><strong>Changing Clinical Practice for Changing Times</strong></td>
</tr>
<tr>
<td>Friday, 2 - 3:15 p.m.</td>
</tr>
<tr>
<td>S 157</td>
</tr>
</tbody>
</table>

No CME credit is offered for this session.
No CPE credit is offered for this session.

<table>
<thead>
<tr>
<th>Adult ID / Pediatric ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>167. Oral Abstract Session</strong></td>
</tr>
<tr>
<td><strong>Late Breaker Oral Abstract Session #1</strong></td>
</tr>
<tr>
<td>Friday, 2 - 3:15 p.m.</td>
</tr>
<tr>
<td>S 152-154</td>
</tr>
</tbody>
</table>

No CME credit is offered for this session.
No CPE credit is offered for this session.

<table>
<thead>
<tr>
<th>Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>168. Oral Abstract Session</strong></td>
</tr>
<tr>
<td><strong>Novel Therapies for Superbugs</strong></td>
</tr>
<tr>
<td>Friday, 2 - 3:15 p.m.</td>
</tr>
<tr>
<td>S 158</td>
</tr>
</tbody>
</table>

No CME credit is offered for this session.
No CPE credit is offered for this session.

<table>
<thead>
<tr>
<th>Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>169. Oral Abstract Session</strong></td>
</tr>
<tr>
<td><strong>Respiratory and Gastroenteritis Viruses</strong></td>
</tr>
<tr>
<td>Friday, 2 - 3:15 p.m.</td>
</tr>
<tr>
<td>W 2002</td>
</tr>
</tbody>
</table>

No CME credit is offered for this session.
No CPE credit is offered for this session.

<table>
<thead>
<tr>
<th>Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>170. Symposium</strong></td>
</tr>
<tr>
<td><strong>Diagnostic Updates: Clinical Mycology Update</strong></td>
</tr>
<tr>
<td>Friday, 3:30 - 4:45 p.m.</td>
</tr>
<tr>
<td>N 24</td>
</tr>
<tr>
<td><strong>Objectives:</strong> At the conclusion of this session, participants will be able to:</td>
</tr>
<tr>
<td>• explain the principles, advantages, and limitations of MALDI-TOF MS as a diagnostic tool for the identification of clinical fungal pathogens</td>
</tr>
<tr>
<td>• discuss methodologies, indications, interpretation, and predictive value of in vitro antifungal resistance testing</td>
</tr>
<tr>
<td>• understand laboratory diagnosis of emerging fungal pathogens</td>
</tr>
<tr>
<td><strong>Intended Audience:</strong> academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists</td>
</tr>
<tr>
<td>ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-245-L01-P</td>
</tr>
</tbody>
</table>

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-245-L01-P
Scientific Sessions (continued)

171. Symposium
**ID Physicians in the Age of Value-Based Healthcare**
Friday, 3:30 - 4:45 p.m.  S 206-208

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss macro-issues within the U.S. healthcare system that will influence the clinical practice of ID
- explain the body of literature that identifies the value that ID physicians play in the treatment of patients with severe infection
- describe how to deliver the value of ID message at the local level using resources provided by IDSA

**Intended Audience:** clinicians

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

**ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-313-L04-P**

172. Symposium
**My Puppy Gave Me That? Updates in Pet and Other Zoonotic-Related Infections**
Friday, 3:30 - 4:45 p.m.  S 305-314

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the update on current zoonotic infections both in the U.S. and abroad
- explain the One Health approaches to combating zoonotic outbreaks

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-313-L04-P

173. Named Lecture
**SHEA Lecture: A Wrinkle in Time: Reflections on Advances and Unmet Needs in Healthcare Epidemiology**
Friday, 3:30 - 3:55 p.m.  N Hall D

**Objectives:** At the conclusion of this session, participants will be able to:
- describe recent advances, including disruptive innovations and cultural shifts in healthcare epidemiology
- compare and contrast challenges in healthcare epidemiology since these advances
- discuss the synergy of healthcare epidemiology with the quality improvement movement

174. Oral Abstract Session
**SHEA Featured Oral Abstract**
Friday, 3:55 - 4:10 p.m.  N Hall D

No CME credit is offered for this session.
No CPE credit is offered for this session.

**Intended Audience:** Adult ID / Epidemiology and Infection Control / Global ID / HIV-STD-TB / Investigative ID / Pediatric ID / Trainee / Transplant ID

175. Awards Session
**Awards Session**
Friday, 4:10 - 4:20 p.m.  N Hall D

No CME credit is offered for this session.
No CPE credit is offered for this session.

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

176. Symposium
**Influential Publications in Antimicrobial Stewardship from the Past Year**
Friday, 4:20 - 4:45 p.m.  N Hall D

**Objectives:** At the conclusion of this session, participants will be able to:
- identify influential publications in antimicrobial stewardship from the past year
- identify influential publications in healthcare epidemiology from the past year

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists
177. Named Lecture
Stanley A. Plotkin Lectureship in Vaccinology
Friday, 3:45 - 4:45 p.m.  N 25

Objectives: At the conclusion of this session, participants will be able to:
• discuss vaccine hesitancy in the broader context of human thought patterns and belief systems
• discuss how to engage stakeholders in developing strategies to improve immunization rates despite pervasive anti-vaccinationism

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-244-L04-P

178. Oral Abstract Session
PIDS Featured Oral Abstract
Friday, 3:30 - 3:45 p.m.  N 25

No CME credit is offered for this session.
No CPE credit is offered for this session.

Business Meeting
Cocktails and Conversation with CDC Director Robert Redfield, MD, and an IDSA/HIVMA update: “Reflecting the New Face of ID”
Friday, 5 - 6 p.m.  N Hall D

No CME credit is offered for this session.
No CPE credit is offered for this session.

179. Meet-the-Professor Session
B-lactam / B-lactamase Inhibitor Combinations: Which one?
Saturday, 7:15 - 8:15 a.m.  S 214-216

Objectives: At the conclusion of this session, participants will be able to:
• define the differences in activity between ceftazidime/avibactam, cefepime/tazobactam, meropenem/vaborbactam, and imipenem/relebactam
• define the correct role for each agent on the hospital formulary

Intended Audience: investigators, pharmacists, scientists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-248-L01-P

Pediatric ID / Adult ID / HIV-STD-TB

180. Meet-the-Professor Session
Clinical Teaching for the ID Provider
Co-organized by the IDSA Education Committee and IDSA Medical Education Workgroup
Saturday, 7:15 - 8:15 a.m.  S 155

Objectives: At the conclusion of this session, participants will be able to:
• describe the basic components of several evidence-based clinical teaching models
• apply these teaching models in their own clinical setting
• summarize current research on clinical teaching models
• set personal goals for applying the skills learned in this workshop to one’s own practice setting, and review a tool designed to assess performance of new teaching skills

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training

Maximum of 1.00 hour of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

181. Meet-the-Professor Session
Creepy, Dreadful, Wonderful Parasites and Other Creatures
Saturday, 7:15 - 8:15 a.m.  S 151-153

Objectives: At the conclusion of this session, participants will be able to:
• discuss different parasitic infections and infestations in a case-based format
• discuss management of parasitic infections and infestations in a case-based format

Intended Audience: academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, nurses, pharmacists, public health practitioners

Maximum of 1.00 hour of AMA PRA Category 1 Credit™
ACPE 1 application-based contact hours of pharmacy CE; 0221-9999-18-252-L01-P
Scientific Sessions (continued)

182. Meet-the-Professor Session
Diagnosing & Preventing Urinary Tract Infection: Science, Behavior Change, & “Aha” Moments
Saturday, 7:15 - 8:15 a.m. W 2014-2016

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss ways to improve the prevention and diagnosis of urinary tract infections
- explain the difference between asymptomatic bacteriuria and urinary tract infection

**Intended Audience:** clinicians, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, microbiologists, nurses, public health practitioners

Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

ACPE 1 knowledge-based contact hours of pharmacy CE: 0221-9999-18-249-L01-P

183. Meet-the-Professor Session
Diagnosis of Toxoplasmosis in Special Populations
Saturday, 7:15 - 8:15 a.m. S 206-208

**Objectives:** At the conclusion of this session, participants will be able to:
- describe optimal laboratory approaches to the diagnosis of toxoplasmosis in special patient populations, including test selection, interpretation and clinical implications in the diagnosis of congenital toxoplasmosis and the diagnosis of toxoplasmosis in the immunocompromised host

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, public health practitioners

Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-250-L04-P

184. Meet-the-Professor Session
Dollar Dollar Bills Y’All: Billing and Coding in ID
Saturday, 7:15 - 8:15 a.m. S 158

**Objectives:** At the conclusion of this session, participants will be able to:
- review optimal strategies for coding inpatient, outpatient, and non-face-to-face care
- facilitate discussion of new opportunities to employ advanced level practitioners or non-traditional settings such as nursing facilities, telemedicine, or other novel strategies to enhance revenues

**Intended Audience:** clinicians, HIV clinicians, hospital administrators, infectious diseases pediatricians, infectious diseases physicians

Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

No CPE credit is offered for this session.

185. Meet-the-Professor Session
Educating Trainees about Stewardship
Co-organized with the IDSA Education Committee and Medical Education Workgroup
Saturday, 7:15 - 8:15 a.m. W 2001-2003

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the guidelines for educating trainees in antimicrobial stewardship
- describe behavioral interventions for improving antimicrobial use and stewardship among trainees

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, pharmacists

Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-250-L04-P

186. Meet-the-Professor Session
Emerging Drug Resistance in STIs
Saturday, 7:15 - 8:15 a.m. S 157

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the current trends in drug resistance in STIs and propose management strategies

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, infectious diseases physicians, investigators, public health practitioners, scientists

Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-251-L01-P
Scientific Sessions (continued)

187. Meet-the-Professor Session
NHSN Update
Saturday, 7:15 - 8:15 a.m.  S 156

Objectives: At the conclusion of this session, participants will be able to:
- describe updates to the NHSN Patient Safety and Outpatient Procedure Components and NHSN data analytics
- identify answers to frequently asked questions about NHSN surveillance protocols and analysis

Intended Audience: epidemiologists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, public health practitioners

Maximum of 1.00 hour of AMA PRA Category 1 Credit™
No CPE credit is offered for this session.

188. Meet-the-Professor Session
Rapid Fire: Curbsides in Transplant ID
Saturday, 7:15 - 8:15 a.m.  S 152-154

Objectives: At the conclusion of this session, participants will be able to:
- identify common clinical dilemmas in transplant infectious diseases
- discuss management approaches in transplant infectious diseases
- evaluate nuances in the practice of transplant infectious diseases

Intended Audience: clinicians, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

Maximum of 1.00 hour of AMA PRA Category 1 Credit™
ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-253-L01-P

189. Meet-the-Professor Session
Updates from the Antibacterial Resistance Leadership Group
Saturday, 7:15 - 8:15 a.m.  W 2002

Objectives: At the conclusion of this session, participants will be able to:
- define elements of a pragmatic clinical trial
- discuss how host gene expression-based diagnostics distinguish bacterial and viral infection
- describe three future challenges of antimicrobial drug resistance

Intended Audience: academicians, clinicians, epidemiologists, fellows, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, researchers, scientists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-254-L01-P

190. Interactive Session
Shots Across the Bow: Debates in Vaccinology
Saturday, 8:45 - 10 a.m.  N 24

Objectives: At the conclusion of this session, participants will be able to:
- explain the complexity of vaccine trials in pregnant women
- discuss the impact of 3 versus 4 pneumococcal vaccines in children in the U.S.
- describe the known immune responses to repeated influenza vaccination

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-261-L01-P

191. Symposium
Big Beasts II
Saturday, 8:45 - 10 a.m.  W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:
- explain how to diagnose and treat herpes simplex virus, Klebsiella pneumoniae, and Cryptococcosis
- asymptomatic bacteriuria from urinary tract infection

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, researchers, scientists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-254-L01-P
### 192. Symposium

**Global Perspectives on Antimicrobial Resistance and Antimicrobial Stewardship Programs**

**Saturday, 8:45 - 10 a.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the status of global antimicrobial stewardship efforts
- discuss the World Health Organization’s activities in tracking antimicrobial resistance and promoting antimicrobial stewardship in Eastern Europe
- describe the landscape of antimicrobial resistance and trends in South America

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

*Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-255-L01-P*

### 193. Symposium

**ID Physicians and Addiction Medicine**

**Saturday, 8:45 - 10 a.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the status of the opioid epidemic, its impact on patients and as a driver of infectious diseases
- discuss how ID clinicians can integrate addiction medicine into ID practice
- describe how ID clinicians can overcome common challenges faced in the care of patients with substance dependence

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

*Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-256-L01-P*

### 194. Symposium

**Malignancies in Patients with HIV**

**Saturday, 8:45 - 10 a.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- review the effects of smoking and lung cancer in patients with HIV
- identify key issues for treating lymphoma in patients with HIV
- describe the epidemiology and therapeutic approaches to malignancies in resource-limited settings

**Intended Audience:** fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners

*Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-257-L01-P*

### 195. Symposium

**Neonatal Infectious Disease: Chagas, Zika, and LCMV**

**Saturday, 8:45 - 10 a.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the diagnosis and treatment of infants with congenital Chagas disease
- describe diagnostic testing and neurodevelopmental outcomes in infants with congenital Zika infection
- discuss the diagnosis and treatment of infants with congenital lymphocytic choriomeningitis virus (LCMV) infection

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

*Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-258-L01-P*

### 196. Symposium

**Non-Zika Arboviruses in the Americas**

*Co-organized with the Panamerican Society of Infectious Diseases, Brazilian Society of Infectious Diseases*

**Saturday, 8:45 - 10 a.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- review the common and unusual presentations of infections caused by the Chikungunya virus
Scientific Sessions (continued)

- discuss the clinical presentation of dengue and controversies with the vaccine in the Americas
- assess the clinical impact of the yellow fever outbreak in Brazil

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, pharmacists

**Maximum of 1.25 hours of AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-259-L01-P

**Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID**

197. Symposium

**Pediatric Infection Prevention: Small Patients, Big Challenges**
Saturday, 8:45 - 10 a.m. W 2006-2008

**Objectives:** At the conclusion of this session, participants will be able to:
- describe effective strategies for the prevention of mucosal barrier injury central line-associated bloodstream infections in children
- review infectious risks associated with animal-assisted therapy in pediatric healthcare facilities and offer practical solutions based on SHEA expert guidance
- discuss safe infant feeding practices in healthcare facilities with an emphasis on current challenges, including breast milk misadministrations

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, medical students and residents, members-in-training, nurses, pharmacists, public health practitioners

**Maximum of 1.25 hours of AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-260-L01-P

**Trainee / Pediatric ID / Investigative ID / Adult ID**

198. Symposium

**The Future of Transplant ID: Novel Diagnostics and Therapeutics**
Saturday, 8:45 - 10 a.m. S 214-216

**Objectives:** At the conclusion of this session, participants will be able to:
- evaluate new diagnostic tools and their applications in transplant infectious diseases
- review and categorize approaches to immunosuppressive therapy, emphasizing the relevance of each from an infectious diseases perspective
- discuss emerging transplant modalities and the implications for infectious diseases providers

**Trainee / Pediatric ID / Investigative ID / Adult ID**

199. Oral Abstract Session

**Clinical Trials that May Change Your Practice**
Saturday, 8:45 - 10 a.m. S 158

**Objectives for all IDWeek Oral Abstract Sessions:** ALL IDWeek Oral Abstract Session objectives coincide with the IDWeek meeting objectives and are available online at www.idweek.org.

**Intended Audience for all IDWeek Oral Abstract Sessions:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.
No CPE credit is offered for this session.

**Trainee / Pediatric ID / Investigative ID / Adult ID**

200. Oral Abstract Session

**Public Health: Epidemiology and Outbreaks**
Saturday, 8:45 - 10 a.m. S 157

No CME credit is offered for this session.
No CPE credit is offered for this session.

**Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID**

201. Oral Abstract Session

**The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment**
Saturday, 8:45 - 10 a.m. S 156

No CME credit is offered for this session.
No CPE credit is offered for this session.

**Trainee / Pediatric ID / Epidemiology and Infection Control / Adult ID**

202. Oral Abstract Session

**Transplant and Immunocompromised Hosts: Emerging Issues**
Saturday, 8:45 - 10 a.m. W 2002

No CME credit is offered for this session.
No CPE credit is offered for this session.
203. Interactive Session

**Tropical Medicine Cases: Conundrums and Case Management**
Saturday, 10:30 - 11:45 a.m.  
S 305-314

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the work-up of a variety of tropical diseases in a case-based format
- discuss the management of a variety of tropical diseases in a case-based format

**Intended Audience:** academicians, clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, public health practitioners

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
ACPE 1.25 application-based contact hours of pharmacy CE; 0221-9999-18-270-L01-P

204. Symposium

**Advances in Transplantation for Patients with HIV**
Saturday, 10:30 - 11:45 a.m.  
W 2014-2016

**Objectives:** At the conclusion of this session, participants will be able to:
- describe advances in transplantation for patients with HIV
- evaluate solid organ transplantation in patients with HIV
- summarize the latest approaches to bone marrow transplantation in patients with HIV

**Intended Audience:** academicians, clinicians, fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, researchers, scientists

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-263-L02-P

205. Symposium

**Changing Landscape of Rapid Diagnostic Tests and Their Impact**
Saturday, 10:30 - 11:45 a.m.  
S 206-208

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss the benefits and limitations of CIDTs
- explore the public health implications of CIDTs

**Intended Audience:** clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, scientists

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-266-L04-P

206. Symposium

**Controlling Antimicrobial Resistance Across Borders**
Saturday, 10:30 - 11:45 a.m.  
W 2005-2024

**Objectives:** At the conclusion of this session, participants will be able to:
- describe local and regional experiences and approaches to controlling the spread of antimicrobial resistance
- identify public health challenges and opportunities for controlling the spread of resistance among states
- discuss examples of how antimicrobial resistance can be controlled across national borders

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-265-L04-P

207. Symposium

**Cool Ways to Discover Antibiotics**
Saturday, 10:30 - 11:45 a.m.  
N 25

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss novel and cutting-edge approaches to discover antibiotics
- evaluate chemical strategies to modify antibiotics and provide new strictures with potential clinical utility
- discuss the discovery of antibiotics using a deep understanding of host-pathogen interactions

**Intended Audience:** academicians, clinicians, investigators, lab personnel, microbiologists, pharmacists, researchers, scientists

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-264-L04-P
<table>
<thead>
<tr>
<th>Scientific Sessions (continued)</th>
</tr>
</thead>
</table>

### 208. Symposium
**I'm Better than You and I Can Prove It: Quality Metrics for Clinical ID**
Saturday, 10:30 - 11:45 a.m.  
**W 2006-2008**

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the use of quality metrics that apply to specific infectious diseases
- discuss the role of metrics in improving the care of patients with infectious diseases

**Intended Audience:** clinicians, epidemiologists, fellows, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-267-L04-P

---

### 209. Symposium
**Infections in Immunocompromised Hosts**
Saturday, 10:30 - 11:45 a.m.  
**S 214-216**

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the presentation and management of complicated pneumonia
- explain the different approaches to treat complicated appendicitis
- discuss the management and treatment of pediatric ventricular shunt infections

**Intended Audience:** clinicians, epidemiologists, fellows, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, pharmacists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

No CME credit is offered for this session.

---

### 210. Symposium
**Influenza Vaccines: 100 Years After the Spanish Influenza: Past, Present, and Future**
Saturday, 10:30 - 11:45 a.m.  
**N 24**

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the history of the current influenza vaccine
- identify the strengths and weaknesses of the current influenza vaccine
- summarize the goals of universal immunization

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-268-L01-P

---

### 211. Oral Abstract Session
**Diagnostics Making a Difference**
**Healthcare Epidemiology: You Can Try This at Home—Innovative Epi Abstracts**
Saturday, 10:30 - 11:45 a.m.  
**S 158**

No CME credit is offered for this session.

No CPE credit is offered for this session.

---

### 212. Oral Abstract Session
**Late Breaker Oral Abstracts**
Saturday, 10:30 - 11:45 a.m.  
**S 157**

No CME credit is offered for this session.

No CPE credit is offered for this session.

---

### 213. Oral Abstract Session
**Optimizing HIV Treatment**
Saturday, 10:30 - 11:45 a.m.  
**S 156**

No CME credit is offered for this session.

No CPE credit is offered for this session.

---

### 214. Oral Abstract Session
**Translating Microbiome Science into Practice**
Saturday, 10:30 - 11:45 a.m.  
**W 2002**

No CME credit is offered for this session.

No CPE credit is offered for this session.
### Scientific Sessions (continued)

<table>
<thead>
<tr>
<th>Poster Abstract Sessions</th>
<th>S Poster Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday</strong></td>
<td></td>
</tr>
<tr>
<td>10 a.m. - 6 p.m.</td>
<td>On Display</td>
</tr>
<tr>
<td>12:30 - 1:45 p.m.</td>
<td>Lunch in the Exhibit Hall</td>
</tr>
<tr>
<td>12:30 - 1:45 p.m.</td>
<td>Presenters at Posters</td>
</tr>
</tbody>
</table>

| **216.** Antimicrobial Stewardship: Global Perspectives |
| **217.** Antimicrobial Stewardship: Impact of Allergy |
| **218.** Antimicrobial Stewardship: Impact of New Diagnostics |
| **219.** Antimicrobial Stewardship: New Methods and Metrics |
| **220.** Antimicrobial Stewardship: Non-hospital Settings |
| **221.** Antimicrobial Stewardship: Outpatient Settings |
| **222.** Antimicrobial Stewardship: Potpourri |
| **223.** Antimicrobial Stewardship: Qualitative Research |
| **224.** Antiviral Therapies |
| **225.** Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis |
| **226.** Clinical Practice Issues: OPAT |
| **227.** Clinical Trials |
| **228.** Diagnostics: Bacteria and Mycobacteria |
| **229.** Diagnostics: Biomarkers and Novel Approaches |
| **230.** Diagnostics: Mycology |
| **231.** Diagnostics: Parasitology |
| **232.** Diagnostics: Resistance Testing |
| **233.** Diagnostics: Virology |
| **234.** Healthcare Epidemiology: Device-associated HAIs |
| **235.** Healthcare Epidemiology: Surgical Site Infections |
| **236.** Healthcare Epidemiology: Epidemiologic Methods |
| **237.** Healthcare Epidemiology: HAI Surveillance |
| **238.** Hepatitis A, B, and C |
| **239.** HIV and Viral Hepatitis Co-Infection |
| **240.** HIV: Malignancy |
| **241.** HIV: Metabolic, Cardiovascular, and Renal Complications |
| **242.** HIV: Opportunistic Infections and other Infectious Complications |
| **243.** HIV: Sexually Transmitted Infections |
| **244.** Miscellaneous Vaccines |
| **245.** Molecular & Sequence Based Diagnostics |
| **246.** Pediatric Healthcare-Associated Infections |
| **247.** Pediatric Bacterial Infections |
| **248.** Pediatric Viral Infections |
| **249.** Skin and Skin Structure Infection |
| **250.** Treatment of AMR Infections |
| **251.** Adolescent Vaccines |
| **252.** Vaccine Policy and Hesitancy |
| **253.** Vaccines for Herpes Zoster Virus |
| **254.** Vaccines for the Elderly and Immune Compromised |
| **255.** Virology Potpourri |

**Intended Audience for all IDWeek Poster Discussion Rounds:**
- academicians,
- clinicians,
- epidemiologists,
- fellows,
- healthcare workers,
- HIV clinicians,
- HIV specialists,
- hospital administrators,
- hospital epidemiologists,
- infection preventionists,
- infectious diseases pediatricians,
- infectious diseases physicians,
- investigators,
- lab personnel,
- medical students and residents,
- members-in-training,
- microbiologists,
- nurses,
- pharmacists,
- public health practitioners,
- researchers,
- scientists,
- vaccinologists

No CME credit is offered for this session.
No CPE credit is offered for this session.

**257. Poster Discussion Round Diagnostics**
**Saturday, 12:30 - 1:45 p.m.**

No CME credit is offered for this session.
No CPE credit is offered for this session.

**258. Poster Discussion Round Co-Morbidities and Metabolic Disorders**
**Saturday, 12:30 - 1:45 p.m.**

No CME credit is offered for this session.
No CPE credit is offered for this session.

**259. Poster Discussion Round Immunocompromised Hosts**
**Saturday, 12:30 - 1:45 p.m.**

No CME credit is offered for this session.
No CPE credit is offered for this session.

**260. Symposium Advances in Epidemiology Research Methods**
**Saturday, 2 - 3:15 p.m.**

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss strategies for using implementation science
- describe the use of location mapping in infection prevention
- recognize novel sources of data for quality studies

**Intended Audience:**
- academicians,
- epidemiologists,
- fellows,
- hospital administrators,
- hospital epidemiologists,
- infection preventionists,
- infectious diseases pediatricians,
- infectious diseases physicians,
- investigators,
- medical students and residents,
- members-in-training,
- nurses,
- pharmacists,
- public health practitioners,
- researchers,
- scientists

Maximum of 1.25 hours of **AMA PRA Category 1 Credit™**

ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-271-L04-P
261. Symposium
Infection Prevention in Post-Acute Care: Controversies and Challenges
Saturday, 2 - 3:15 p.m.  S 206-208

Objectives: At the conclusion of this session, participants will be able to:
• review implementation of contact precautions for multidrug-resistant organisms (MDROs) in long-term care settings, balancing risks and benefits
• discuss infection prevention challenges in long-term acute care hospitals (LTACHs)
• describe antibiotic stewardship interventions in long-term care settings

Intended Audience: clinicians, fellows, infection preventionists, medical students and residents, members-in-training, pharmacists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-272-L01-P

262. Symposium
Intersection of Surgery and Pediatric Infectious Disease
Saturday, 2 - 3:15 p.m.  S 214-216

Objectives: At the conclusion of this session, participants will be able to:
• describe the presentation and management of complicated pneumonia
• discuss the different approaches to treat complicated appendicitis
• discuss the management and treatment of pediatric ventricular shunt infections

Intended Audience: academicians, clinicians, epidemiologists, fellows, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-314-L01-P

263. Symposium
Old Foes and Emerging Threats: Multidrug-Resistant Bacterial Infections in Children
Saturday, 2 - 3:15 p.m.  W 2006-2008

Objectives: At the conclusion of this session, participants will be able to:
• evaluate the current status of community-acquired and healthcare-acquired gram-positive bacterial infections in children and why these infections continue to be a threat to pediatric patients
• describe the evolution of resistance in gram-negative bacteria and how this emergence of multidrug-resistance is impacting children
• discuss the potential niches of newer antibiotic agents with enhanced gram-negative activity

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-273-L01-P

264. Symposium
Pain Management and Mental Health in Patients with HIV
Saturday, 2 - 3:15 p.m.  W 2014-2016

Objectives: At the conclusion of this session, participants will be able to:
• evaluate strategies for managing pain in patients with HIV
• identify approaches to treating opioid addiction in patients with HIV
• describe key considerations in monitoring and managing the mental health of aging patients with HIV

Intended Audience: fellows, HIV clinicians, HIV specialists, infectious diseases physicians, pharmacists, public health practitioners

Maximum of 1.25 hours of AMA PRA Category 1 Credit™
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-274-L02-P

265. Symposium
Strategy Trials: A New Paradigm in Infectious Diseases Research
Saturday, 2 - 3:15 p.m.  W 2005-2024

Objectives: At the conclusion of this session, participants will be able to:
• explain the rationale for performing strategy trials in infectious diseases
• summarize data for two of the more common infections addressed by strategy

Intended Audience: academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab
Scientific Sessions (continued)

personnel, medical students and residents, members-in-training, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-275-L04-P

Trainee / HIV-STD-TB / Investigative ID / Adult ID

266. Symposium

**Syphilis in the 21st Century**
Saturday, 2 - 3:15 p.m.  N Hall D

**Objectives:** At the conclusion of this session, participants will be able to:
- review the syphilis diagnostic and therapeutic pipeline
- describe the host-pathogen interactions in syphilis and their implications on vaccine development
- review the behavioral aspects associated with the current STI and syphilis epidemic

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, HIV clinicians, HIV specialists, hospital epidemiologists, infectious diseases physicians, medical students and residents, microbiologists, pharmacists, public health practitioners, researchers, scientists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-276-L01-P

Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Epidemiology and Infection Control / Adult ID

267. Symposium

**When Does PK/PD Matter for Patient Care?**
Saturday, 2 - 3:15 p.m.  S 305-314

**Objectives:** At the conclusion of this session, participants will be able to:
- describe the clinical relevance of antibiotic pharmacokinetics
- explain when adjustment may be needed for optimal therapy
- discuss the literature exploring the impact of organ specific antibiotic pharmacokinetics

**Intended Audience:** academicians, clinicians, infectious diseases pediatricians, infectious diseases physicians, pharmacists, researchers, scientists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-277-L04-P

Transplant ID / Trainee / Pediatric ID / Global ID / Adult ID

268. Symposium

**When Transplant Tours the World**
Saturday, 2 - 3:15 p.m.  N 25

**Objectives:** At the conclusion of this session, participants will be able to:
- discuss issues surrounding tuberculosis infection from a transplant perspective, including infection prevention, identification, diagnosis, and treatment
- examine the infectious disease challenges that arise from transplant tourism
- review emerging arbovirus infections as they pertain to organ transplant donors and recipients

**Intended Audience:** clinicians, fellows, healthcare workers, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses, pharmacists

Maximum of 1.25 hours of *AMA PRA Category 1 Credit™*
ACPE 1.25 knowledge-based contact hours of pharmacy CE; 0221-9999-18-278-L01-P

Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Epidemiology and Infection Control / Adult ID

269. Oral Abstract Session

**Flu and other Vaccines in Children**
Saturday, 2 - 3:15 p.m.  W 2002

No CME credit is offered for this session.
No CPE credit is offered for this session.

Investigative ID / Adult ID

270. Oral Abstract Session

**Genomics and Susceptibility of Superbugs**
Saturday, 2 - 3:15 p.m.  S 157

No CME credit is offered for this session.
No CPE credit is offered for this session.

Trainee / Pediatric ID / Investigative ID / Epidemiology and Infection Control / Adult ID

271. Oral Abstract Session

**Novel Diagnostics for Fungi, Parasites, and CNS Infection**
Saturday, 2 - 3:15 p.m.  S 158

No CME credit is offered for this session.
No CPE credit is offered for this session.

Trainee / Pediatric ID

272. Oral Abstract Session

**Pediatric Viral Infections**
Saturday, 2 - 3:15 p.m.  S 156

No CME credit is offered for this session.
No CPE credit is offered for this session.
273. Named Lecture

**Joseph E. Smadel Lecture**
Saturday, 3:30 - 3:55 p.m.  
N Hall D

**Objectives:** At the conclusion of this session, participants will be able to:

- describe the research potential of partnerships between academic and public health institutions
- discuss the impact of post-licensure studies on vaccine effectiveness

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 0.25 hours of *AMA PRA Category 1 Credit™*
ACPE .4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-279-L04-P

274. Awards Session

**Awards Session**
Saturday, 3:55 - 4:05 p.m.  
N Hall D

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

No CME credit is offered for this session.
No CPE credit is offered for this session.

275. Oral Abstract Session

**Featured Oral Abstract**
Saturday, 4:05 - 4:20 p.m.  
N Hall D

No CME credit is offered for this session.
No CPE credit is offered for this session.

276. Named Lecture

**Edward H. Kass Lecture**
Saturday, 4:20 - 4:45 p.m.  
N Hall D

**Objectives:** At the conclusion of this session, participants will be able to:

- describe the evolution of opportunistic infections as a challenge to durable survival of patients with HIV
- discuss the broad range of skills that an ID practitioner has the opportunity to use to meet the challenges of infectious pathogens
- summarize the professional skills that are needed to be an effective ID practitioner

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 0.25 hours of *AMA PRA Category 1 Credit™*
ACPE .4 knowledge-based contact hours of pharmacy CE; 0221-9999-18-280-L02-P

277. Interactive Session

**ID BugBowl**
Saturday, 5 - 6 p.m.  
N Hall D

**Objectives:** At the conclusion of this session, participants will be able to:

- TBD

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.00 hour of *AMA PRA Category 1 Credit™*
No CPE credit is offered for this session.
278. Mini-Symposium

Does Detection Equal Infection: Application of the IDSA Diarrhea Infectious Disease Guidelines in an Era of Changing Diagnostics

Sunday, 8 - 9 a.m.  W 2001-2003

**Objectives:** At the conclusion of this session, participants will be able to:

- explain how to use the 2017 Infectious Diseases Society of America guideline
- improve their approach to patients with potentially infectious causes of diarrhea

**Intended Audience:** clinicians, fellows, infectious diseases pediatricians, infectious diseases physicians, lab personnel, medical students and residents, microbiologists, public health practitioners

Maximum of 1.00 hour of AMA PRA Category 1 Credit™

No CPE credit is offered for this session.

279. Mini-Symposium

Red Book Update

Sunday, 8 - 9 a.m.  W 2006-2008

**Objectives:** At the conclusion of this session, participants will be able to:

- discuss recent changes in recommendations in the Red Book: A Report of the AAP Committee on Infectious Diseases
- apply current recommendations in the administration of pediatric vaccines

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, medical students and residents, members-in-training, nurses

Maximum of 1.00 hour of AMA PRA Category 1 Credit™

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-281-L04-P

280. Mini-Symposium

Tele-Antimicrobial Stewardship

Sunday, 8 - 9 a.m.  W 2014-2016

**Objectives:** At the conclusion of this session, participants will be able to:

- list and characterize the types of tele-antimicrobial stewardship programs that have been developed
- describe challenges and opportunities in the development of tele-antimicrobial stewardship programs

**Intended Audience:** clinicians, epidemiologists, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-315-L04-P

281. Plenary Session

Closing Plenary: From Science Fiction to Clinical Trial: The Use of Phage to Treat Antibiotic-Resistant Infections

Sunday, 9:15 - 10:45 a.m.  W 2005-2024

**Objectives:** At the conclusion of this session, participants will be able to:

- describe the rationale, opportunities, and challenges to the use of bacteriophages for the treatment of bacterial infections
- discuss how phage lysins work as therapeutic agents against antibiotic-resistant bacteria and their effectiveness

**Intended Audience:** academicians, clinicians, epidemiologists, fellows, healthcare workers, HIV clinicians, HIV specialists, hospital administrators, hospital epidemiologists, infection preventionists, infectious diseases pediatricians, infectious diseases physicians, investigators, lab personnel, medical students and residents, members-in-training, microbiologists, nurses, pharmacists, public health practitioners, researchers, scientists, vaccinologists

Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE 1 knowledge-based contact hours of pharmacy CE; 0221-9999-18-316-L04-P
30. Oral Abstract Session  
**Healthcare Epidemiology: Hot Topics**  
Thursday, 8:45 - 10 a.m.  

109 Differences in Gram-Negative Antibiotic Susceptibility among Patients Receiving Fecal Microbiota Transplant for *Clostridioides difficile*  
110 The Burden and Preventability of Sepsis-Associated Mortality in Six U.S. Acute Care Hospitals  
111 Increasing Duration of Surgical Prophylaxis Increases Antimicrobial-Associated Adverse Events but Does Not Decrease Surgical Site Infections: An Opportunity for Stewardship  
112 Sick Employee Online Log System for Tracking Employee Illnesses during the 2017-18 Influenza Season Provided Real-Time Surveillance and Early Detection of Influenza-Like Illnesses Among Employees  
113 Accuracy of the NHSN Central Line-Associated bloodstream Infection (CLABSI) Definition  

31. Oral Abstract Session  
**Infant Viral Infections**  
Thursday, 8:45 - 10 a.m.  

114 Birth Prevalence of Congenital Cytomegalovirus Infection and Language, Hearing, and Developmental Outcomes in a Cohort of HIV-Exposed, Uninfected Preschool Children  
115 Results of a Targeted Neonatal Screening Program for Congenital Cytomegalovirus Infection in Montreal, Quebec  
116 Role of Maternal Antibodies in Protection Against Postnatal Cytomegalovirus Acquisition  
117 Effect of Nasopharyngeal Pneumococcal Carriage on RSV and hMPV Illness Severity in Infants in Nepal  
118 Nasopharyngeal (NP) Bacterial Detection in Infants with Respiratory Syncytial Virus (RSV) Infection: Impact on Clinical Outcomes  

32. Oral Abstract Session  
**Tuberculosis and other Mycobacterial Infections**  
Thursday, 8:45 - 10 a.m.  

119 Prospective Validation of a Three-Gene Signature for Tuberculosis Diagnosis, Predicting Progression, and Evaluating Treatment Response  
120 A Randomized Double-Blind Trial Assessing the Efficacy of M72/AS01, Vaccine Against Pulmonary Tuberculosis Disease in Adults with Latent *Mycobacterium tuberculosis* Infection  

121 Improving Predictive Value of Phase 2a TB Drug Development Models through PET/CT Imaging (NexGen EBA)  
122 All-cause Mortality Increased with Nontuberculous Mycobacterial Lung Disease in U.S. Medicare  
123 Hansen’s Disease and Complications Among Marshallese-Americans in Northwest Arkansas, 2003–2017  

33. Oral Abstract Session  
**What's Hot in UTIs and STIs**  
Thursday, 8:45 - 10 a.m.  

124 Microbiological Outcomes with Plazomicin (PLZ) Versus Meropenem (MEM) in Patients (pts) with Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP) in the EPIC Study  
125 eGISP: Enhanced Surveillance of *Neisseria gonorrhoeae* Antimicrobial Susceptibility in the United States  
126 Robust and Persistent Vaginal Colonization with LACTIN-V Vaginal *Lactobacillus crispatus* Probiotic in a Double-Blind, Placebo Controlled (DBPC) Phase 2b Trial to Prevent Recurrent UTI (rUTI)  
127 Urinary Tract Infection Incidence is Associated with Recent Environmental Temperatures  
128 Sexually Transmitted Infection Incidence is Associated with Recent Environmental Temperatures  

44. Oral Abstract Session  
**Adult and Adolescent Vaccines**  
Thursday, 10:30 - 11:45 a.m.  

149 Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial  
150 Relative Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017.  
151 Evaluation of Pneumococcal Vaccine Effectiveness Against Invasive Pneumococcal Disease Among U.S. Medicare Beneficiaries >=65 Years Old  
152 Protective Antibody Levels 7.5 Years after Primary Vaccination in Adolescence with a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults: Phase IIIb Clinical Findings  
153 The Effect of Timing of Tetanus-Diphtheria and Pertussis Vaccine Administration in Pregnancy on the Avidity of Pertussis Antibodies
### 45. Oral Abstract Session

**Cool Findings in Bacteremia and Endocarditis**

**Thursday, 10:30 - 11:45 a.m.**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>154</td>
<td>Diagnosis and Genotyping of <em>Coxiella burnetii</em> Causing Endocarditis in a Patient with Prosthetic Pulmonary Valve Replacement (PVR) Using Next-Generation Sequencing (NGS) of Plasma</td>
</tr>
<tr>
<td>155</td>
<td>Infective Endocarditis and Cardiac Valve Surgery During the Opioid Epidemic in North Carolina, 2007 to 2017</td>
</tr>
<tr>
<td>156</td>
<td>Direct Detection and Quantification of Bacterial Cell-free DNA in Patients with Infective Endocarditis (IE) Using the Karius Plasma Next Generation Sequencing (NGS) Test</td>
</tr>
<tr>
<td>157</td>
<td>Reducing Blood Culture Contamination Rates Through the Use of a Red Top Tube Discard</td>
</tr>
<tr>
<td>158</td>
<td>The Effect of Insurance Coverage on Appropriate Selection of Hospital Discharge Antibiotics for <em>Staphylococcus aureus</em> Bacteremia</td>
</tr>
</tbody>
</table>

### 46. Oral Abstract Session

**Healthcare Epidemiology: Special Populations**

**Thursday, 10:30 - 11:45 a.m.**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>159</td>
<td>Genomic Epidemiology of MRSA at Intake to a Large Inner-City Jail—Evidence for Community Transmission Networks?</td>
</tr>
<tr>
<td>160</td>
<td>Reduction in the Spread of Hospital-Associated Infections Among Pediatric Oncology Patients in an Animal-Assisted Intervention Program from a Canine Decolonization Procedure</td>
</tr>
<tr>
<td>161</td>
<td>Prevalence and Risk Factors for <em>Candida auris</em> Colonization Among Patients in a Long Term Acute Care Hospital—New Jersey, 2017</td>
</tr>
<tr>
<td>162</td>
<td>Association between Antibiotic Use and Multidrug-Resistant Organism Detection in Advanced Cancer Patients on Palliative Chemotherapy</td>
</tr>
<tr>
<td>163</td>
<td>Development of an Electronic Flagging Tool for Identifying Cardiac Device Infections: Insights from the VA CART Program</td>
</tr>
</tbody>
</table>

### 47. Oral Abstract Session

**Science Relevant to ID**

**Thursday, 10:30 - 11:45 a.m.**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>164</td>
<td>Reporting the High-Resolution Structure of the Enterococcal Ribosome—A New Template for Antibiotic Discovery</td>
</tr>
<tr>
<td>165</td>
<td><em>Mycobacterium Tuberculosis</em> Produces Molecules that Trigger Nociceptive Neurons to Activate Cough</td>
</tr>
<tr>
<td>166</td>
<td>TGFβ Restricts T Cell IFNγ Production in Pulmonary Tuberculous Granulomas</td>
</tr>
</tbody>
</table>

### 48. Oral Abstract Session

**Late Breaker Oral Abstracts**

**Thursday, 10:30 - 11:45 a.m.**

See meeting app.

### 84. Oral Abstract Session

**Antimicrobial Stewardship: Better Prescribing, Better Outcomes**

**Thursday, 2 - 3:15 p.m.**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>854</td>
<td>The Impact of the CMS SEP-1 Core Measure on Antimicrobial Utilization: A Multicenter Interrupted Time-Series (ITS) Analysis</td>
</tr>
<tr>
<td>855</td>
<td>Impact of FDA Black Box Warning on Fluoroquinolone and Alternative Antibiotic Use in Southeastern U.S. Hospitals</td>
</tr>
<tr>
<td>856</td>
<td>Impact of Early Discontinuation of Antimicrobial Therapy on Survival in Culture-Negative Clinically Suspected Serious Infection: An Electronic Health Record-Based Analysis from 111 U.S. Hospitals</td>
</tr>
<tr>
<td>857</td>
<td>A Tele-Antibiotic Stewardship Program Influences Antibiotic Use at 2 Rural Veterans Affairs Medical Centers</td>
</tr>
<tr>
<td>858</td>
<td>Preoperative “Dirty” Urinalysis Leads to Antibiotic Use Without Benefit</td>
</tr>
</tbody>
</table>

### 85. Oral Abstract Session

**Preventing and Identifying New HIV Infections**

**Thursday, 2 - 3:15 p.m.**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>859</td>
<td>Same-day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-In STD Clinic Appointments is a Safe, Feasible, and Effective Method to Engage Patients at Risk for HIV in PrEP Care</td>
</tr>
<tr>
<td>860</td>
<td>Immediate Access to Post-Exposure Prophylaxis (PEP) through a 24/7 New York City PEP Hotline</td>
</tr>
</tbody>
</table>

---

*Final Program IDWeek 2018*
## Oral Abstract Sessions (continued)

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>861</td>
<td>Health Disparities in HIV and Pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>862</td>
<td>Spatial Distribution of HIV Transmission in Ethiopia and Characteristics of HIV Clusters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>863</td>
<td>Increasing PrEP Uptake: A Diffusion-Based Network Intervention for HIV Prevention Among Young Black Men Who Have Sex with Men</td>
<td></td>
<td></td>
</tr>
<tr>
<td>864</td>
<td>Therapeutic Immunosuppression to Treat Rabies Encephalitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>865</td>
<td><em>Acanthamoeba</em> Disease Associated with the Practice of Nasal Rinsing in Immunocompromised Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>866</td>
<td>Increased Diagnosis of Varicella Zoster Virus Infection of the Central Nervous System with the BioFire FilmArray Meningitis/Encephalitis Panel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>867</td>
<td>Upregulated Matrix Metalloproteinase-2 Relates to Milder Hearing Impairment in Bacterial Meningitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>868</td>
<td>Prospective Pathogen Detection in Patients with Central Nervous System Inflammation Using Metagenomic Sequencing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>869</td>
<td>Evaluation of Broad-Spectrum Antibiotic De-Escalation in Patients with Healthcare-Associated Pneumonia (HCAP) and No Microbiological Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>870</td>
<td>Incidence and Temporality of Influenza-Related Parotitis—Arkansas, 2016–2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>871</td>
<td>Symptomatic Respiratory Syncytial Virus and Adenovirus Upper Respiratory Tract Infections Increase the Risk of Invasive Aspergillosis after Allogeneic Hematopoietic Cell Transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>872</td>
<td>PROPHETIC: Predicting Pneumonia in Hospitalized Patients in the ICU—A Model and Scoring System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>873</td>
<td>Using the Host Immune Response to Identify Viral-Bacterial Coinfection in Children with <em>Respiratory syncytial virus</em> Infection</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Adult ID / Investigative ID / Pediatric ID  |

## 86. Oral Abstract Session

### Pushing the Envelope in CNS Infections

**Thursday, 2 - 3:15 p.m.**  
**S 158**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>874</td>
<td>Therapeutic Immunosuppression to Treat Rabies Encephalitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>875</td>
<td><em>Acanthamoeba</em> Disease Associated with the Practice of Nasal Rinsing in Immunocompromised Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>876</td>
<td>Increased Diagnosis of Varicella Zoster Virus Infection of the Central Nervous System with the BioFire FilmArray Meningitis/Encephalitis Panel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>877</td>
<td>Upregulated Matrix Metalloproteinase-2 Relates to Milder Hearing Impairment in Bacterial Meningitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>878</td>
<td>Prospective Pathogen Detection in Patients with Central Nervous System Inflammation Using Metagenomic Sequencing</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Pediatric ID / Investigative ID / Adult ID  |

## 87. Oral Abstract Session

### Respiratory Infections: An Update

**Thursday, 2 - 3:15 p.m.**  
**W 2002**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>879</td>
<td>Evaluation of Broad-Spectrum Antibiotic De-Escalation in Patients with Healthcare-Associated Pneumonia (HCAP) and No Microbiological Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>880</td>
<td>Incidence and Temporality of Influenza-Related Parotitis—Arkansas, 2016–2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>881</td>
<td>Symptomatic Respiratory Syncytial Virus and Adenovirus Upper Respiratory Tract Infections Increase the Risk of Invasive Aspergillosis after Allogeneic Hematopoietic Cell Transplantation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>882</td>
<td>PROPHETIC: Predicting Pneumonia in Hospitalized Patients in the ICU—A Model and Scoring System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>883</td>
<td>Using the Host Immune Response to Identify Viral-Bacterial Coinfection in Children with <em>Respiratory syncytial virus</em> Infection</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Pediatric ID / Investigative ID / Adult ID  |

## 90. Oral Abstract Session

### Featured Oral Abstract

**Thursday, 4:05 - 4:20 p.m.**  
**N Hall D**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>885</td>
<td>Sex Differences in Academic Achievement and Faculty Rank in Academic Infectious Diseases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Transplant ID / Trainee / Pediatric ID / Investigative ID / HIV-STD-TB / Global ID / Epidemiology and Infection Control / Adult ID  |

## 112. Oral Abstract Session

### Bacterial Infections and Antimicrobial Stewardship

**Friday, 8:45 - 10 a.m.**  
**S 156**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>919</td>
<td>Clinical and Microbiologic Characteristics Associated with Long Term Orthopedic Complications Following <em>Staphylococcus aureus</em> Acute Hematogenous Osteoarticular Infections in Children</td>
<td></td>
<td></td>
</tr>
<tr>
<td>920</td>
<td>A Sharp Fall in Antibiotic Use in Infants is Correlated with a Population-Wide Reduction in Asthma Incidence for Children Under Five</td>
<td></td>
<td></td>
</tr>
<tr>
<td>921</td>
<td>Antibiotic Prescribing for Children in Family Medicine Clinics within a Practice Research Network</td>
<td></td>
<td></td>
</tr>
<tr>
<td>922</td>
<td>Barriers to Pediatric Staff Nurse Participation in Antimicrobial Stewardship Programs (ASP) Linked to Organizational Culture</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Adult ID / Epidemiology and Infection Control / Pediatric ID  |

## 113. Oral Abstract Session

### Healthcare Epidemiology: Outbreaks!

**Friday, 8:45 - 10 a.m.**  
**W 2002**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>923</td>
<td>Rapid Emergence of <em>Candida auris</em> in the Chicago Region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>924</td>
<td>Incidence of Symptomatic and Asymptomatic Influenza Among Healthcare Workers: A Multicenter Prospective Cohort Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>925</td>
<td>Healthcare-Associated Legionnaires’ Disease, California, 2015-2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>926</td>
<td>Outbreak of Invasive Nontuberculous <em>Mycobacterium</em> (NTM) Infections Associated with a Pediatric Dental Practice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>927</td>
<td>Tap Water Avoidance Decreases Rates of Nontuberculous Mycobacteria in Intensive Care Units</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Adult ID / Epidemiology and Infection Control / Investigative ID / Pediatric ID  |

## 114. Oral Abstract Session

### Hepatitis C: Epidemiology and Elimination

**Friday, 8:45 - 10 a.m.**  
**W 2002**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>928</td>
<td>Major Decrease in Prevalence of Hepatitis C Viremia in Key Populations Following the 2nd Year of Treatment as Prevention for Hepatitis C (TraP HepC) Program in Iceland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>929</td>
<td>Hepatitis C Virus in Women of Child-Bearing Age, Pregnant Women, and Young Children</td>
<td></td>
<td></td>
</tr>
<tr>
<td>930</td>
<td>HCV Treatment is Associated with a Reduced Risk of Cardiovascular Disease Events: Results from ERCHIVES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>931</td>
<td>Telemedicine for the Treatment of Hepatitis C: A Systematic Review and Meta-Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>932</td>
<td>Universal Hepatitis C Virus Screening in a Tennessee Tertiary Care Emergency Department</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Adult ID / Epidemiology and Infection Control / Pediatric ID  |
115. Oral Abstract Session
HIV-Related Comorbidities and Complications
Friday, 8:45 - 10 a.m. S 157

933  Serum Albumin is Associated with Higher Inflammation and Carotid Atherosclerosis in Treated HIV Infection

934  Incidence of Skin and Soft Tissue Infection in People Living with HIV in a Large Urban Public Health Care System in Houston, Texas, 2009-2014

935  Repeat Pregnancies Among Women Living with HIV: Evaluating Temporal Changes in HIV Disease Status and Exploring the Association Between Preterm Birth and Protease Inhibitor Use in Pregnancy

936  Body Fat Redistribution/Accumulation, Pancreatic Disorders, Musculoskeletal Disorders, IRIS, Severe Systemic Rash and Hypersensitivity Reactions Following Initiation of Commonly Prescribed Antiretrovirals

937  Virally Suppressed PLH Switching from Abacavir to Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation

124. Oral Abstract Session
Adventures with Globally Acquired Infections
Friday, 10:30 - 11:45 a.m. S 158

962  Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing

963  Whole Blood Transcriptome Analysis Reveals Differences in Erythropoiesis and Neurologically Relevant Pathways between Cerebral Malaria and Severe Malarial Anemia

964  Impact of Doxycycline as Malaria Prophylaxis on Risk of Influenza Like Illness among International Travelers

965  Applying Clinical Prediction Tools to Patients with Lassa Fever


125. Oral Abstract Session
Fungal Infections
Friday, 10:30 - 11:45 a.m. W 2002

967  Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis

968  Managing Invasive Aspergillosis in the Era of Diagnostic PCR and Increasing Triazole Resistance: A Modelling Study of Different Strategies

969  GRP78 and Integrin β1/α3 Play Disparate Roles in Epithelium Invasion During Mucormycosis

970  Emerging Pathogen Candida auris Evades Neutrophil Attack

971  Breakthrough Invasive Fungal Infections (IFI) in Acute Leukemia (AL) Patients Receiving Antifungal Prophylaxis

126. Oral Abstract Session
Healthcare Epidemiology: The Poop Pager and Other Novel Perspectives on C. difficile in the Healthcare Setting
Friday, 10:30 - 11:45 a.m. S 156

972  Asymptomatic Carriage of Clostridiodes difficile and Risk of Subsequent Infection

973  Inter-Facility Patient Sharing and Clostridium difficile Incidence in the Ontario Hospital Network: A 13-Year Longitudinal Cohort Study of 116 Hospitals

974  Impact of Mandatory Infectious Disease (ID) Specialist Approval on Hospital-Onset Clostridium difficile (HO-CDI) Testing and Infection Rates: Results of a Pilot Study

975  Clostridium difficile Infection and Antibiotic Prescription Rates in the Community: Explaining the Gender Gap

976  Clostridium difficile Colonization, Molecular Epidemiology, and Anti-Toxin Serological Responses in Healthy Infants: A Prospective Cohort Study

127. Oral Abstract Session
Medical Education
Friday, 10:30 - 11:45 a.m. S 157

977  An Innovative 3-Year Medical Student Spiral Curriculum in Antimicrobial Stewardship and Infectious Diseases

978  Assessing the Impact of a Mobile Device-Based Clinical Decision Support Tool on Guideline Adherence and Mental Workload

979  Standardizing Medical Student Learning for Infectious Diseases Consult Electives: Prioritizing Content

980  Using Videoconferencing with the Clinical Microbiology Lab to Enhance Medical Student Learning during Clinical Rotations

981  A Comprehensive Survey of Infectious Diseases Curriculum among United States Pharmacy Schools

128. Oral Abstract Session
PIDS Featured Oral Abstract Caroline B. Hall Lecture
Friday, 10:30 - 10:45 a.m. S 214-216

982  Summer Outbreak of Severe RSV-B Disease, Minnesota, 2017
Oral Abstract Sessions (continued)

165. Oral Abstract Session
**Antibiotic Stewardship: Developing and Implementing Effective Programs**
Friday, 2 - 3:15 p.m.  S 156

1629 Targeted Antimicrobial Use Admission Provides an Actionable Denominator for Antimicrobial Stewardship Programs Evaluating Inpatient Length of Therapy

1630 Antibiotics Prescribed for Infection Prophylaxis Prior to Dental Procedures Are Frequently Unnecessary in the United States

1631 Made to Measure: Development of a Scoring Tool to Customize Antimicrobial Stewardship Goals across a Large Health-System

1632 Non-Visit-Based and Non-Infection-Related Ambulatory Antibiotic Prescribing

1633 A Multifaceted Intervention to Improve Prescribing for Acute Respiratory Infection in Adults and Children in Emergency Department and Urgent Care Settings (MITIGATE Trial)

166. Oral Abstract Session
**Changing Clinical Practice for Changing Times**
Friday, 2 - 3:15 p.m.  S 157

1634 A 9-Point Risk Assessment for Patients Who Inject Drugs Requiring Intravenous Antibiotics May Allow Health Systems to Focus Inpatient Resources on Those at Greatest Risk of Ongoing Drug Use

1635 Do Persons with Opioid Use Disorder and Injection-Related Infections Really Need Prolonged Hospitalizations to Complete Intravenous Antibiotic Therapy?

1636 Variation in Clinical Practice Patterns among Infectious Diseases Faculty at a Large Academic Institution

1637 Improving Transitions of Care in the Division of Infectious Diseases

1638 Tele-Infectious Disease Consultation Produces Equivalent Outcomes as In-Person Consultation

167. Oral Abstract Session
**Late Breaker Oral Abstracts**
Friday, 2 - 3:15 p.m.  S 152-154

See meeting app.

168. Oral Abstract Session
**Novel Therapies for Superbugs**
Friday, 2 - 3:15 p.m.  S 158

1639 Efficacy of Voriconazole Prophylaxis Followed by Therapeutic Liposomal Amphotericin B for the Treatment of Murine Pulmonary Aspergillosis Caused by Azole Resistant Aspergillus fumigatus Strains

1640 Towards New Anti-Biofilm Therapies: High Mobility Group Box 1 (HMGB1) Protein and its Structural Variants Can Be Used to Disrupt Bacterial Biofilms (BBs)

1641 Treatment of Recurrent Clostridium difficile Infection with SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes

1642 Safety and Efficacy of Bacteriophage Therapy: Analysis of Clinical Case Series Data

1643 Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI)

169. Oral Abstract Session
**Respiratory and Gastroenteritis Viruses**
Friday, 2 - 3:15 p.m.  W 2002

1644 A Potent Broadly Neutralizing Antibody Isolated from Human Memory B-Cells Binding to Conserved Site IV on the RSV F Protein

1645 Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time, and Influenza Type B Virus Infection (CAPSTONE-1 Study)

1646 Combined Resistance Analyses from Phase 2b Studies of Presatovir Treatment in RSV-Infected Adults

1647 Real-Time Metagenomic Sequencing Reveals Discrete Transmission Clusters within a Hospital-Associated Norovirus Outbreak

1648 Incidence of Norovirus and Rotavirus from Multisite Active Surveillance in Veteran’s Affairs Hospitals, December 2016–February 2018: Results from the SUPERNOVA Network
### Oral Abstract Sessions (continued)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
</table>
| 178 | Oral Abstract Session | PIDS Featured Oral Abstract  
**Friday, 3:30 - 3:45 p.m. N 25**  
178. Marked Improvement in Pandemic H1N1 Component Shedding and Immunogenicity in 2017-18 Russian-Backbone Live Attenuated Influenza Vaccine (LAIV) in Gambian Children  
199 | Oral Abstract Session | Clinical Trials that May Change Your Practice  
**Saturday, 8:45 - 10 a.m. S 158**  
1715 A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Trial to Examine the Effects of DAS181 in Immunocompromised (IC) Patients with Parainfluenza Virus (PIV) Lower Respiratory Tract Infection (LRTI) on Supplemental Oxygen (SO)  
1716 Results of the Respiratory Protection Effectiveness Clinical Trial (ResPECT)  
1717 The Impact of Routine Molecular Point-Of-Care Testing for Gastrointestinal Pathogens in Adults Hospitalized With Suspected Gastroenteritis: Results of a Pragmatic Randomized Controlled Trial (GastroPOC)  
1718 Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study  
1719 Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial |
| 200 | Oral Abstract Session | Public Health: Epidemiology and Outbreaks  
**Saturday, 8:45 - 10 a.m. S 157**  
1721 An Outbreak of Botulism Associated with Nacho Cheese Sauce from a Gas Station in California  
1722 The Changing Epidemiology of Candidemia in the United States: Injection Drug Use as an Emerging Risk Factor for Candidemia  
1723 Mumps Attack Rates Following Administration of a Third Dose of MMR Vaccine To School-Aged Children, Arkansas, 2016 – 2017  
1724 Characteristics of the Ongoing Measles Outbreak in Greece in the Context of the Recent European-Wide Epidemic and Public Health Measures |
| 201 | Oral Abstract Session | The World Around Us: Reducing Exposures to Pathogens in the Healthcare Environment  
**Saturday, 8:45 - 10 a.m. S 156**  
1725 Addressing Presenteeism: Variability in Facility Healthcare Personnel Work Restriction Policy Monitoring and Enforcement  
1726 A Random Forest Prediction Model Accurately Identifies Periods at Increased Risk for Positive Legionella Cultures in a Hospital Water Distribution System  
1727 Sustained Antimicrobial Activity of a Novel Disinfectant Against Healthcare Pathogens  
1728 Effectiveness and Healthcare Personnel (HCP) Perceptions of a Multi-Site Personal Protective Equipment (PPE) Free Zone Intervention  
1729 Effect of Glove Disinfection on Bacterial Contamination of Healthcare Worker Hands |
| 202 | Oral Abstract Session | Transplant and Immunocompromised Hosts: Emerging Issues  
**Saturday, 8:45 - 10 a.m. W 2002**  
1730 Outcomes of Patients with Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-Blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients  
1731 Disseminated Metacestode Infection Due to an Unknown Versteria Species  
1732 Adenovirus Load Dynamics Are Consistently Correlated with Risk of Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients: Findings from the Landmark AdVance Study  
1733 10 Years of DTAC Experience with Donor-Derived Cryptococcus Transmission in Solid Organ Transplantation in the U.S.  
1734 Cytokine Levels In Bronchoalveolar Lavage Fluid of Rhinovirus Infected Hematopoietic Cell Transplant Recipients: Associations with Mortality |
| 211 | Oral Abstract Session | Diagnostics Making a Difference  
**Saturday, 10:30 - 11:45 a.m. S 158**  
1756 Prediction of Bloodstream Infection Prior to Onset of Symptoms by Plasma Metagenomic Sequencing in Pediatric Patients with Relapsed or Refractory Malignancy (PREDSEQ) |
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Session Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1757</td>
<td>Using the Desirability of Outcome Ranking for Management of Antimicrobial Therapy (DOOR-MAT) to Assess Antibiotic Therapy Guided by Rapid Molecular Diagnostics (RMD) in Bloodstream Infection (BSI) Caused by <em>Escherichia coli</em> (<em>Ec</em>) and <em>Klebsiella pneumoniae</em> (<em>Kpn</em>)</td>
<td>2018</td>
<td></td>
</tr>
<tr>
<td>1758</td>
<td>Impact of Accelerated Pheno™ Rapid Blood Culture Detection System on Laboratory and Clinical Outcomes in Bacteremic Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1759</td>
<td>High Proportion of Discordant Results in Culture-Independent Diagnostic Tests (CIDT) for Shiga Toxin, Foodborne Disease Active Surveillance Network (FoodNet), 2012–2017</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1760</td>
<td>Interferon Gamma Release Assay for Diagnosis of Lyme Disease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**212. Oral Abstract Session**

**Healthcare Epidemiology: You Can Try This at Home—Innovative Epi Abstracts**
Saturday, 10:30 - 11:45 a.m.  
S 157

- **1761** Effect of Carbapenem-Resistant Enterobacteriaceae (CRE) Surveillance Case Definition Change on CRE Epidemiology - Selected U.S. Sites, 2015-2016
- **1762** The Adjusted Ranking Metric (ARM) and its Use in Composite Measures for HAI Prevention in the National Healthcare Safety Network (NHSN)
- **1763** Estimating Median Survival Time to Central Line-Associated Bloodstream Infection (CLABSI) among Patients in Intensive Care Units Reported to National Healthcare Safety Network (NHSN)
- **1764** The Gut: A Veiled Reservoir for Multidrug-Resistant Organisms (MDROs) below the Tip of the Iceberg
- **1765** Use of a Natural Language Processing-Based Informatics Pipeline for Infectious Disease Syndrome Surveillance

**213. Oral Abstract Session**

**Late Breaker Oral Abstracts**
Saturday, 10:30 - 11:45 a.m.  
S 152-154
See meeting app.

**214. Oral Abstract Session**

**Optimizing HIV Treatment**
Saturday, 10:30 - 11:45 a.m.  
S 156

- **1766** Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy among Highly Treatment-Experienced Individuals
- **1767** Structured Treatment Interruptions in HIV-Infected Patients Receiving Antiretroviral Therapy—Implications for Future HIV Cure Trials: A Systematic Review and Meta-Analysis
- **1768** Efficacy and Safety of Switching from Boosted-Protease Inhibitors (bPI) plus Emtricitabine/Tenofovir Disoproxil Fumarate (E/TDF) Regimens to the Once Daily (OD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (D/C/E/TAF) in Virologically-Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial
- **1769** Viral Suppression among Participants of the Patient-Centered HIV Care Model Project—a Collaboration between Community-Based Pharmacists and HIV Clinical Providers
- **1770** The Association of Unmet Needs with Subsequent Retention in Care and HIV Suppression among Hospitalized Patients with HIV Who Are Out of Care

**215. Oral Abstract Session**

**Translating Microbiome Science into Practice**
Saturday, 10:30 - 11:45 a.m.  
W 2002

- **1771** Gut Resistome Changes in Response to Prophylactic Antibiotic Administration during Chemotherapy in Children with Acute Lymphoblastic Leukemia
- **1772** *Vancomycin-Resistant Enterococcus* Alters the Gastrointestinal Microbiome in Critically Ill Patients
- **1773** Impact of Antibiotics Used to Treat Community Acquired Pneumonia on the Gut Microbiome and Resistome in Healthy Volunteers
- **1774** Ridinilazole (RDZ) for *Clostridium difficile* infection (CDI): Correlation of *In Vitro* Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
- **1775** Microbiome-Based Classifiers Accurately Differentiate Infectious Diarrhea from Functional Gastrointestinal Disorders and Provide Population-Scale Confidence Measures of Fecal Microbiota Restoration in Recurrent C. Difficile Infection
269. Oral Abstract Session
Flu and other Vaccines in Children
Saturday, 2 - 3:15 p.m. W 2002

1. Individual Patient-Level Data Meta-Analysis of Live Attenuated and Inactivated Influenza Vaccine Effectiveness among U.S. Children, 2013-14 through 2015-16

2. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine

3. Predicting Risk of Breakthrough Invasive Pneumococcal Disease in Children after 13-Valent Pneumococcal Conjugate Vaccination

4. Retrospective Evaluation of Mismatch from Egg-Based Isolation of Influenza Strains Compared to Cell-Based Isolation and the Possible Implications for Vaccine Effectiveness

5. A Model to Estimate the Potential Impact of Immunizations on Respiratory Syncytial Virus (RSV) Disease Burden among Infants in the United States

270. Oral Abstract Session
Genomics and Susceptibility of Superbugs
Saturday, 2 - 3:15 p.m. S 157

1. Predicting ß-Lactam Resistance Using Whole Genome Sequencing (WGS) in Klebsiella pneumoniae: The Challenge of ß-lactam Inhibitors

2. Incidence and Clinical Impact of Discordant Genotypic and Phenotypic Categorization of Methicillin Susceptibility in Staphylococcus aureus Bacteremia

3. Multispecies Outbreak of KPC-2 Producing Enterobacteriaceae in a Chilean Pediatric Hospital

4. Using Whole Genome Sequencing to Assess the Emergence of Antibiotic Resistance during Treatment of Enterococcus faecium and Enterococcus faecalis Bacteremia at Mount Sinai Hospital

5. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics-Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data

271. Oral Abstract Session
Novel Diagnostics for Fungi, Parasites, and CNS Infection
Saturday, 2 - 3:15 p.m. S 158

1. Clinical Metagenomic Next-Generation Sequencing for Diagnosis of Meningitis and Encephalitis

2. Clinical Validation of a Commercial LAMP Test for Ruling Out Malaria in Returning Travelers: A Prospective Diagnostic Trial

2565. A Novel Prognostic Gene Set for the Prediction of Severe Dengue

2566. Diagnosis of Pneumocystis jiroveci pneumonia in HIV-Negative Immunocompromised Patients: Is the Gomori-Methenamine Silver Stain of Bronchoalveolar Lavage Fluid the Gold Standard or Sub-Standard?

2567. Diagnosis of Invasive Aspergillosis in Hematological Malignancy Patients Receiving Mold-Active Antifungals: Performance of Interleukins 6 and 8, Asp LFD, and Aspergillus PCR in Same-Day Blood and Bronchoalveolar Lavage Fluid Samples
49. Poster Abstract Session
Antimicrobial Stewardship: Interventions in Pediatric Populations
Thursday, 12:30 - 1:45 p.m.

- 169 Targets for Optimizing Oral Antibiotic Prescriptions for Pediatric Outpatients in Japan
- 170 Characterization of Appropriate Antibiotic Prescribing for Pediatric Respiratory Tract Infections: Setting the Stage for Stewardship
- 171 Impact of Limiting Antimicrobial Indication Options in a Pediatric Electronic Health Record
- 172 Antimicrobial Stewardship in High Risk Pediatric Patients
- 173 Nationwide Outpatient Oral Antimicrobial Utilization by Children in Japan
- 174 Treatment of Tracheitis and Antimicrobial Stewardship Interventions
- 175 Implementation of Clinical Practice Guidelines for Care of Neonates with Necrotizing Enterocolitis Reduces Broad Spectrum Antibiotic Use in the Neonatal Intensive Care Unit
- 176 Comparison of Prescribing Practices for Community-Acquired Pneumonia (CAP) among Outpatient versus Emergency Department Settings

50. Poster Abstract Session
Antimicrobial Stewardship: Interventions Leveraging the Electronic Health Record
Thursday, 12:30 - 1:45 p.m.

- 177 Use of Electronic Best Practice Alert (BPA) to Reduce Inappropriate Testing for *Clostridium difficile* infection (CDI) at a Tertiary Care Center
- 178 Impact of a Best Practice Alert Linking *Clostridium difficile* Infection Test Results to a Severity-Based Treatment Order Set
- 179 A Passive, Prescriber-Directed, Electronic Alert Plus Prescriber Education Decreased Antibiotic Prescribing for Ambulatory Adults with Acute, Uncomplicated Bronchitis in a Large Integrated Health System
- 180 Best Practice Advisory Decreases Inpatient Urine Culture Orders
- 181 Evaluation of a Pilot Initiative for Tracking and Monitoring Indications Associated with Antibiotic Orders
- 182 Successes of a System-Directed and Multi-Faceted Inpatient Antimicrobial Stewardship Program in a Large, Integrated Delivery Organization
- 183 Alerting and Education via the Electronic Health Record (EHR) Decreases Inappropriate Fluoroquinolone Prescribing in the Emergency Department of a Large Integrated Hospital Network
- 184 Implementation and Evaluation of an Electronic Antimicrobial Prior Authorization Approval Process at a Large Academic Medical Center
- 185 Implementation of a Clinical Decision Support System (CDSS) for Ordering Antimicrobials in a Veterans Affairs Medical Center (VAMC): Results from a Pilot Quality Improvement (QI) Project
- 187 Comparison of Active versus Passive Strategies in Improving Compliance to Antimicrobial Stewardship Interventions
- 188 A Novel Inpatient Antibiotic Stewardship Assistance Program (ASAP) using Real-Time Electronic Health Record Data, Prediction Modeling, and Epidemiologic Data to Provide Personalized Empiric Antibiotic Recommendations
- 189 Evaluating the Impact of Mandatory Indications on Antibiotic Utilization: A Retrospective Study
- 190 Promise and Pitfalls: Analyzing the Accuracy and Perceptions of Documenting Antibiotic Indication during Order Entry
- 191 Accuracy of Clinical Indications for Use When Ordering Antibiotics for Cystitis in Community Hospitals
- 192 More Low-Hanging Fruit: Antibiotic Chelation Drug Interactions
- 193 Duration of Antimicrobial Therapy: The Impact of Defaults
- 194 Mandatory Antimicrobial Duration at the Time of Computerized Physician Order Entry: What’s the Harm?

51. Poster Abstract Session
Antimicrobial Stewardship: Interventions to Improve Outcomes
Thursday, 12:30 - 1:45 p.m.

- 195 The Effect of Two Antibiotic Stewardship Interventions in a Telemedicine Practice
- 196 Public Health Can Play a Role Implementing a Successful Outpatient Antimicrobial Stewardship in Primary and Urgent Care
- 197 Implementation of a Prospective, Pharmacist-Led Methicillin-Resistant *Staphylococcus aureus* Nasal PCR Screening Pilot Protocol to Reduce Overutilization of Vancomycin
- 198 Pharmacist-Led Antimicrobial Prompting during Interdisciplinary Team Rounds as a Novel Antimicrobial Stewardship Intervention
- 199 The Urgent Need for Urgent Care Antimicrobial Stewardship: Evaluating Prescribing and Patient Outcomes Associated with a Pharmacist-Led Stewardship Program
- 200 Pharmacist Prescribing and Care for Patients with Uncomplicated Urinary Tract Infections in the Community: Antimicrobial Utilization and Stewardship Results of the R_OUTMAP Study
- 201 Outcomes of an Antibiotic Stewardship Team at an Academic Medical Center: 11 Years of Experience
- 202 Implementation and Three-Year Results of Antimicrobial Stewardship Program in a Three Hospital Community Health System
- 203 Impact of an Infectious Diseases Fellow-Led Antimicrobial Stewardship Initiative in a Medical/Surgical ICU
Poster Abstract Sessions (continued)

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>204</td>
<td>Impact of Education and Data Feedback Interventions on Outpatient Prescribing for Urinary Tract Infections</td>
</tr>
<tr>
<td>205</td>
<td>Reduction of Antibiotic Prescribing within a Veterans Affairs Emergency Department through Peer Comparison</td>
</tr>
<tr>
<td>206</td>
<td>Respiratory Viral Testing is Associated with Lower Frequency of Antibiotic Prescribing for Acute Upper Respiratory Infections at a Large Ambulatory Cancer Center</td>
</tr>
<tr>
<td>207</td>
<td>Impact of Educational Interventions on Antibiotic Prescribing for Acute Upper Respiratory Tract Infections in the Ambulatory Care Setting</td>
</tr>
<tr>
<td>208</td>
<td>Trends in Antibiotic Prescribing for Acute Respiratory Tract Infections and Implementation of a Provider-Directed Intervention within the Veterans Affairs Healthcare System (VA)</td>
</tr>
<tr>
<td>209</td>
<td>Impact of a Risk-Based CAP Prescribing Guideline Paired with Antimicrobial Stewardship to Improve Antibiotic Prescribing for Patients at Low Risk for Drug-Resistant Pathogens</td>
</tr>
<tr>
<td>210</td>
<td>Improved Antimicrobial Utilization in the Emergency Department: Impact of a Point of Care Polymerase Chain Reaction Test for the Rapid Detection of Influenza</td>
</tr>
<tr>
<td>211</td>
<td>Does Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus PCR Nasal Screening Decrease Time to De-escalation of MRSA Coverage in Patients with Pneumonia?</td>
</tr>
<tr>
<td>212</td>
<td>Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Initiative on Pneumonia Treatment at an Academic Teaching Hospital</td>
</tr>
<tr>
<td>214</td>
<td>Antimicrobial Usage and Outcomes Following Laboratory Suppression of Antimicrobial Susceptibility Results for Pseudomonas aeruginosa in Sputum Cultures</td>
</tr>
<tr>
<td>215</td>
<td>Unintended Consequences of Fluoroquinolone Stewardship: Impact on Overall Antimicrobial Use Data and Implications for Benchmarking</td>
</tr>
<tr>
<td>216</td>
<td>Step-Down Therapy with Oral Fluoroquinolones vs. Oral Beta-Lactams for Hospitalized Adult Patients with Community-Acquired Pneumonia: A Multi-Hospital Cohort Study</td>
</tr>
<tr>
<td>217</td>
<td>Bang for the Buck: Lessons Learned from an Ambulatory Stewardship Pilot to Reduce Excess Antibiotic Prescribing for Adult Upper Respiratory Infections</td>
</tr>
<tr>
<td>218</td>
<td>IV to PO Conversion of Antimicrobials: Small Intervention, Big Impact</td>
</tr>
<tr>
<td>220</td>
<td>Taking Off with Antimicrobial Intervention Rounds (AIR): Successes of a Pilot Stewardship Service at a Tertiary-Care VA Medical Center</td>
</tr>
<tr>
<td>221</td>
<td>Save the Quinolones! Impact of a Non-Restrictive Fluoroquinolone Reduction Initiative on Antibiotic Resistance at an Urban Teaching Hospital</td>
</tr>
<tr>
<td>222</td>
<td>The Impact of Education and Prospective Audit and Feedback on Reducing Ciprofloxacin Utilization at a Small Community Academic Hospital</td>
</tr>
<tr>
<td>223</td>
<td>Impact of Different Stewardship Strategies Applied to a Single Antibiotic Over Time</td>
</tr>
<tr>
<td>224</td>
<td>Cost Analysis of a Significant Decrease in Vancomycin Use as a Result of an Antimicrobial Stewardship Intervention</td>
</tr>
<tr>
<td>225</td>
<td>Antimicrobial Stewardship Program Interventions Targeting Intravenous Vancomycin Use at a Community Hospital Improves Prescribing and Safety</td>
</tr>
<tr>
<td>226</td>
<td>An Emergency Department Antimicrobial Stewardship Intervention to Improve Antibiotic Selection and Duration for Skin and Soft Tissue Infections in Adult and Pediatric Outpatients</td>
</tr>
<tr>
<td>227</td>
<td>Provider Education Paired with Peer Comparison Demonstrates Sustained Reduction in Overall Antibiotic Prescribing within a Veterans Affairs Primary Care System</td>
</tr>
<tr>
<td>228</td>
<td>Impact of Early Alert to Antimicrobial Stewardship Interventions with the Prospective Audit and Feedback Strategy</td>
</tr>
<tr>
<td>229</td>
<td>The Role of Antimicrobial Stewardship Program on Appropriate Use, Dose, and Duration of Vancomycin Treatment</td>
</tr>
<tr>
<td>230</td>
<td>Characterization of Antibiotic Timeout Program Strategies Across the United States</td>
</tr>
<tr>
<td>231</td>
<td>Facilitating the Everyday Steward: Impact of Mandatory Antimicrobial Indication/Duration and a 48-Hour Timeout</td>
</tr>
<tr>
<td>232</td>
<td>Do Antibiotic Timeouts Improve Antibiotic Utilization?</td>
</tr>
<tr>
<td>233</td>
<td>Evaluation of an Antimicrobial Timeout on Antimicrobial Utilization at a Large Health System</td>
</tr>
<tr>
<td>234</td>
<td>Improving Antimicrobial Prescribing and Rate of Infectious Diseases Consult Utilizing a Best-Practice Alert and Targeted Education for Staphylococcus Aureus Bacteremia</td>
</tr>
<tr>
<td>235</td>
<td>If Symptoms Aren’t Described, Antibiotics Aren’t Prescribed: Implementation of a Multifaceted Toolkit Targeting Overtreatment of Asymptomatic Bacteriuria across a Large Health System</td>
</tr>
<tr>
<td>236</td>
<td>The Impact of Earlier Intervention by an Antimicrobial Stewardship Team on Appropriate Antimicrobial Therapy for Specific Antimicrobial Agents</td>
</tr>
<tr>
<td>237</td>
<td>Antibiotic Assessment at Discharge-Room for Stewardship Intervention</td>
</tr>
<tr>
<td>238</td>
<td>Sharing Unit-Specific Stewardship Metrics with Front-Line Providers to Improve Antibiotic Prescribing</td>
</tr>
<tr>
<td>239</td>
<td>Implementation of a Vertical Antimicrobial Stewardship Intervention for Patients Colonized with Clostridium difficile</td>
</tr>
<tr>
<td>240</td>
<td>Estimated Clinical and Economic Impact Through Use of an Initial Specimen Diversion Device to Reduce Blood Culture Contamination: A Cost-Benefit Analysis</td>
</tr>
<tr>
<td>241</td>
<td>Reducing Fluoroquinolone Use Through Implementation of a Urinary Tract Infection (UTI) Treatment Pathway and Healthcare Provider Education: A Pre- and Post-Intervention Study</td>
</tr>
<tr>
<td>242</td>
<td>Evaluating the Effectiveness of Antimicrobial Restriction at an Academic Medical Center</td>
</tr>
<tr>
<td>243</td>
<td>Prioritization of Antibiotic Administration for STAT Orders in the Septic Patient: A Retrospective Analysis</td>
</tr>
<tr>
<td>244</td>
<td>Impact of Antibiotic Susceptibility Reporting on Broad-Spectrum Antibiotic Use in Serratia and Morganella Bacteremia</td>
</tr>
</tbody>
</table>
### Poster Abstract Sessions (continued)

#### 52. Poster Abstract Session

**Antimicrobial Stewardship: Special Populations**

- **Thursday, 12:30 - 1:45 p.m.**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>245</td>
<td>Elimination of Routine Urinalysis Before Elective Orthopedic Surgery Reduces Antibiotic Utilization Without Impacting Catheter-Associated Urinary Tract Infection or Surgical Site Infection Rates</td>
</tr>
<tr>
<td>246</td>
<td>Antimicrobial Stewardship Program (ASP) Efforts to Reduce Antimicrobial Usage in Geriatric Patients without Affecting Outcomes</td>
</tr>
<tr>
<td>247</td>
<td>Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria</td>
</tr>
<tr>
<td>248</td>
<td>Antimicrobial Therapy for Suspected Urinary Tract Infection in Advanced Cancer Patients Transitioning to Comfort Measures</td>
</tr>
<tr>
<td>249</td>
<td>Frequency of Antimicrobial Complications Following Initiation of Palliative Chemotherapy in Advanced Cancer Patients</td>
</tr>
<tr>
<td>250</td>
<td>Antimicrobial Management in Extracorporeal Membrane Oxygenation: The AMMO study</td>
</tr>
<tr>
<td>251</td>
<td>Overuse of Antimicrobials in the End-of-Life Care: Factors Influencing Physicians’ Prescribing Behaviors in Treating Patients with an Advanced Stage of Illnesses in the Robust Era of Antimicrobial Stewardship</td>
</tr>
<tr>
<td>252</td>
<td>Relative Use of Carbapenems in Immunocompromised Patients</td>
</tr>
<tr>
<td>253</td>
<td>Febrile Neutropenia Antibiotic De-Escalation Study in Acute Myeloid Leukemia Patients with Prolonged Neutropenia</td>
</tr>
<tr>
<td>254</td>
<td>Antimicrobial Use in Hospitalized Older Patients with Advanced Cancer</td>
</tr>
<tr>
<td>255</td>
<td>Evaluation of Antibiotic Prescribing at University-Affiliated Dental Clinics</td>
</tr>
</tbody>
</table>

#### 53. Poster Abstract Session

**Pediatric Antimicrobial and Diagnostic Stewardship**

- **Thursday, 12:30 - 1:45 p.m.**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>257</td>
<td>A Whole Country Analysis of Antimicrobial Stewardship Resources, Activities, and Barriers for Children in Hospitals in Australia</td>
</tr>
<tr>
<td>258</td>
<td>Variation in Antibiotic Use Among Neonates Hospitalized in United States Academically Affiliated Centers</td>
</tr>
<tr>
<td>259</td>
<td>A Retrospective Cross-Sectional Comparison of the Neonatal Gut Microbiota after Antimicrobial Exposure: Implications for Stewardship</td>
</tr>
<tr>
<td>260</td>
<td>Effect of Antibiotic Indications on Clinician Documentation and Pharmacy Workflow in Hospitalized Children</td>
</tr>
<tr>
<td>261</td>
<td>Alternative Antibiotic Prescribing for Community Acquired Pneumonia (CAP) in Pediatric Patients in Relation to Allergy Status</td>
</tr>
<tr>
<td>262</td>
<td>Pediatric Antibiotic Use in the Duke Antimicrobial Stewardship Outreach Network</td>
</tr>
<tr>
<td>263</td>
<td>Effect of Microbiologic Data on Prospective Audit and Feedback Recommendations</td>
</tr>
<tr>
<td>264</td>
<td>Simple and Feasible NICU Antimicrobial Stewardship Program in a Japanese Community Hospital</td>
</tr>
<tr>
<td>265</td>
<td>Identification of Solid Organ Transplant Antimicrobial Stewardship Opportunities in Pediatric Liver Transplant Patients</td>
</tr>
<tr>
<td>266</td>
<td>Implementation and Evaluation of a Pharmacist-Managed Pediatric Vancomycin Protocol</td>
</tr>
<tr>
<td>267</td>
<td>Viral Respiratory Infections in Children with Neuromuscular Disease and Chronic Lung Disease Hospitalized in the Pediatric Intensive Care Unit and Associated Antibiotic Use</td>
</tr>
<tr>
<td>268</td>
<td>Cardiothoracic Surgery Antimicrobial Prophylaxis in Pediatric Patients: Reducing Antimicrobial Exposure</td>
</tr>
<tr>
<td>269</td>
<td>De-Labeling of Allergies to Beta-Lactam Antibiotics (De-LABeL) Program—Development and Pilot of An Inpatient Pediatric Program</td>
</tr>
<tr>
<td>270</td>
<td>Prevalence and Impact of β-Lactam Allergies at a Canadian Pediatric Center</td>
</tr>
<tr>
<td>271</td>
<td>Diagnosis and Management of Polymicrobial Bloodstream Infections with Multiplex PCR in Hospitalized Children</td>
</tr>
<tr>
<td>272</td>
<td>Impact of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) on Time to Optimal Antimicrobial Therapy in Pediatric Patients with Positive Blood Cultures at Children’s Cancer Hospital-Egypt (CCHE-57357)</td>
</tr>
<tr>
<td>273</td>
<td>Effects of a Rapid Meningitis/Encephalitis Panel on Antimicrobial Use and Clinical Outcomes in Children</td>
</tr>
<tr>
<td>274</td>
<td>Diagnostic Stewardship for Positive Endotraacheal Cultures in a Pediatric Intensive Care Unit (PICU)—Reassessing the Role of Neutrophil Quantification in Clinician Decision-Making</td>
</tr>
<tr>
<td>275</td>
<td>Evaluation of Vancomycin Prescribing Quality in Hospitalized Pediatric Patients</td>
</tr>
<tr>
<td>276</td>
<td>Vancomycin Utilization in a Neonatal Intensive Care Unit</td>
</tr>
<tr>
<td>277</td>
<td>Assessment of a Pharmacist-Driven Voriconazole Clinical Practice Guideline in a Children’s Hospital</td>
</tr>
<tr>
<td>278</td>
<td>Developing a Logistic Regression Model to Aid Clinicians to Evaluate Outpatients and Predict Odds of Hospital Transfer in a Nicaraguan Pediatric Population: Comparison of Epidemiological Models to Predict Hospitalization with a Focus on Antimicrobial Stewardship</td>
</tr>
<tr>
<td>279</td>
<td>A Decision Tree Using Clinical Characteristics to Predict a Hospitalized Child’s Risk of a Multidrug-Resistant Gram-Negative Bloodstream Infection</td>
</tr>
<tr>
<td>280</td>
<td>The Impact of a Revised Neutropenic Fever Guideline on Vancomycin-Resistant Enterococcus Rates in Pediatric Oncology Patients</td>
</tr>
<tr>
<td>281</td>
<td>Cefdinir Prescribing Increased in Low-Income Children in Kentucky from 2012-2016</td>
</tr>
<tr>
<td>282</td>
<td>Adherence to Acute Otitis Media Guidelines in Pediatricians’ Offices, Urgent Care Centers, and a Pediatric Emergency Department</td>
</tr>
</tbody>
</table>
Poster Abstract Sessions (continued)

54. Poster Abstract Session

**Bone and Joint Infections**

Thursday, 12:30 - 1:45 p.m.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>283</td>
<td>Antibiotic Utilization for Pneumonia and other Respiratory Infections in Pediatricians’ Offices, Urgent Care Centers, and a Pediatric Emergency Department</td>
</tr>
<tr>
<td>284</td>
<td>Antibiotic Usage in the First Year of Life in Hiv-Exposed, Uninfected Infants in Malawi: Results from the Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study</td>
</tr>
<tr>
<td>285</td>
<td>Challenging the Dogmas of Outpatient Parenteral Antimicrobial Therapy Through a Randomized Controlled Trial</td>
</tr>
<tr>
<td>286</td>
<td>Rapid, One-Tier Diagnosis for Lyme Arthritis</td>
</tr>
<tr>
<td>287</td>
<td>The Attributable Mortality of Prosthetic Joint Infection after Primary Hip and Knee Arthroplasty among Medicare Beneficiaries, 2005—2012</td>
</tr>
<tr>
<td>288</td>
<td>Expediting Discharge in Acute Bacterial Skin and Skin Structure Infections: A Clinical and Economic Comparison between Vancomycin and Oritavancin</td>
</tr>
<tr>
<td>289</td>
<td>International Validation of a Methicillin-Resistant <em>Staphylococcus aureus</em> (MRSA) Risk Assessment Tool for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)</td>
</tr>
<tr>
<td>290</td>
<td>Safety and Effectiveness of Oral Sodium Fusidate (Fusidic Acid) as Chronic Antibiotic Suppressive Therapy in Patients with Staphylococcal Bone or Joint Infections</td>
</tr>
<tr>
<td>291</td>
<td>Effect of Previous Antibiotic Exposure on the Yield of Bone Biopsy Culture in Patients with Osteomyelitis</td>
</tr>
<tr>
<td>292</td>
<td>Ceftolozane/Tazobactam for Treatment of Osteomyelitis due to Multidrug-Resistant <em>Pseudomonas aeruginosa</em></td>
</tr>
<tr>
<td>293</td>
<td>Concurrent Atlantoaxial Septic Arthritis and Septic Thrombosis of the Ophthalmic Vein due to <em>Staphylococcus aureus</em>: A Case Report and Review of the Literature</td>
</tr>
<tr>
<td>294</td>
<td>Spondylodiscitis after Spine Surgery: Microbiology, Clinical Findings, Outcome, and Comparison with Spontaneous Spondylodiscitis</td>
</tr>
<tr>
<td>295</td>
<td>Outcomes of Orthopedic Hardware-Related Osteomyelitis Treated Via a County Hospital Outpatient Parenteral Antimicrobial Therapy (OPAT) Program</td>
</tr>
<tr>
<td>296</td>
<td>Outcomes from a Novel Transition-of-Care OPAT Service Targeting Orthopedic Device-Related Infections</td>
</tr>
<tr>
<td>297</td>
<td>Risk Factors for Infections in Open Fractures</td>
</tr>
<tr>
<td>298</td>
<td>Vertebral Osteomyelitis due to <em>Candida</em>: Increasing Incidence in Appalachia</td>
</tr>
<tr>
<td>299</td>
<td>Tolerance and Serum Concentration of Cefepime Used Subcutaneously (SC) in the Management of Bone and Joint Infections</td>
</tr>
<tr>
<td>300</td>
<td>Armed to the Teeth—Human Bite Associated Septic Arthritis</td>
</tr>
<tr>
<td>301</td>
<td>The Use of Multiplex Touchdown PCR to Genotype <em>Cutibacterium (Propionibacterium)</em> Acnes Isolated from Periprosthetic Shoulder Infections</td>
</tr>
<tr>
<td>302</td>
<td>Role of Inflammatory Markers in Diagnosing Diabetic Foot Infection: A Meta-Analysis</td>
</tr>
<tr>
<td>303</td>
<td>Clinical Characteristics and Outcomes of Patients Naive Septic Arthritis caused by Methicillin-Resistant <em>Staphylococcus aureus</em></td>
</tr>
<tr>
<td>304</td>
<td>Comparison of Short and Long Courses of Antibiotics in Patients with Prosthetic Joint Infection: A Systemic Review and Meta-Analysis</td>
</tr>
<tr>
<td>305</td>
<td>Enterobacteriaceae Native Joint Septic Arthritis</td>
</tr>
<tr>
<td>306</td>
<td>Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections</td>
</tr>
<tr>
<td>307</td>
<td>Evaluation of the Diagnostic Approach to Native Spondylodiskitis</td>
</tr>
<tr>
<td>308</td>
<td>Identification of Prosthetic Hip and Knee Joint Infections in Administrative Databases</td>
</tr>
<tr>
<td>309</td>
<td>The Infected Spacer: The Impact ofSpacer Exchanges and Debridements on Two-Stage Exchange Arthroplasty Outcomes</td>
</tr>
<tr>
<td>310</td>
<td>Assessment of MSIS Diagnostic Criteria as Predictors of Treatment Success in Total Knee Arthroplasty (TKA) Infections Treated with Two-Stage Exchange</td>
</tr>
<tr>
<td>311</td>
<td>Low Rate of Microbiologic Relapse in Two-Stage Exchange for Knee Prosthetic Joint Infections</td>
</tr>
<tr>
<td>312</td>
<td>Comparison of Short Course and Long Course of Antibiotics in Patients with Osteomyelitis: A Systemic Review and Meta-Analysis</td>
</tr>
<tr>
<td>313</td>
<td>Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis</td>
</tr>
<tr>
<td>314</td>
<td>Discordant Microbiology Cultures from Paired Osteomyelitis Bone Specimens Should Question the Current Approach To Evaluation</td>
</tr>
<tr>
<td>315</td>
<td>Oral versus Intravenous Antibiotic Treatment for Gram-Positive Prosthetic Joint Infections: A Retrospective Study</td>
</tr>
<tr>
<td>316</td>
<td>Joint Initiative between Infectious Diseases and Podiatry in Outpatient Settings Improves Diabetic Foot Infection Patients’ Compliance and Outcomes</td>
</tr>
<tr>
<td>317</td>
<td>Risk Factors for Fungal Prosthetic Joint Infections (PJIs)</td>
</tr>
<tr>
<td>318</td>
<td>Treatment Outcomes of Prosthetic Joint Infections: An Internal Assessment of Adherence to Best Practice Guidelines</td>
</tr>
<tr>
<td>319</td>
<td>Is Chronic Vertebral Disk Infection with Low Virulence Bacteria a Common Cause of Back Pain?</td>
</tr>
<tr>
<td>320</td>
<td>Variation in Use of Chronic Antibiotic Suppression (CAS) for Treatment of <em>Staphylococcus aureus</em> Prosthetic Joint Infection (PJI)</td>
</tr>
<tr>
<td>321</td>
<td>Assessing the Role of Daptomycin as Antibiotic Therapy for Staphylococcal Prosthetic Joint Infection</td>
</tr>
<tr>
<td>322</td>
<td>Joint Spacer Retention, Antimicrobial Suppression, and Risk of Reinfection</td>
</tr>
</tbody>
</table>

55. Poster Abstract Session

**CNS Infections**

Thursday, 12:30 - 1:45 p.m.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>323</td>
<td>Childhood Outcomes Following Parechovirus Central Nervous System Infection in Young Infants at a U.S. Children’s Hospital</td>
</tr>
</tbody>
</table>
Poster Abstract Sessions (continued)

324 Lack of Accuracy of the International Classification of Disease, Ninth (ICD-9) Codes in Identifying Patients with Encephalitis

325 Neurosyphilis Management in the Post-Procaine Penicillin Era

326 Malaria vs. Bacterial Meningitis in Children with Spinal Tap in the Luanda Children’s Hospital, Angola

327 Comparison of Clinical Outcome, Causative Serotypes, and Antimicrobial Susceptibilities between Pneumococcal Meningitis and Pneumococcal Bacteremic Pneumonia in Adult Patients in the Republic of Korea

328 National Expertise Group to Improve Management of Complex Encephalitis Cases

329 Impact of the Biofire® FilmArray (FA) Meningitis/Encephalitis (ME) Panel in Colombia

330 Head and Spine Injuries Increase Risk of Streptococcus pneumoniae Meningitis in Adults

331 Vascular Complications among Children and Adolescents with Acute Complicated Sinusitis

332 Phaeohyphomycosis Due to Scopulariopsis Brumptii in a Hematopoietic Stem Cell Transplant (HSCT) Recipient

333 Meningitis in Well-Appearing Febrile Infants Aged 1-90 Days

334 Implementation of FilmArray Meningitis/Encephalitis Panel at a Tertiary Medical Center

335 Missed and Delayed Diagnosis of Herpes Simplex Encephalitis in Inpatient and Ambulatory Care Settings

336 Characteristics of Acute Bacterial Meningitis and Predictors of Mortality

337 The Use of Adjunctive Steroids in 438 Adults with Herpes Simplex Virus Encephalitis

338 The Use of Multiplex PCR Panel in the Diagnosis of Meningitis in Children

339 An Unusual Complication after Dental Procedure Prophylaxis

340 Clinical Use of a Multiplex PCR Meningitis/Encephalitis Panel at an Urban Tertiary Care Center

341 Characteristics, Risk Factors, and Outcomes of Encephalitis in Older Adults

342 Time to Antimicrobial De-Escalation/Discontinuation after Implementation of Cerebrospinal Fluid Polymerase Chain Reaction Tool

343 Compliance to Standard of Care in the Diagnosis and Management of Suspected Encephalitis

344 Post Malaria Neurological Syndrome: A Rare Complication of Malaria

345 Diagnosis of Acute Bacterial Meningitis by Polymerase Chain Reaction vis-a-vis Conventional Culture Method

346 Prognostic Factors in Adults with Encephalitis: An Analysis of 340 Cases

347 Capnocytophaga canimorsus Meningitis: Diagnosis Using Polymerase Chain Reaction Testing and Systematic Review of the Literature

348 Streptococcus agalactiae, Streptococcus pneumoniae, Neisseria meningitidis, and Enterobacteriaceae as Leading Causes of Bacterial Meningitis in Infants Younger than Three Months Old in a Mexican Hospital: Six Years of Active Surveillance

349 Retrospective Descriptive Analysis of West Nile Neuroinvasive Disease in Northwest Louisiana

350 Epidemiology of Bacterial Meningitis in Pediatric Population after the Introduction of Pneumococcal Conjugated Vaccine in Costa Rica

351 It’s Not Always Tuberculosis: Cytomegalovirus Polyradiculopathy and Encephalitis in Two Filipino Men with Advanced HIV Infection

352 Towards Earlier Diagnosis of Transmissible Spongiform Encephalopathies (TSEs): A Case Series, Including One Associated with Squirrel Brain Consumption

353 HSV Induced Anti-NMDAR Encephalitis

56. Poster Abstract Session

Fungal Disease: Management and Outcomes

Thursday, 12:30 - 1:45 p.m.

354 Evidence of Aspergillosis among Patients with Influenza-Associated Hospitalizations—United States, 2005–2017

355 Invasive Pulmonary Aspergillosis (IPA) Complicating Respiratory Viral Infections in Patients with Hematologic Malignancies

356 Bronchoalveolar Lavage Fluid Cytology by GMS Stain for the Diagnosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Malignancies: Analysis of 67 Episodes

357 Aspergillus Isolates Remain Largely Susceptible to Azoles and Other Antifungals at a Large Transplant Program using Azole Prophylaxis

358 Comparison of Voriconazole (VORI), Isavuconazole (ISAV) and Posaconazole (POSA) in the Initial Treatment of Patients with Invasive Aspergillosis (IA)

359 Baseline Serum Aspergillus Galactomannan Index among Aspergillus Species in Hematologic Malignancies Patients with Invasive Pulmonary Aspergillosis

360 Breakthrough Invasive Pulmonary Aspergillosis during Isavuconazole Prophylaxis in Patients with Hematologic Malignancies: A Single Center Experience

361 Changing Epidemiology of Blastomyces Dermatitidis Infection in Quebec, Canada: A Retrospective Multicenter Study

362 Species Distribution and Trends of Invasive Candidiasis in the United States, 2009-2015, Using a Large Electronic Medical Record Database

363 National Burden of Candidemia, United States, 2017

364 The Capital District of New York State, Likely a New Blastomycosis Endemic Region

365 Candida Bloodstream Infections in a Tertiary Care Hospital in Costa Rica, Five-Year Experience

366 Impact of Obesity in Patients with Candida Bloodstream Infections

367 Influence of Body Weight and Outcomes in Candidemia

368 Community-Onset Candidemia: Trends Over Seven Years

369 Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis

370 Efficacy of Cochleated Amphotericin B (C-AMB) in Mouse Models of Oropharyngeal and Vulvovaginal Candidiasis
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>371</td>
<td>Risk Factors for Non-Albicans Candidal Vulvovaginitis</td>
</tr>
<tr>
<td>372</td>
<td>Attributable Mortality of Candidemia after Introduction of Echinocandins</td>
</tr>
<tr>
<td>373</td>
<td>Impact of Concurrent Renal Replacement Therapy on Treatment Outcomes of Candidemia in Adults</td>
</tr>
<tr>
<td>374</td>
<td>Candidemia Management and Associated Clinical Outcomes in Hospitalized Patients: An Opportunity for Antifungal Stewardship</td>
</tr>
<tr>
<td>375</td>
<td>Tolerability of Anidulafungin for Candidemia in Patients with Hepatic or Renal Dysfunction</td>
</tr>
<tr>
<td>376</td>
<td>Predictive Model for Fluconazole Resistance in Patient with Candida Bloodstream Infection</td>
</tr>
<tr>
<td>377</td>
<td>High Resistance and Mortality Rates in Patients with Ventricular Assist Device (VAD) Associated Candidemia: A Need for Alternative Antifungal Strategies</td>
</tr>
<tr>
<td>378</td>
<td><em>Candida auris</em> Fungemia: Risk Factors and Outcome</td>
</tr>
<tr>
<td>379</td>
<td>Pediatric Bloodstream Infections by <em>Candida auris</em> in Colombia: Clinical Characteristics and Outcomes of 34 Cases</td>
</tr>
<tr>
<td>380</td>
<td><em>Drosophila melanogaster</em> as a Facile Model for Large-Scale Studies of Virulence Mechanisms and Antifungal Drug Efficacy in <em>Candida auris</em> Candidiasis</td>
</tr>
<tr>
<td>381</td>
<td>Morphologic Changes Associated with Echinocandin Tolerance Enhance Immunoevasion of <em>C. glabrata</em> (Cg)</td>
</tr>
<tr>
<td>382</td>
<td>Virulence in <em>Candida glabrata</em> is Not Attenuated by FKS Mutations but Associated with the Frequency of Cells with Distinct Morphology</td>
</tr>
<tr>
<td>383</td>
<td>An Increased Rate of <em>Candida parapsilosis</em> Infective Endocarditis is Associated with Injection Drug Use</td>
</tr>
<tr>
<td>384</td>
<td>Findings From a <em>Candida auris</em> Admission Screening Pilot in New York State</td>
</tr>
<tr>
<td>385</td>
<td>The Value Added from <em>Candida auris</em> Point Prevalence and Environmental Studies in New York State</td>
</tr>
<tr>
<td>386</td>
<td>A Reexamination of Disseminated Coccidioidomycosis: The Natural History in the Pre-Antifungal Era</td>
</tr>
<tr>
<td>387</td>
<td>Coccidioidomycosis In Children Younger than Two Years of Age: A Retrospective Review</td>
</tr>
<tr>
<td>388</td>
<td>New Observations in Coccidioidomycosis Serology</td>
</tr>
<tr>
<td>389</td>
<td>Pediatric Musculoskeletal Coccidioidomycosis In Central California: Single Center Experience</td>
</tr>
<tr>
<td>390</td>
<td>Sociodemographic Factors Associated with Patients Hospitalized for Coccidioidomycosis in California and Arizona, State Inpatient Database 2005-2011</td>
</tr>
<tr>
<td>391</td>
<td>Evaluation of 2nd Generation Triazoles in the Treatment of Refractory Coccidioidomycosis</td>
</tr>
<tr>
<td>392</td>
<td>Evaluation of the Long-Term Tolerability and Efficacy of Fluconazole in Patients with Coccidioidomycosis</td>
</tr>
<tr>
<td>393</td>
<td>Isavuconazole in the Treatment of Coccidioidal Meningitis</td>
</tr>
<tr>
<td>394</td>
<td>Outcomes in Patients with Disseminated Non-Central Nervous System Cryptococcus</td>
</tr>
<tr>
<td>395</td>
<td>Missed Opportunities for Diagnosis of Cryptococcal Disease in Patients from Florida</td>
</tr>
<tr>
<td>396</td>
<td>Clinical Features of Proven and Probable Cases of Histoplasmosis and the Role of Urinary Histoplasma Antigen Testing: A Case Series from India</td>
</tr>
<tr>
<td>397</td>
<td>Long-term Mortality of HIV Patients Following Cryptococcal Infection</td>
</tr>
<tr>
<td>398</td>
<td>Review of Mucormycosis Cases at the University of Colorado Hospital from 2012-2018 and Evaluation of Risk Factors and Appropriateness of Antifungal Prophylaxis</td>
</tr>
<tr>
<td>399</td>
<td>Multi-Centre Observational Study on Epidemiology, Treatment, and Outcome of Mucormycosis in India</td>
</tr>
<tr>
<td>400</td>
<td>The Frequency and Clinical Characteristics of Positive Galactomannan Assay Results in Patients with Mucormycosis</td>
</tr>
<tr>
<td>401</td>
<td><em>Pneumocystis jirovecii</em> Pneumonia in Renal Transplant Recipients after a 6-Month Trimethoprim-Sulfamethoxazole Prophylaxis: A Case-Control Study</td>
</tr>
<tr>
<td>402</td>
<td>Breakthrough <em>Pneumocystis jirovecii</em> Pneumonia among Cancer Patients: Opportunity for Antimicrobial Stewardship?</td>
</tr>
<tr>
<td>403</td>
<td>Prognostic Factors in 260 Adults with Invasive Scedosporiosis from Literature and FungiScope™</td>
</tr>
<tr>
<td>404</td>
<td>Tinea Capitis: Are Epidemiologic Shifts Associated with Distinct Clinical Presentations?</td>
</tr>
<tr>
<td>405</td>
<td>Outbreak of Prototheca Wickerhamii Algaemia in a Tertiary Care Chemoradiation Oncology Unit</td>
</tr>
<tr>
<td>406</td>
<td>Achievement of Clinical Isavuconazole (ISA) Serum and Plasma Drug Concentrations in Two Patients with Isavuconazonium Capsules Administered via Nasogastric Feeding Tube (NGT)</td>
</tr>
<tr>
<td>407</td>
<td>Changes in the Utilization Patterns of Antifungal Agents, Medical Cost, and Clinical Outcomes of Candidemia by Healthcare Benefit Expansion to Include Newer Antifungal Agents</td>
</tr>
<tr>
<td>408</td>
<td>Invasive Fungal Petrositis and Carotiditis (IFPAC) Syndrome in Immunocompromised Hosts: An Unrecognized, Often Catastrophic Invasive Fungal Disease (IFD)</td>
</tr>
<tr>
<td>409</td>
<td>Changing Epidemiology of Fungal Bloodstream Infections in a Tertiary Care Center in India</td>
</tr>
<tr>
<td>410</td>
<td>Impact of Pediatric Antifungal Adverse Drug Reactions on Prescribing Practices</td>
</tr>
<tr>
<td>411</td>
<td>Tolerability of Isavuconazole after Posaconazole Toxicity in Leukemia Patients</td>
</tr>
<tr>
<td>412</td>
<td>Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis with Continuous Micafungin Compared to Posaconazole with Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A Six-Year Cohort-Analysis</td>
</tr>
<tr>
<td>413</td>
<td>Intravenous and Tablet Formulation of Posaconazole in Antifungal Therapy and Prophylaxis: A Retrospective, Non-Interventional, Multicenter Analysis of Patients Treated in German Tertiary-Care Hospitals</td>
</tr>
<tr>
<td>414</td>
<td>Diagnostic Usefulness of Differential Time to Positivity (DTP) in Neutropenic Cancer Patients with Suspected Catheter-Related Candidemia (CRC)</td>
</tr>
<tr>
<td>415</td>
<td>Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis</td>
</tr>
<tr>
<td>416</td>
<td>Culture-Documented Invasive Mold Infections (cIMIs) at MD Anderson Cancer Center (MDACC) in Houston, TX, Pre- and Post-Hurricane Harvey</td>
</tr>
<tr>
<td>417</td>
<td>Clinical Mycology in Latin America and the Caribbean: Diagnostic Capabilities and Antifungal Therapy</td>
</tr>
</tbody>
</table>
### Poster Abstract Sessions (continued)

#### 57. Poster Abstract Session
**Global Health and Travel Medicine**  
Thursday, 12:30 - 1:45 p.m.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>418</td>
<td>Evaluation of β-D-Glucan (BG) and Galactomannan (GM) Detection Assays in the Diagnosis of Invasive Fungal Infections in High-Risk Pediatric Cancer Patients</td>
</tr>
<tr>
<td>419</td>
<td>Diagnostic Performance of Immunohistochemistry Test to Differentiate Aspergillosis from Mucormycosis with Formalin-fixed Tissue Specimens</td>
</tr>
<tr>
<td>420</td>
<td>A Rapid PCR Assay Detects Fungemia due to Mixed <em>Candida</em> Species that is Missed by the Clinical Microbiology Laboratory</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>421</td>
<td>Babesiosis: Retrospective Review of 38 Cases from Upper Midwest</td>
</tr>
<tr>
<td>422</td>
<td>Brucellosis Regimens Comparison in a Saudi Tertiary Academic Medical Center</td>
</tr>
<tr>
<td>423</td>
<td>Ten-Year Experience of <em>Burkholderia pseudomallei</em> Infections in a Singapore Tertiary Hospital</td>
</tr>
<tr>
<td>424</td>
<td>Southern Arizona Town: Homes Colonized by Kissing Bugs: Is Chagas Disease Being Transmitted?</td>
</tr>
<tr>
<td>425</td>
<td>Chikungunya in Solid Organ Transplant Recipients, a Case Series and Literature Review</td>
</tr>
<tr>
<td>426</td>
<td>Post-Chikungunya Chronic Disease and its Impact on Quality of Life, Depression, Anxiety, Fatigue, and Sleep Quality: Results from a 2-Year Follow-Up Comparative Study of 62 Patients in La Virginia, Risaralda, Colombia</td>
</tr>
<tr>
<td>427</td>
<td>Symptoms Associated with Fasciola Hepatica Infection: A Community Based Study in Cusco, Peru</td>
</tr>
<tr>
<td>428</td>
<td>Mobile Phone Access and Comfort: Implications for HIV and Tuberculosis Care in India and South Africa</td>
</tr>
<tr>
<td>429</td>
<td>Delayed Diagnosis of Leprosy in a Non-Endemic Area: Lessons from a Retrospective Case Series</td>
</tr>
<tr>
<td>430</td>
<td>The First Case Reports of Leptospirosis and Melioidosis in the Aftermath of Hurricanes Irma and Maria—Saint Thomas/Saint John District, U.S. Virgin Islands, September-October 2017</td>
</tr>
<tr>
<td>431</td>
<td>Enhanced Malaria Surveillance in Greece, 2009-2017</td>
</tr>
<tr>
<td>432</td>
<td>Hold That Buzz: Timely Malaria Medication Access in New Orleans, LA</td>
</tr>
<tr>
<td>433</td>
<td>Impact of Malaria Prophylaxis on Risk of Travelers’ Diarrhea among International Travelers</td>
</tr>
<tr>
<td>434</td>
<td>Neurocysticercosis in Houston</td>
</tr>
<tr>
<td>435</td>
<td>Serological Cross-Reactivity between <em>Rickettsia japonica</em> and <em>Orientia tsutsugamushi</em>, and among <em>Orientia tsutsugamushi</em> Serotypes</td>
</tr>
<tr>
<td>436</td>
<td>A Survey of Schistosomiasis and Strongyloidiasis among Eritrean Immigrants to Israel</td>
</tr>
<tr>
<td>437</td>
<td>Spatial Distribution of Schistosomiasis after Repeated Praziquantel Treatments in a Rural Community in Brazil</td>
</tr>
<tr>
<td>438</td>
<td>Finding Toxocara Eggs in Park Soil from Montgomery County, Pennsylvania</td>
</tr>
<tr>
<td>439</td>
<td>Impact of Pre-Travel Consultation on Clinical Management and Outcomes of Traveler’s Diarrhea</td>
</tr>
<tr>
<td>440</td>
<td>The Masqueraders Presenting a Multi-System Disease: Unusual and Atypical Clinical Features of Scrub Typhus in Fukushima, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>442</td>
<td>The Results of a Primary Care-Based Screening Program for <em>Trypanosoma cruzi</em> in East Boston, MA</td>
</tr>
<tr>
<td>443</td>
<td>West Nile Virus in Humans in Greece, 2010-2017</td>
</tr>
<tr>
<td>444</td>
<td>Zika Testing in a Large Academic Center during a Continental U.S. Outbreak</td>
</tr>
<tr>
<td>445</td>
<td>Cross-Reactivity between Zika and Dengue Virus: A Cross-Sectional Analysis in Rio Grande do Norte, Brazil</td>
</tr>
<tr>
<td>446</td>
<td>Leveraging Partnerships to Care for Mothers born After Maternal Zika Infection - U.S. Virgin Islands (USVI)</td>
</tr>
<tr>
<td>447</td>
<td>Infant Microcephaly during the Zika Virus Epidemic in Dominican Republic, 2016-2017</td>
</tr>
<tr>
<td>448</td>
<td>Can Electronic Clinical Notes Identify Travelers with Zika?</td>
</tr>
<tr>
<td>449</td>
<td>Post-Hurricane Maria Surveillance for Infectious Diseases in the Veterans Affairs San Juan Medical Center, Puerto Rico</td>
</tr>
<tr>
<td>450</td>
<td>Using Geographical Information Systems to Interpret the Efficacy of Mass Drug Administration for Soil-Transmitted Helminthiasis in Rural Madagascar</td>
</tr>
<tr>
<td>451</td>
<td>High Frequency of MultiDrug-Resistant Organisms (MDRO) at University Teaching Hospital (UTH), Lusaka, Zambia</td>
</tr>
<tr>
<td>452</td>
<td>Spectrum of Respiratory Pathogens Detected by Multiplex PCR in a Study of Respiratory Tract Infections Among Travelers</td>
</tr>
<tr>
<td>453</td>
<td>Understanding Travel Medicine Provider’s Risk Assessment of Travel-Associated Diseases</td>
</tr>
<tr>
<td>454</td>
<td>Barriers and Facilitators to Control of Hospital-Acquired Infections in Jimma, Ethiopia</td>
</tr>
<tr>
<td>455</td>
<td>Epidemological Surveillance in Points of Care for Refugees/Migrants: the 2016-2017 Experience in Greece</td>
</tr>
<tr>
<td>456</td>
<td>Discrepant Trip Experiences Among Travelers Attending a Tertiary Care Center Family Travel Medicine Clinic</td>
</tr>
</tbody>
</table>

#### 58. Poster Abstract Session
**Healthcare Epidemiology: Advances in Hand Hygiene**  
Thursday, 12:30 - 1:45 p.m.

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>457</td>
<td>Relationship Between Healthcare Worker (HCW) Perceptions of Safety and Rates of Healthcare Associated Infections (HAI) and Hand Hygiene (HH) Compliance</td>
</tr>
<tr>
<td>458</td>
<td>Using a Humanoid Robot to Improve Hand Hygiene Compliance</td>
</tr>
<tr>
<td>459</td>
<td>Patient-Based Surveys to Better Understand Patients’ Perceptions of Healthcare Providers’ Hand Hygiene Practices and If Patient Responses Validate Secret Observers’ Hand Hygiene Compliance Reporting</td>
</tr>
<tr>
<td>460</td>
<td>Teaching an Old Dog New Tricks—Environmental Cleaning Services Not So Set in Their Ways That They Can’t Be Taught Better Hand Hygiene Practices</td>
</tr>
<tr>
<td>461</td>
<td>Electronic Hand Hygiene Compliance Monitoring Systems: Not All Are Created Equal</td>
</tr>
</tbody>
</table>
Poster Abstract Sessions (continued)

462 “All Eyes on You”: A Covert Observational Study on Contact Precaution Compliance in Six Hospitals at the Detroit Medical Center

463 Healthcare Workers’ Perceptions Regarding the Use of an Electronic Hand Hygiene Monitoring System at a VA Hospital

464 The Efficacy of Alcohol-Based Wipes, Gel, Foam, and Spray Compared to Liquid Soap in Eliminating Transient Hand Bacteria

465 Microbial Removal Efficacy of a Novel Non-Antimicrobial Hand Soap

59. Poster Abstract Session

Healthcare Epidemiology: Updates in C. difficile

Thursday, 12:30 - 1:45 p.m.

466 Use of Administrative Data to Characterize Clostridium difficile Infections (CDI) Reported by California Hospitals to the California Department of Public Health (CDPH) via the National Healthcare Safety Network (NHSN): 2014–2015

467 Investigation of a Clostridium difficile Infection (CDI) Outbreak in a Community Teaching Hospital

468 Diagnosis of Clinical Clostridium Difficile Infection: An Unmet Challenge

469 Validation and Characterization of Community-Acquired Clostridium difficile Infections from the Quebec Clostridium difficile Infection Surveillance Program (QCISP)

470 Concomitant Antibiotic Use and Death among a National Cohort of Veterans with Clostridium difficile Infection (CDI)

471 Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh

472 Prevalence, Risk Factors, and Outcome of Postoperative Clostridium difficile Infection After Orthopedic Surgery

473 Molecular Typing of Clostridium difficile: Concordance between PCR-Ribotyping and Multilocus Sequence Typing (MLST)

474 Temporal Trends of Inpatient C. difficile Infections within the Veterans Affairs Hospitals: A Bioinformatics Analysis of Nationwide Metadata from the Past Decade

475 Burden of Clostridium difficile Infection in South Carolina: A Population-Based Study

476 Comparison of Community-Associated Clostridium difficile Infections with other Reportable Enteric Pathogens, Minnesota, 2016


478 Improving Acid Suppression Therapy to Reduce Hospital-Onset C. difficile Infection (HO-CDI): Impact of a Novel Analytic Application

479 Trends in C. difficile Incidence, Mortality, and NAP1/027 Strain in the Population of Monroe County, NY

480 Reduction in Clostridium difficile Infection Rates Following a Prevention Collaborative in Orange County, CA, 2014-2017

481 Implementation of a Prospective, Pharmacist-Driven Clostridium difficile PCR Pre-Authorization Process to Optimize Appropriate Testing

482 Association between Socioeconomic Status Factors and Incidence of Community-Associated Clostridium difficile Infection Utilizing Factor Analysis—United States, 2014–2015

483 Clinical Characteristics of Military Trauma Patients with Clostridium difficile Infections

484 A Severity Score for Predicting In-Hospital Death in Patients with Clostridium difficile Infection: A Hospital-Based Cohort Study

485 On- and Post-Antibiotic Effects on the Risk of Hospital-Acquired Clostridium difficile Infection (CDI)

486 Endemic Corridors: A Useful Tool for the Approach of Clostridium difficile. A 5-Year Epidemiologic Surveillance Program in a Teaching Hospital of a Middle-Income Country

487 Severity and Clinical Outcomes of Clostridium difficile Infection Based on Toxin B Assay Results

488 Oral Vancomycin plus Intravenous Metronidazole for Severe Clostridium difficile Infection in Critically Ill Patients

489 Validation of the SHEA/IDSA Severity Criteria to Predict Poor Outcomes among Inpatients and outpatients with Clostridium difficile Infection

490 Comparison of Clostridium difficile Infection Outcomes by Diagnostic Testing Method

491 Clinical Manifestations and Outcomes of Clostridium difficile Infection in Long Term Care Patients: An 8-Year Retrospective Cohort Study

492 Long Term Outcomes of Clostridium difficile Infection among Medicare Beneficiaries

493 Development of a Simple Clostridium difficile Infection Clinical Risk Prediction Tool for Medical Inpatients

494 Use of a Clinical Prediction Tool to Predict Clostridium difficile Infection

495 Predictors of C. difficile Infection and Impact of Primary Prophylaxis among Asymptomatic C. difficile Colonized Patients: A Cross Sectional Study

496 Secondary Prophylaxis for Clostridium difficile infection—A Physician Practice Assessment

497 Identification of Patients at Risk of Clostridium difficile Infection for Enrollment in Vaccine Clinical Trials

498 Molecular Epidemiology of C. difficile within a Community Hospital: A Pilot for a Regional Survey

499 Determining Risk of Clostridium difficile Using Electronic Health Record (EHR) Data

500 Efficacy of 30-Day Fidaxomicin for Treatment of Acute Clostridium difficile Infection with History of Multiple Recurrences


502 Enhanced Sporulation and Vancomycin Resistance Associated with Clostridium difficile from Recurrent Infections
Poster Abstract Sessions (continued)

503 Risk and Timing of Clostridium difficile Infection Relapse after Antibiotic Exposure
504 Change in Clostridium difficile Strain Type Distribution after Implementation of Diagnostic Stewardship
505 Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
506 The Impact of Bowel Management System (BMS) on the Incidence of Hospital-Onset (HO) Clostridium difficile Infection Laboratory-ID Events despite Diagnostic Stewardship
507 Degree of Concordance of Clostridium difficile Strains in Adults with Community-Associated Clostridium difficile Infection and Infants with Clostridium difficile Colonization.
508 High Rates of Cure and Long-Term Symptom Resolution with Both Capsule and Lower Gastrointestinal Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
509 Spatio-Temporal Clustering of CDI Cases at the University of Iowa Hospitals and Clinics
510 First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals
511 What is the Current State of Patient Education after Clostridium difficile Infection?
512 Tracking the Use of Soap and Sanitizer for Hand Hygiene after Caring for Clostridium difficile Patients
513 Effectiveness of Pulsed Xenon Ultraviolet Light Disinfection System to Decrease Clostridium difficile Infections at the South Texas Veterans Health Care System
514 The Effect of Probiotics on the Incidence of Clostridium difficile
515 Estimating the Effect of Proton Pump Inhibitor Stewardship in Reducing Clostridium difficile Transmission
516 Implementation of a Probiotic for the Primary Prevention of Hospital-Onset Clostridium difficile Infection
517 Impact of Doxycycline in place of Azithromycin for Community Acquired Pneumonia on Clostridium difficile Infections
518 Modeling the Potential Impact of Administering Vaccines against Clostridium difficile Infection to Individuals in Healthcare Facilities
519 Longer Length of Antibiotic Therapy for Community-Acquired Pneumonia and Risk of Clostridium difficile Infection
520 Reducing Inappropriate Clostridium difficile Testing by Empowering Nurses
521 Clostridium difficile Timeout: A Nurse—Driven Protocol to Optimize Testing Stewardship
522 Impact of a Multicomponent Intervention Bundle on Healthcare Facility-Onset Clostridium difficile Rates
523 Use of Whole-Genome Sequencing to Guide a C. difficile Diagnostic Stewardship Program
524 The Journey to Implement a Computerized Clinical Decision Support (CDS) Tool to Improve Testing for Clostridium difficile Infection (CDI)
525 The Impact of Switching to Molecular Testing on Clostridium difficile Infection Rates: Large-Scale Assessment Using an Interrupted Time Series Poisson Regression Approach
526 An EMR-Based Diagnostic Stewardship Intervention for GI mPCR Aimed at Reducing Inappropriate C. difficile Tests
527 New Robust Antimicrobial Stewardship Program (ASP) Results in Reduction of Clostridium difficile 30-Day Readmission
528 Lab Stewardship for Clostridium difficile Testing Improves Appropriate Testing While Decreases Unnecessary Testing and Saves Laboratory Resources While Dramatically Helping to Reduce C diff Standardized Infection Ratios (SIR)
529 Overdiagnosis of Clostridiodes difficile with a Multiplex PCR Panel
530 The Perfect Storm for Improved Standardized Infection Ratio (SIR)—Recognizing More Community Onset Clostridium difficile (C diff) Infections Increases the Expected Number of C diff Cases While Also Helping to Decrease the Actual Observed Number of Hospital Onset C diff Cases
531 Reducing Inappropriate Hospital-Acquired Clostridium difficile Diagnoses
532 Recurrent C. difficile in Children: Not Easy to Cure
533 Scaling Pediatric Access to Fecal Microbiota Transplantation in the United States: A Time-Series Geospatial Analysis
534 Clostridium difficile Reduction: An Agent-Based Simulation Modeling Approach to Evaluating Intervention Comparative Effectiveness at Pediatric Hospitals
535 Transmission of Clostridium Difficile from Patients ≤ 2 Years of Age in a Pediatric Oncology Setting
536 Clostridium difficile Colonization in the First Year of Life
537 Engaging the Bedside Nurse in Reducing Clostridium difficile Infection Through an Innovative Patient Care Rounding Program

60. Poster Abstract Session

HIV: Antiretroviral Therapy
Thursday, 12:30 - 1:45 p.m.

538 Integrase Inhibitor-Based HAART is Associated with Greater BMI Gains in Blacks, Hispanics, and Women
539 GS-CA2: A Novel, Potent, and Selective First-In-Class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans
540 Investigating the Mechanism of a Unique Human Immunodeficiency Virus-1 (HIV-1) Entry Inhibitor, MF275
541 Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4+ Count, and WHO Clinical Staging
542 Efficacy of MK-8591 Against Diverse HIV-1 Subtypes and NRTI-Resistant Clinical Isolates
<table>
<thead>
<tr>
<th>Poster Abstract Sessions (continued)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>543</td>
<td>An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults</td>
</tr>
<tr>
<td>544</td>
<td>Pharmacokinetic Profile of ibalizumab from a Phase 3 Trial</td>
</tr>
<tr>
<td>545</td>
<td>Rational Design of Doravirine (DOR): A Review of Development from Bench to Patients (pts)</td>
</tr>
<tr>
<td>546</td>
<td>No Difference in MK-8891 and Doravirine Pharmacokinetics after Co-Administration</td>
</tr>
<tr>
<td>547</td>
<td>Results of Patient-Reported Outcome Data from the Phase III BRIGHTE Study of Fostemsavir</td>
</tr>
<tr>
<td>548</td>
<td>Antiretroviral Therapy Regimen Characteristics within an Urban, Safety-Net Clinic in the United States</td>
</tr>
<tr>
<td>549</td>
<td>Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen</td>
</tr>
<tr>
<td>550</td>
<td>Adherence and Persistence with Modern Single vs Multi-Tablet Antiretroviral (ARV) Regimens in 1st treatment of HIV in Clinical Practice</td>
</tr>
<tr>
<td>551</td>
<td>MK-8891 Does Not Alter the Pharmacokinetics of the Oral Contraceptives Ethinyl Estradiol and Levonorgestrel</td>
</tr>
<tr>
<td>552</td>
<td>Evaluation of Relationships between UGT1A1 Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics among HIV-infected subjects in the LATTE-2 Study</td>
</tr>
<tr>
<td>553</td>
<td>A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir</td>
</tr>
<tr>
<td>554</td>
<td>Does Protease Inhibitor (PI) Monotherapy Select Primary PI Resistance?</td>
</tr>
<tr>
<td>555</td>
<td>Characteristics of HIV+ Patients Prescribed Raltegravir QD in the United States</td>
</tr>
<tr>
<td>556</td>
<td>Factors Associated with Integrase Strand Transfer Inhibitor Use between 2008-2015</td>
</tr>
<tr>
<td>557</td>
<td>Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV Infected Patients</td>
</tr>
<tr>
<td>558</td>
<td>Genotype-Guided versus Standard First-line Antiretroviral Regimen for Treatment Naïve HIV-infected Patients in Thailand: A Prospective Randomized Controlled Trial</td>
</tr>
<tr>
<td>559</td>
<td>Efficacy and Tolerability of Integrase Inhibitors—Experiences from a Nationwide Real-life Cohort</td>
</tr>
<tr>
<td>560</td>
<td>Immune Recovery of Acute HIV Treated Patients is Characterized by an Increase in Immune Senescence</td>
</tr>
<tr>
<td>561</td>
<td>Higher “No Show” Rates Are Associated with Lower Rates of Retention in HIV Care and Viral Suppression</td>
</tr>
<tr>
<td>562</td>
<td>Implementing HIV Rapid Entry in a Community Infectious Disease Practice</td>
</tr>
<tr>
<td>563</td>
<td>Earlier Linkage and ART Initiation Via Fast Track Referral System for New HIV Patients Leads to Stronger Engagement and Better Outcomes</td>
</tr>
<tr>
<td>564</td>
<td>Stigma, Secrecy, and Spirituality: An Exploratory Study of How Sociocultural Practices and Perceptions Influence Care Engagement among HIV-Positive Adults in Akwatia, Ghana</td>
</tr>
<tr>
<td>565</td>
<td>The Impact of Disclosure Stigma on Virologic Outcomes in People Living with HIV</td>
</tr>
<tr>
<td>566</td>
<td>Pre-Tained: Early Intervention for HIV Patients at High Risk of Becoming Un-retained</td>
</tr>
<tr>
<td>567</td>
<td>The Effects of Loss of Control, Social Support, and Stigma on the HIV Care Continuum in the Aging HIV-Infected Population</td>
</tr>
<tr>
<td>568</td>
<td>In a Well Characterized Cohort with Universal Access to Care and Medications Racial Disparities in HIV Virologic Outcomes are No Longer Observed</td>
</tr>
<tr>
<td>569</td>
<td>Cascade of HIV Care of Newly-Diagnosed Citizens in Israel 2011-2015: A Population-Based Cohort Study</td>
</tr>
<tr>
<td>571</td>
<td>Late Diagnosis of HIV in South Carolina: Prevalence, Cause, and Consequences</td>
</tr>
<tr>
<td>572</td>
<td>Older HIV-infected Adults are Twice More Likely to Present Late to Care</td>
</tr>
<tr>
<td>573</td>
<td>Continuing Disparities in Virologic Control for People Living with HIV (PLWH) Receiving Care at a Large, Urban, Safety-Net Clinic</td>
</tr>
<tr>
<td>574</td>
<td>Barriers to Transitions of Care in the Detroit Young HIV Population</td>
</tr>
<tr>
<td>575</td>
<td>Virtual vs. True: Identifying Out-of-Care HIV Patients at Lower Risk for Poor Health Outcomes</td>
</tr>
<tr>
<td>576</td>
<td>Acceptability of Home-Based Medical Assessment to Facilitate Re-Engagement of HIV-Positive Out-Of-Care Persons into Clinical Care, New York City</td>
</tr>
</tbody>
</table>

61. Poster Abstract Session

**HIV: Linkage to Care and Viral Suppression in the Care Cascade**

Thursday, 12:30 - 1:45 p.m.

| 561 | Co-Occurring Psychosocial Barriers to Viral Suppression Among Men Who Have Sex with Men (MSM) in India |
| 562 | Management and Outcomes of Patients with Acute HIV Infection in an Expanded Testing and Linkage to Care Program |

62. Poster Abstract Session

**HIV: Management and Clinical Outcomes**

Thursday, 12:30 - 1:45 p.m.

| 580 | Key Factors for Treatment Changes within One Year after Starting ART in the German ClinSurv Cohort; between 2005 and 2014 |
| 581 | Do Comorbidities and Polypharmacy Lead to Virologic Failure in All Populations Living with HIV? |
| 582 | Strengthening HIV Care and Treatment in the RoC Military |
| 583 | Demographic Factors and Clinical Outcomes Associated with Mental Health Medication Use in People Living with HIV |
| 584 | Investigation of the Association between Neurocognitive Function and Depression in HIV Infection |
| 585 | Hospitalization Rates and Diagnoses Vary by Age Group among Persons with HIV (PWH) in 2014-2015 |
586 The Aging Epidemic: Virologic Control, Immunologic Recovery, Treatment Regimens, and Clinical Outcomes among Older Adults Living with HIV in Washington, DC

587 HIV Care Outcomes among PWID in San Francisco, 2009-2015

588 Retrospective Analysis of Clinical Characteristics and Treatment Patterns Among HIV Patients with Commercial and Medicare Advantage Health Insurance in the U.S.

589 Assessment of an Antiretroviral Therapy Policy in Patients with Human Immunodeficiency Virus at a Large Academic Medical Center

590 Tackling HIV/AIDS in Brooklyn, NY, Within a Network of Federally Qualified Health Centers

591 Impact of an Antimicrobial Stewardship (ASP) Initiative Evaluating Antiretroviral Regimens for HIV-Positive Patients

592 Determining the Impact of an Antiretroviral Stewardship Team on the Care of HIV-Infected Patients Admitted to an Academic Research Institution

593 A Nationwide Assessment of Predictive Factors for Provision of Continuity of Care Resources for HIV-Positive Detainees in ICE Health Service Corps-staffed Facilities, 2015 and 2017

594 The Prevention and Management of HIV:Online Education as a Tool to Improve Knowledge and Confidence among HIV/ID Specialists

595 Changes in Ryan White Clinic Referral Patterns among HIV-infected Patients following Implementation of the Affordable Care Act

596 Case Study of Motivational Interviewing Intervention in Patients Non-Adherent to Antiretroviral Therapy

597 Pharmacist-Led Interventions for Inpatient HIV-Related Medication Errors

598 Choosing Wisely with CD4 Counts: When Less is More

599 Expanding HIV Training in Internal Medicine Residency Program: A Prospect to Meet the HIV Workforce Demand

600 To Study the Status of HIV Disclosure in Children and Adolescents

601 Prescription Drug Misuse in an HIV-Infected U.S. Military Cohort

602 Factors Associated with Erectile Dysfunction Diagnosis in HIV-Infected Individuals: A Case-control Study

603 Multi-Morbidity and Impaired CD4/CD8 ratios in Older Adults with well controlled HIV

604 Impact of Substance and Alcohol Abuse on Smoking-Related Behaviors When Using a Smoking Cessation Decisional Algorithm Among People Living with HIV (PLWH)

605 Loneliness among Older Adults Living with HIV: A Study and Online Community

606 Risk Factors for Congenital Infection in the United States: Analysis of the Kids’ Inpatient Database (KID)

607 Group B Streptococcus Resistance to Clindamycin: Regional Antibiogram Surveillance in Los Angeles County

608 The Effect of Prenatal Screening for Chlamydia trachomatis (CT) on Chlamydial Conjunctivitis in Infants

609 Acute Kidney Injury during Treatment with Intravenous Acyclovir (AKITA) for Suspected Neonatal Herpes Simplex Virus Infection

610 Barriers and Facilitators to Uptake of Male Partner Attendance for HIV VCT During Prenatal Care in Brazil

611 Placental Pathology and Neonatal Outcomes in Pregnancies of Perinatally versus Non Perinatally HIV Infected Women

612 Increase in Perinatal HIV Infection in North Florida - Missed Opportunities to Prevent Maternal to Child Transmission in Rural Areas

613 Transmission of Influenza Virus in Mother and Infant Transmission Events in Nepal

64. Poster Abstract Session

Microbiome and Beyond

Thursday, 12:30 - 1:45 p.m.

614 Modeling Changes in Gastrointestinal and Respiratory Tract Bacterial Community Diversity Attributable to Common Antibiotic Exposures During Long-Term Acute Care

615 Can We Restore the Lung Microbiome with Fecal Microbiota Transplant (FMT)?

616 Vancomycin is Frequently Administered to Hematopoietic Cell Transplant Recipients Without a Provider Documented Indication and Correlates with Microbiome Disruption and Adverse Events

617 Characterization and Development of the Infant Gut Virome: A STORK Study

618 Do Clinical Factors Affect Microbial Engraftment After Fecal Microbiota Transplantation in Recurrent Clostridium difficile Infection?

619 Intestinal Microbiome Changes Associated with Immune Status and Clostridium difficile Colonization in Hospitalized Children

620 Oral Beta-Lactamase Therapies Prevent Microbiome Damage and Attenuate Antibiotic Resistance from IV and Oral Antibiotics in Large Animal Models of Antibiotic-Mediated Gut Dysbiosis

621 Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose Dependent Manner

622 Increased IgA Coating of Gut Microbes After Administration of Killed, Whole-Cell Oral Cholera Vaccine

623 Dynamic Nature of the Gut Resistome Among Infants in Singapore

624 Microbiota and Associations with Treatment Outcome in Fecal Microbiota Transplantation
Poster Abstract Sessions (continued)

65. Poster Abstract Session  
**Pathogenesis and Immune Response**  
Thursday, 12:30 - 1:45 p.m.

- **625** Metabolic Interactions Drive Staphylococcus aureus Adaptation to the Skin
- **626** An Inexpensive Quantitative Method for Testing Anti-Fungal Drug Activity Using the Invertebrate Caenorhabditis elegans
- **627** Differences In C. difficile Toxin A Binding In Humans: Adults Versus Infants
- **628** Short-Term Water-Pipe (Shisha) Smoke Exposure Worsens Lung Inflammation in Mice Infected with Respiratory Syncytial Virus
- **629** Blood Transcriptome Variations Predict Infection and Rejection in the Older Kidney Transplant Recipient
- **630** Identification of a Depressed Mucosal Immune Environment in HIV Infection
- **631** Markers of Immune Response in Patients with Acute, Chronic, and Fatal Infection with Chikungunya Virus in Colombia during the 2015 Epidemic
- **632** Recurrent Pneumococcal Meningitis in Adults
- **633** HIV-1 Vpu Immune Correlates in a Narrow-Source Infection Cohort: Impact of ADCC and KIR-Associated Pressure
- **634** Transcriptional Stimulation of Antiviral Response Components by the Structural and Accessory Human Coronavirus OC43 Proteins
- **635** In HIV Infected Patients Killing of Latently HIV-Infected CD4 T Cells by Autologous CD8 T Cells is Modulated by Nef
- **636** The Hepcidin-25 and Iron Kinetics during the Acute Phase of Systemic Infection
- **637** Beta-lactam (BL) Antibiotics Promote an IL-1β Response in Patients with Staphylococcus aureus Bacteremia (SaB)
- **638** CMV-Specific T Cell Immune Responses in Older Versus Younger Kidney Transplant Recipients
- **639** Indoleamine 2,3 Dioxygenase, Age, and Chronic Immune Activation in HIV Patients
- **640** Prospective Association of Serum Vitamin D level with Sepsis-Mortality in Postmenopausal Women: Results from the Women's Health Initiative
- **641** Development of Structural Epitope Targeting During B cell ontogeny by Exploration of Relatives of Gp41 Structural Epitope Binding Antibody 6F5
- **642** B and T cell Responses to Pneumococcal Polysaccharide and Protein Vaccine Antigens in Recently-Diagnosed HIV-1-Infected Patients
- **643** Coronary Artery Aneurysms are Found on Blindly Read Echocardiograms from Febrile Patients with and without Kawasaki Disease
- **644** How Antibody Isotype Affects Anti-Capsular Antibody Protection Against Carbapenem-Resistant Klebsiella pneumoniae Infection
- **645** Mucosal Associated Invariant T cells in renal tissue from patients with Recurrent Urinary Tract Infections
- **646** Activated Macrophages as Pathogenesis Factors in Ebola Virus Disease in Humans
- **647** Characterization and Development of Monoclonal Antibodies to Pneumococcal Serotype 3
- **648** Urinary Tract-Associated Escherichia coli Bacteremia Strains are Genetically More Virulent than Those Originating from Non-Urinary and Neutropenaic Infective Foci
- **649** The Clinical Significance of Sequence Type 17 of Vancomycin-Resistant Enterococcus faecium
- **650** Genomic Analysis of Shiga Toxin-Producing Escherichia coli from Symptomatic Patients and Asymptomatic Carriers
- **651** Non-Encapsulation of Pneumococci as a Potential Evasion Mechanism from Vaccines
- **652** What’s Blood Got to Do with It? Genetic Susceptibility to Norovirus and Rotavirus Infection: Results from the SUPERNOVA Network
- **653** To Treat or Not to Treat Corynebacterium striatum? That is the Question
- **654** Biofilm Forming Methicillin-Resistant Staphylococcus aureus Induces Renal Deterioration and Severe Virulence in a Mouse Bacteraemic Model
- **655** Antimicrobial Susceptibility and Prevalence of Extra-intestinal Enterotoxigenic Bacteroides fragilis Among a 5-year Collection of Isolates Causing Sepsis in Kuwait
- **656** E. coli Clone Sharing and Persistence within Households (HHs) in Relation to Fluoroquinolone (FQ) Resistance and ST131 Status
- **657** Epstein-Barr Virus Genetic Diversity in Blood versus Saliva Samples from Patients with Infectious Mononucleosis

66. Poster Abstract Session  
**Public Health: Epidemiology and Outbreaks**  
Thursday, 12:30 - 1:45 p.m.

- **658** Trends in Mumps Cases and Incidence, United States, January 2016–April 2018
- **659** Mumps Outbreak in a High School: Uptake and Parental Perceptions of 3rd Dose MMR Recommendations, Dallas County, TX, 2017
- **660** Are U.S. Clinicians Thinking Measles in the Post-Elimination Era? Surveillance for Measles-Like Illness in a Commercially Insured U.S. Population
- **661** Surveillance of Rabies Prophylactic Treatments after Exposure to Animals: 5 years Experience
- **662** Tick Borne Associated Thrombocytopenia Among United States Veterans in Long Island, NY
- **663** Characteristics, Treatment Patterns, and Outcomes of Outpatients with Rickettsial Diseases in a Large, Commercially Insured Population—United States, 2005–2016
- **664** Factors Associated with the Need for ICU Care Among Patients with Human Ehrlichiosis
- **665** Key Clinical and Laboratory Features in Early Diagnosis of Ehrlichiosis in an Endemic Area of Long Island, NY
- **666** Human Granulocytic Anaplasmosis and Ehrlichiosis Presenting to an Upstate New York Emergency Department
- **667** An Emerging Tick-Borne Disease in Long Island, NY: Relapsing Fever Caused by Borrelia miyamotoi
668 Clinical Spectrum of Powassan Virus Infection in Patients Presenting with Suspected Acute Tick-borne Illness from a Lyme-endemic Focus in the Midwest

669 Changing Epidemiology of Murine Typhus in Texas

670 Estimating Bordetella pertussis Seroprevalence in Persons Aged 10-25 Years in Mexico Using the 2012 United States National Health and Nutrition Survey (ENSA.NUT)—Challenges and Lessons Learned

671 Increased Disease Severity and Larger Household Size among Hispanic Infants with Pertussis—Chicago, IL, 2010-2016

672 The Impact on Humans of Treating Dogs with Amoxicillin/Clavulanate

673 Syphilis Outbreak in Women Who Have Sex with Men in Japan: A Case-Control Study in Tokyo, 2017-2018

674 Epidemiology of Diphtheria and Antimicrobial Resistance Among Diphtheria Cases, Bijapur district, Karnataka, India, 2012 to 2015

675 Current Physician Knowledge, Attitudes, and Clinical Practice regarding Legionnaires’ Disease in the Aftermath of the Flint Water Crisis in Genesee County, MI

676 A Retrospective Forensic Review of Sudden Unexpected Infectious Deaths

677 Using a Multisectorial One Health Approach to Prioritize Zoonotic Diseases in the U.S.

678 Outbreak of Shiga Toxin-Producing Escherichia coli Infections at Marine Corps Recruit Depot (MCRD), San Diego and Camp Pendleton, CA, October–November, 2017

679 Mass-Scale Post-Hurricane Sheltering of Evacuees from Hurricane Harvey: Infectious Disease Surveillance and Prevention—Dallas County, TX, 2017

680 “There’s More to This than Meets the Eye”: Opportunities for Infection Prevention in Optometry Clinics

681 Epidemiology and Outcomes of Patients with Carbapenem-Resistant Bloodstream Infection in United States (U.S.) Hospitals, 2010-2015

682 The Changing Epidemiology of Bacterial Meningitis During 2015-2017 in Turkey: A Hospital-Based Prospective Surveillance Study

683 Cost Calculator for Mass Vaccination Response to a U.S. College Campus Outbreak of Serogroup B Meningococcal Disease

684 Risk Stacking for Pneumococcal Disease in Costa Rica

685 Correlation between Hospitalized Influenza and Group A Streptococcus Infections in Minnesota, 2010 – 2016

686 Use of an Influenza-like Illness School Absenteeism Monitoring System to Identify Seasonal Influenza Outbreaks in the Community: ORCHARDS (Wisconsin, September 2014—June 2017)

687 Modeling the Impact of Introduction of Influenza Vaccination on ILI Cumulative Case Count in Cameroon

688 Impact of Expanded Influenza Post-Exposure Prophylaxis on Health Care Worker Absenteeism at a Tertiary Care Center during the 2017–2018 Season

689 Narcolepsy During the 2009–2010 H1N1 Pandemic

690 Bacterial Coinfections Among Adults Hospitalized with Community-Associated Influenza, 2016-2017

691 Real-Time Local Influenza Forecasting using Smartphone-Connected Thermometer Readings

692 Effects of Regional Climatic Variability on West Nile Virus Outbreaks in the United States

693 Congenital Zika Syndrome: Assessing the Fatality Rate Since the 2015 Zika Outbreak

694 The CAGE Study: Prevalence of Acute Gastroenteritis and Enteric Virus Infection in the Community

67. Poster Abstract Session

**Resistance Mechanisms: Gram-Negative**

Thursday, 12:30 - 1:45 p.m.

695 Regional and Longitudinal Mapping of Escherichia coli Antibiotic Susceptibility

696 Mechanism of Ceficerocol High MIC Mutants Obtained in Non-Clinical FoR Studies

697 Pseudomonas aeruginosa PcrV and Psl, the Molecular Targets of Bispecific Monoclonal Antibody ME3902, are Conserved Among Diverse Hospital Isolates Collected from an International Surveillance Study

698 Nacubactam Inhibits Class A and C β-lactamases

699 Relationship between Klebsiella pneumoniae Antimicrobial Resistance and Biofilm Formation

700 Identification and Whole Genome Sequencing (WGS) of Meropenem-Vaborbactam (MV) Resistant Klebsiella pneumoniae (MVRKP) Among Patients without Prior Exposure to MV: Collateral Damage

701 Rapid Detection of Antimicrobial Resistance Determinants with the BioFire® System

702 Zinc Blockade of Antimicrobial Resistance Genes in Enteric Bacteria

703 Mechanisms of High-Level Ceftolozane/Tazobactam (CT) Resistance against Pseudomonas aeruginosa and Synergy between CT and tobramycin (TOB)

704 Klebsiella pneumoniae Carbapenemase and Verona Integron-Encoded Metallo-Beta-Lactamase among Carbapenem-Resistant Enterobacteriaceae in Kentucky

705 Four Superbugs Isolated from a Single Patient in the United States: E. coli (EC) and K. pneumoniae (KP) harboring NDM-5, P. aeruginosa (PA) Harboring NDM-1 and Candida auris

706 Ceftazidime-avibactam (CZA) and Meropenem (MER) are Synergistic and Bactericidal against Genetically-Diverse KPC-Producing Klebsiella pneumoniae (Kp)

707 Clarifying the Role of CrrB in Polymxyin Resistant Klebsiella pneumoniae Clinical Isolates Utilizing a Novel CRISPR-Cas9 System

708 Incidence and Relatedness of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Infections in Previously Colonized or Infected Patients

709 Activity of Key β-Lactam Agents against Gram-Negative Bacilli from ICU Patients with Lower Respiratory Tract Infections – SMART United States 2015-2017
68. Poster Abstract Session
Resistance Mechanisms: Gram-Positive
Thursday, 12:30 - 1:45 p.m.

710 Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in *Clostridioides difficile*

711 Molecular Epidemiology of Daptomycin Non-Susceptibility in Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia

712 Identification of a Novel Tedizolid Resistance Mutation in *rpoB* of Methicillin-Resistant *Staphylococcus aureus*

713 Vancomycin Heteroresistance in Coagulase Negative *Staphylococci* (CoNS) Causing Central Line Associated Bloodstream Infection (CLABSI) in Pediatric Patients with Leukemia

69. Poster Abstract Session
Respiratory Infections: Viral
Thursday, 12:30 - 1:45 p.m.

714 Predictors of Influenza-Associated Hospitalization and Pneumonia in a Pediatric Population in Bangkok, Thailand

715 Increase in Reported Respiratory Syncytial Virus Cases among Adults in the Minneapolis-St. Paul Metropolitan Area, 2014-2018

716 Molecular Epidemiology of Respiratory Syncytial Virus in Children and Adults in Seattle, WA

717 Cumulative Incidence of Asthma/Wheeze among Neonates/Infants/Toddlers Clinically Diagnosed with Respiratory Syncytial Virus Infection in the United States: A Retrospective Database Analysis

718 Viral Coinfection and Nasal Cytokines in Children with Acute Bacterial Sinusitis (ABS)

719 The Respiratory Pathogen Panel and Antibiotic Utilization in the Emergency Department

720 Respiratory and Non-Respiratory Complications among Patients Hospitalized with Influenza, FluSurv-NET, 2016-17

721 Clinical Respiratory Syndromes and Association with Influenza Clinical Diagnostic Testing and Antiviral Treatment among Children Hospitalized with Acute Respiratory Illness, 2015-2016

722 Normal Clinical Signs and Duration of Antibiotics in Hospitalized Patients with Pneumonia

723 Validation of a Wild-Type Influenza A/Texas-like H3N2 Human Challenge Model with Comparison to the Validated A(H1N1)pdm09 Model

724 Neurologic Complications in Hospitalized Pediatric Patients with Influenza Infection - A Multicenter Retrospective Study in Korea

725 Clinical Outcomes of Elderly Individuals Presenting with Acute Respiratory Infections

726 Viral Genomic Load, Cytokine Profiles and Life-Threatening Respiratory Syncytial Virus Infection in Previously Healthy Infants

727 Evaluation of Antibiotic Prescribing Practices for Upper Respiratory Infections in the Adult and Pediatric Emergency Departments

728 Regional Validation of Distinct RSV Seasonality Thresholds for Antigen and PCR Testing

729 Improved Detection of Adenovirus with the FilmArray Respiratory Panel 2 Panel in a Pediatric Population

730 Hospital Readmissions following Laboratory-confirmed Influenza

731 Investigating Clinical Factors Contributing to Continued Antibiotic Therapy in Patients with Viral Upper Respiratory Tract Infections

732 Description of Diagnoses and Antibiotic Management of Otitis Media and Otitis Externa in Adults

733 Incidence and Evaluation of the Change in Functional Status Associated with Respiratory Syncytial Virus Infection in Hospitalized Older Adults

734 Post-Exposure Management of Influenza in Roommates at a Tertiary Care Cancer Center


736 Incidence and Etiology of Community-Acquired Pneumonia Requiring Hospitalization among American Indian/Alaskan Native Adults

737 The Prevalence of Diagnosed Chronic Lung Disease in U.S. Infants by Gestational Age: Implications for RSV Policy

738 Role of Respiratory Syncytial Virus and *Mycoplasma pneumoniae* in Pediatric Community-Acquired Lower Respiratory Tract Infections

739 Middle East Respiratory Syndrome Coronavirus Infection Profile in Qatar: A 7-year retrospective study


741 Impact of Adenovirus Co-Detections on Illness Severity

742 “Troponin Leaks” in Patients with Acute Respiratory Viral Infections Enrolled in SUPERNOVA: A Marker of Worse Clinical Outcomes

743 Severity and Costs of Respiratory Syncytial Virus and Bronchiolitis Hospitalization in Commercially Insured Preterm and Term Infants Before and After the 2014 American Academy of Pediatrics Guidance Change on Immunoprophylaxis

744 Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine and Influenza Vaccine against Pneumococcal Pneumonia among Elderly Patients Aged 65 Years and Older in The Republic of Korea: A Case-Control Study

745 Surveillance for Oseltamivir-Resistant Influenza A(H1N1)pdm09 Virus Infections During 2016-2017 and 2017-2018, United States

746 Characteristics of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Adults—United States, 2014–2017

747 Antibiotic Therapy for Community-Acquired Pneumonia: A Systematic Review and Network Meta-Analysis of Randomized Trials
Poster Abstract Sessions (continued)

748 The Impact of a Positive Respiratory Viral Panel among Hospitalized Adult Patients with Negative Rapid Influenza Testing at an Academic Tertiary Care Facility: A Matched Cohort Study

749 Healthcare Utilization After Hospitalization for Respiratory Syncytial Virus or Unspecified Bronchiolitis in the First Year of Life

750 Respiratory Virus Infections and Airflow Obstruction after Allogeneic Hematopoietic Cell Transplantation

751 Acute Respiratory Illness Hospitalizations Among Young Children—Multi-Center Viral Surveillance Network, United States, 2015-2016

70. Poster Abstract Session

Tuberculosis and Other Mycobacterial Infections

Thursday, 12:30 - 1:45 p.m.

752 Geographic Analysis of Latent Tuberculosis Screening: A Health System Approach

753 Screening for Late Mycobacterium tuberculosis Infection (LTBI): A Clinical Conundrum of Public Health Concern

754 Prevalence of Latent Tuberculosis Infection among Healthcare Workers at a Tertiary Care University Hospital

755 Clinical Adherence to Latent Tuberculosis Screening Recommendations in Adults with Inflammatory Bowel Disease (IBD) Prior to Biologic Therapy

756 Targeting the Birth-Cohort of the Pre-Antibiotic Era; A Proposal to Screen for Tuberculosis in Seniors in Arkansas

757 Community Prevalence of Bacteriologically Confirmed Pulmonary Tuberculosis: A Seven-Year Retrospective Study

758 Tuberculosis Recurrence in New York City: A Retrospective Study

759 Molecular Characterization and Epidemiology of Multidrug-Resistant Mycobacterium tuberculosis (MDR-TB) and Identification of Possible Cases of Local Transmission of MDR-TB in Kuwait

760 The Diversity of Mycobacterium tuberculosis in India is Underestimated and Underreported

761 Age Related Incidence of TB Infection Supporting Efficacy of BCG Vaccination

762 Sex Differences in The Epidemiology of Tuberculosis in Tunisia

763 Risk Factors for Homeless Status and Mortality among Homeless TB Cases in Texas, 2010-2017

764 Impact of Diabetes Mellitus on the Presentation and Response to Treatment of Adults with Pulmonary Tuberculosis in Qatar

765 Tuberculosis and Diabetes Mellitus among Prison Inmates in Peru: Results of a National Survey, 2016

766 Migration Flows and Increase of Extrapulmonary Tuberculosis in a Low Prevalence Setting: A Retrospective Analysis in Two Italian Centers

767 A Seven-Year Retrospective Study of Pediatric tuberculosis in a Third Level Hospital in Mexico City

768 Epidemiological and Clinical Profile of Miliary Tuberculosis in Southern Tunisia

769 An Outbreak of Multidrug-Resistant Tuberculosis, Minnesota, 2016–2017

770 Multidrug-Resistant Tuberculosis Cases in Arkansas in 2017: A Tale of Two Threats

771 Drug Resistance Tuberculosis (DR-TB), Comorbidities, and Risk Factors Identified in a Prospective Multicenter Cohort Study in Indonesia

772 Factors Associated with Healthcare Delay of Active Pulmonary Tuberculosis after Hospitalization

773 Statins Decrease the Risk of Active tuberculosis: A Propensity Score-Matched Analysis

774 Extrapulmonary Tuberculosis: Impact of Early Diagnosis and Treatment on Mortality

775 An Epidemiological Analysis of Patients with Multidrug-Resistant Tuberculosis among Tibetan Refugees in India

776 Tuberculosis Screening among People Living with HIV in Arkansas: A Ryan White Program Evaluation

777 Ten-Year Experience of Tertiary Hospital Regarding Epidemiology, Diagnostic Method, and Drug Resistance of Tuberculosis - Jeddah, Saudi Arabia

778 Trend of tuberculosis Meningitis and Associated Mortality in Texas, 2010-2017, a Large Population-Based Analysis

779 Mycobacterium tuberculosis Prosthetic Joint Infections: A Case Series and Literature Review

780 Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare, 2008-2015

781 Non Tuberculous Mycobacterium: Often a Missed Entity

782 Risk Factors, Clinical Characteristic, and Treatment Outcomes for Nontuberculous Mycobacterial Disease in Mexico

783 Characterization of Non-tuberculous Mycobacteria Isolates in a National Mycobacterial Laboratory in Panama: 2012 - 2015

784 The Changing Epidemiology of Disseminated Mycobacterium avium Complex in the U.S.

785 Treatment of Mycobacterium immunogenum Skin and Soft Tissue Infections: A Case in a Peritoneal Dialysis Patient

786 Ceftaroline and Avibactam? Is This a Potential Combination for Mycobacterium abscessus Infection?

787 The Addition of Avibactam Augments the Activity of Piperacillin against Mycobacterium abscessus in vitro, and is Effective in Treating M. abscessus Infection in a Galleria mellonella in vivo Model

788 Therapeutic Drug Monitoring for Pyrazinamide during Tuberculosis Treatment: What is the Diagnostic Accuracy?

789 Comparison of Interferon-Gamma Release Assays (IGRAs) for Diagnosis of Latent or Active Tuberculosis in Cancer Patients

790 The Efficacy of the Interferon-Gamma Releasing Assay-Based Isoniazid Treatment for Preventing Active tuberculosis in Kidney Transplant Recipients: A Quasi-Experimental Study

791 Hyponatremia Incidence and its Association with Mortality in Patients with Tuberculosis
792  Number and Volume of Cavitary Lesions on Chest Computed Tomography Associated with Prolonged Time to Culture Conversion in Drug-Susceptible Pulmonary Tuberculosis
793  Diagnostic Accuracy of Single versus Multiple Gene Xpert for Discontinuation of Airborne Infection Isolation in Suspected Pulmonary Tuberculosis Patients at a U.S. Safety-Net Hospital
794  Infectivity of Smear Positive Pulmonary TB after Two Weeks of Rifampicin Based Anti-Tuberculous Therapy
795  Review of Treatment of Latent Tuberculosis Infection at VA Portland Health Care System
796  Treatment of Latent Tuberculosis Infection in a Refugee Population
797  Tuberculosis Treatment: Combined Forms vs Dissociated Forms
798  The Role of Whole Genome Sequencing in Characterizing the Mechanism of Action of Anti-Tuberculosis Compounds: Demonstrated with Para-Amino Salicylic Acid and its Analogue
799  Genetic Diversity of Mycobacterium tuberculosis Strains Causing Drug Resistant tuberculosis in Central Region of Mozambique. The Whole Genome Sequencing
800  Drug Resistant TB: An Experience from Qatar
801  Emergence of Multidrug-Resistance Tuberculosis during the Treatment Course of Pan-Susceptible TB: A Case Series
802  Use of N-acetylcysteine for Prevention and Treatment of Isoniazid Induced Liver Injury during Treatment of Mycobacterial Infections
803  Overcoming β-lactam Resistance in Mycobacterium abscessus
804  Impact of Azithromycin Prophylaxis in Lung Transplant Recipients on the Risk of Nontuberculous Mycobacterial Infections
805  Amikacin Liposome Inhalation Suspension (ALIS) Add-On Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
806  2013-2015 Nationwide Tuberculosis Contact Investigation in Childcare Centers and Schools in Korea
807  A Risk-Stratified Approach to Healthcare-Associated Tuberculosis Exposures Following the “Stone in the Pond” Principle
808  Perinatal Depression among HIV and TB Infected and Uninfected Women in an Urban Slum in India: Prevalence and Associated Birth Outcomes
809  Osteitis Caused by Bacillus Calmette-Guerin Tokyo 172 Strain in Immunocompetent Patients
810  Diagnosis of BCG Aortitis by Plasma Metagenomic Sequencing
811  A Randomized Controlled Trial of Prednisolone vs Interleukin 17 A Inhibitor Secuimunab in the Management of Type 1 Lepra Reaction in Leprosy Patients
812  Case Control Trial to Evaluate the Cytokine Response to the Use of Capsule Thalidomide in Erythema Nodosum Leprosum in Leprosy Patients
813  Combination of N-acetyl-cysteine with Clarithromycin against Mycobacterium avium infection

130. Poster Abstract Session
Adult and Pediatric Influenza Vaccine
Friday, 12:30 - 1:45 p.m.
984  Maternal and Infant Factors Influencing Influenza Vaccination among Young Children Born in Colorado from 2008 to 2016
985  Safety of Guidelines Recommending LAIV for Routine Use in Children and Adolescents with Asthma
986  Evaluation of Moderate-to-Severe Influenza Disease in Children 6 months to 8 years of age in Colorado
987  Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV): A Randomized, Observer Blind, Multicenter Study
988  Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, U.S. Flu VE Network, 2010-2018
989  Clinical Effectiveness of High-Dose Trivalent versus Quadrivalent Influenza Vaccination among Veterans Health Administration Patients
990  Impact of Influenza Vaccination Setting on Timing of Vaccination in a National Sample of Influenza-Vaccinated Adults
991  Randomized Trial of High Dose, Adjuvanted, and Standard Inactivated Influenza Vaccine Immune Response Against Egg- and Cell-propagated Vaccine Strains in Older Adults, 2016-2017 Season
992  2016/2017 Influenza Burden of Disease and End-of-Season Influenza Vaccine Effectiveness (VE) Estimates for Preventing Influenza-Related Hospitalization Among Canadian Adults: An Analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network
993  Combining Key Residues of the Russian and U.S. Live-Attenuated Influenza Viruses for a More Attenuated Virus
994  AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells
995  Effectiveness of Influenza Vaccine for Prevention of Influenza-Associated Hospitalizations among High-Risk Adults in the U.S., 2015 – 2016
996  A Cluster-Randomized Trial of Adjuvanted Trivalent Influenza Vaccine vs. Standard Dose in U.S. Nursing Homes
997  Protection of Unvaccinated Individuals by Influenza Vaccine Coverage of Household Contacts

131. Poster Abstract Session
Bacteremia and Endocarditis
Friday, 12:30 - 1:45 p.m.
998  Misclassification of Community and Hospital Onset Bloodstream Infections Using Laboratory-Identified Events
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>999</td>
<td>Ongoing Burden of Streptococcus pneumoniae Sepsis in Children after Introduction of Pneumococcal Conjugate Vaccines</td>
</tr>
<tr>
<td>1000</td>
<td>Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program</td>
</tr>
<tr>
<td>1002</td>
<td>Epidemiology of Pneumococcal Bacteremia in a Large Tertiary Center</td>
</tr>
<tr>
<td>1003</td>
<td>Clinical Implications of Emerging Nonvaccine-Serotype Invasive Pneumococcal Disease among Adults in The Republic of Korea in the Era of Protein Conjugated Pneumococcal Vaccine</td>
</tr>
<tr>
<td>1004</td>
<td>Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bloodstream Infections in United States Medical Centers (2015-2017)</td>
</tr>
<tr>
<td>1005</td>
<td>HIV-Associated Bloodstream Infection (BSI): Trends Over Seven Years</td>
</tr>
<tr>
<td>1006</td>
<td>Demographic, Clinical, Microbiological Characteristics and Outcome of Patients Admitted to the Emek Medical Center with Bloodstream Infection Acquired in LTCF: A 5 Years Surveillance</td>
</tr>
<tr>
<td>1007</td>
<td>Etiology of Sepsis; a Systematic Review of Emergency Department Sepsis</td>
</tr>
<tr>
<td>1008</td>
<td>Cluster Analysis to Define Distinct Clinical Phenotypes Among Septic Patients with Bloodstream Infections</td>
</tr>
<tr>
<td>1009</td>
<td>VENOUS 1: A Prospective Multicenter Cohort Study of Enterococcal Bacteremia</td>
</tr>
<tr>
<td>1010</td>
<td>Effectiveness of Oral Antibiotics for Definitive Therapy of Gram-positive Bloodstream Infections</td>
</tr>
<tr>
<td>1011</td>
<td>Sepsis and Secondary Hemophagocytic Lymphohistiocytosis</td>
</tr>
<tr>
<td>1012</td>
<td>Group B Streptococcus Bacteremia in Non-Pregnant Adults in a Tertiary Care Hospital between 2008 and 2017 in Korea</td>
</tr>
<tr>
<td>1013</td>
<td>If Blood Cultures Were Not Done Before Starting Antibiotics, Is It of Any Value to Obtain Them Later?</td>
</tr>
<tr>
<td>1014</td>
<td>Microbiology and Outcome of Bloodstream Infections in Children with Intestinal Failure</td>
</tr>
<tr>
<td>1015</td>
<td>Enhanced Detection of Bloodstream Pathogens from Positive Blood Culture Specimens with an Improved Multiplex PCR Molecular Diagnostic System</td>
</tr>
<tr>
<td>1016</td>
<td>Bloodstream Infection Survey in High-Risk Oncology Patients (Bishop) with Fever and Neutropenia (FN): Predictors for Morbidity and Mortality</td>
</tr>
<tr>
<td>1017</td>
<td>Impact of Enterococcal Bloodstream Infection on Mortality in Patients with Acute Myelogenous Leukemia</td>
</tr>
<tr>
<td>1018</td>
<td>Prevalence of Bacteremia/Fungemia and Pneumonia in Remission Induction Chemotherapy for Adult Acute Myeloid Leukemia from 1987 to 2005: Japan Adult Leukemia Study Group (JALSG)</td>
</tr>
<tr>
<td>1019</td>
<td>Treatment Outcomes for Enterococcus faecium Bacteremia in Solid Organ Transplant Patients: Implications for Daptomycin</td>
</tr>
<tr>
<td>1020</td>
<td>Injection Drug Use-Associated Staphylococcus aureus Bacteremia in a Large Urban Hospital in Atlanta, GA</td>
</tr>
<tr>
<td>1021</td>
<td>Repeat Infective Endocarditis (rIE) in Persons Who Inject Drugs (PWID)</td>
</tr>
<tr>
<td>1022</td>
<td>Rising Rates of Injection Drug Use Associated Infective Endocarditis in Virginia with Missed Opportunities for Injection Drug Use Disorder Treatment Referral: A Retrospective Cohort Study</td>
</tr>
<tr>
<td>1023</td>
<td>A Controlled-Release Prescription Oral Opioid can Prolong S. aureus Survival in Injection Drug Preparation Equipment and Potentially Increase Bacteremia Risk</td>
</tr>
<tr>
<td>1024</td>
<td>First Episode Infective Endocarditis in Persons Who Inject Drugs (PWIDs); a Retrospective Cohort Study</td>
</tr>
<tr>
<td>1025</td>
<td>Microbial Epidemiology of Infectious Endocarditis in the Intravenous Drug Abuse Population: A Retrospective Study in East Tennessee</td>
</tr>
<tr>
<td>1026</td>
<td>Trends in Infective Endocarditis During the Substance Use Disorder Epidemic at an Academic Medical Center</td>
</tr>
<tr>
<td>1027</td>
<td>Outpatient Parenteral Antimicrobial Therapy (OPAT) in Injection Drug Users (IDUs): Is It Safe?</td>
</tr>
<tr>
<td>1028</td>
<td>Synergizing Infectious Diseases and Substance Use Treatment to Improve the Outcomes of Endocarditis in People who Inject Drugs at a Large Academic Hospital</td>
</tr>
<tr>
<td>1029</td>
<td>Outcome of Candida Graft Vascular Infection: Results from a Prospective Cohort</td>
</tr>
<tr>
<td>1030</td>
<td>Risk Predictive Model for Candida Endocarditis in Patients with Candidemia: A 12-year Experience in a Single Tertiary Care Hospital</td>
</tr>
<tr>
<td>1031</td>
<td>Nationwide Temporal Trends of Candidemia Incidence over 18 Years within the Veteran Health Administration System</td>
</tr>
<tr>
<td>1032</td>
<td>A Case Series of Clostridium septicum Aortitis</td>
</tr>
<tr>
<td>1033</td>
<td>Thinking Outside the Bowel - Clostridium difficile Bacteremia Case Series</td>
</tr>
<tr>
<td>1034</td>
<td>“Four-Leaf Clover Sign” as a Rapid Identification of Coagulase Negative Staphylococci Species by Gram Stain of Blood Culture</td>
</tr>
<tr>
<td>1035</td>
<td>Differentiation between True Infection and Contamination of Coagulase-Negative Staphylococci by Developing a Prediction Rule</td>
</tr>
<tr>
<td>1036</td>
<td>Whole Genome Sequencing Analysis of a Large Cohort of Staphylococcus epidermidis Blood Culture Positive Isolates from a Multicenter Clinical Trial</td>
</tr>
<tr>
<td>1037</td>
<td>Effect of Oral Step-Down Therapy on Readmission Rates in Escherichia coli Bacteremia</td>
</tr>
<tr>
<td>1038</td>
<td>Edwardsiella tarda Bacteremia: Epidemiology, Clinical Features, and Outcomes</td>
</tr>
<tr>
<td>1039</td>
<td>Surveillance Blood Cultures Associated With Decreased Mortality in Gram-Negative Bacteremia</td>
</tr>
<tr>
<td>1040</td>
<td>Comparative Characteristics of Patients with Pseudomonas Bacteremia Receiving Intravenous Only versus Intravenous Followed by Oral Therapy</td>
</tr>
<tr>
<td>1041</td>
<td>How Do Healthcare Providers Approach Empiric Beta-lactam (BL) Treatment of Bloodstream Infections (BSI) Caused by Gram-Negative Rods (GNRs)? Analysis of Escherichia coli (Ec) and Klebsiella pneumoniae (Kpn) BSI from the Veterans Health Administration (VHA)</td>
</tr>
</tbody>
</table>
Poster Abstract Sessions (continued)

1042 *Stenotrophomans maltophilia* Bacteremia, a 10-Year Tertiary Center Experience

1043 Evaluation of Early Clinical Failure Criteria for Gram-Negative Bloodstream Infections

1044 Aztreonam (AZT) versus Cephalosporin (CEP) Therapy for the Treatment of Gram-Negative Bacteremia

1045 A Multicenter Propensity Score-Adjusted Retrospective Study for Comparison of the Outcome of Treatment with Third-Generation Cephalosporin versus Broad-Spectrum Antibiotics for Enterobacter Bacteremia

1046 Clinical and Microbiological Characteristics of Patients with Septicemia Caused by IMP-1-Producing Enterobacteriaceae in a Tertiary Hospital in Japan


1048 Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes from a Large, Multi-National Cohort

1049 Outcome and Impact of Empirical Antimicrobial Treatment in Bacteraemia with Bacteroides Species; A Retrospective Cohort Study in a Region of Southern Sweden

1050 Oral Antibiotics for the Treatment of Gram-negative Bloodstream Infections: Prescribing Practices and Outcomes at a Large Academic Medical Center

1051 Increased Mortality In Bacteremia by *Enterobacter* Species with Discordant Imipenem and Erta penem Susceptibilities

1052 Do Healthcare Providers De-escalate Beta-lactam (BL) Antibiotic Therapy Based on Results of Antibiotic Susceptibility Testing (AST)? Analysis of Bloodstream Infections (BSI) Caused by *Escherichia coli* (Ec) and *Klebsiella pneumoniae* (Kpn) from the Veterans Health Administration (VHA)

1053 Biofilm Production and Clinical Characteristics of *S. maltophilia* Causing Persistent or Relapsing Bacteremia

1054 Biofilm Formation Among *Escherichia coli* Bloodstream Infection Isolates is Associated with Source of Bacteremia and Bacterial Sequence Type

1055 Epidemiology and Mechanisms of Carbapenem Resistance in Recurrent Extended-Spectrum Beta-lactamase-Producing *Enterobacteriaceae* Bacteremia

1056 Predicting Central Nervous System Complications in *Staphylococcus aureus* Bacteremia using Clinical Scoring System

1057 Treatment Efficacy of Ceftriaxone versus Cefazolin for Methicillin-Susceptible *Staphylococcus Aureus* Infections

1058 Prognostic Biomarkers for Persistent Bacteremia and Mortality in Complicated *S. aureus* Bloodstream Infection

1059 *Staphylococcus aureus* Bacteremia Treatment: Results from Pilot Surveillance in Four U.S. States

1060 Risk Factors for Recurrent *Staphylococcus aureus* Bacteremia

1061 Comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II Score and the Pitt Bacteremia Score to Predict Mortality in Methicillin-Resistant *Staphylococcus aureus* Bacteremia

1062 Daptomycin/Ceftaroline in Combination versus Vancomycin for the Treatment of Methicillin-Resistant *Staphylococcus aureus* Bacteremia

1063 Impact of Rapid Organism Identification and a Standardized Algorithm on Antimicrobial Therapy in Patients with Bacteremia

1064 Clinical Outcomes of Daptomycin in Combination with Ceftraroline or Anti-Staphylooccal Penicillins for Patients with Persistent MRSA Bacteremia

1065 Evaluation of a *Staphylococcus aureus* Bacteremia Treatment Checklist

1066 Adjuvant *β*-lactam Therapy Combined with Vancomycin for Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia: Does *β*-lactam Class Matter?

1067 Comparative Effectiveness of Nafcillin or Oxacillin, Cefazolin, and Piperacillin/Tazobactam in Methicillin-Sensitive *Staphylococcus aureus* Bacteremia

1068 Evaluation of Cefazolin versus Anti-Staphylococcal Penicillins for the Treatment of Methicillin-Susceptible *Staphylococcus aureus* Bloodstream Infections in Acutely-Ill Adult Patients: Results of a Systematic Review and Meta-Analysis

1069 Predictive Factors for Metastatic Infection with Bacteremia Caused by *Staphylococcus aureus*

1070 Epidemiological and Clinical Features of Panton-Valenton Leukocidin Positive *Staphylococcus aureus* bacteremia: A Case-Control Study

1071 Impact of Standard versus Prolonged Courses of Antibiotics for the Treatment of Uncomplicated *Staphylococcus aureus* Bacteremia (SAB) in Patients with Hematologic Malignancies

1072 Streamlining to Oral Beta-Lactam versus Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia

1073 Predictors of Vancomycin Switch or Escalation in Patients with Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infection

1074 Management and Outcomes of Infective Endocarditis due to Nutritionally Variant Streptococci

1075 A Retrospective Comparison of Native Valve Endocarditis and Prosthetic Valve Endocarditis in a Large Tertiary Care Teaching Hospital from 2007-2015

1076 What is the Positivity Delay of Blood Cultures in Infective Endocarditis?

1077 Heart Transplantation as Salvage Treatment for Intractable Infective Endocarditis

1078 Use of PCR/Electrospray Ionization Mass Spectrometry for Rapid Identification and Antibiotic Treatment Adaptation in Patients Suffering from Infective Endocarditis

1079 When Does a Trans-Esophageal Echocardiogram (TEE) Change Management of *Staphylococcus aureus* Bacteremia (SAB)?

1080 Time to Blood Culture Positivity in *Staphylococcus aureus* Bacteremia is Associated with the Risk of Infectious Endocarditis

1081 Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers
Poster Abstract Sessions (continued)

1082 Meta-Analysis of Survival Outcomes in People who Inject Drugs after Cardiac Surgery for Infective Endocarditis
1083 Long-Term Prognosis of 448 Infectious Endocarditis followed by an Endocarditis Team
1084 Nocardia cyriacigeorgica Endocarditis
1085 Enterococcal Cardiac Implantable Electronic Device (CIED) Infections: Clinical Features and Outcomes
1086 Impact of Systematic Thoraco-Abdomino-Pelvic CT Scan on the Diagnosis of Infective Endocarditis
1087 Aortic Graft Infections Caused by Propionibacterium acnes at the Minneapolis Veterans Affairs Health Care System (MVAHCS) 2007 – 2017

132. Poster Abstract Session
Diarrhea Diagnostic Dilemmas
Friday, 12:30 - 1:45 p.m.

1089 Analytical Performance of an Ultrasensitive Immunossay for Detection of Clostridium difficile Toxins in Stool
1090 Patient Outcomes with Prevented versus Negative Clostridium difficile Tests Using Computerized Clinical Decision Support (CCDS)
1091 Algorithmic Release of Clostridium difficile PCR Results from a Multiplex Gastrointestinal (GI) Panel in Children < 3 years old
1092 Tuning Down Clostridioides difficile PCR Sensitivity Reduces Treatment for C. difficile Infection in Toxic-Negative Patients with No Increase in Adverse Outcomes
1093 Single Molecule Counting Technology for Ultrasensitive Quantification of Clostridium difficile Toxins A and B
1094 Performance of Toxin Enzyme Immunoassays and PCR Cycle Threshold for Differentiating Clostridium difficile Infection from Colonization in Children with Diarrhea
1095 The Value of Hardwiring Diagnostic Stewardship in the Electronic Health Record: Electronic Ordering Restrictions for PCR-Based Rapid Diagnostic Testing of Diarrheal Illnesses

133. Poster Abstract Session
Enteric Infections
Friday, 12:30 - 1:45 p.m.

1096 Effect of Diarrheal Illness During Pregnancy on Adverse Birth Outcomes in Nepal
1097 Is Early Bisphosphonate Treatment Safe or Effective for Pyogenic Vertebral Osteomyelitis with Osteoporosis?
1098 Clinical Features and Outcomes of United States Marine Corps Recruits Hospitalized with Shiga Toxin-Producing Escherichia coli Infection and Hemolytic-Uremic Syndrome
1099 Antibiotic Prescriptions for Acute Gastroenteritis during Office and Emergency Department Visits—United States, 2006–2015

1100 Characterization of Enteropathogenic Escherichia coli (EPEC) in Cancer Patients with Diarrhea
1101 Comparison of Clinical Characteristics and Demographics of GII.4 versus other GII Noroviruses associated with Sporadic Acute Gastroenteritis in Children in Nashville, TN, 2012-2015
1102 Food Insecurity and Reported History of Cholera in Haitian Households: An Analysis of the 2012 Demographic and Health Survey (DHS)
1104 Deployment-Associated Infectious Gastroenteritis and Associations with Irritable Bowel Syndrome, Post-Traumatic Stress Disorder, and Combat Stress: A Retrospective Cohort Study Among Deployed United States Military Personnel
1105 Vibrio Titer Variation and Likelihood of Protection in Children Compared to Adults in a Cholera Endemic Area
1106 Infectious Etiologies of Acute Gastroenteritis in Children during the First 100 Days Post-Allogeneic Hematopoietic Cell Transplant
1107 The MAAGE Study: Health Care Utilization for the Treatment of Medically-Attended Acute Gastroenteritis
1108 Diagnostic Yield of the BioFire® FilmArray Gastrointestinal Panel in Hospitalized Children at an Academic Children’s Center
1109 Factors Impacting the Decision to Order Stool Diagnostic Testing in Patients with Acute Gastroenteritis Among Primary Care Providers
1110 A Multicenter Evaluation of Outcomes Associated with Oral Vancomycin Dose in Patients with Clostridium difficile Infection
1112 Detection of Enteric Viruses in Children with Acute Gastroenteritis
1113 Real Time Evolution of Extensively Drug Resistant Vibrio cholerae
1114 Utility of a Bedside Diagnostic Testing Algorithm to Screen for Hospital-Onset Clostridium difficile Infection
1115 Use of a Fluoroquinolone (FQ) versus a Non-Fluoroquinolone (Non-FQ) Based Antibiotic Regimen in the Treatment of Acute, Uncomplicated Diverticulitis
1116 Comparison of Short-Course versus Prolonged-Course Antimicrobial Therapy in the Management of Intra-Abdominal Infections
1117 Avascular Necrosis of the Femoral Head as a Sequela of Shiga Toxin-Producing Escherichia coli (STEC) Infection
1118 Viral Species Richness and Composition in Young Children with Loose or Watery Stool in Ethiopia
1119 Risk Factors for Clostridium difficile Acquisition and Persistence among Guatemalan Children
1120 Clostridium difficile Infection Risk Factors, Severity, and Outcomes in Patients Infected with NAP1/027 Strain in a Non-Epidemic Setting
1121 Epidemiology and Risks for Infection following Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy at an Australian Centre
Poster Abstract Sessions (continued)

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1122</td>
<td>Evaluation of Fecal Microbiota Transplant (FMT) in Elderly Patients with recurrent <em>Clostridium difficile</em> infection (CDI)</td>
</tr>
<tr>
<td>1123</td>
<td>Individual and Household Risk Factors for Symptomatic Cholera Infection: A Systematic Review and Meta-Analysis</td>
</tr>
<tr>
<td>1124</td>
<td>Effects of Co-infection on the Severity, Response to Treatment, and Duration of Hospital Stay in Patients with <em>Clostridium difficile</em> Infection</td>
</tr>
<tr>
<td>1125</td>
<td>Reduced Time to Pathogen Identification and Antibiotic Prescription using Multiplex Molecular Testing for Gastrointestinal Infections</td>
</tr>
<tr>
<td>1126</td>
<td>Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration</td>
</tr>
<tr>
<td>1127</td>
<td>Genomic Analysis of Biofilm-Forming Enteroinvasive <em>E. coli</em> Emergent Pathogen</td>
</tr>
</tbody>
</table>

134. Poster Abstract Session

**Fungi and Parasites in Immunocompromised Patients**

Friday, 12:30 - 1:45 p.m.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1128</td>
<td>Utility of Anaerobic and Fungal Blood Cultures in the Pediatric Oncologic Population</td>
</tr>
<tr>
<td>1129</td>
<td>Targeted Voriconazole Prophylaxis in Heart Transplantation Recipients</td>
</tr>
<tr>
<td>1130</td>
<td>Low Risk of <em>Pneumocystis jiroveci</em> Pneumonia in Patients with Waldenstrom’s Macroglobulinemia on Ibrutinib</td>
</tr>
<tr>
<td>1131</td>
<td>Characteristics and Risk Factors for Mortality in Hematologic Patients with Invasive Non-Aspergillus Mold Infections: A Single Center 7-Year Cohort Study</td>
</tr>
<tr>
<td>1133</td>
<td>Epidemiology of Invasive Fungal Infections in Lung Transplant Recipients: Harnessing Data Mining Tools to Build a Comprehensive Database</td>
</tr>
<tr>
<td>1134</td>
<td>Novel T2Candida Panel Assay Compared to Blood Cultures for Detection of Candidemia in Transplant and Non-Transplant Patients</td>
</tr>
<tr>
<td>1135</td>
<td>Strongyloides Stercolaris Serology in Transplant Patients: to Test or Not?</td>
</tr>
<tr>
<td>1136</td>
<td>Universal Prophylaxis for Prevention of Invasive Aspergillus in Lung Transplant Recipients</td>
</tr>
<tr>
<td>1137</td>
<td>Implementation of Universal Screening for Strongyloidiasis Among Solid Organ and Hematopoietic Stem Cell Transplantation Candidates in a Non-endemic Area</td>
</tr>
<tr>
<td>1138</td>
<td>Retrospective Cohort Analysis of Ampicillin B Nephrotoxicity in Kidney Transplant Recipients</td>
</tr>
<tr>
<td>1139</td>
<td>Novel Formulation SUBA-Itraconazole Prophylaxis in Patients with Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow Up Survival Data</td>
</tr>
<tr>
<td>1140</td>
<td>GATA2 Mutations are Frequently Identified among Patients with Myeloid Malignancies who Develop Invasive Aspergillosis</td>
</tr>
</tbody>
</table>

135. Poster Abstract Session

**Healthcare Epidemiology: Environmental and Occupational Health**

Friday, 12:30 - 1:45 p.m.

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1141</td>
<td>Microbial Assessment of Healthcare-Associated Pathogens on Various Environmental Sites in Patient Rooms after Terminal Room Disinfection</td>
</tr>
<tr>
<td>1142</td>
<td>Use of DNA Markers to Assess the Potential for Pathogen Transmission from Physicians’ White Coats</td>
</tr>
<tr>
<td>1143</td>
<td>Epidemiologic Characteristics of Outbreaks Associated with the Healthcare Environment</td>
</tr>
<tr>
<td>1144</td>
<td>Modern Problem, Medieval Cure – Resistant <em>Aeromonas</em> in Medicinal Leeches</td>
</tr>
<tr>
<td>1145</td>
<td>Sparring with Spores: Ultrasounds as a Vector for Pathogen Transmission in the Intensive Care Unit</td>
</tr>
<tr>
<td>1146</td>
<td>Effectiveness of Ultraviolet Irradiation on <em>Candida auris</em>: A Laboratory Study</td>
</tr>
<tr>
<td>1147</td>
<td>Pseudo-Outbreak of <em>Clostridium paraputrificum</em> Related to Anaerobic Tent Contamination</td>
</tr>
<tr>
<td>1148</td>
<td>Reduction of Blood Culture Contamination Rates by an Altered Sampling Protocol: Single Center, Prospective, Randomized, Controlled, Open Label Trial</td>
</tr>
<tr>
<td>1149</td>
<td>Environmental Disinfection with Photocatalyst as an Adjunctive Measure to Control Multidrug-Resistant Organisms Transmission: A Prospective Cohort Study in High Incidence Setting</td>
</tr>
<tr>
<td>1150</td>
<td>Cleaning High Touch Surfaces of Patients’ Rooms: Make it Easier, and it Simply Gets Cleaner</td>
</tr>
<tr>
<td>1151</td>
<td>A Safer, More Effective Method for Cleaning and Disinfecting GI Endoscopic Procedure Rooms</td>
</tr>
<tr>
<td>1152</td>
<td>Leveraging Human Factors Engineering to Optimize Low Level Disinfection of Bedside Medical Tools</td>
</tr>
<tr>
<td>1153</td>
<td>UV-C Technology is an Effective Adjunct to Terminal Cleaning in Environmental Pathogen Reduction in a Tertiary Pediatric Hospital</td>
</tr>
<tr>
<td>1154</td>
<td>Comparison of Five Testing Modalities for the Assessment of Patient Environment Cleanliness</td>
</tr>
<tr>
<td>1155</td>
<td>Excessive Movement, Unnecessary Contamination: <em>Clostridium difficile</em> Patients in the Hospital</td>
</tr>
<tr>
<td>1156</td>
<td>Observation of Stethoscope Sanitation Practices in an Emergency Department Setting</td>
</tr>
<tr>
<td>1157</td>
<td>Optimal Isolation Periods Based on Time Interval to Elimination of Scabies after Topical Agent in the Real Clinical Practice</td>
</tr>
<tr>
<td>1158</td>
<td>Needlestick Injuries and Other Potential Exposures to Bloodborne Pathogens Among Police Officers in a City Police Department, 2011–2016</td>
</tr>
<tr>
<td>1159</td>
<td>Influenza Symptoms in Vaccinated Healthcare Workers in an H3N2-Dominant Season</td>
</tr>
<tr>
<td>1160</td>
<td>Infrequency of Respirator Change Following Annual Respiratory Fit Testing at an Academic Medical Center</td>
</tr>
<tr>
<td>1161</td>
<td>Infection Control after Debridement of Brucella melitensis Hardware Infection</td>
</tr>
<tr>
<td>Poster Abstract Sessions (continued)</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>136. Poster Abstract Session</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Healthcare Epidemiology: MDR-Gram Negative Infections</strong></td>
<td></td>
</tr>
<tr>
<td>Friday, 12:30 - 1:45 p.m.</td>
<td></td>
</tr>
<tr>
<td>1162</td>
<td>Epidemiology of Carbapenem-Resistant <em>Pseudomonas aeruginosa</em> Identified through the Emerging Infections Program (EIP), United States, 2016–2017</td>
</tr>
<tr>
<td>1163</td>
<td>Impact of Difficult-to-Treat Resistance on Survival in Gram-Negative Bacteremia: A Risk-Adjusted Analysis Using Electronic Health Record–Based Clinical Data from 140 U.S. Hospitals</td>
</tr>
<tr>
<td>1164</td>
<td>County-Level Geographic Distribution of Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae across Outpatient Settings of the Veterans Health Administration, 2000-2017</td>
</tr>
<tr>
<td>1165</td>
<td>Comparing Patient Risk Factors, Sequence Type, and Resistance Loci Identification Approaches for Predicting Antibiotic Resistance in <em>Escherichia coli</em> Bloodstream Infections</td>
</tr>
<tr>
<td>1166</td>
<td>Development of a Bedside Tool to Predict the Probability of Drug-Resistant Pathogens among an Adult Population with Gram-Negative Infections</td>
</tr>
<tr>
<td>1167</td>
<td>Trends in Multidrug-Resistant Gonorrhea, Gonococcal Isolate Surveillance Project, United States, 1987-2016</td>
</tr>
<tr>
<td>1168</td>
<td>Role of Extended-Spectrum Cephalosporin-Resistance in Recurrent Enterobacteriaceae Urinary Tract Infections</td>
</tr>
<tr>
<td>1170</td>
<td>Applying Machine Learning Algorithms to Predict Multidrug-Resistant Bacterial Infections from Prior Drug Exposure</td>
</tr>
<tr>
<td>1171</td>
<td>Impact on Mortality, Length of stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized with Carbapenemase-producing Enterobacteriaceae</td>
</tr>
<tr>
<td>1172</td>
<td>Travel-Associated Multidrug-Resistant Organism Acquisition and Risk Factors among U.S. Military Personnel</td>
</tr>
<tr>
<td>1173</td>
<td>A Cluster of Carbapenemase-Producing <em>Acinetobacter baumannii</em></td>
</tr>
<tr>
<td>1174</td>
<td>Epidemiology of Carbapenem-Resistant Enterobacteriaceae, a 5-year Experience at a Tertiary Care Hospital</td>
</tr>
<tr>
<td>1175</td>
<td>Clinical and Microbiological Features of <em>Klebsiella pneumoniae</em> Liver Abscess Caused by Multidrug-Resistant Strains</td>
</tr>
<tr>
<td>1176</td>
<td>Risk Factors for ESBL <em>Enterobacteriaceae</em> Colonization Identified by Universal Admission Screening in a London Teaching Hospital</td>
</tr>
<tr>
<td>1177</td>
<td>Carbapenemase-Producing Carbapenem-Resistant Organism Colonization Screening Surveys—Maryland, April 2017–April 2018</td>
</tr>
<tr>
<td>1178</td>
<td>A Multicenter Prospective Study of Clinical and Molecular Epidemiological Analysis of Carbapenem-Resistant <em>Enterobacteriaceae</em> (CRE) and Carbapenemase-Producing <em>Enterobacteriaceae</em> (CPE) in Japan</td>
</tr>
<tr>
<td>1179</td>
<td>Incidence of Bacteremia and Bacteriuria with Antibiotic-resistant <em>Enterobacteriaceae</em> after Transrectal Ultrasound-Guided Biopsy of the Prostate (TRUSBP)</td>
</tr>
<tr>
<td>1180</td>
<td>Addition of Chronic Kidney Disease Status to Pitt Bacteremia Score Improves Prediction of Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Infections</td>
</tr>
<tr>
<td>1181</td>
<td>Use of the Combination Antibigram in the Era of MDR Gram Negative Pathogens</td>
</tr>
<tr>
<td>1182</td>
<td>Risk Factors for the Acquisition of IMP-Type Carbapenemase-Producing Carbapenem-Resistant <em>Enterobacteriaceae</em> in Japan: A Matched Case-Control Study</td>
</tr>
<tr>
<td>1183</td>
<td>Epidemiological, Clinical, and Microbiological Characteristics of Carbapenemase-Producing Enterobacteriaceae Bloodstream Infection in Republic of Korea</td>
</tr>
<tr>
<td>1184</td>
<td>Resistance Patterns and Susceptibility Analysis of <em>Klebsiella pneumoniae</em> Infections in Service Members Who Sustained Trauma in Iraq and Afghanistan</td>
</tr>
<tr>
<td>1185</td>
<td>Impact of Bloodstream Infections Caused by Multidrug-Resistant Organisms on Performance Status: A KARS-Net Study</td>
</tr>
<tr>
<td>1186</td>
<td>Prevalence of Carbapenemase-Producing <em>Enterobacteriaceae</em> (CPE) in Hospital Drains in Southern Ontario</td>
</tr>
<tr>
<td>1187</td>
<td>Retrospective and Prospective Analysis of <em>Acinetobacter</em> Modern-Day Clinical Isolates in a Large Midwest Hospital System</td>
</tr>
<tr>
<td>1188</td>
<td>Could Chlorhexidine (CHX) bathing decrease the incidence of Carbapenem-resistant Enterobacteriaceae (CRE) bacteremia in previously Colonized CRE Hematopoietic Stem Cell Transplant recipients (HSCT)?</td>
</tr>
<tr>
<td>1189</td>
<td>A Comprehensive Characterization of the Emerging Carbapenem-Resistant <em>Klebsiella pneumoniae</em> Clinical Isolates from a Public Hospital in Lima, Peru</td>
</tr>
<tr>
<td>1190</td>
<td>Reduction of Carbapenem-Resistant Enterobacteria (CRE) infections and Total Polymyxin B Use Due to a Comprehensive Infection Control strategy in Colombia</td>
</tr>
<tr>
<td>1192</td>
<td>Identification of a Novel <em>Enterobacter cloacae</em> Isolate Producing an IMP-13 Metallo-Beta-Lactamase</td>
</tr>
<tr>
<td>1193</td>
<td>Comparison of the Clinical Outcomes of Patients with IMP-Type Carbapenemase-Producing Carbapenem-resistant <em>Enterobacteriaceae</em> and Carbapenem-Sensitive <em>Enterobacteriaceae</em> in Japan</td>
</tr>
<tr>
<td>1194</td>
<td>Carbapenem-Resistant Enterobacteriaceae in Kentucky - Initial Six Months of Mechanism Testing</td>
</tr>
<tr>
<td>1195</td>
<td>Where You Live Matters: United States Region as a Significant Predictor of Mortality for ESBL Infection Based on a Descriptive Study using NIS Database</td>
</tr>
<tr>
<td>1196</td>
<td><em>Serratia marcescens</em> Strains Carrying <em>bla</em>&lt;sup&gt;POC-2&lt;/sup&gt; and <em>bla</em>&lt;sup&gt;POC-3&lt;/sup&gt; Carbapenemase Associated with Chronic Mechanical Ventilation</td>
</tr>
<tr>
<td>1197</td>
<td>Microbiological Surveillance of Duodenoscopes Before and After High-Level Disinfection Following Endoscopic Retrograde Cholangiopancreatography (ERCP)</td>
</tr>
</tbody>
</table>
1198. Clinical Characteristics and Outcomes of Klebsiella pneumoniae Infections in Service Members Who Sustained Trauma in Iraq and Afghanistan

1199. Epidemiology of Carbapenem Resistant Klebsiella pneumoniae: A Comparative Study between Facilities in the United States and the Dominican Republic

1200. Molecular Epidemiology of Cephalosporinases and Extended Spectrum Beta-lactamas (ESBLs) in Proteus mirabilis Isolates from Croatia: Following the Spread of Resistance Determinants between Long-Term Care Facilities and the Community

1201. A Prolonged Multispecies Outbreak of Carbapenemase-Producing Enterobacteriaceae Due to Transmissible Plasmid with Carbapenemase Gene

1202. Multimodal Sequencing of a Clonal Case Cluster of Carbapenem-Resistant Citrobacter Reveals Unexpectedly Rapid Dynamics of KPC3-Containing Plasmids

1203. Molecular Screening for Multidrug-Resistance Genes in Hospitalized Veterans

1204. The MDR Upon Admission Score for Shortening Time to Initiation of Appropriate Antimicrobial Therapy in the Era of Widespread Resistance to Antimicrobials

1205. Emergence of Carbapenemase Producing Enterobacteriaceae in South Central Ontario, Canada

1206. Risk Factors of Antibiotic Resistance in E. coli Isolated from the MAL-ED Birth Cohort Study in Rural Tanzania

1207. Acquisition and Quantification of Antimicrobial Resistance Genes in the Gut Microbiome of Ugandan Women Exposed to Small-Scale Chicken Farming

137. Poster Abstract Session

Healthcare Epidemiology: MSSA, MRSA, and Other Gram-Positive Infections

Friday, 12:30 - 1:45 p.m.

1208. Impact of Admission to an Inpatient Infectious Disease Unit on Methicillin-resistant Staphylococcus aureus Bloodstream Infections

1209. Expanding an Economic Evaluation of the Veterans Affairs Initiative to Prevent Methicillin-Resistant Staphylococcus aureus Infections to Include Prevention of Gram-Negative Bacteria

1210. Staphylococcal Acute Post-Operative Prosthetic Joint Infection (PJI) Treated with ‘DAIR’ (Debridement and Implant Retention) and Impact of Rifampin: A Retrospective Cohort Study in France


1212. Whole Genome Sequencing for High Resolution Methicillin-Resistant Staphylococcus aureus Outbreaks Tracing in Neonatal Intensive Care Units and In Silico Resistance and Virulence Markers Detection

1213. Evaluation of an Alcohol-Based Antiseptic for Nasal Decolonization of Methicillin-Resistant Staphylococcus aureus (MRSA)

1214. High Frequency of Genes Encoding Resistance to Heavy Metals in Methicillin-Resistant Staphylococcus aureus (MRSA) Endemic Lineages from South America

1215. Geographic Distribution of Staphylococcus aureus with Reduced Sensitivity and Resistance to Vancomycin in the Dominican Republic

1216. Cost-Effectiveness of Penicillin Skin Allergy Testing in Methicillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia

1217. Staphylococcus Protein A (spa) Typing Demonstrates Genetic Heterogeneity of Methicillin-Susceptible Staphylococcus aureus (MSSA) in a Neonatal Intensive Care Unit (NICU)

1218. Retapamulin as a Potential Decolonizing Agent: Activity against Mupirocin-Resistant Strains from Pediatric Patients with Methicillin-Resistant Staphylococcus aureus infection

1219. Increasing Methicillin Resistance of Staphylococcus lugdunensis in a Tertiary Care Community Hospital in Japan

1220. Impact of Mandatory Infectious Diseases Consultation on the Use of Core Measures and Mortality in Staphylococcus aureus Bacteremia (SAB) at an Academic Medical Center

1221. Genetic Characteristics of Healthcare-Associated Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Belonging to Clonal Complex 5 (CC5) in Latin America

1222. Risk Factors and Outcomes for Daptomycin Non-Susceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

1223. Increasing Incidence of Methicillin-Resistant Staphylococcus aureus in Greenland

1224. Drug-Resistance Dynamics of Staphylococcus aureus at a Tertiary Hospital, Beijing, China, 2013-2017

1225. High Rate of Linezolid (LZD) Non-Susceptibility (LNS) among Enteric Vancomycin-Resistant Enterococci (VRE) Recovered from Hospitalized Patients Actively Screened for VRE Rectal Colonization (VREC)

1226. Can Universal Decolonization Obitate the Need for Screening and Contact Precautions for Carriers of Methicillin-Resistant Staphylococcus aureus in a Medical Intensive Care Unit with MRSA Endemicity? An Interrupted Time Series Study

1227. Development of a Clinical Prediction Model for Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia

1228. Incidence of Staphylococcus aureus Infection after Elective Surgeries among Adults in U.S. Hospitals

1229. Prevalence and Acquisition of MRSA in Females During Incarceration at a Large Inner-City Jail


1231. Patient-Level Factors Associated with Vancomycin-Resistant Enterococci Transmission to Healthcare Workers’ Gowns or Gloves

1232. Phylogenomics of Enterococcus faecium from South America: Revisiting Worldwide VRE Population Structure

1233. An Automated e-mail Notification Systemic to Infectious Disease Specialists and Effect on the Management of Staphylococcus aureus Bacteremia in a Community Hospital setting
1234 Racial Disparities in Invasive Staphylococcus aureus (SA) Disease in Metropolitan Atlanta, a Population-Based Assessment, 2016

1235 Transmission of Genetically Related, Multidrug-Resistant, and Invasive Vancomycin-Resistant Enterococci (VRE) between Patients and Rooms on the Stem Cell Transplant (SCT) and Leukemia (LKM) Units

Poster Abstract Sessions (continued)

1238. Poster Abstract Session
Healthcare Epidemiology: Non-acute Care Settings
Friday, 12:30 - 1:45 p.m.

1236 Infection Control Risk Mitigation and Implementation of Best Practice Recommendations in Long-term Care Facilities

1237 New York State Outpatient Regional Antibiogram for Urinary Pathogens: Have We Reached a Post Antibiotic Era for the Treatment of UTIs?

1238 A National Comparison of Antibiograms Between Veterans Affairs Long-Term Care Facilities and Affiliated Hospitals

1239 Frequently Identified Infection Control Gaps in Outpatient Hemodialysis Centers

1240 Antibiotic Prescribing in U.S. Nursing Homes Using National Pharmacy Transaction Data

1241 Surveillance for Viral Respiratory Infections in Pediatric Chronic Care Facilities

1242 Quantitative Analysis of Microbial Burden on LTCF Environmental Surfaces

1243 Comparative Analysis of Antimicrobial Related Adverse Events in the Outpatient Treatment of Staphylococcal Infections

1244 Evaluation of Antibiotic Prescribing Practices for Geriatric Patients in the Outpatient Setting in a Veterans Affairs Hospital: Identification of Stewardship Targets

1245 Infection Prevention and Control (IP&C) and Antibiotic Stewardship (AS) Practices in Pediatric Long-term Care Facilities

1246 Acinetobacter baumannii in the Post-Acute Care Setting: Prevalence and Resistance Rates in Patients, Health Care Personnel, and the Environment

1247 Genomic Epidemiology of MRSA During Incarceration at a Large Inner-City Jail

1252 A Challenging Burkholderia (Bu) Outbreak Investigation Across Multiple Units at an Academic Medical Center from 6/2017-2/2018

1253 Healthcare-Associated Transmission of Burkholderia cepacia complex Associated with Extrinsically Contaminated Nasal Spray

1254 Outbreak of Mycobacterium chelonae Skin Infections Associated with Human Chorionic Gonadotropin Injections at Weight Loss Clinics

1255 First Outbreak Due to Vancomycin Resistant Enterococcus Epidemic Clone ST796 in Europe

1256 New Acquisitions of ET-12 Burkholderia Cenocepacia in Adults With Cystic Fibrosis: Role of Whole Genome Sequencing in Outbreak Investigation

1257 Assessing Risk Factors for an Outbreak of Burkholderia cenocepacia in Non-Cystic Fibrosis (CF) Patients

1258 The Eyes Have It: Investigating a Cluster of Non-lactose Fermenting Gram-Negative Bacilli from Donor Corneal Rim Tissue

1259 The Local Hospital Milieu and Healthcare-Associated VRE Acquisition

1260 Decreasing Hospital-Acquired Bloodstream Infections through Self-Investigation by Hospital Wards

1261 Utility of a Multiplex Molecular Gastrointestinal Panel in Rapid Identification and Control of a Norovirus Outbreak in a Pediatric Tertiary Care Centre

1262 Investigation and Mitigation of a Multi-Species Outbreak of Invasive Fungal Infections on Two Oncology Wards

1263 Managing an Influenza Outbreak Which Spilled Over to an Acute Care Hospital from a Behavioral Health Unit

1264 Healthcare Acquired Influenza in Critical Ill Patients

1265 Application of the ALERT Influenza Trigger for Enhanced Prevention Activities

1266 Multifaceted Infection Control Strategies to Control Multidrug-resistant Acinetobacter baumanii in Adult Intensive Care Unit in a Tertiary Hospital in Eastern Region, Saudi Arabia

1267 Norventilator Hospital Acquired Pneumonia (NV-HAP) Prevention Initiative in Colombia - Bogotá

1268 Transmissibility of Candida auris by Type of Inpatient Healthcare Facility

139. Poster Abstract Session
Healthcare Epidemiology: Outbreaks
Friday, 12:30 - 1:45 p.m.

1248 Genomic Sequencing and Clinical Data Integration for Next-Generation Infection Prevention

1249 Emergence of Diverse Carbapenem-Resistant Enterobacteriaceae (CRE) in the Dominican Republic

1250 Prevalence and Risk Factors for Acquiring Carbapenem-Resistant Enterobacteriaceae in an Intensive Care Unit at a Tertiary Hospital

1251 Contaminated Sinks May be an Environmental Source for Serial Transmission of Carbapenem-Resistant Enterobacteriaceae (CRE) to ICU Patients

140. Poster Abstract Session
HIV: Diagnosis and Screening
Friday, 12:30 - 1:45 p.m.

1269 HIV Testing in a Large Community Health Center Serving a Multi-Cultural Population: A Qualitative Study of Providers

1270 Are HIV-Related Diagnostics Excessively Ordered? A Pilot Intervention Study to Improve Test Use in the Inpatient Setting

1271 Prevalence and Factors Associated with HIV Testing Among Sexually Experienced 18-49-Year-Old Hong Kong Residents

1272 A Routine, HIV and HCV Testing and Treatment Program in a Large, Multi-Campus Emergency Department Finds High Prevalence of Acute HIV and Chronic Hepatitis C
1273 Routine Opt-Out HIV Screening and Detection of HIV Infection Among Emergency Department Patients
1274 Universal HIV and HCV Screening in San Diego Emergency Departments: Implications for other Settings with a High Density of free of charge HIV Screening Programs
1275 Will an App-Optimized HIV Self-Testing Strategy Work for South Africans? Results from a Large Cohort Study
1276 Human Immunodeficiency Virus (HIV) Diagnostic Limbo: a Retrospective Review of Discordant HIV Test Results in a Large, Academic Health Center Over a 10-Year Period to Guide Clinicians in Distinguishing False Positive versus Acute HIV Infection
1277 Universal Screening is Key: Identifying Gaps in Adolescent HIV Infection Diagnosis at Local Pediatric Health System as Compared to Regional Adult Hospital
1278 Comparing Rates of Routine HIV and HCV Screening to Estimate the Impact of Consent on Identifying Patients with Undiagnosed HIV
1279 Prevalence of HIV Among the Youth Aged 15-24 In Nigeria - A Need to Increase Access for Young Adolescents To HIV Counseling And Testing

141. Poster Abstract Session
HIV: Molecular Epidemiology
Friday, 12:30 - 1:45 p.m.

1280 Geospatial Spread of HIV in the Cologne-Bonn Region, Germany, From 2001-2016
1281 Emergence of a B/F1 HIV Recombinant in the Philippines: A Potentially New Circulating Recombinant Form
1282 Detection of HIV Transmitted Drug Resistance by Next-Generation Sequencing in a CRF01_AE Predominant Epidemic
1283 Pre Treatment HIV-1 Drug Resistance in Transmission Clusters of the Cologne-Bonn Region, Germany
1284 Study of Single Nucleotide Polymorphisms Associated with HIV-1 Set-Point Viral Load in Antiretroviral Therapy-Naïve HIV-Positive Participants of the START Study

142. Poster Abstract Session
HIV: Prevention
Friday, 12:30 - 1:45 p.m.

1285 Impact of an Educational Program on Knowledge, Attitude, and Practice to Prevent HIV Infection among HIV-Negative Heterosexual Partners of HIV-Infected Patients
1286 Evaluating Strategies to Reduce Risk of HIV Infection in the U.S. Blood Supply
1287 Seizing Opportunities for Intervention: Changing HIV Knowledge among Men Who Have Sex with Men and Transgender Women Attending Trusted Community Centers in Nigeria
1288 Adolescents’ Knowledge and Acceptance of Pre-Exposure Prophylaxis (PrEP) in the Capital District Region of NY
1289 Knowledge, Attitudes and Barriers of Pre-Exposure Prophylaxis for HIV Infection Among Resident Physicians in Rural, Eastern North Carolina
1290 A Model for “At-Distance” PrEP Navigation: Acceptability and Early Insights
1291 Assessing Uptake of HIV Pre-Exposure Prophylaxis (PrEP) Among High Risk Demographics in a Community-based Clinic in Brooklyn
1292 HIV Pre-Exposure Prophylaxis (PrEP) Implementation at Silom Community Clinic in Bangkok, Thailand, 2016-2018
1294 Acceptability and Feasibility of a Pharmacist-Led Pre-exposure Prophylaxis Program in the Midwestern United States
1295 Advancing the PrEP Continuum: A Novel Collaboration between a Public Health Department and a Federally Qualified Health Care Center in the Southern United States
1296 Potential Use of Sexually Transmitted Infection (STI) Testing for Expanding HIV Pre-Exposure Prophylaxis (PrEP) at an Urban Hospital Center
1297 Characteristics for PrEP Uptake, Retention, and Discontinuation: Data from the ANCHOR Study
1298 Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report
1299 Iowa TelePrEP: Preliminary Experience with a Public Health-Partnered, Telemedical PrEP Delivery Model in a Rural State
1300 Young Heterosexual Men in Rural South Africa Want Access to PrEP
1301 Evaluation of the Rates of HIV Post-Exposure Prophylaxis Completion After the Implementation of an Automated Referral System in the Emergency Department

143. Poster Abstract Session
Medical Education
Friday, 12:30 - 1:45 p.m.

1302 Antibiotic Prescribing Knowledge: A Brief Survey of Providers and Staff at an Ambulatory Cancer Center during Antibiotic Awareness Week 2017
1303 Provider Knowledge and Attitudes Towards Antibiotic Prescribing and Antibiotic Stewardship in Outpatient Rural Clinics
1304 From Information Bolus to Continuous Infusion: Resident Knowledge and Satisfaction with an “Antibiotic of the Month” Educational Initiative at an Academic Children’s Hospital
1305 Application of Standard Antibiotic Use Criteria to Evaluate Inpatient Antibiotic Use
1306 Antimicrobial Resistance Knowledge, Attitudes, and Perceptions Among Medical Students in Southern India
1307 Emerging Treatments in Ongoing Battle Against Community-Acquired Bacterial Pneumonia (CABP): The Positive Impact of Online Education
1308 Predictors of Career Interest in Infectious Diseases among U.S. Pharmacy Students
1309 The Impact of Clinical Practice Guideline Using Educational Intervention for Improvement of Diabetic Foot Infections Treatment Outcomes
1310 Improving Infectious Disease Electronic Medical Records Documentation – A Quality Improvement Study in an Academic Teaching Hospital
1311 Incorporating an “Escape Room” Game Design in Infectious Diseases Instruction
1312 Division Divided: Using Debate as an Educational Tool to Teach Evidence-Based Clinical Decision-Making
1313 Does Time Fly When Having Fun? A Study Assessing the Relationship Between Estimated Time on Task and Enjoyment of Infectious Diseases Serious Games
1315 Mind the Gap: Medical Trainees Require Training in Hepatitis C, Drug Use, and Mental Health to Help Address the Opioid Crisis
1316 An Integrative Approach to Teaching History of Medicine in Medical School
1317 Online Simulation-Based Education to Improve Primary Care Providers’ Knowledge about Best Practices in HIV Preexposure Prophylaxis Care
1318 Are we PrEPared? Awareness and Prescribing Patterns of HIV Pre-Exposure Prophylaxis (PrEP) by Internal Medicine Resident Physicians at an Academic Medical Center
1319 Examining PrEP Knowledge and Prescribing Likelihood Among Medical Residents Before and After PrEP Education
1320 Continuing Education Improves HIV Screening and Use of PrEP in High-Risk Patients
1321 The UNZA/UMB MMed ID Collaboration: Training and Retaining HIV Specialist Physicians in Zambia
1322 Impact of Hospital Medicine on Trends in Infectious Diseases and Other Subspecialty Fellowship Applications
1323 Implementation and Effectiveness of the Asia Pacific HIV Practice Course: Building Capacity of Healthcare Workers in the Region
1324 Development of HIV-ASSIST, an Online, Educational, Clinical Decision Support Tool to Guide Patient-Centered ARV Regimen Selection
1325 HIV, Aging, and Comorbid Conditions: Case-Based, Online Education Improves HIV/ID Specialists’ Management Strategies
1326 Inter-Professional Education and Training to Build Capacity Among Healthcare Workers in Singapore
1327 Educational Intervention to Improve Communication with Patients Who Have Opioid Use Disorder
1328 Medical Education in an Epidemic: Historical Lessons from the Early Days of HIV in America (1982-1986)
1329 Beyond Reporting: Using an Accreditation Council for Graduate Medical Education (ACGME) Milestone-Linked Evaluation System to Improve Clinical Infectious Diseases Rotations for Baylor College of Medicine Internal Medicine (BCM IM) Residents
1330 Diagnosis and Management of NTM Lung Disease: Effect of Online Educational Interventions on Infectious Disease Specialist Knowledge
1331 Learning Experiences Within Infectious Diseases Pharmacy Residency Programs Demonstrate High Degrees of Consistency
1332 West Coast Transplant ID Conferences, A Model for Building Community in ID Disciplines?
1333 Developing an Educational Tool to Improve Housestaff Knowledge, Attitudes, and Behavior in Managing Common Infectious Diseases

144. Poster Abstract Session

Novel Agents

Friday, 12:30 - 1:45 p.m.

1334 Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support APX001 Dose Selection
1335 Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics
1336 Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenem-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model
1337 SYN-004 (ribaxamase) Protects the Gut Microbiome of Patients Treated with Ceftriaxone from Disruption and Reduces the Emergence of Antimicrobial Resistance
1338 A Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-Blind Studies to Evaluate the Safety and Efficacy of Iclaprim Versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections
1339 Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) versus Imipenem/Cilastatin Plus Colistin (IMI+CS) in Patients (Pts) with Imipenem-Nonsusceptible (NS) Bacterial Infections
1340 Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
1341 ASN100-Mediated Neutralization of Staphylococcus aureus Cytotoxicity against Bacterial Isolates Collected from Mechanically Ventilated Patients
1342 Comparison of Lysin CF-301 (Exebacase) Activity Against S. aureus Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102) to Contemporary Surveillance Isolates
1343 Prophylactic Dosing of Baloxavir Acid Eliminates Mortality in Mice Lethal Influenza A Virus Infection Model
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1344</td>
<td>Ridinilazole (RDZ) for <em>Clostridium difficile</em> Infection (CDI): Impact of Diagnostic Method on Outcomes from a Phase 2 Clinical Trial</td>
</tr>
<tr>
<td>1345</td>
<td>Comparative Activity of Plazomycin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States</td>
</tr>
<tr>
<td>1346</td>
<td>The Tetrazole VT-1598 is Efficacious in a Murine Model of Invasive Aspergillosis with a PK/PD Expected of a Mold-Active CYP51 Inhibitor</td>
</tr>
<tr>
<td>1347</td>
<td>Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials</td>
</tr>
<tr>
<td>1348</td>
<td><em>In vitro</em> Activity of Plazomycin, a Next-Generation Aminoglycoside, against Carbapenem-Producing <em>Klebsiella pneumoniae</em></td>
</tr>
<tr>
<td>1349</td>
<td>Global Surveillance of Cefiderocol against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015</td>
</tr>
<tr>
<td>1350</td>
<td>Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets</td>
</tr>
<tr>
<td>1351</td>
<td><em>In vitro</em> Activity of Cefiderocol (S-649266), a Siderophage Cephalosporin, Against Enterobacteriaceae with Defined Extended-Spectrum β-lactamases and Carbapenemases</td>
</tr>
<tr>
<td>1352</td>
<td>A Computational Approach for Exploring the Binding Mechanism of Chebulinic acid on Herpes Simplex Virus-2 and its Implication on Chikungunya and Dengue</td>
</tr>
<tr>
<td>1353</td>
<td><em>In Vitro</em> Activity of Lefamulin (LEF) against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data from the United States</td>
</tr>
<tr>
<td>1354</td>
<td>Novel Formulation SUBA-Itraconazole in Fed and Fasted Healthy Volunteers: Expanding the Clinical Utility of the Established Mold Active Agent</td>
</tr>
<tr>
<td>1355</td>
<td>Global Activity of Imipenem-Relebactam and Comparators against Clinical Gram-Negative Pathogens – SMART 2017</td>
</tr>
<tr>
<td>1356</td>
<td>Improvement in Quality of Life for Adults with Acute Bacterial Skin and Skin Structure Infections Following Treatment with Omadacycline or Linezolid</td>
</tr>
<tr>
<td>1357</td>
<td>A Combination of Itraconazole and Amiodarone is Highly Effective against <em>Trypanosoma cruzi</em> Infection of Human Stem Cell Derived Cardiomyocytes</td>
</tr>
<tr>
<td>1359</td>
<td>Activity of Meropenem/Nacubactam Combination against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017</td>
</tr>
<tr>
<td>1360</td>
<td>Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes</td>
</tr>
<tr>
<td>1361</td>
<td>Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for <em>Clostridium difficile</em> Infection (CDI): From Animal Models to Patients</td>
</tr>
<tr>
<td>1362</td>
<td>A Novel Intravesical Antimicrobial for CAUTIs</td>
</tr>
<tr>
<td>1363</td>
<td>Sulopenem Activity against <em>Enterobacteriaceae</em> Isolates from Patients with Urinary Tract Infection or Intra-Abdominal Infection</td>
</tr>
<tr>
<td>1364</td>
<td>Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials</td>
</tr>
<tr>
<td>1365</td>
<td><em>In Vitro</em> Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results from Asia-Pacific (APAC) and Latin America (LA)</td>
</tr>
<tr>
<td>1366</td>
<td><em>In Vitro</em> and <em>In Vivo</em> Activity of Cefiderocol against <em>Stenotrophomonas maltophilia</em> Clinical Isolates</td>
</tr>
<tr>
<td>1367</td>
<td>Clinical Cure in Secondary Efficacy Populations in Patients with Complicated Urinary Tract Infection Treated with ZTI-01 (fosfomycin for injection): Findings from the ZEUS Trial</td>
</tr>
<tr>
<td>1368</td>
<td>Assessment of the <em>In Vivo</em> Efficacy of Human-simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination against β-lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model</td>
</tr>
<tr>
<td>1369</td>
<td>Combined Analysis of the <em>In Vitro</em> Activity of Ridinilazole (RDZ) Against More than 500 <em>Clostridium difficile</em> (CD) Clinical Isolates and Impact of RDZ on Cell Morphology</td>
</tr>
<tr>
<td>1370</td>
<td>Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug-Resistant <em>K. pneumoniae</em> and <em>P. aeruginosa</em></td>
</tr>
<tr>
<td>1371</td>
<td>Safety, Tolerability, and Pharmacokinetics of Multiple Doses of TP-6076, a Novel, Fully Synthetic Tetracycline, in a Phase 1 Study</td>
</tr>
<tr>
<td>1372</td>
<td><em>In Vitro</em> Activity of Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations against Carbapenem-Non-Susceptible <em>Enterobacteriaceae</em> Isolates by Phenotype Collected in Latin America from 2014-2017 as part of the INFORM Surveillance Program</td>
</tr>
<tr>
<td>1373</td>
<td>Activity of Ceftriaxone-Sulbactam-EDTA against Multidrug-Resistant <em>A. baumannii</em>, <em>P. aeruginosa</em>, and Enterobacteriaceae Isolates (WHO Critical Priority Pathogens) Collected from Various Hospitals in India</td>
</tr>
<tr>
<td>1374</td>
<td>Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic</td>
</tr>
<tr>
<td>1375</td>
<td><em>In vitro</em> Activity of Cefiderocol and Comparator Agents against Gram-Negative Isolates from Cancer Patients</td>
</tr>
<tr>
<td>1376</td>
<td>Antifungal Activity of Cerium Nitrate against Fungal Isolates Associated with Combat-Related Injuries Including Burns</td>
</tr>
<tr>
<td>1377</td>
<td>Omadacycline <em>In Vitro</em> Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms</td>
</tr>
<tr>
<td>1378</td>
<td>Evaluation of the <em>in vitro</em> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <em>Enterobacteriaceae</em>, Including Isolates Resistant to Ceftazidime-Avibactam</td>
</tr>
<tr>
<td>Poster Abstract Sessions (continued)</td>
<td></td>
</tr>
<tr>
<td>------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td><strong>145. Poster Abstract Session</strong></td>
<td><strong>1396</strong> Predictions of Isavuconazonium Sulfate Dosage in Patients Aged 6 months - &lt;18 years by Physiologically Based Pharmacokinetic Modeling</td>
</tr>
<tr>
<td><strong>PK/PD Studies</strong></td>
<td><strong>1397</strong> Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Penetration into Epithelial Lining Fluid (ELF) based on Multiple Bronchoalveolar Lavage (BAL) Sampling Time Points in a Swine Pneumonia Model</td>
</tr>
<tr>
<td></td>
<td><strong>1398</strong> β-lactam Probability of Target Attainment (PTA) and Penetration into Epithelial Lining Fluid (ELF) against Methicillin-Resistant Staphylococcus Aureus (MRSA) in Neutropenic (I-) vs Immunocompetent (I+) Murine Models of Pneumonia</td>
</tr>
<tr>
<td></td>
<td><strong>1399</strong> Efficacy of Daptomycin Combination with β-lactams for Daptomycin Resistant Enterococcus faecium Harboring LiaSR Substitutions</td>
</tr>
<tr>
<td><strong>1379</strong> Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)</td>
<td><strong>1400</strong> Mass Balance, Metabolism, and Excretion of [14C]-Plazomicin in Healthy Human Subjects</td>
</tr>
<tr>
<td><strong>1380</strong> Effect of Absolute Body Weight on Clinical Outcomes of Obese Patients Treated with Cefepime</td>
<td><strong>1401</strong> A Randomized, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects</td>
</tr>
<tr>
<td><strong>1381</strong> Impact of Total Body Weight on Efficacy of Ceftriaxone in Obese Patients</td>
<td><strong>1402</strong> Cystatin C Improves Estimation of Vancomycin Clearance in Critically Ill Children Using a Population Pharmacokinetic Modeling Approach</td>
</tr>
<tr>
<td><strong>1382</strong> Acute Kidney Injury with Piperacillin-Tazobactam and Vancomycin in the Intensive Care Unit</td>
<td><strong>1403</strong> Daptomycin Combined with Low Dose Ceftriaxone Prevents the Emergence of Daptomycin Resistance against Streptococcus mitis-oralis Group in an In vitro Model of Simulated Endocardial Vegetations (SEVs)</td>
</tr>
<tr>
<td><strong>1383</strong> In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of NOSO-502, a First-in-Class Odiolarhabdin Antibiotic, against E. coli (EC) and K. pneumoniae (KPN) in the Murine Neutropic Thigh Model</td>
<td><strong>1404</strong> A Pharmacokinetic Study on CMS and Colistin and its Impact on Clinical Cure and Acute Kidney Injury in Critically Ill Patients with Normal Renal Function from South India</td>
</tr>
<tr>
<td><strong>1384</strong> RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development</td>
<td><strong>1405</strong> Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination against Serine β-lactamase-Producing Gram-Negative Bacteria in the Neutropenic Murine Thigh Infection Model</td>
</tr>
<tr>
<td><strong>1385</strong> Efficacy of Cefazidime-Avibactam in Combination with Aztreonam (COMBINE): Solutions for Metallo-β-lactamase producing-Enterobacteriaceae (MBL)</td>
<td><strong>1406</strong> Augmented Renal Clearance Using Aminoglycoside Population-Based Pharmacokinetic Modeling with Bayesian Estimation in Children in the Pediatric Intensive Care Unit</td>
</tr>
<tr>
<td><strong>1386</strong> Efficacy of Repeat Dosing of Oral Fosfomycin in a Dynamic Bladder Infection In Vitro Model</td>
<td><strong>1407</strong> Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)</td>
</tr>
<tr>
<td><strong>1387</strong> Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects</td>
<td><strong>1408</strong> Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of Asn-1 and Asn-2 after ASN100 Administration to Healthy Subjects</td>
</tr>
<tr>
<td><strong>1388</strong> Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically-Based Pharmacokinetic (mPBPK) Model</td>
<td><strong>1409</strong> Evaluation of Alternative Piperacillin-Tazobactam Dosing Strategies against ESBL-Producing Enterobacteriaceae using a Hollowfiber Infection Model</td>
</tr>
<tr>
<td><strong>1389</strong> Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropic Murine Pneumonia Model against S. aureus (SA) and S. pneumoniae (SPN)</td>
<td><strong>1410</strong> Novel Framework to Compare the Effectiveness of Tazobactam, Relebactam, and Avibactam against Extended-Spectrum β-lactamase-Producing Enterobacteriaceae</td>
</tr>
<tr>
<td><strong>1390</strong> Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida</td>
<td><strong>1411</strong> Teclopilin (TEI) vs Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)</td>
</tr>
<tr>
<td><strong>1391</strong> Vancomycin Area Under the Curve (AUC) to Predict Nephrotoxicity: A systematic Review and Meta-analysis of observational studies</td>
<td><strong>1412</strong> Caspofungin and Anidulafungin Behave as Fungistatic Agents Against Candida auris</td>
</tr>
<tr>
<td><strong>1392</strong> Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection</td>
<td></td>
</tr>
<tr>
<td><strong>1393</strong> A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects under Fasting Conditions of Orally Administered Sulopenem Etzadoxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem</td>
<td></td>
</tr>
<tr>
<td><strong>1394</strong> A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid (CSF) and Plasma Concentrations of Cefepime</td>
<td></td>
</tr>
<tr>
<td><strong>1395</strong> Defining the Magnitude of AUC:MIC Driver for Efficacy of the β-lactamase Inhibitor VNRX-5133 when combined with Cefepime against KPC- and VIM/NDM-Producing Enterobacteriaceae and P. aeruginosa</td>
<td></td>
</tr>
</tbody>
</table>
Poster Abstract Sessions (continued)

1413  A Phase IIa Efficacy, Safety, Tolerability, and Pharmacokinetic (PK) Study of Encocchleated Amphotericin B in Patients with Mucocutaneous (Esophageal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies

1414  Inoculum Effect of Piperacillin/Tazobactam Concentration on Emergence of Resistance in Klebsiella aerogenes

1415  Implementation and Validation of a Vancomycin AUC/MIC Calculator and Dosing Protocol at a Large Community Hospital

1416  Piperacillin/Tazobactam Therapeutic Drug Monitoring: True Intertreatment Variability or Compound Instability?

1417  Evaluating the Dissonance between $C_{\text{min}}$ and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study

1418  Pharmacokinetics (PK) and Toxicity of Intravenous Amikacin (AMK) Dosed Three Times a Week (TIW) for Treatment of Disseminated Mycobacterium abscessus Infection in Children

1419  24-Hour Pharmacokinetic Relationships for Intravenous Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury

1420  Case Report: Ganciclovir Subtherapeutic Dosing in a Pediatric Patient on Extracorporeal Membrane Oxygenation

1421  IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects

1422  Comparative Monte Carlo Analysis of Atrzenonam-Aviabactam vs Ceftazidime-Aviabactam against Carbapenem-Resistant Gram-Negative Pathogens

1423  Plasma and Intrapulmonary Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients with Pneumonia

1424  Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults with Presumed or Documented Staphylococcal Infections

1425  Population Pharmacokinetic Analysis of Ciprofloxacin and Levofloxacin in Critically Ill Trauma, Surgical, and Burn Patients

1426  Impact of Routine Pediatric PCV13 on the Incidence and Severity of Invasive Pneumococcal Disease in Adults in Ontario, Canada

1427  A Dynamic Modelling Study of the Effect of Introducing a New Higher Valent Pneumococcal Conjugate Vaccine in a Pediatric Population in the United States

1428  Modeling Reductions in Antibiotic Prescriptions Due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination

1429  Emergence of Multidrug-Resistant Serotype 24 among Children under 2 years old with Invasive Pneumococcal Disease after the Introduction of PCV13 in Argentina

1430  Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease

1431  Dynamics of Antibiotic Prescription Rate Following Pneumococcal Conjugate Vaccine (PCV) Implementation in Children <2 Years Old: Comparison between High and Low Prescribing Clinics in Two Different Ethnic Groups

1432  County-Wide Pediatric IPD Experience Following Prevnar 13 Implementation

1433  Association between Impact of Pneumococcal Conjugate Vaccines (PCVs) on Acute Respiratory Infections Rates and Impact on Antibiotic Consumption Rates in Young Children

1434  Cost-Effectiveness of Sequential Vaccination with the 13-Valent Pneumococcal Conjugate Vaccine (Pcv13) Followed by the 23 Valent Polysaccharide Vaccine (Ppv23) in the Netherlands

1435  The Cost-Effectiveness of Vaccinating with an Adjuvanted Trivalent Influenza Vaccine for the 65+ Population in Argentina

1436  Risk Factors for Invasive Pneumococcal Disease in Adults ≥65 Years Old Following Pneumococcal Conjugate Vaccine Recommendation

1437  Family Duty and Safety Linked to Overcoming Attitudinal Barriers to Adult Pneumococcal Vaccination in Disparate Populations

1438  Uptake of 13-Valent Pneumococcal Conjugate Vaccine in High-Risk Adults Aged 19-64 Years: A Kaplan-Meier Approach

1439  The Cost-Effectiveness of Vaccinating Adults at Increased Risk of Pneumococcal Disease Against Pneumococcal Disease in the Netherlands

1440  Potential Impact of Routine Use of 13-valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada

1441  Doses of 13-valent Conjugated Pneumococcal Vaccine (PCV13) for Patients with Multiple Myeloma (MM)

1442  Pneumonia Hospitalizations Averted with 13-valent Pneumococcal Conjugate Vaccination of Adults Aged 18-64 Years with Diabetes in the United States

1443  Serotypes 8 and 3 are the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2015-2017)

1444  Trends in Antimicrobial Non-susceptibility of PCV13-type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017

1445  Impact of 10-valent Pneumococcal Conjugate Vaccine Introduction on Pneumococcal Carriage and Antibiotic Susceptibility Patterns among Children Aged <5 Years and Adults with HIV Infection, Kenya 2009–2013

1446  Correlation between Adult Invasive and Non-Invasive Streptococcus pneumoniae Disease in 13-valent Pneumococcal Conjugate Vaccine Serotypes in the United States
147. Poster Abstract Session
Respiratory Infections: CAP
Friday, 12:30 - 1:45 p.m.

1447 Molecular Epidemiology, Serotype Distribution, Antimicrobial Sensitivity, and Clinical Findings of Adult Pneumococcal Pneumonia Patients in Japan; Hospital-Based Study

1448 Impact of Mental Illness on Outcomes of Outpatients with Community-Acquired Pneumonia

1449 Comparison of Emergency Department versus Inpatient Pediatric Treatment for Empiric Community-Acquired Pneumonia in Infants and Children over 3 months of age

1450 Clinical Characteristics of Patients with Community-Acquired Pneumonia due to Moraxella catarrhalis in Adults: a Retrospective Single Center Study in Okinawa Miyako Island in Japan

1451 Predictive Values of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Swab PCR Assay for MRSA Pneumonia


1453 Ninety-One Day Quality of Life Post-Pneumonia Diagnosis in Adult Patients in Japan

1454 Beta-Hemolytic Non-Group A Streptococcus Pharyngitis in Children

1456 Biomarkers in Different Etiologies of Pneumonia in Pediatrics in Indonesia

1457 Escherichia Coli Community-Acquired Pneumonia

1458 A Single Center Quasi-Experimental Study to Evaluate the Impact of Utilizing Rapid Diagnostic Technology to Detect Methicillin-Resistant Staphylococcus aureus in Respiratory Culture Samples

1459 The Scope of Mycoplasma Pneumonias Pneumonia Diagnosed by Multiplex Polymerase Chain Reaction Respiratory Viral Panel in Pediatric Patients in Hawaii

1460 Community-Acquired Bacteremic Pneumonia in Post-Pneumococcal Vaccination Era in a Pediatric Hospital

1461 Non-Invasive Pneumococcal Pneumonia in the United States, 2013-2014

1462 Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score

1463 Comparative Evaluation of Adverse Tendon Events between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin among Veterans Affairs Patients with Community-Acquired Bacterial Pneumonia

1464 The Clinical Features of Pneumonia Caused by Legionella pneumophila vs. Streptococcus pneumoniae: A Retrospective Study

1465 Discovering Outpatient Stewardship Targets: An Evaluation of Community-Acquired Pneumonia in the Outpatient Setting

1466 Adherence to Empiric Treatment Recommended by IDSA/PIDS Pediatric Community-Acquired Pneumonia (CAP) Guidelines According to Immunization Status

1467 Clinical Significance of Microbiologic Treatment Failure following Clinical Cure of Pneumonia

1468 PCV13 Serotype Trends Over Time in Pneumococcal Community-Acquired Pneumonia: Which Method(s) Work Best?

1469 Microbial Etiology of Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults

1470 Neurocognitively-Acting Potentially Inappropriate Medications, Alcohol, and Community-Acquired Pneumonia among Patients with and without HIV

148. Poster Abstract Session
Respiratory Infections: Miscellaneous
Friday, 12:30 - 1:45 p.m.

1471 Case Report: Andes Virus Hantavirus Pulmonary Syndrome in a Traveler Returning to the United States

1472 Antibiotic De-Escalation Compared with Continued Empirical Treatment in Non-Ventilated Hospital-Acquired Pneumonia

1474 Etiology of Pulmonary Granulomas: How Common is Unsuspected Infection?

1475 Etiology and Outcome of Fever and Respiratory Distress in Adult Patients Presenting to Medical Emergency in a Tertiary Care Hospital in North India

1476 Objective Surveillance Definitions for Hospital-Acquired Pneumonia in Non-Ventilated Patients

1477 MUCOVIB Project: Concordance Between Upper and Lower Airway Microbiota in Children with Cystic Fibrosis

1478 A Retrospective Review of Pseudomonas aeruginosa Infection in a Quarternary Intensive Care Unit: Epidemiology, Outcomes, and Antimicrobial Susceptibilities: 2013-2016

1479 Evaluating the Impact of Procalcitonin on Antibiotic Utilization in Chronic Obstructive Pulmonary Disease Exacerbations

1480 Impact of a Guidance Document, Order Set Changes and Physician Education on Antibiotic Prescribing in Acute Exacerbation of COPD

1481 Clinical Outcomes of Escherichia coli Infections in Cystic Fibrosis (CF) Patients

1482 Changing Patterns of HIV-TB Coinfection Among Patients in a Public Health Department Ambulatory Care Setting: A 5-year Experience from a U.S. Metropolitan Area

1483 Pleural Empyema Caused by Stenotrophomonas maltophilia in A National Cohort of Hospitalized Veterans

1484 Impact of Combination versus Monotherapy on Clinical Outcomes Associated with Stenotrophomonas maltophilia Pneumonia

1485 Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Patients with Pneumonia in U.S. Medical Centers
Poster Abstract Sessions (continued)

1486 Missed and Delayed Diagnosis of Pneumocystis Pneumonia in HIV and non-HIV-Infected Individuals
1487 Variability of Pneumocystis jirovecii Prophylaxis Use Among Pediatric Solid Organ Transplant Providers
1488 Invasive Pulmonary Aspergillosis in Patients with Solid Tumors: Risk Factors and Predictors of Clinical Outcomes

149. Poster Abstract Session
Sexually Transmitted Infections
Friday, 12:30 - 1:45 p.m.

1489 Trends in Antimicrobial Resistance in N. gonorrhoeae Isolated in Korea during 2015 to 2017
1490 Lymphogranuloma Venereum: Correct Diagnosis Makes all the Difference
1491 Mycoplasma genitalium: A Concordance Study in Heterosexual Partnerships at Risk for Chlamydial Infection
1492 Chlamydia, Gonorrhea, Syphilis, and HIV Screening among Men Presenting with STI-related Complaints at a Community Based Emergency Department in Columbus, Ohio: A 5-Year Retrospective Study
1493 Effect of HIV Status on Early Syphilis Treatment Response in the Era of Combination Antiretroviral Therapy
1494 Vaginal pH: Associations with Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis
1495 Incidence of Sexually Transmitted Infections (STIs) in Patients on Pre-exposure Prophylaxis (PrEP)
1496 Anorectal Mycoplasma genitalium is Common among Nigerian MSM and Associated with HIV
1497 Evidence-Based Care for Sexually Transmitted Infections: Missed Opportunities in an Academic Medical Center
1498 Sexually Transmitted Infections among Persons Living with HIV Infection and Receiving Care in the District of Columbia: Time with Viral Load above 1500 as Proxy for Risk of Transmission
1499 Gonorrhea and Chlamydia Infections in the Department of Veterans Affairs (VA), 2013-2017
1500 At Risk Drinking is Common among HIV infected Department of Defense (DoD) Beneficiaries but was not Associated with Prevalent GC/CT Infections

150. Poster Abstract Session
Urinary Tract Infection
Friday, 12:30 - 1:45 p.m.

1501 Comparative Effectiveness of Antibiotic Therapy for the Outpatient Treatment of Urinary Tract Infections Among Otherwise Healthy, Premenopausal Women
1502 Identifying Risk Factors for Recurrent Urinary Tract Infections among Female Outpatients
1503 No Benefit to Treating Male UTI for Longer than 7 Days: An Outpatient Database Study
1504 Patient Demographics and Comorbidity Profiles Associated with Hospitalized Patients Admitted with Resistant vs. Susceptible Urinary Tract Infections (UTI): A Multicenter Analysis
1505 Predictive Value of Early Post-Transplant Bacteriuria on Rates of Recurrent Urinary Tract Infections in the First Year After Renal Transplantation
1506 Association of Antibiotic Treatment Duration with First Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients
1507 Evaluating the Effects of a “Urinalysis to Reflex Culture” Process Change in the Emergency Department (ED) at a Veterans Affairs (VA) Hospital
1508 Urinary Tract Infections (UTIs) in the First Year Post-Renal Transplant: Risks and Opportunities
1509 Clinical Significance of Staphylococcus aureus Bacteriuria
1510 Treatment of Asymptomatic Bacteriuria prior to Transcatheter Aortic Valve Replacement
1511 Utility of Clinical Scoring Models in Predicting Community Acquired Urinary Tract Infections with Extended-Spectrum β-lactamase-Producing Escherichia coli in a General Hospital in Mexico City
1512 Variation in Outpatient Urine Testing Practices for Uncomplicated Urinary Tract Infections
1513 A New Method for Rapid Phenotypic Antimicrobial Susceptibility Testing Directly from Patient Samples
1514 Clinical Decision-Making in Suspected Urinary Tract Infection in Hospitalized Patients: Which Factors Lead to Treatment, and How Would Reflex Urine Cultures Impact Diagnosis?
1515 Patient-Based Stratification of Weighted-Incidence Syndromic Antibiogram (WISCA) for Empirc Antibiotic Prescribing
1516 Evaluating Appropriate Antimicrobial Selection and Duration of Therapy for Urinary Tract Infections in Outpatient Clinics
1518 Assessment of Antibiotic Prescribing in the Outpatient Setting for Uncomplicated Urinary Tract Infection in Pediatrics (UTIP Trial) with a Review of Local E. coli Susceptibilities
1519 Management and Outcomes of Children with Extended-Spectrum Cephalosporin-Resistant Urinary Tract Infections (ESC-R UTIs)
1520 Determining the Management of Children with Acute UTI/Pyelonephritis Who Do Not Fit Current Management Recommendations
1521 Heterogeneity of Recent Phase 3 cUTI Clinical Trials with New Antibiotics
1522 Initial Clinical Response of Children with Extended-Spectrum Cephalosporin-Resistant Urinary Tract Infections (ESC-R UTIs) Started on Discordant Antibiotics
1523 Antimicrobial Activity of Cefazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program
1524 Are Providers Shifting from NTF to Fosfomycin for Inpatient UTI? Big Data Reveals Small Shifts
1525 Evaluation of Clinical Outcomes with Fosfomycin for E. coli and non-E. coli Enterobacteriaceae Urinary Tract Infections
Poster Abstract Session

Poster Abstract Session (continued)

1526 Oral Fosfomycin Use for Urinary Tract Infections and its Clinical Impact on Hospital Stay
1527 The Prevalence of Enterobacteriaceae (ENT) Resistant to All Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outcomes
1528 A Real World Perspective on Treatment of CRE UTIs with Oral Agents
1529 Suprapubic Catheter Placement Improves Antimicrobial Stewardship in a Veterans Affairs Long-Term Care Facility
1530 De-Implementation Strategy to Reduce the Inappropriate Use of Urinary and Intravenous CATheters: The RICAT-Study

151. Poster Abstract Session

Viruses and Bacteria in Immunocompromised Patients
Friday, 12:30 - 1:45 p.m.

1531 A CMV Vaccine Based on Non-Replicating Lymphocytic Choriomeningitis Virus Vectors Expressing gB and pp65 is Safe and Immunogenic in Healthy Volunteers, Allowing for Development of a Phase II Clinical Trial in Living Donor Kidney Transplant Recipients
1532 Increased Risk of Bacterial, Fungal, and Other Viral Infections During CMV Infection: Decreased Cytokine Production in Response to Toll-Like Receptor Ligands
1533 The Use of QuantIFERON®-CMV Gamma Interferon-releasing Assay as a Diagnostic Stewardship Tool Following Kidney Transplantation
1534 Prevalence and Outcome of Neutropenic Enterocolitis Among Pediatric Acute Myeloid Leukemia Patients: A Developing Country Experience
1535 Utility of CT Abdomen in Evaluation of Neutropenic Fever in Patients with Hematological Malignancies
1536 Donor Derived Mycobacterium tuberculosis Infection after Solid-Organ Transplantation: A Comprehensive Review
1537 Reactivation of Latent Cytomegalovirus Infection in Patients with Rheumatologic Disease: A Case-Control Study
1538 High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopoietic Cell Transplant Recipients
1539 Diagnosis of Yersinia enterocolitica in Cancer Patients with Diarrhea in the Era of Molecular Diagnostics for Gastrointestinal Infections
1540 Left Ventricular Assist Device Driveline Infections: Relapsed Infections and Minimum Inhibitory Concentration Changes
1541 Infectious Complications in Adult Patients with Hemophagocytic Lymphohistiocytosis: A Single Center Experience
1542 Infectious Complications in Patients (Pt) following Umbilical Cord Blood Transplant (UCBT) for Hematologic Malignancy
1543 The More Resistant, the More Fatal: Results of 414 Bacteremia Episodes in Febril Neutropenic Patients
1544 Kinetics of BK Virus in Urine Associated with BKV DNAemia and BKVAN in Pediatric Kidney Transplantation
1545 Gram-Negative Bacteremia in Neutropenic Patients: Risk Factors for Mortality in the Era of Multiresistance
1546 Incidence of Carbapenemase-Producing Klebsiella pneumoniae Colonization in Hematopoietic Stem Cell Transplant Recipients in King Chulalongkorn Memorial Hospital (KCMH), Thailand
1547 BK Virus Reactivation in Solitary Heart Transplant Recipients: Prevalence and Relationship to Kidney Dysfunction
1548 Risk of Severe Herpes Zoster (H2) in Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
1549 Development and Validation of a Cycle-Specific Risk Score for Febrile Neutropenia after Chemotherapy in Patients with Cancer: The cFENCE Score
1550 Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?
1551 The Impact of Recurrent CMV Disease on Long-Term Survival in Solid Organ Transplant Recipients
1552 Absolute Lymphocyte Threshold: A Simple Readily Available Tool to Predict Risk of Cytomegalovirus Infection after Transplantation
1553 Infectious Complications Following Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiency Diseases
1554 Reactivation of Varicella Zoster Virus in Solid Organ Transplant Recipients: Identification of Risk Factors Using Data Mining Tools
1555 A New Perspective about Disseminated Adenovirus Infection and its Outcomes in Pediatric Solid Organ Transplantation
1556 Infectious Disease Complications with Use of Checkpoint Inhibitors in Solid Organ Malignancies
1557 Ayclovir-Resistant (ACV-R) Herpes Simplex Virus (HSV) Disease in Patients with Hematologic Malignancies (HM) and Hematopoietic-Cell Transplant (HCT) Recipients
1558 Commensal Neisseria Species as a Cause of Disease in Patients Taking Eculizumab
1559 Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Bloodstream Infections
1560 Clinical Presentation of BK Virus-Associated Hemorrhagic Cystitis (HC) after Hematopoietic Cell Transplantation (HCT)
1561 Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant
1562 Impact of Skin Biopsy on Diagnosing Infections and Changing Treatment in Cancer Patients with New Skin Rash
1563 Relationship of Cumulative Viral Burden of Adenovirus with Mortality in Allogeneic Hematopoietic Cell Transplant Recipients with Early Adenovirus Viremia
1564 Lower Rates of Epstein-Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis
1565 Lymphocyte Subsets as Predictors of Cytomegalovirus Infection after Transplantation
1566 Is Primary CMV Infection Post-Transplant Influenced by Circadian Rhythms?
1567 Predicting Mortality among Immunocompromised Patients Who Present with Infection
1568 Implementation of a Standard Diet Regimen for Neutropenic High Risk Cancer Patients: Effects on Incidence of Infections, Foodborne Diseases, and Outcome
1569 Incidence, Risk Factors, and Impact of Antiviral Prophylaxis Duration on Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative [D+R-] Orthotopic Heart Transplant Recipients [OHTR]
1570 Infectious Disease (ID) Complications in Immunocompromised (IC) Patients with Cancer Post-Hurricane Harvey at a Comprehensive Cancer Center in 2017
1571 Cost-Effectiveness Analysis of Duration of Valganciclovir Prophylaxis among CMV Serology Mismatched (Donor+/Recipient-) Lung Transplant Recipients
1572 Conjugate Pneumococcal Vaccination Reduces Invasive Pneumococcal Disease Post Haematopoietic Stem Cell Transplant
1573 Discrepancies Between Premortem and Postmortem Diagnoses of Infectious Diseases Found on Autopsy in Hematopoietic Cell Transplantation Recipients at a High-volume Academic Transplant Center
1574 Cancer Chemotherapy May Induce Acquisition of Antibiotic Resistance Genes in Antibiotic- Naive Cancer Patients
1575 Clinical Validation of a Novel ELISpot-Based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients
1576 Risk of Clinical Tuberculosis (TB) among Patients with Latent TB Infection (LTBI) who Undergo Allogeneic Hematopoietic-Cell Transplantation (HCT)
1577 Evaluation of a Routine Screening Program with Tuberculin Skin Testing on Rates of Detection of Latent Tuberculosis Infection and Prevention of Active tuberculosis in Patients with Multiple Myeloma at a Canadian Cancer Center
1578 Back to Bactrim – Utilizing Preferred Prophylaxis Strategies in Immunocompromised Hosts via a Trimethoprim-Sulfamethoxazole Rechallenge Program
1579 Evaluation of MATCH: An Electronic Individual Patient-Focused Management System Aimed at Preventing Cytomegalovirus Disease Following Solid Organ Transplantation
1580 Characteristics of Early vs. Late Onset Post-Transplant Lymphoproliferative Disorder after Liver Transplant - A Descriptive Study of the United Network of Organ Sharing (UNOS) Database
1581 Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin
1582 Is Antibiotic Prophylaxis Needed for All Acute Variceal Bleeds in Decompensated Cirrhosis? A Retrospective Pilot Study
1583 The Utility of the Immunodeficiency Scoring Index (ISI) to Predict Outcomes of Coronavirus (HCoV) Infections in Hematopoietic Cell Transplant (HCT) Recipients
1584 Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next Generation Sequencing
1585 Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever and Neutropenia (FN): Correlation between Initial Empiric Antibiotic Regimen Correlation and Susceptibility Patterns
1586 Prevalence and Significance of Pre-Transplant BK Viremia and Viruria in Deceased and Living Kidney Donors and Kidney Transplant Recipients
1587 Analysis of Breakthrough Bloodstream Infections in Left Ventricular Assist Device Recipients Managed with Chronic Antimicrobial Suppressive Therapy
1588 Clinical Prediction Tool for Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae as the Etiology of Bacteremia in Solid Organ Transplant Recipients
1589 Increased Detection of Diarrheal Pathogens in Hematopoietic Stem Cell Transplant Recipients using a Multiplexed PCR Panel
1590 A Hybrid CMV Prevention Strategy is Effective in Preventing CMV Disease Outcomes in Pediatric Solid Organ Transplant Patients
1591 Infectious Outcomes of Levofloxacin Prophylaxis in Obese versus Non-Obese Patients with Hematologic Malignancies
1592 Safety of Oral Trimethoprim/Sulfamethoxazole Prophylaxis in Renal Transplant Recipients
1593 Recurrence of Clostridium difficile Infection in Multiple Myeloma patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole versus No Prophylaxis
1594 Evaluating Clinical Outcomes of an Alternative Cefepime Dosing Regimen as Empirc Antibiotic Therapy in Hospitalized Adults with Febrile Neutropenia
1595 Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy
1596 Thinking Locally: Can Unit-Specific Methicillin-Resistant Staphylococcus aureus Screening Augment Stewardship Interventions for Febrile Neutropenia?
1597 Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus (CMV) Infection and Disease in Solid Organ Transplant (SOT) Recipients
1598 Oral Step Down Therapy with Levofloxacin for Low Risk Febrile Neutropenia in Children
1599 Rejection Outcomes in Lung Transplant Recipients Post Respiratory Syncytial Virus Infections
1600 An Optimal Respiratory Syncytial Virus (RSV) Treatment in Lung Transplant Recipients: Oral Ribavirin, Inhaled Ribavirin, or Conservative Approach
1601 Effect of Preemptive Rituximab Therapy on Epstein-Barr Reactivation in Allogenic Hematopoietic Stem Cell Transplant Recipients
1602 Clostridium difficile Infection as a Predictor of Acute Graft versus Host Disease among Allogenic Stem Cell Transplant Recipients
1603 Our Experience with M. marinum cutaneous Infections in Three Patients Receiving Anti TNFα
216. Poster Abstract Session  
**Antimicrobial Stewardship: Global Perspectives**  
Saturday, 12:30 - 1:45 p.m.

- 1776 Establishing an Antimicrobial Stewardship Program in a Resource Limited Setting: Experience of an Ethiopian Hospital
- 1777 Implementation of an Antimicrobial Stewardship Program (ASP) at the Princess Margaret Hospital, Nassau, Bahamas
- 1778 Exploring Bacterial Resistance in Northern Oman, a Stewardship Initiative to Improve Antibiotic Prescription
- 1779 Defining Antimicrobial Use and Resistance in a Teaching Hospital in the Dominican Republic: Key First Steps for Development of Antimicrobial Stewardship in a Resource Limited Setting
- 1780 Results of a Successful Implementation of an Antimicrobial Stewardship Program in a Public Hospital in São Paulo, Brazil
- 1781 Impact of an Antimicrobial Stewardship Intervention in India: Evaluation of Post Prescription Review and Feedback as a Method of Promoting Optimal Antimicrobial Use
- 1782 Guideline- Discordant Carbapenem Prescribing Policies at a Large, Urban Hospital in Manila, Philippines
- 1783 Implementation of New Strategy for Real Time Antimicrobial Stewardship (ASP) in a Secondary Healthcare Hospital in Mexico City
- 1784 Impact of a Novel Multidisciplinary Anti-Tubercular Stewardship Program in a Tertiary Care Center in India
- 1785 Regional Variation of Antimicrobial Use in Japan from 2013 to 2016

217. Poster Abstract Session  
**Antimicrobial Stewardship: Impact of Allergy**  
Saturday, 12:30 - 1:45 p.m.

- 1786 Safety, Efficacy, and Clinical Impact of Penicillin Allergy Skin Testing in Immunocompromised Cancer Patients at a Comprehensive Cancer Center
- 1787 The Safety and Efficacy of an Oral Penicillin Rechallenge Program in Cancer Patients – A Pilot Multicentre Study
- 1788 Cost-Effectiveness of Penicillin Skin Testing among Patients with Methicillin Sensitive *Staphylococcus aureus* bacteraemia and Reported Penicillin Allergy
- 1789 Inpatient Penicillin Skin Testing: Outcomes from a Propensity-Matched Case-control Study
- 1790 Clinical and Economic Outcome Evaluation with Penicillin Skin Testing as an Antimicrobial Stewardship Initiative in a Not-for-Profit Community Health System
- 1791 The Impact of a Beta-lactam Allergy Assessment on Aztreonam Utilization within a Healthcare System
- 1792 Assessing Outcomes of Antimicrobial Stewardship Interventions along with a Hospital-Wide Beta-Lactam Allergy Guideline through Aztreonam Use: A 5-Year Observation
- 1793 Description of a Pharmacist-Managed Penicillin Allergy Skin Testing (PAST) Service at a Community Teaching Hospital
- 1794 Impact of a Pharmacist-Driven Detailed Penicillin Allergy Interview
- 1795 Safety Outcomes of the Use of Beta-Lactam Therapy in Patients with Documented Beta-Lactam Allergy
- 1796 Inappropriate Aztreonam Usage Identified as an Opportunity to Reduce Pharmaceutical Expenditures

218. Poster Abstract Session  
**Antimicrobial Stewardship: Impact of New Diagnostics**  
Saturday, 12:30 - 1:45 p.m.

- 1797 Combining Rapid Diagnostics with Pharmacy Resident-Led Antimicrobial Stewardship to Optimize Outcomes for Bacteremia with Methicillin-Resistant *S. aureus* (MRSA-B), Methicillin-Susceptible *S. aureus* (MSSA-B), and Coagulase-Negative *Staphylococcus* (CoNS) at Yale New Haven Hospital (YNHH)
- 1798 Phenotypic and Genotypic Impact of Antibiotic Stewardship Intervention on Daptomycin-nonsusceptible *Enterococcus faecium* (DNSE) Clinical Isolates
- 1799 Impact of Real-Time Electronic Notifications to Pharmacists of Rapid Diagnostic Blood Culture Results
- 1800 Clinical Impact of Real-Time Predictive Model to Facilitate Antibiotic Prescribing in Gram-Negative Bacteremia
- 1801 Impact of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) on Clinical Outcomes in Patients with Gram-Positive Blood Cultures in a Diverse, Multicenter Healthcare System with a Central Laboratory
- 1802 Evaluation of Clinical Pharmacists use of a Blood Culture Follow-up Protocol Utilizing Rapid Molecular Diagnostic Testing
- 1803 Clinical Impact of Rapid Blood Culture Diagnostics Differs by Time of Day and Gram Stain Type: Lessons from Implementation of Verigene® Blood Culture Testing in a Children’s Hospital
- 1804 Impact of Susceptibility Testing Method on Antibiotic Selection for Methicillin-Resistant *Staphylococcus Aureus* (MRSA) Bacteremia
- 1805 Impact of Antimicrobial Stewardship Interventions Using Rapid Molecular Testing on the Appropriate Use of Antiviral Therapy and Reduction of Unnecessary Antibiotic Therapy for Patients Admitted with Acute Influenza
- 1806 Implementation of Rapid Diagnostic Testing without Active Stewardship Team Notification for Gram-Positive Blood Cultures in a Community Teaching Hospital
- 1807 The Impact of Rapid Diagnostic Testing and Antimicrobial Stewardship on the Time to Escalation/De-Escalation of Antimicrobial Regimens for Gram-Negative Bloodstream Infections at a Large Community Hospital
<table>
<thead>
<tr>
<th>Postera</th>
<th>Title</th>
<th>Venue</th>
</tr>
</thead>
<tbody>
<tr>
<td>1808</td>
<td>Matrix-Assisted Laser Desorption/Ionization-Time of Flight (MALDI-TOF) and Vitek 2 along with Antimicrobial Stewardship (ASP) Result in Faster Antimicrobial Therapy for Infected Patients: The CHI Health Experience</td>
<td>220. Poster Abstract Session Antimicrobial Stewardship: Non-hospital Settings Saturday, 12:30 - 1:45 p.m.</td>
</tr>
<tr>
<td>1809</td>
<td>Improved Vancomycin Utilization with Rapidly Available Xpert MRSA/SA BC PCR and Microbiologist Case Review</td>
<td>1826 Interventions to Enhance Clinical Nurse Partnership in Acute Care and Nursing Home (NH) Antibiotic Stewardship Efforts: A Scoping Review</td>
</tr>
<tr>
<td>1810</td>
<td>Therapeutic Drug Monitoring of Azole Antifungals at an Academic Medical Center: Opportunities and Lessons Learned</td>
<td>1827 Clinical Staff Retention and Leadership Stability and Antibiotic Utilization in Nursing Homes</td>
</tr>
<tr>
<td>1812</td>
<td>Impact of Rapid Identification of Blood Cultures with Antimicrobial Stewardship at Three Community Hospitals within a Health System</td>
<td>1829 A Systems Approach to Nursing Home Antimicrobial Stewardship</td>
</tr>
<tr>
<td>219. Poster Abstract Session Antimicrobial Stewardship: New Methods and Metrics Saturday, 12:30 - 1:45 p.m.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1813</td>
<td>Development and Validation of Novel Ambulatory Antibiotic Stewardship Metrics</td>
<td>1830 Avoiding Routine Urinalysis (UA) and Improving Urine Culture (UC) Utilization: An Antibiotic Stewardship Imperative in Geriatric Psychiatry and Emergency Medicine (EM)</td>
</tr>
<tr>
<td>1814</td>
<td>External Validation of Precision Antibiotic Therapy for Enterococcal Bloodstream Infections</td>
<td>1831 Point Prevalence and Epidemiology of Antimicrobial Use in U.S. Nursing Homes, 2017</td>
</tr>
<tr>
<td>1815</td>
<td>Effects of Syndrome-Based Antimicrobial Stewardship Prospective Audit and Feedback Interventions on Antimicrobial Use in an Urban Community Hospital</td>
<td>1832 Concordance in End-of-Life Antimicrobial Prescribing Practices among Medicine Subspecialists</td>
</tr>
<tr>
<td>1816</td>
<td>Large-Scale Comparison of Antibiotic Prescription Guidelines Uncovers Disparities among Stewardship Approaches</td>
<td>1833 Impact of Antibiotic Stewardship on Antimicrobial use for Urinary Tract Infection at a Veteran’s Affairs Long-Term Care Facility</td>
</tr>
<tr>
<td>1817</td>
<td>Benchmarking Outpatient Antimicrobial Use in Manitoba through Population-Based Research</td>
<td>1834 Implementation of the Core Elements of Outpatient Antibiotic Stewardship in Urgent Care Centers and Federally Qualified Health Centers in New York City, 2016–2017</td>
</tr>
<tr>
<td>1818</td>
<td>Characteristics of a Cohort of Patients on Broad-Spectrum Antibiotics Targeted for Prospective Audit and Feedback</td>
<td>1835 Evaluating Regional Nursing Home Antibiograms to Advance Stewardship at 233 Skilled Nursing Facilities in Georgia, USA</td>
</tr>
<tr>
<td>1819</td>
<td>Antibiotic Prescribing Feedback: Description of Denominator Metrics to Standardize Prescribing Rates for Peer Comparison</td>
<td>1836 Characteristics of Nursing Homes Associated with Self-Reported Implementation of Centers for Disease Control and Prevention (CDC) Core Elements of Antibiotic Stewardship</td>
</tr>
<tr>
<td>1820</td>
<td>Indirect Standardization: A Convenient Benchmarking Approach to Antibiotic Utilization Based on Patient Mix</td>
<td>1837 Comparison of Antibiotic Use in Post-Acute and Long-Term Care Facilities Based on Proportion of Short Stay Residents Using a Long-Term Care Pharmacy Database</td>
</tr>
<tr>
<td>1821</td>
<td>Understanding the Components and Calculation of the SAAR, Illustrative Data</td>
<td>1838 Digging Deeper: A Closer Look at Core Elements of Antibiotic Stewardship for Long-Term Care Facilities</td>
</tr>
<tr>
<td>1822</td>
<td>Veterans Are Special: Clinical Decision Tree Misses ESBL Status in Bacteremic Veterans</td>
<td></td>
</tr>
<tr>
<td>1823</td>
<td>Signal or Noise? A Comparison of Methods to Identify Outliers in Antimicrobial Use (AU)</td>
<td></td>
</tr>
<tr>
<td>1824</td>
<td>Care Transformation in Infectious Diseases: Using a Novel Approach for Tracking Antimicrobial Stewardship Metrics</td>
<td></td>
</tr>
<tr>
<td>1825</td>
<td>Electronic Measure of Unnecessary Antimicrobial Use in U.S. Veterans Affairs Medical Centers</td>
<td></td>
</tr>
</tbody>
</table>

221. Poster Abstract Session Antimicrobial Stewardship: Outpatient Settings Saturday, 12:30 - 1:45 p.m. |

<p>| 1839    | Expanding Antimicrobial Stewardship into the Community: Development of Patient and Provider Education Resources to Improve Antibiotic Awareness | 1840 Development of an Innovative Antibiotic Prescribing Dashboard to Enhance Antimicrobial Stewardship in the Ambulatory Care Setting |
| 1841    | Implementation of an Outpatient Antimicrobial Stewardship Program to Reduce Fluoroquinolone Overprescribing at a Veterans Affairs Medical Center (VAMC) | 1842 Fluoroquinolone Usage Reduction in the Outpatient Setting |</p>
<table>
<thead>
<tr>
<th>Poster Abstract Sessions (continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1843 Prescribers' Characteristics and Unnecessary/Inappropriate Antimicrobial Prescription in the Emergency Department: An Observational Study at a Tertiary Care Center</td>
</tr>
<tr>
<td>1844 Improving Management of Community Acquired Pneumonia through Collaborative Integrated Care in an Antimicrobial Stewardship initiative</td>
</tr>
<tr>
<td>1845 Implementing Outpatient Antimicrobial Stewardship in a Primary Care Office through Pharmacist-Led Audit and Feedback</td>
</tr>
<tr>
<td>1846 Outpatient Antibiotic Use in Viral Acute Upper Respiratory Tract Infections at a Military Treatment Facility: A Target for Stewardship Intervention</td>
</tr>
<tr>
<td>1847 Impact of Antimicrobial Stewardship Commitment Posters on Antibiotic Prescribing for Upper Respiratory Tract Infections in a Rural Outpatient Setting</td>
</tr>
<tr>
<td>1848 Evaluation of Antibiotic Prescribing Practices in Outpatient Clinics for the Treatment of Skin &amp; Soft Tissue Infections</td>
</tr>
<tr>
<td>1849 Identification of Antimicrobial Stewardship Targets in the Outpatient Setting</td>
</tr>
<tr>
<td>1850 Impact of Targeted Feedback on Ciprofloxacin Prescribing in Outpatient Clinics Areas</td>
</tr>
<tr>
<td>1851 Impact of an Antimicrobial Stewardship Initiative on Fluoroquinolone Utilization in the Outpatient Setting at an Academic Medical Center</td>
</tr>
<tr>
<td>1852 Rethinking Empirical Treatment for Urinary Tract Infections in the Outpatient Setting</td>
</tr>
<tr>
<td>1853 Impact of Antimicrobial Stewardship Interventions on Antimicrobial Utilization in Asymptomatic Bacteriuria</td>
</tr>
<tr>
<td>1854 Effective Antimicrobial Stewardship for Outpatient Parenteral Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Disease Physician Infusion Centers</td>
</tr>
<tr>
<td>1855 Antimicrobial Stewardship (AMS) In the Outpatient Parenteral Antimicrobial Therapy (OPAT) Setting</td>
</tr>
<tr>
<td>1856 Comparison of Antibiotic Susceptibility in Hospitals versus Hospital-Based Emergency Departments</td>
</tr>
<tr>
<td>1857 Implementing Antimicrobial Stewardship in Urgent Care Centers</td>
</tr>
<tr>
<td>1858 Use and Perceptions of an Institution-Specific Antibiotic Prescribing “App” among Emergency Department and Urgent Care Clinicians</td>
</tr>
<tr>
<td>222. Poster Abstract Session</td>
</tr>
</tbody>
</table>

**Antimicrobial Stewardship: Potpourri**

Saturday, 12:30 - 1:45 p.m.

| 1859 Prevalence of Antimicrobial Use in U.S. Hospital Patients, 2011 vs. 2015 |
| 1860 Small State, Big Collaboration: Creation of First New Hampshire Statewide Antibiogram Guides Stewardship Efforts |
| 1862 The Role of Infection Preventionists in Antimicrobial Stewardship Programs in Acute Care Hospitals |
| 1863 Antibiotic Prescribing Before and After an FDA Boxed Warning on Fluoroquinolones in 2016 |
| 1864 Implementation of the National Healthcare Safety Network’s (NHSN) Antimicrobial Use Option in the U.S. Veterans Affairs (VA) Medical Facilities |
| 1865 Antibiotic Susceptibilities of Organisms Isolated from Urine Cultures of Patients Diagnosed with a Urinary Tract Infection (UTI) and Discharged from the Emergency Department (ED) |
| 1866 Adverse Outcomes Associated with Potentially Inappropriate Antibiotic Use in Heart Failure Admissions |
| 1867 A Regional Collaboration to Share Antimicrobial Stewardship Resources in Three Geographically Related Veterans Affairs Medical Centers |
| 1868 Successful Use of Telemedicine versus On-site Infectious Diseases Consultation After Implementation of a System-wide Antimicrobial Stewardship-Led Staphylococcus aureus Bacteremia Care Bundle |
| 1869 Telepharmacy Support of an Antimicrobial Stewardship Program in a Small Rural Canadian Acute Care Hospital |
| 1870 Excess Antibiotic Duration in Patients Hospitalized for Pneumonia: A Multi-Hospital Cohort Study |
| 1871 Identifying Time Periods of High and Low Vancomycin Use |
| 1872 Antimicrobial Utilization Variability Among Training Services at an Academic Medical Center |
| 1873 Next Steps in Predicting Anti-MRSA Antibiotic Prescribing |
| 1874 Adherence to Practice Guidelines for Treating Diabetic Foot Infections: An Opportunity for Syndromic Stewardship |
| 1875 How Many Different Antimicrobial Regimens Are There and Which are Emerging and Declining? |
| 1876 Patient- and Hospital-Level Factors and Outcomes Associated with Treatment of Asymptomatic Bacteriuria in Hospitalized Patients: A Multi-Hospital Cohort Study |
| 1877 Discrepant Susceptibilities have Minimal Impact on Antibiotic Prescribing for Patients with Two or More Blood Cultures Positive for Coagulase-Negative Staphylococci |
| 1878 Expanding Kentucky’s “One and Done” Tradition: Lipoglycopeptide Administration in the Emergency Department at a Tertiary, Academic Medical Center |
| 1880 Does the Label Matter: Initial Use of Newly Approved Antimicrobial Agents in Community Hospitals without Robust Antimicrobial Stewardship Programs |
| 1881 Empiric Pseudomonal Monotherapy versus Combination Therapy for Community-Onset Pneumonia in Older Adults |
| 1882 Resistance (R) Trends in Gram-Negative Bacilli (GNB) to Fluoroquinolones (FQ), [Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MOX)], Trimethoprimsulfamethoxazole (TMP/SMX), and Nitrofurantoin (NFT) over a 7-year period: Pre- and Post- Implementation of FQ Restriction at a Tertiary Care Veterans Affairs Medical Center (VAMC) |
| 1883 Acute Kidney Injury in Patients with Pneumonia on Concomitant Anti-Methicillin Resistant Staphylococcus aureus and Anti-Pseudomonal Beta-Lactam Therapy |
**Poster Abstract Sessions (continued)**

1884  Assessment of Potential Antimicrobial-Related Harms in Hospitalized Adults with Common Infections
1885  Cost-Effectiveness of Ceftazidine-Avibactam Compared to Colistin for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia and Pneumonia

### 223. Poster Abstract Session

**Antimicrobial Stewardship: Qualitative Research**

Saturday, 12:30 - 1:45 p.m.

1886  Provider’s Close Approximation of Parental Desire for Antibiotics Doesn’t Diminish Concern of Anticipated Conflict
1887  Primary Care Physicians’ Attitudes and Perceptions towards Antibiotic Resistance and Outpatient Antibiotic Stewardship: A Qualitative Study
1888  Clinicians’ Beliefs, Knowledge, Attitudes, and Planned Behaviors on Antibiotic Prescribing in Acute Respiratory Infections
1889  A Clinical Practice Assessment on *Clostridium difficile* Infection
1890  Healthcare Professionals’ Knowledge, Attitudes, and Beliefs Regarding Factors that Contribute to Inappropriate Antibiotic Use
1891  Assessing the Needs for Antimicrobial Stewardship Education and Acceptance Across a Spectrum of Prescribers, Nurses, and Pharmacists at a Large Academic Medical Center
1892  Preparing for an Antibiotic Stewardship Intervention through Nursing Surveys of Knowledge and Safety
1893  Barriers and Facilitators to Nursing (RN) Involvement in Antibiotic Stewardship (AS): Multisite Qualitative Study of Prescribers
1894  Antimicrobial Stewardship in the Intensive Care Unit: Survey of Critical Care and Infectious Diseases Physicians

### 224. Poster Abstract Session

**Antiviral Therapies**

Saturday, 12:30 - 1:45 p.m.

1895  The Anti-Parasitic Drug Atovaquone Inhibits Arbovirus Replication
1896  A Retrospective Cohort Analysis to Determine the Incidence of CMV Viremia and Progression to CMV Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation at an Academic Children’s Hospital
1897  Letermovir Salvage for Complicated Cases of Resistant CMV
1898  Clinical Characteristics of Patients (pts) with Solid Organ Transplantation (SOT) and Norovirus (NV) Infections
1899  The Cellular Kinase Inhibitor OSU-03012 Inhibits Enterovirus 71 In Vitro
1900  Low Prevalence of Protective Antibodies to Measles among Young Adults in Argentina
1901  Safety, Tolerability, and Efficacy of Fluvoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study
1902  A Survey of Pediatric Bone Marrow Transplant Centers Regarding Local Cytomegalovirus Prophylaxis Management Practices and Interest in a Future Randomized Trial

### 225. Poster Abstract Session

**Clinical Practice Issues: HIV, Sepsis, QI, Diagnosis**

Saturday, 12:30 - 1:45 p.m.

1903  Cost Minimization Analysis of a Preferred ARV Prescribing Pathway for Treatment-Naïve HIV-Positive Patients
1904  Impact of Mail Order Pharmacy Use on Viral Suppression Among HIV-Infected Patients
1905  Real-World Insights into Quality Improvement across 11 HIV Clinics in the U.S.
1906  Hospitalization Rates among Persons with HIV Who Gained Medicaid or Private Insurance in 2014
1907  Barriers at the Last Hurdle: Implementing Advance Care Planning for People Living with HIV
1908  Development of an Electronic Health Record Generated Alert for Prophylaxis against *Pneumocystis Jirovecii Pneumonia* in the Setting of High Dose Steroids
1909  Do Infectious Disease Services Save Money? Accounting Analysis Before and After Introduction of a New Clinical Infectious Disease Service at a Tertiary Hospital in New Zealand
1910  Developing a Multi-Disciplinary Team for Infective Endocarditis: A Quality Improvement Project
1911  Implementation of Diabetes Medication Management by Pharmacists in a Multidisciplinary Limb-Salvage Clinic
1912  Implementation of Sepsis-3 Definition in the Emergency Department: Proposed of Case Detection in Real-Life Practice
1913  Clinical Performance of the qSOFA Score Among Non-ICU Infections with Infection at a Tertiary Hospital in Jamaica from 2015 To 2016
1914  Adherence to the Sepsis Bundle in Hospital-Onset v. Community-Onset Sepsis
1915  Predicting Real-Time Risk of Complications in the Postoperative Setting with Temperature as a Single Variable
1916  Diagnostic Stewardship in Infectious Diseases Molecular Viral Testing: A Pilot Project
1917  Diagnostic Errors in Bacterial Osteomyelitis in Children
1918  Is it Time to Assess the Role of Blood Cultures in the Current Practice of Medicine?
1919  Outpatient Care-Seeking Prior to Acute Respiratory Infection Hospitalization in the United States, 2012–2014
1920  Ocular Involvement in Candidemia Patients at an Urban Tertiary Care Center: Is Inpatient Ophthalmologic Consultation Essential?
1921  Attributable Inpatient Costs of Hospital-Onset *Clostridium difficile* Infection: A Nationwide Case-Control Study in Japan
1922  The Challenges of Caring for People Who Inject Drugs: An Opportunity for an Infectious Diseases Service
### Poster Abstract Sessions (continued)

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1923</td>
<td>OPAT or No-PAT? Evaluation of Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Daptomycin or Ertaopenem for “Ease of Administration”</td>
</tr>
<tr>
<td>1924</td>
<td>Most Patients Tolerate Penicillin Administration Despite History of Non-Anaphylactic Penicillin Allergy: A Systematic Review and Meta-analysis</td>
</tr>
<tr>
<td>1925</td>
<td>Vancomycin Treatment and Time to Adverse Drug Reactions during Outpatient Parenteral Antimicrobial Therapy (OPAT)</td>
</tr>
<tr>
<td>1926</td>
<td>Evaluation of Safety and Effectiveness of Continuous Infusion Ceftolozane/Tazobactam as Outpatient Parenteral Antimicrobial Therapy</td>
</tr>
<tr>
<td>1927</td>
<td>Preference for Intravenous versus Oral Antibiotics at Hospital Discharge</td>
</tr>
<tr>
<td>1928</td>
<td>Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who were Treated with Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting</td>
</tr>
<tr>
<td>1929</td>
<td>Risk of Acute Kidney Injury in Combat-Injured Patients Associated with Concomitant Vancomycin and Extended-Spectrum β-Lactam Antibiotic Use</td>
</tr>
</tbody>
</table>

#### 226. Poster Abstract Session

**Clinical Practice Issues: OPAT**

**Saturday, 12:30 - 1:45 p.m.**

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1930</td>
<td>Developing an Electronic Medical Record System to Monitor Patients on Outpatient Parenteral Antibiotic Therapy at an Academic Medical Center</td>
</tr>
<tr>
<td>1931</td>
<td>Health-Related Social Vulnerabilities in a Pediatric Outpatient Antimicrobial Therapy (OPAT) Program</td>
</tr>
<tr>
<td>1932</td>
<td>Healthcare Utilization in Older vs Younger Adults on Outpatient Parenteral Antimicrobial Therapy According to Discharge Location</td>
</tr>
<tr>
<td>1933</td>
<td>Economic Evaluation of Outpatient Parenteral Antimicrobial Therapy in Children</td>
</tr>
<tr>
<td>1934</td>
<td>Who Really Benefits Financially from OPAT: Patients/Families or Healthcare Institutions?</td>
</tr>
<tr>
<td>1935</td>
<td>Outpatient Parenteral Antimicrobial Therapy in Nonagenarians</td>
</tr>
<tr>
<td>1936</td>
<td>Implementation of IV Push Antibiotics for OPAT in a Safety Net Hospital Following a National Fluid Shortage</td>
</tr>
<tr>
<td>1937</td>
<td>A Dedicated OPAT Program Reduces Readmission and Complications Rates</td>
</tr>
<tr>
<td>1938</td>
<td>Sustained Reduction in 30-day Readmission Rates after Implementation of an OPAT Program in an Academic Medical Center</td>
</tr>
<tr>
<td>1939</td>
<td>Socioeconomic Predictors of Hospital Readmission in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients</td>
</tr>
<tr>
<td>1940</td>
<td>Outcomes among Patients Enrolled in an Outpatient Parenteral Antibiotic Therapy Program at an Academic Medical Center</td>
</tr>
<tr>
<td>1941</td>
<td>Comparison of Patient Outcomes in a Pharmacist-Led Outpatient Parenteral Antimicrobial Therapy (OPAT) Program</td>
</tr>
<tr>
<td>1942</td>
<td>Expansion of Outpatient Parenteral Therapy Program with Addition of Advanced Practice Providers Can Lead to Reduced Readmission Rates</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1943</td>
<td>Collateral Benefits of Diabetes Management Associated with Self-Administered Outpatient Parenteral Antimicrobial Therapy</td>
</tr>
<tr>
<td>1944</td>
<td>Patients with Prosthetic Joint Infections Receiving Outpatient Parenteral Antimicrobial Therapy: Characteristics and Readmission Rates</td>
</tr>
<tr>
<td>1945</td>
<td>Making the EMR Work for You—Modifications to Epic to Improve Management of Outpatient Parenteral Antibiotic Therapy (OPAT) Patients</td>
</tr>
<tr>
<td>1946</td>
<td>Heterogeneous Hospitalization Outcomes of People Who Use Drugs: The Type of Drug(s) Used Matters</td>
</tr>
</tbody>
</table>

#### 227. Poster Abstract Session

**Clinical Trials**

**Saturday, 12:30 - 1:45 p.m.**

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1947</td>
<td>Influenza Vaccination via Oral Tablet is Protective and Induces a Unique Mucosal Immune Response</td>
</tr>
<tr>
<td>1948</td>
<td>A Host-Response Assay Distinguishes Between Simple Influenza Patients and Influenza Patients with Bacterial Coinfection</td>
</tr>
<tr>
<td>1949</td>
<td>Safety and Efficacy of Ambulatory Outpatient Treatment of Febrile Neutropenia in Children with Cancer in Mexico: A Multicenter Randomized Controlled Trial</td>
</tr>
<tr>
<td>1950</td>
<td>Prevention of Recurrent <em>Clostridium difficile</em> at Six Months Following Treatment with Microbiota-Based Therapy RBX2660: Durability Results from a Phase 2 Open-Label Study</td>
</tr>
<tr>
<td>1951</td>
<td>Nephrotoxicity Associated with Imipenem/Cilastatin/Relebactam (IMI/REL) versus Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) bacterial infections</td>
</tr>
<tr>
<td>1952</td>
<td>Evaluation of Relapse and Reinfection Using Whole-Genome Sequencing of <em>Clostridium difficile</em> Isolates from Elderly Patients with <em>C. difficile</em> Infection (CDI) in the EXTEND Randomised, Controlled, Comparative Study of Extended-Pulsed Fidaxomicin and Vancomycin for the Treatment of CDI</td>
</tr>
<tr>
<td>1953</td>
<td>Comparative Effectiveness of High- Versus Standard-Dose Influenza Vaccine on Hospitalization for Acute Myocardial Infarction in Nursing-home Residents: A Post-Hoc Analysis from a Large Cluster-Randomized Trial</td>
</tr>
<tr>
<td>1954</td>
<td>A Randomized Study to Evaluate the Shedding and Immunogenicity of H1N1 Strains in Trivalent and Quadrivalent Formulations of FluMist in Children 24 to &lt;48 Months of Age</td>
</tr>
<tr>
<td>1955</td>
<td>A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants ≤3 Months of Age</td>
</tr>
<tr>
<td>1956</td>
<td>Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial</td>
</tr>
<tr>
<td>1957</td>
<td>Pharmacist Prescribing and Care in Patients with Uncomplicated Urinary Tract Infections in the Community: Efficacy and Safety Outcomes of the R_OUTMAP Study</td>
</tr>
<tr>
<td>Year</td>
<td>Title</td>
</tr>
<tr>
<td>------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>1958</td>
<td>Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (UNJ-8678), in RSV-infected Infants with Bronchiolitis, in the Phase 1b Study 53718678RVS1005</td>
</tr>
<tr>
<td>1959</td>
<td>Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-blind Trial): Outcomes in Patients Infected with Ceftriaxone Non-Susceptible, Extended Spectrum Beta-Lactamase and Multidrug-Resistant Pathogens at Baseline</td>
</tr>
<tr>
<td>1960</td>
<td>Antibiotic Challenge Dose Testing Improves Patient Care and Lowers Costs in a Community Hospital: A Two-year Prospective Study</td>
</tr>
<tr>
<td>1961</td>
<td>A Randomized Controlled Trial of the Effect of Accelerated Copper Textiles on Healthcare-Associated Infections and Multidrug-Resistant Organisms: The “Investigating Microbial Pathogen Activity of Copper Textiles” (IMPACT) Study</td>
</tr>
<tr>
<td>1962</td>
<td>TRAIL Level and ImmunoXpert™ Score Complement Molecular Viral Detection in the Classification of Febrile Children: An Interim Analysis from the AutoPilotDX-Study</td>
</tr>
<tr>
<td>1963</td>
<td>Combined Microbiological Response Rates From Two Phase 3 Trials Demonstrating the Activity of Eravacynlce in the Treatment of Complicated Intra-abdominal Infections: A Pooled Analysis of IGNITE1 and IGNITE4</td>
</tr>
<tr>
<td>1964</td>
<td>Microbiological Outcomes with Plazomicin (PLZ) versus Colistin (CST) in Patients (pts) with Bloodstream Infections (BSI) Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) in the CARE Study</td>
</tr>
<tr>
<td>1965</td>
<td>Safety and Efficacy of Glecoprevir/Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials</td>
</tr>
<tr>
<td>1966</td>
<td>Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived from a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent <em>Clostridium difficile</em> Infections (rCDI)</td>
</tr>
<tr>
<td>1967</td>
<td>Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) When Co-Administered with Other Vaccines in Healthy Adolescents</td>
</tr>
<tr>
<td>1968</td>
<td>Procalcitonin-Guided Antibiotic Therapy for Lower Respiratory Tract Infections in a U.S. Academic Medical Center</td>
</tr>
<tr>
<td>1969</td>
<td>Comparison of Adverse Event Rates Between Patients Treated with Ceftaroline or Ceftriaxone</td>
</tr>
<tr>
<td>1970</td>
<td>Phase 1 Clinical Trial of Intrasal Immunization with M2-deficient, Single Replication, Live Influenza Vaccine (M2SR): Safety and Immune Response in Adults</td>
</tr>
<tr>
<td>1971</td>
<td>A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects</td>
</tr>
<tr>
<td>1972</td>
<td>Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared to PCV-13 in Healthy Older Adults Previously Vaccinated with 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)</td>
</tr>
<tr>
<td>1973</td>
<td>A Meta-Analysis of the Effectiveness of LAIV and IV against Influenza A/H3N2 Strains in Children 2–18 Years of Age during the 2016–2017 Season</td>
</tr>
<tr>
<td>1974</td>
<td>Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis</td>
</tr>
<tr>
<td>1975</td>
<td>1g versus 2g Daily Intravenous Ceftriaxone in the Therapy of Community Onset Pneumonia: a Propensity Score Analysis from a Data of Japanese Multicenter Registry</td>
</tr>
<tr>
<td>1976</td>
<td>Pooled Analysis of Safety Data from Phase 2 and 3 Clinical Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections</td>
</tr>
<tr>
<td>1977</td>
<td>Comparative Effectiveness of Linezolid vs. Trimethoprimsulfamethoxazole for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) at a Veterans Affairs Hospital</td>
</tr>
<tr>
<td>1978</td>
<td>Efficacy of Eravacycline in Secondary Bacteremia: A Post Hoc Analysis of Two Phase 3 studies of Complicated Intra-Abdominal Infection</td>
</tr>
<tr>
<td>1979</td>
<td>Time to Viral Suppression does not Impact SVR in Patients Treated with Glecoprevir/Pibrentasvir for 8 Weeks</td>
</tr>
<tr>
<td>1980</td>
<td>Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed <em>Clostridium difficile</em> Infection (CDI)</td>
</tr>
<tr>
<td>1981</td>
<td>Real-World Data on Safety and Effectiveness of Glecoprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results from the German Hepatitis C-Registry</td>
</tr>
<tr>
<td>1982</td>
<td>Multiplex PCR-Based Analysis of Enteric Pathogens in Fecal Samples from Patients with <em>Clostridium difficile</em> Infection in the Randomised, Controlled EXTEND Study Comparing the Efficacy of Extended-Pulsed Fidaxomicin with Vancomycin Therapy</td>
</tr>
<tr>
<td>1983</td>
<td>Oral Therapy with Rifampin Associated with Minocycline or Moxifloxacin in Vertebral Osteomyelitis due to Gram-Positive Micro-organisms: A Retrospective Study of 64 Cases</td>
</tr>
<tr>
<td>1984</td>
<td>Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of Failed Patients with Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis)</td>
</tr>
<tr>
<td>1985</td>
<td>Atypical Symptoms and High Mortality Associated with Serogroup B Meningococcal Disease in Cartagena Colombia 2012-2016</td>
</tr>
</tbody>
</table>

228. Poster Abstract Session

**Diagnostics: Bacteria and Mycobacteria**

Saturday, 12:30 - 1:45 p.m.

- **1987** Validation of a MALDI-TOF MS-Based Direct-On-Target Microdroplet Growth Assay (DOT-MGA) for Rapid Detection of Extended-Spectrum Beta-Lactamase (ESBL) and AmpC in Clinical *Enterobacteriaceae* Isolates
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Development of a Laboratory Stewardship Algorithm for <em>Anaplasma phagocytophilum</em> Polymerase Chain Reaction Testing</td>
</tr>
<tr>
<td>1989</td>
<td>Evaluation of Laser Light Scattering Technology in Rapid Diagnosis of Urinary Tract Infections in Children</td>
</tr>
<tr>
<td>1990</td>
<td>Reactivity and Specificity of a Research Use Only (RUO) Prototype of a Highly Multiplexed Sample-to-Answer PCR System for the Detection of Pathogens from Positive Blood Culture</td>
</tr>
<tr>
<td>1991</td>
<td>A Prospective Pilot Evaluation of a Research Use Only (RUO) Prototype of a Highly Multiplexed Sample-to-Answer PCR System for the Detection of Pathogens from Positive Blood Culture</td>
</tr>
<tr>
<td>1992</td>
<td>Automated Classification of Pulmonary Tuberculosis-Associated Radiograph in the U.S. Hospital-Scale Chest X-Ray Database by using Deep Convolutional Neural Network</td>
</tr>
<tr>
<td>1993</td>
<td>The Contribution of Commensal Bacteria on the Severity of Symptoms During the 2017-2018 Influenza Season</td>
</tr>
<tr>
<td>1994</td>
<td>Development of a Meningococcal Serogroup B Serum Bactericidal Assay Using Fetal Bovine Serum</td>
</tr>
<tr>
<td>1995</td>
<td>Implementation of <em>Helicobacter pylori</em> Stool Antigen Testing in a Large Metropolitan Centre: A Prospective Comparative Diagnostic Trial</td>
</tr>
<tr>
<td>1996</td>
<td>Addressing Pulmonary Nocardiosis Risk in Immunocompromised Patients: Development and Validation of a Commercially Available PCR</td>
</tr>
<tr>
<td>1997</td>
<td>Impact of Blood Culture Fill Volumes</td>
</tr>
<tr>
<td>1998</td>
<td>Urine Culture Incubation time: One vs two days</td>
</tr>
<tr>
<td>1999</td>
<td>Performance of Pneumococcal Urinary Antigen Testing: Riding the Vaccination Waves</td>
</tr>
<tr>
<td>2000</td>
<td>Rapid, Point-of-Care Diagnosis of Tuberculosis with Novel Truenal Assay: Cost-effectiveness and Budgetary Impact Analysis for India's Public Sector</td>
</tr>
<tr>
<td>2001</td>
<td>Susceptibility of <em>Aerococcus urinae</em> to Fluoroquinolones: Broth Microdilution and Gradient Diffusion</td>
</tr>
<tr>
<td>2002</td>
<td>Evaluation of the BioFire® Pneumonia Panel in ICU Patients with Suspected Ventilator-Associated Pneumonia</td>
</tr>
<tr>
<td>2003</td>
<td>Routine Use of Anaerobic Blood Cultures at Thammasat University Hospital, Thailand</td>
</tr>
<tr>
<td>2004</td>
<td>Clinical Application of Xpert SA Nasal Complete for Diagnosing <em>Staphylococcus aureus</em> and Methicillin-Resistant <em>Staphylococcus aureus</em> in Nasal Swabs in Pediatric Care Setting</td>
</tr>
<tr>
<td>2005</td>
<td>T-SPOT®.TB Test for Latent Tuberculosis Infection Diagnosis and Treatment Guidance in Thai Healthcare Professionals</td>
</tr>
<tr>
<td>2006</td>
<td>Implementation of the T2 Biosystems T2Bacteria Panel in a Level-One Trauma Center, Safety Net Hospital</td>
</tr>
<tr>
<td>2007</td>
<td>To Treat or Not To Treat: Does a More Sensitive and Specific Testing Methodology Make the Treatment Decision More Clear?</td>
</tr>
<tr>
<td>2008</td>
<td>Effective &amp; Early Diagnosis of Pneumonia in Patients with Acute Leukemia in a Comprehensive Cancer Center: How Can We Improve the Microbiological Diagnosis?</td>
</tr>
<tr>
<td>2009</td>
<td>Misidentification Rate of <em>Acinetobacter baumannii</em> Isolated from Invasive Infections in Children</td>
</tr>
</tbody>
</table>

**229. Poster Abstract Session**

**Diagnostics: Biomarkers and Novel Approaches**

Saturday, 12:30 - 1:45 p.m.

- 2010 Volatile Organic Compounds Patterns in Breath, Plasma, and Stool in Patients with *Clostridium difficile* Infection: A Cross-Sectional Proof of Concept Study
- 2011 Identification of *Streptococcus agalactiae* on Human Fetal Membrane Tissues using Raman Microscopy
- 2012 FilmArray® Measurement of Host Response Signatures Rapidly Discriminates Viral, Bacterial, and Non-Infectious Etiologies of Illness
- 2013 Procalcitonin Current State Evaluation within a Large Health-System
- 2014 TLDA Validation of a Host Response Signature to Discriminate Bacterial, Viral, and Non-Infectious Causes of Illness
- 2015 Host Gene Expression Identifies Infectious Triggers of Asthma Exacerbation
- 2016 TaqMan Multiplex PCR of a Seven-Gene Host Biomarker to Discriminate Bacterial from Viral Infections
- 2017 Improving Timely Diagnosis of Meningitis and Encephalitis: The Effectiveness of Online CME
- 2018 Host Gene Expression Classifiers Distinguish Bacterial and Viral Infections in Sri Lankan Patients with Acute Febrile Respiratory Illness
- 2019 Host Gene Expression Signatures for Diagnosis of Acute Respiratory Infections in the Elderly
- 2020 Concordance of Direct Versus Indirect Pathogen Detection Using the BioFire® System
- 2021 An Ultra-Rapid Host Response Assay to Discriminate Between Bacterial and Viral Infections Using Quantitative Isothermal Gene Expression Analysis
- 2022 Modeling Improved Patient Management and Hospital Savings with Septicyte LAB in the Diagnosis of Sepsis at ICU Admission
- 2023 A Prospective, Multi-Center U.S. Clinical Trial to Determine Accuracy of FebriDx Point-of-Care Testing for Acute Upper Respiratory Infections With and Without a Confirmed Fever
- 2024 Modeled Impact of Rapid Diagnostics on the Treatment of Gram-Negative Bacteremia at a Tertiary-Care VA Medical Center
- 2025 Procalcitonin Reference Cutoff and Specimen Type Validation
- 2026 Phenotypic and Molecular Characterization of Drug Resistance and Biofilm Production in *Stenotrophomonas maltophilia* obtained in a ten-year period from a Mexican Hospital
- 2027 Immune Correlates of Protection against Herpes Zoster (HZ) in People Living with HIV (PLWH)
- 2028 ID Consultant EMR Hyperlinked Recommendation as a Tool to Curb “Routine”Following of Inflammatory Markers
- 2029 Comparison of Primers Amplifying Two Different Regions of the 16S Ribosomal RNA Gene for Microbiologic Diagnosis of Cardiovascular Implantable Electronic Device Infection
230. Poster Abstract Session

**Diagnostics: Mycology**

Saturday, 12:30 - 1:45 p.m.

- **2030** How Machine-Learning Technique Using Artificial Neural Network Determines Whether the Fever is Actually Related to the Bacteremia
- **2031** False Positive Serologic Results Attributable to IVIG Therapy

**2032** Predictors of 6-week Mortality in Patients with Positive Bronchoalveolar Lavage (BAL) Galactomannan (GM)

**2033** Incorporating T2Candida Testing into Rational Antifungal (AF) Management: A Successful Pilot Study of Diagnostic Stewardship (DS) Directed Toward Specific Intensive Care Unit (ICU) Patients (pts) At-Risk for Sepsis due to Invasive Candidiasis (IC)

**2034** Natural Antibodies Affects the Formation of Titan Cells in Cryptococcus neoformans in vitro

**2035** Detection of Blastomyces dermatitidis Antigen in Urine Using a Novel Quantitative Enzyme-Linked Immunosorbent Assay

**2036** Plasma (1→3)-β-D-Glucan Levels correlate with Neurocognitive Functioning in HIV infected Adults

**2037** Utilization of the T2 Magnetic Resonance in the Early Detection of Invasive Candidiasis

**2038** Invasive Mucormycosis Management: Mucorales PCR Provides Important, Novel Diagnostic Information

**2039** New York State 2016-2018: Progression from Candida auris Colonization to Bloodstream Infection

**2040** Clinical Application of Aspergillus Lateral Flow Device (AspLFD) in Bronchoalveolar Lavage (BAL) Fluid of Patients (pt) with Classic Risk Factors for Invasive Pulmonary Aspergillosis (IPA)

**2041** Impact of T2 Candida Panel on Species Specific Anti-Fungal De-Escalation

**2042** Clinical Application of AspLD PCR Alone and in Combination with Aspergillus Lateral Flow Device (AspLFD) in Bronchoalveolar Lavage (BAL) Fluid of Patients (pt) with Classic Risk Factors for Invasive Pulmonary Aspergillosis (IPA)

**2043** T2-Candida (T2MR) versus Beta-D-Glucan (BDG) for Preemptive Antifungal Stewardship in the Intensive Care Unit (ICU)

**2044** Utility of Serum Beta-D Glucan Assay for Diagnosis of Invasive Fungal Infections in Solid Organ Transplant Recipients

**2045** Pitfalls in the Use of MALDI TOF Mass Spectrometry for the Identification of Problematic Yeast Isolates from a Historical Collection.

**2046** FungiScope™—News on the Global Emerging Fungal Infection Registry

**2047** Study of Molecular Epidemiology, Risk Factor Analysis, and Comparison of Diagnostic Methods for Rapid Diagnosis of Fungal Pneumonia in Critically III Cirrhotics

**2048** Comparison Between Endpoint and Real-Time (RT) Polymerase Chain Reaction (PCR) for the Diagnosis of Pneumocystis Pneumonia (PCP)

**2049** Pneumocystis jiroveci Detection by Nested PCR in HIV-Infected Peruvian Patients

**2050** Plasma Next-Generation Sequencing for Pathogen Detection in Pediatric Patients at Risk for Invasive Fungal Infection

**2051** Detection of Candida auris among Previously Unidentified Yeasts Isolated from Ear Discharge Specimens in Japan

**2052** Performance of the BioFire FilmMarray Meningitis/Encephalitis Panel in Cryptococcal Meningitis Diagnosis

**2053** Tissue-Based Molecular Diagnostics: A Sensitive and Specific Way for the Identification of Invasive Fungal Infections in the Combat-Related Setting

**2054** Physician Responses to Positive Rapid Diagnostic Tests for Candida Fungemia in the Absence of Concomitant Positive Blood Cultures

**2055** Utility of Aspergillus Galactomannan Assay in Allogeneic Stem Cell Transplant Recipients

231. Poster Abstract Session

**Diagnostics: Parasitology**

Saturday, 12:30 - 1:45 p.m.

- **2056** Trypanosoma cruzi DNA Detection by PCR in Dried Blood Spots Preserved in Filter Paper

- **2057** Predictors for Gastrointestinal Protozoa Detection in U.S. Children Presenting with Acute Diarrhea

232. Poster Abstract Session

**Diagnostics: Resistance Testing**

Saturday, 12:30 - 1:45 p.m.

- **2058** Comparison of Drug Resistance Rates of Mycobacterium tuberculosis by the Conventional Drug Susceptibility Test and Sequencing Method

- **2059** Comparative Evaluation of Ceftaroline Susceptibility Methods in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus (MRSA): Results from a Multicenter Study

- **2060** Comparison of Plazomicin MIC Test Strip and Broth Microdilution MIC Results for 125 Enterobacteriaceae

- **2061** Impact of a Penicillin-Binding Protein 2a Rapid Diagnostic Test on Patients Who Present with Staphylococcus aureus Orthopedic Hardware Infections

- **2062** Evaluation of Susceptibility Testing Methods for Fosfomycin against Enterobacteriaceae and Pseudomonas aeruginosa

- **2063** Extracellular Release of β-lactamase is Responsible for the Cefazolin Inoculum Effect (CzIE) in Methicillin-Susceptible Staphylococcus aureus

- **2064** Rapid Detection of Carbapenemase-Producing Klebsiella Pneumoniae (CPK) Directly from Respiratory Secretion and Clinical Characteristics of Patients with CPK from a 1200-Bed Tertiary Care Hospital in Thailand

- **2065** Whole Genome Sequencing for Antimicrobial Resistance Prediction in MRSA and VRE: A Real World Application

2067. Novel Methodology for Same-Day Antimicrobial Susceptibility Testing on VITEK®2 for Gram-Negative Rod Bacteremia

2068. Evaluation of Ceftazidime-Avibactam Disks from Different Commercial Manufacturers for Susceptibility Testing against Meropenem Non-Susceptible Enterobacteriaceae

2069. Automation Process Improving Microbiological Laboratory Efficiency

2070. Antibiotic Therapy Effects on Enterobacteriaceae Detection Directly from Blood: Pilot Study Implications for Future Clinical Trial Setting

2071. Evaluation of BD Phoenix™ CPO Detect Assay for Detection of Carbapenemase Producing Organisms in Clinical Samples in Singapore

2072. Multicenter Evaluation of the Etest Versus Agar Dilution for Susceptibility Testing of Helicobacter pylori

2073. Positive Clinical Impact of MALDI-TOF for the Management of Inpatient Pneumonia Without Additional Antimicrobial Stewardship (AS) Support

2074. Performance and Impact Evaluation of Direct Rapid Antibiotic Susceptibility Testing on Antibiotic Treatment Accuracy in Clinical Trial Setting

2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program & Rapid Genotypic Organism/Resistance Marker Identification


234. Poster Abstract Session

Healthcare Epidemiology: Device-associated HAIs
Saturday, 12:30 - 1:45 p.m.

2082. Using a Commercially Available Assay Measuring Cytomegalovirus (CMV)-Specific CD4+ and CD8+ T-Cell Immunity by Intracellular Cytokine Staining to Predict Clinically Significant CMV Events

2083. Rapid Diagnosis and Differentiation of Dengue During Peri-Monsoon Season in Tropical Resource Limited Facilities

2084. Prospective, Multi-Center Analysis of a BioFire® FilmArray® Childhood Systemic Infection (CSI) Panel for Detection of Viral Bloodstream Infections in a Pediatric Emergency Department Setting

2085. Evaluation of Panther Fusion Flu A/B/RSV, AdV/hMPV/ RV and Parafiu Assays for the Detection of Respiratory Viruses in Children

2086. Perils of CMV PCR Primer/Probe Design: Emergence of Mutations in Clinical Samples from Two Pediatric Patients

2087. Comparison of Alere™ i Influenza Flu A & B 2 and Cobas® Influenza A/B Nucleic Acid Amplification Tests for Detection of Influenza A/B in Nasopharyngeal Swabs Collected from Children

234. Poster Abstract Session

Diagnostics: Virology
Saturday, 12:30 - 1:45 p.m.

2078. Adherence to Laboratory Screening Recommendations for Neonatal Herpes Simplex Virus Infection at a Tertiary Children’s Hospital

2079. The Relation Between Panel Reactive Antibody Assay and Cytomegalovirus Reactivation in Seropositive Solid Organ Transplantation Recipients

2080. Impact of the Implementation of a Rapid Meningitis/Encephalitis Multiplex Polymerase Chain Reaction Panel on Clinical Outcomes: Multicenter, Retrospective Cohort of Adult and Pediatric Patients

2081. Building a Decision Tree with Serial Serology Measurements Improves Classification in a Flavivirus Co-Circulation Region

2082. Using a Commercially Available Assay Measuring Cytomegalovirus (CMV)-Specific CD4+ and CD8+ T-Cell Immunity by Intracellular Cytokine Staining to Predict Clinically Significant CMV Events

2083. Rapid Diagnosis and Differentiation of Dengue During Peri-Monsoon Season in Tropical Resource Limited Facilities

2084. Prospective, Multi-Center Analysis of a BioFire® FilmArray® Childhood Systemic Infection (CSI) Panel for Detection of Viral Bloodstream Infections in a Pediatric Emergency Department Setting

2085. Evaluation of Panther Fusion Flu A/B/RSV, AdV/hMPV/ RV and Parafiu Assays for the Detection of Respiratory Viruses in Children

2086. Perils of CMV PCR Primer/Probe Design: Emergence of Mutations in Clinical Samples from Two Pediatric Patients

2087. Comparison of Alere™ i Influenza Flu A & B 2 and Cobas® Influenza A/B Nucleic Acid Amplification Tests for Detection of Influenza A/B in Nasopharyngeal Swabs Collected from Children
Poster Abstract Sessions (continued)

2100 Nitroglycerin-Citrate-Ethanol Catheter Lock Solution is Highly Effective in Eradicating Candida auris Biofilms

2101 Catheter-Related Infections Complicating Central Venous Catheter Access Device Insertion; A Retrospective Audit and Comparison of Two Cohorts

2102 Peripherally Inserted Central Catheter (PICC) placement: Indications and Financial Impact

2103 Clinical Profile of Patients with Burkholderia cepacia complex Bacteremia and Contaminated Ultrasound Gel as Possible Source of Infection

2104 Impact of a Supervision and Education Directed Bundle in Ventilator Associated Pneumonia (VAP) on a Pediatric Critical Care Unit of a Teaching Hospital

2105 Electronic Records of Daily Subglottic Suctioning Predict Infectious and Non-Infectious Adverse Ventilator-Associated Events During Critical Care

2106 What Metrics Should We Use to Evaluate CAUTI Performance for Inpatient Rehabilitation Units? An Evaluation of a Large, National Healthcare System

2107 Decision Trees vs. Neural Networks for Supervised Machine Learning-Based Prediction of Healthcare-Associated Urinary Tract Infections

2108 Perfluorocarbon Omniphobic Treatment Prevents Bacterial Colonization of Urinary Catheter in A Rat Model

2109 Reducing Catheter Associated Urinary Infections (CAUTI) in the Intensive Care Unit (ICU): Changing the Culture of Culturing

2110 Taurolidine-Citrate Lock Solution for the Prevention of Central-Line Associated Bloodstream Infection (CLABSI) in Pediatric Hematology-Oncology and Gastrointestinal Failure Patients with High Baseline CLABSI Rates

2111 Changing the Culture: A Quasi-Experimental Study Assessing the Burden of Urine Cultures and the Impact of Stewardship of Testing in an Urban Community Hospital

2112 Assessing the Accuracy of Catheter-Associated Urinary Tract Infections (CAUTI) Identification Using Urinalysis Results

2113 Process Change Implementation to Decrease Catheter-Associated Urinary Tract Infections

2114 How to Predict Multidrug-Resistance in Community-acquired Urinary Tract Infection? Performance of an Easy and Simple New Scoring Model

2115 A Successful Bundled Approach to Decrease Catheter-Associated Urinary Tract Infections in a Community Hospital

2116 Impact of an Evidence-Based Intervention on Urinary Catheter Utilization in Switzerland

2117 Catheter-Related Bacteremia in Hemodialysis Patients on Antibiotic Lock Therapy: Are Antibiotic Locks Ineffective?

2118 Healthcare-Associated Infection in Intensive Care Patients Infected and Non-Infected by Human Immunodeficiency Virus

2119 Reducing Catheter-Associated Urinary Tract Infections using an Evidence-Based Urine Culture Algorithm at an Academic Medical Center

2120 The Culture of Culturing Catheterized Patients: A Multi-Hospital Survey of Nurses and Physicians

235. Poster Abstract Session

Healthcare Epidemiology: Surgical Site Infections

2121 Shifting Surgical Site Infection Denominators and Implication on NHSN Reporting

2122 Can Chlorhexidine Reduce Bacterial Colonization in Surgical Drains and Surgical Site Infections after Breast Cancer Surgery? A Randomized Controlled Trial

2123 High Utilization of Post-Discharge Antibiotics after Mastectomy in a Nationwide Cohort of Commercially Insured Women

2124 A Bundled Intervention was Associated with Decreased Risk of Complex Staphylococcus aureus Surgical Site Infections among Patients Undergoing Clean Operative Procedures

2125 Cardiovascular Daytime Varying Effect on Surgical Site Infections and 1-year Mortality in Cardiac Surgery

2126 Comparative Effectiveness of Infection Prevention Interventions for Reducing Procedure-Related Cardiac Device Infections: Insights from the VA CART program

2127 The Role of Prophylactic Antibiotics for Reducing Infections Following Knee Arthroscopy

2128 Predictors of Post-Discharge Prophylactic Antibiotics Following Spinal Fusion

2129 Utilization of Post-Discharge Antibiotics in Spinal Fusion in a Nationwide Cohort of Commercially Insured Individuals

2130 Impact of Sarcopenic Obesity on Surgical Site Infection after Gastric Cancer Surgery: a Retrospective Study of 1038 Patients

2131 A Pre-operative Nursing Implemented Methicillin Resistant Staphylococcus aureus Decolonization Protocol to Decrease Surgical Site Infections

2132 Infections after Pediatric Ambulatory Surgery: Incidence and Risk Factors

2133 Cutibacterium acnes Surgical Site Infections – Case Series from a University-Affiliated Hospital Network

2134 Risk of Surgical Site Infection Following Carpal Tunnel Release in the Operating Room Versus Clinic-based Procedure Room within a Veterans Affairs Medical Center

2135 Costs versus Earnings in Colon Surgery and Coronary Artery Bypass Grafting Under a Prospective Payment System: Sufficient Financial Incentives to Reduce Surgical Site Infections?

2136 Systematic Review of Surgical Wound Class Reveals Marked Service-Related Discrepancies and Can Improve Appropriateness of Classification Impacting the Expected Number of Infections and the Standardized Infection Ratio (SIR)

2137 Risk Factors for Surgical Site Infection After Joint Replacement Surgery: Data from the Swiss National Surveillance System

2138 Impact of De-escalation of Antibiotic Prophylaxis in Lung Transplant Recipients

2139 Improving Peri-Operative Skin Prep Technique at a Large Tertiary Medical Center—a Quality Improvement and Educational Initiative
2140 Healthcare Associated Infection Outbreak Investigation of an Elevation of Surgical Site Infections at a Critical Access Hospital
2141 Characteristics and Prognosis of Patients With a Prosthetic Vascular Graft Infection (PVGI): A Prospective Cohort of 200 Patients
2142 Understanding Errors in Sterile Processing of Surgical Instruments that Lead to Need for Immediate Use Sterilization in the Operating Room
2143 Incidence of Infection in Patients Receiving Short versus Long Duration of Antimicrobial Prophylaxis in Neurosurgery
2144 Vital Signs are Vital in Identifying High-Risk Postoperative Patients
2145 Etiology, Incidence, and Risk Factors for Meningitis after Craniotomy
2146 Efficacy and Patterns of Antimicrobial Prophylaxis for Gunshot Wound Infection in a South African Hospital Setting: A Prospective Study Using Propensity Score-Based Analyses

236. Poster Abstract Session
Healthcare Epidemiology: Epidemiologic Methods
Saturday, 12:30 - 1:45 p.m.

2147 Sample Size Estimates for Cluster Randomized Trials in Infection Control and Antimicrobial Stewardship
2148 100 Years of Sepsis: Using Topic Modeling to Understand Historical Themes Surrounding Sepsis
2149 Real-Time Nationwide Surveillance for Antimicrobial Resistance of Major Pathogens using Automated Data Collection System in Korea: A KARS-Net Study
2150 Discontinuation of Vancomycin-resistant Enterococci (VRE) Surveillance and Contact Isolation in ICU and Transplant Units
2151 Accuracy of Physician Adjudication of Infection in Patients with Systemic Inflammatory Response Syndrome (SIRS)
2152 Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections
2153 Impact of Norovirus Testing Changes on Hospital-Acquired Norovirus Infections
2154 How Well are We Estimating the True Burden of Acute Gastroenteritis? Validation of Acute Gastroenteritis-Related ICD Codes in Pediatric and Adult U.S. Populations
2155 Elevated Temperature Results in Earlier Diagnosis of Infectious and Inflammatory Postoperative Complications
2156 Cyclical Continuum Modeling: A Process-Based Approach to Identifying and Quantifying Health Disparities in Patients with Serious Musculoskeletal Infections
2157 Design, Implementation, and Analysis Considerations for Cluster Randomized Trials in Infection Control and Hospital Epidemiology: A Systematic Review

237. Poster Abstract Session
Healthcare Epidemiology: HAI Surveillance
Saturday, 12:30 - 1:45 p.m.

2158 Introducing the Population Standardized Infection Ratio (SIR): A Metric that Marries the Device SIR to the Standardized Utilization Ratio (SUR)
2159 Methodological Threats to the Standardized Infection and Standardized Antimicrobial Administration Ratios
2160 Benchmarking Healthcare-Associated Infections for Prevention in Developing Countries
2161 Pilot Implementation of a Nationwide Automated Multidrug-Resistant Organism Tracking and Alert System in Veterans Affairs
2162 Factors Affecting the Geographic Variability of Antibiotic-Resistant Healthcare-Associated Infections in the United States using the CDC’s Antibiotic Resistance Patient Safety Atlas
2164 A Feasibility Study to Investigate the Spread of Antimicrobial Resistance in the Community Suggests Ongoing Dissemination within Households
2165 Risk Factors for CPE Colonization in Household Contacts of CPE Colonized/Infected Patients
2167 Predicting Carbapenem-Resistant Enterobacteriaceae (CRE) Carriage on Admission using Updated Statewide Hospital Discharge Data
2168 Regional Variation in Community-Onset and Hospital-Identified Clostridium difficile Infection, 2017
2169 Map the Gap: A Novel Approach Using Big Data to Determine the State of the Infectious Diseases Workforce and Fecal Transplant Centers with Regards to Clostridium difficile Infection
2170 The National Burden of Pneumonia and Influenza in U.S. Nursing Homes, 2013-2015
2171 Comparing Surveillance Definitions for Non-Catheter Associated Urinary Tract Infections
2172 Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
2173 Surgical Site Infection Determination in Epic® ICON: A Utilization Model
2174 A 10-Year Review of Infection Burden In Hospitalized Burn Patients in the United States
2175 In vitro Potency of Ceftolozane/Tazobactam and Other Antipseudomonal β-lactams Against P. aeruginosa
2176 Single β-lactams v. Combination Regimens: Assessing the Probability that an Active Agent Would be Selected When Considering Empiric Therapy for P. aeruginosa
2177 Use of an Analytic Application for Management of Infection Prevention Data
2178 Detection of Key Potential Healthcare Pathogens Using Periodic Point Prevalence Surveillance
Poster Abstract Sessions (continued)

2179 Variability in the Application of Surveillance Definitions for Central Line-Associated Bloodstream Infection Across U.S. Hospitals
2180 Incidence and Outcomes of Ventilator Associated Events, Utilising Centre for Disease Control Criteria in a Tertiary Intensive Care Unit, Victoria, Australia
2181 Efficacy of UV-C Disinfection with or without Sodium Hypochlorite Compared to Usual Disinfection of Hospital Environmental Surfaces: Pilot study
2182 Perceived Impact of Mandatory Reporting of Healthcare-Associated Infections on Infection Prevention and Control Departments in Acute Care Hospitals
2183 Financial Cost, Length of Stay, and Patient Experience Associated with Healthcare-Associated Infections Across a 43-Hospital Network
2184 Surveillance System of Healthcare-Associated Infection in High and Upper-Middle Income Countries: A Scoping Review
2185 Trend of Multidrug-Resistant Pathogens in a Burn Center during a 6-year Period: A Single Burn Center Study in South Korea
2186 High Adherence to Contact Precautions of Patients with Multidrug-Resistant Organisms (MDRO) and Low In-Hospital Transmission of MDROs
2187 Epidemiology and Risk Factors for Vascular Access-Associated Infections in Patients on Hemodialysis
2188 Effectiveness of a Risk-Stratified Measles Post-Exposure Prophylaxis Strategy to Prevent Nosocomial Transmission

238. Poster Abstract Session
Hepatitis A, B, and C
Saturday, 12:30 - 1:45 p.m.

2189 Hepatitis A Outbreak in San Diego County, 2016-2017: A Morphologic and Epidemiologic Review
2190 Assessing Case Definition During a Hepatitis A Outbreak, San Diego County, 2017–2018
2191 Hepatitis A Outbreak in Southeast Michigan: No Longer a Third-World Disease
2193 Disparities in Hepatitis A Virus (HAV) Vaccination Coverage Among Adult Travelers to High-Risk Countries: The Role of Nativity and Race
2194 Hepatitis B Care Cascade within the VA Maryland Healthcare System
2195 Effectiveness of a Dual-Test Strategy and Software Modifications for Mitigating & Preventing Hepatitis B Virus (HBV) Exposures in a Dialysis Unit
2196 Effect of Depression, Anxiety, Stigma, and Disclosure on Quality of Life among People Living with Hepatitis B Infection in Dalian, China
2197 Hepatitis B Reactivation in Patients with Malignancies Undergoing Treatment for Hepatitis C Infection with Direct-Acting Antivirals
2198 Increased Global Incidence and Altered Demographic Profile of Hepatitis Delta Virus (HDV)

2199 Antiviral Therapy Use in Hepatitis B-Infected Pregnant Women
2201 Prevalence of Hepatitis C in Adults Presenting to Emergency Departments in a Large Hospital System in Texas
2202 The Hepatitis C Virus Cascade of Care at Stony Brook University Hospital: Risk Factors for Linkage to Care
2203 Risk Factors for Hepatitis C in Western Africa: An Observational Study in a STI Clinic
2204 In HCV-Infected Patients, Internalized Stigma, but not Experienced Stigma, is Correlated with Psychological State and Health-Related Quality of Life: Baseline Data from the PROP UP Study
2205 Mandatory Infectious Diseases or Hepatology Consult to Improve HCV Linkage to Care in the Inpatient Setting
2206 In a Non-Urban Hepatitis C Cohort, Linkage to an Infectious Diseases Clinic with Embedded Services is Associated with Better Outcomes than Linkage to a Gastroenterology HCV Clinic Without These Services for Those with Substance Abuse
2207 Barriers to HCV Treatment in a Safety-Net Hospital System
2208 Fibrosis Surveillance by Transient Elastography in Patients with Untreated Hepatitis C Infection
2209 Discordance Between FibroSure and FibroScan Results in Hepatitis C and Human Immunodeficiency Virus Co-Infected Patients Prior to Treatment for Hepatitis C Virus Infection
2210 An Online Survey of Hepatitis C Testing Attitudes and Practice Habits Among Residents at an Urban Medical Center
2211 Hepatitis C Testing and Linkage to Care in a Public Health Setting in North Carolina: Addressing Gaps along the Care Continuum
2212 Preliminary Screening Results Outside the 1945-1965 Birth Cohort: A Forgotten Population for HCV?
2213 Hepatitis C Virus (HCV) Care Continuum Post-Implementation of Electronic Clinical Decision Support (eCDS) Tool to Increase HCV Screening among Baby Boomers in Large Urban Health System
2214 Chronic Hepatitis C: Closing the Gap Towards Eradication: Screening Young Adults vs. Baby Boomers
2215 Polymerase Chain Reaction (PCR) for Detection of Vertically-Acquired Hepatitis C Virus (HCV) Infection in Early Infancy
2216 Hepatitis C Treatment Wanted Yet Not Received: Barriers to Receiving HCV Treatment among People Who Inject Drugs
2217 Demographic Trends and Healthcare Utilization Among Children with Hepatitis C Virus Infection
2218 Low Hepatitis C Treatment Rates among Patients Screened as Inpatients at a Rural Academic Medical Center
2219 Treatment Uptake for Hepatitis C Virus Infection in the Veterans Affairs Healthcare System in the Era of Directly Acting Antiviral Agents: An ERCHIVES Study
220. Poster Abstract Session
HIV and Viral Hepatitis Co-Infection
Saturday, 12:30 - 1:45 p.m.

2220 Wirelessly Observed Therapy with a Digital Medicines Program to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment

2221 Active Substance Use Should Not Be a Contraindication for Hepatitis C Treatment in Hepatitis C and Human Immunodeficiency Virus Co-Infected Patients

2222 Impact of Sustained Virologic Response Achieved Through Newer Direct Acting Antivirals in Hepatitis C Infection on Diabetes Mellitus

2223 Effect of Direct-Acting Antivirals in Hemodialysis Patients with HCV: Real-Life Data

2224 Receipt and Virologic Outcomes of HCV Direct-Acting Antivirals by Alcohol Use and HIV Status

2225 Acute Hepatitis C Virus Infections in HIV-Infected Persons in the Era of Direct-Acting Antiviral Therapy

2226 Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A Prospective Case-Series

2227 Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients

2228 Late Viral Relapse after Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients

2229 Low Hepatitis C Virus Reinfection Rates after Sustained Viral Response in HIV Co-Infected Patients in Houston, TX

2230 Treatment Outcomes for Hepatitis C Patients from Two Federally Qualified Community Health Centers in SC

239. Poster Abstract Session
HIV and Viral Hepatitis Co-Infection
Saturday, 12:30 - 1:45 p.m.

2231 Long-Term Immunogenicity of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-Infected Adults: An Extension of a Randomized Controlled Trial

2232 Zinc Deficiency and Advanced Liver Fibrosis among HIV/HCV Co-Infected Persons in Russia

2233 Hepatitis C Eradication: Who is Being Left Behind in the HIV Population?

2234 Implementing a Co-Located HCV Clinic within an HIV Clinic: Four-Year Experience

2235 A Collaborative Drug Therapy Management Model for the Treatment of Hepatitis C Virus (HCV) in an Urban Clinic

2236 Direct-Acting Antivirals: Efficacy in a Real-World, Urban, Underserved, HIV-HCV Co-Infected Population

2237 Validity of Self-Reported HCV Status among Justice-Involved Persons Living with HIV

2238 Immunogenicity and Safety of 4- vs. 3-Standard Doses HBV Vaccination in HIV-Infected Adults with Isolated Anti-HBc Antibody

240. Poster Abstract Session
HIV: Malignancy
Saturday, 12:30 - 1:45 p.m.

2239 Colorectal Cancer Screening Rates and Outcomes in HIV-Infected and HIV-Uninfected Individuals

2240 Characteristics of Lung Cancer Treatment in Recent ART-era HIV+ Patients

2241 Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer

2242 Clinical Characteristics and Treatment Patterns of Prostate Cancer in HIV-Infected Veterans: A 10-Year Experience

2243 Improving HIV outcomes among HIV-infected patients diagnosed with cancer and followed in an integrated, multidisciplinary, infectious disease / cancer clinic

2244 Non-AIDS cancers contribute to an increasing proportion of deaths in persons living with HIV at a single university-based clinic

2245 Primary Central Nervous System Lymphoma in Patients with HIV and Non-HIV: Should We Treat Them Differently?

2246 Assessment of Factors Impacting Cervical Cancer Screening Rates among Urban Women Living with HIV/AIDS

241. Poster Abstract Session
HIV: Metabolic, Cardiovascular, and Renal Complications
Saturday, 12:30 - 1:45 p.m.

2247 Antiretrovirals Perturb Cholesterol Biosynthesis in PBMCs of HIV-Infected Individuals

2248 Changes in Lipid Profiles for Patients to Tenofovir Alafenamide (TAF)-Containing Regimens: Perspectives from a Military HIV-Positive Cohort

2249 Insulin Resistance is Associated with Higher Viral Loads among HIV-1-Infected Patients Initiated on 12 Months of First-Line Antiretroviral Therapy

2250 Metformin for Preventing Diabetes Mellitus in HIV-infected Patients with Prediabetes: A Randomized Controlled Trial

2251 Comparing Statin Prescribing Rates in Eligible HIV vs. Non-HIV Infected Patients

2252 Predictors of Cardiovascular Outcomes in Older HIV-Infected Patients: CORE50 Cohort 10 Year Follow Up

2253 Comparison of Cardiovascular Risk in Patients Infected with HIV and Hepatitis C

2254 Adherence to Cardiovascular Disease Risk Management Guidelines Among HIV Providers at an Academic HIV Clinic

2255 Fibroblast Growth Factor 23, a Potential Risk Factor for Cardiovascular Diseases is Associated with Abacavir/Lamivudine Use in HIV Patients

2256 Racial Differences in Dyslipidemia Clinical Characteristics and Treatment Among Urban HIV Patients

2257 Non-Infectious Comorbidities Associated with High RDW in HIV-Infected Patients: A Cross-Sectional Study in Miami, FL
2258 Clinical Predictors of Acute Kidney Injury in HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate (TDF)
2259 Effect of Discontinuation of Tenofovir Disoproxil Fumarate (TDF) on Renal Function in Elderly Veterans
2260 HIV Transplantation Awareness and Attitudes Following Implementation of the HOPE Act
2261 Phosphaturia in HIV-exposed Uninfected Neonates Associated with Maternal Use of Tenofovir Disoproxil Fumarate in Late Pregnancy

242. Poster Abstract Session
**HIV: Opportunistic Infections and other Infectious Complications**
Saturday, 12:30 - 1:45 p.m.

2262 Not a Disease of the Past: A Case Series of Progressive Multifocal Leuкоencephalopathy in the Established Antiretroviral Era
2263 HIV-TB Co-infection in Arizona from 1993 - 2016
2264 The Burden of Respiratory Viral Illness in HIV-Infected Patients
2265 The Changing Landscape of AIDS Defining CNS Infections in S. Alberta, Canada, Over 30 Years
2266 Persistent Inflammation in HIV patients with Community-Acquired Pneumonia and its Correlation with Lung Injury
2267 The Effect of Opportunistic Infection (OI) Prophylaxis on the Gastrointestinal Microbiome (GIM) and Immune Reconstitution (IR) in Veterans with HIV and AIDS
2268 Clinical Difference of *Mycobacterium haemophilum* Infections between HIV and Non-HIV Infected Patients

243. Poster Abstract Session
**HIV: Sexually Transmitted Infections**
Saturday, 12:30 - 1:45 p.m.

2269 HIV-Positive Individuals Who Report Being In Care Are Less Likely to be Co-Infected with an STI; An Analysis of “Network Testing”, A Service Program Offering HIV and STI Testing Services to Individuals at Risk for HIV
2270 Frequency of Syphilis Annual Screening Testing, Prevalence of Infection and Re-infection, and Associated Characteristics among People Receiving Care for HIV in an HIV/AIDS Care Clinic in Mexico City (2001-2017)
2271 Adherence to Pre-Exposure Prophylaxis Is Associated with Sexually Transmitted Infections among Men Who Have Sex with Men in the Deep South
2272 High Interest in Doxycycline for Sexually Transmitted Infection Post-Exposure Prophylaxis (doxy-PEP) in a Multi-City Survey of Men Having Sex with Men (MSM) Using a Social-Networking App
2273 Neurosyphilis in Patients with HIV Infection: Clinical Presentation of 94 Cases
2274 Assessment of Anal Papanicolaou Smear Screening and Follow-up Rates in Eastern North Carolina for HIV-Positive Patients who are Men who have Sex with Men

244. Poster Abstract Session
**Miscellaneous Vaccines**
Saturday, 12:30 - 1:45 p.m.

2275 Parental Risk Factors for Fever in their Children 7–10 Days after the First Dose of Measles-containing Vaccines
2276 Immunogenicity of Takeda’s Bivalent Virus-like particle (VLP) Norovirus Vaccine (NoV) candidate in Children from 6 months up to 4 years of Age
2277 Whooping Cough: Epidemiological Changes after Tdap Maternal Immunization Strategy in a Pediatric Hospital
2278 Maternal Immunization Rates with Tetanus-Diphtheria-Acellular Pertussis and Influenza Vaccines in the United States: A Retrospective Claims Database Analysis
2279 A Randomized Open-Label Trial of 2-Dose or 3-Dose Primary Rabies Immunization among Thai Children
2280 Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination
2281 Impact of the Introduction of the *Haemophilus influenzae* Type B Conjugate Vaccine in Southern India
2282 Age-Stratified Analysis of Serotype-Specific Immunity Against Group B Streptococcus
2283 The Impact of a Booster Dose at the Age of 18 on Immunization Against Hepatitis B Four Years Later
2284 Ten-Year Effectiveness of Live Virus Herpes Zoster Vaccine
2285 Burden of Invasive and Non-invasive Group B Streptococcal Infections in Hospitalized Adults, Louisville, Kentucky: A Large Population-based Study
2286 Revisiting Immune Interference: Evaluation of Immune Response to Yellow Fever Vaccine at Various Time Points Following Live-Attenuated Influenza Vaccination
2287 Recently Approved HEPLISAV-B(R) [Hepatitis B Vaccine (Recombinant), Adjuvanted] Shows a Higher Proportion of Subjects Achieving Seroprotection with a More Consistent Immune Response Compared with Engerix-B(R) [Hepatitis B Vaccine (Recombinant)] in Three Comparative Trials
2288 Adherence to Hepatitis B Screening and Treatment Guidelines in Oncology Patients Starting Anti-CD20 Therapy

245. Poster Abstract Session
**Molecular & Sequence Based Diagnostics**
Saturday, 12:30 - 1:45 p.m.

2289 Accuracy of a Rapid Multiplex PCR Plus a Chromogenic Phenotypic Test Algorithm for the Detection of ESBL and Carbapenemase-Producing Gram-Negatives Directly from Blood Cultures
2290 Identification of Pathogens in Synovial Fluid Samples with an Automated Multiplexed Molecular Detection System
2291 A Real-Time Sequencing Approach for Simultaneous Metagenomic and Transcriptomic-Based Diagnosis of Infectious Diseases
2292 Comparison of Molecular Assays for the Diagnosis of Pertussis
246. Poster Abstract Session

**Pediatric Healthcare Associated Infections**

Saturday, 12:30 - 1:45 p.m.

- **2302** Bloodstream Infections due to Carbapenem Resistant Gram-Negative Bacteria in Pediatric Intensive Care Unit (PICU): Risk Factors and Outcomes
- **2303** Differential Effects on MRSA and MSSA Epidemiology in a Neonatal Intensive Care Unit (NICU) during a Year-Long Surveillance and Decolonization Effort
- **2304** Decreased Incidence of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections after Implementation of Routine Surveillance and Decolonization in a Level IV Neonatal Intensive Care Unit (NICU)
- **2305** *Staphylococcus aureus* Screening and Decolonization for Pediatric Patients Undergoing Cardiovascular Surgery at Texas Children’s Hospital (TCH): A Trainee Quality Improvement Initiative
- **2306** Molecular Epidemiology of and Risk Factors for *Staphylococcus aureus* (SA) colonization in a Chinese Neonatal Intensive Care Unit (NICU)
- **2307** Use of Whole Genome Sequencing to Determine Adhesin and Biofilm-associated Gene Profiles among Pediatric *Staphylococcus aureus* Device Related Infection Isolates Compared to Skin and Soft Tissue Infection Isolates
- **2308** The Prevalence of Antiseptic Tolerance Genes Among Gram-Positive Bloodstream Pathogens in Children
- **2309** Promoting Healthcare Worker (HCW) Use of Personal Protective Equipment in Pediatric Ambulatory Settings
- **2310** Reasons Pediatric Providers Obtain Endotracheal Aspirate Cultures and How Results Inform Patient management

**247. Poster Abstract Session**

**Pediatric Bacterial Infections**

Saturday, 12:30 - 1:45 p.m.

- **2311** Atypical Cat Scratch Disease Presentations
- **2312** *Bordetella holmesii* Bacteremia in Pediatric Patients: A Single-Center Experience
- **2313** Risk of Relapsed or Persistent Infection Caused by Enterobacter Species in Children
- **2314** Invasive *Haemophilus influenzae* Infections in Children: A Ten-Year Study
- **2315** *Neisseria meningitidis* Oro-Pharyngeal Carriage, Serogroups and Clonal Complex in Children and Adolescents in Argentina
- **2316** The Frequency of Multifocal Disease and Pyogenic Hip Arthritis in Neonates with Osteomyelitis
- **2317** Multicenter Retrospective Cohort Study of Pediatric Osteomyelitis
- **2318** Comparison of Musculoskeletal Infections Due to Non-Typhoidal Salmonella Species and *Staphylococcus aureus* in Immunocompetent Children
- **2319** Molecular Epidemiology of *Staphylococcus aureus* Isolated from Korean Children
- **2320** Decolonization of the Oropharynx, an Important and Neglected Reservoir of *Staphylococcus aureus* Colonization
- **2321** Epidemiology of *Staphylococcus aureus* Infections in Patients Admitted to Freestanding Pediatric Hospitals, 2009-2016
- **2322** Reduced Vancomycin Susceptibility among Pediatric *Staphylococcus aureus* Bloodstream Infections
- **2323** Unexpected Pediatric Presentation Patterns of Toxic Shock Syndrome
- **2324** Long-Term Health Outcomes of Children Evaluated for Unexplained Fevers in a Pediatric Infectious Diseases Clinic
- **2325** Bloodstream Infections in Hospitalized Children in the United States: Incidence, Pathogens, and Regional Differences
- **2326** Necessity of Anaerobic Blood Cultures for Identification of Pediatric Bloodstream Infections
- **2327** Microbiology and Prognostic Significance of Bloodstream Infections in Necrotizing Enterocolitis
- **2328** Community Onset Invasive Bacterial Infections in Infants Under Three Months-10 Years of Experience in Auckland, New Zealand
- **2329** Preliminary Safety and Effectiveness of Whole Body MRI in Pediatric Patients with Persistent Bacteremia or Febrile Illness
- **2330** Comparison of Clinical Symptoms in Children Who Present with Sore Throat who are Later Determined to be Carriers versus Acutely Infected
- **2331** Household Pets and Recovery of *Moraxella catarrhalis* and Other Respiratory Pathogens from Children with Asthma
### Poster Abstract Sessions (continued)

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2332</td>
<td>Higher Pediatric Vancomycin Dosing Trends Toward Improved Therapeutic Troughs</td>
</tr>
<tr>
<td>2333</td>
<td>Practice of Endotracheal Tube Suction Catheter Flushes with Polymyxin in Extremely Low Birthweight Neonates</td>
</tr>
<tr>
<td>2334</td>
<td>Risk Factors of Multidrug-Resistant Gram-Negative Bacterial Bloodstream Infections in Children's Hospitals in Japan</td>
</tr>
<tr>
<td>2335</td>
<td><em>Acinetobacter baumannii</em> Infection: Clinical Profile, Drug Resistance, and Presence of Virulence Factor <em>AdrRS</em>: Experience from a Pediatric Tertiary Care Centre in North India</td>
</tr>
<tr>
<td>2337</td>
<td>Clinical Characteristics of Children Infected with Macrolide-Resistant Mycoplasma Pneumonia In Central Ohio: Preliminary Data</td>
</tr>
<tr>
<td>2338</td>
<td>Change in Genetic Structure of <em>Streptococcus pneumoniae</em> Isolates from Invasive Diseases after National Immunization Program of Extended-Valency Pnuemococcal Conjugate Vaccines in Korea</td>
</tr>
<tr>
<td>2339</td>
<td>Perianal Infections in Children with Acute Myeloid Leukemia: A Report from the Canadian Infection in Acute Myeloid Leukemia Research Group</td>
</tr>
<tr>
<td>2340</td>
<td>Pneumococcal Colonization in Pediatric Patients Undergoing Bone Marrow Transplantation</td>
</tr>
</tbody>
</table>

### 248. Poster Abstract Session

**Pediatric Viral Infections**

**Saturday, 12:30 - 1:45 p.m.**

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2341</td>
<td>Trends in Adenovirus Infections in Singapore Children and Outcomes of Cidofovir Treatment in the Severely Ill</td>
</tr>
<tr>
<td>2342</td>
<td>Treatment Implications of Herpes Simplex Virus Central Nervous System Infection in Canadian Infants &lt;90 days Old: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study</td>
</tr>
<tr>
<td>2343</td>
<td>A Multicenter Study on Clinical Outcome of Symptomatic Neonatal Herpes Simplex Virus Infection in Korea</td>
</tr>
<tr>
<td>2344</td>
<td>FDA analysis of CD4+ Cell Count Declines Observed in HIV-Infected Children Treated with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide</td>
</tr>
<tr>
<td>2345</td>
<td>Knowledge, Practices, and Attitudes of Youth Providers about STI, HIV Testing, and PrEP</td>
</tr>
<tr>
<td>2346</td>
<td>Severe Head and Neck Infections Following Influenza Virus Infection in Children</td>
</tr>
<tr>
<td>2347</td>
<td>Antiviral Use is Associated with a Decrease in Rate of Influenza-Related Complications and Resource Utilization</td>
</tr>
<tr>
<td>2348</td>
<td>Influenza Complications Among Pediatric Inpatients in Singapore, A Tropical Country</td>
</tr>
<tr>
<td>2349</td>
<td>Long-Term Neurological Outcome and Neutralizing Antibody Titters against Paraechovirus-A3 (PeV-A3) in Children Who Developed PeV-A3-Related Diseases in Neonatal and Infantile Periods</td>
</tr>
<tr>
<td>2350</td>
<td>Parainfluenza Virus Infection Factors: 18 Years’ Active Surveillance in a Pediatric Hospital</td>
</tr>
</tbody>
</table>

### 249. Poster Abstract Session

**Skin and Skin Structure Infection**

**Saturday, 12:30 - 1:45 p.m.**

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2351</td>
<td>Epidemiology and Clinical Characteristics of Parainfluenza Virus Type 4 in Korean Children, 2015-2017</td>
</tr>
<tr>
<td>2352</td>
<td>Increased on Childhood Recurrent Wheezing and Asthma after Respiratory Syncytial Viral (RSV) Infection in Full-Term Infants</td>
</tr>
<tr>
<td>2353</td>
<td>Respiratory Syncytial Virus (RSV) in Preterm Infants: Epidemiology, Clinical Pattern, and Risk Factors in a Pediatric Hospital in Argentina</td>
</tr>
<tr>
<td>2354</td>
<td>Performance of Novel Clinical Case Definitions for Respiratory Syncytial Virus Infections in Young Infants: A Latent Class Analysis</td>
</tr>
<tr>
<td>2355</td>
<td>Clinically versus Serologically Identified Varicella: A Hidden Infection Burden. Lessons of 10-Year Follow-Up in Varicella Endemic Countries</td>
</tr>
<tr>
<td>2356</td>
<td>Neurological Disorders and Radiological Findings. How Are They Related in Congenital Zika Syndrome?</td>
</tr>
<tr>
<td>2357</td>
<td>Radiological Findings in Microcephaly Cases During 2015-2016 Zika Outbreak: A Descriptive Study</td>
</tr>
<tr>
<td>2358</td>
<td>Acute Flaccid Myelitis Among Hospitalized Children in Texas, 2016</td>
</tr>
<tr>
<td>2359</td>
<td>Validation of a Novel Scoring Criteria for Assessing the Severity of Viral Respiratory Infections in Children</td>
</tr>
<tr>
<td>2360</td>
<td>Clinical Outcomes of Clindamycin Use in Skin and Soft Tissue Infections (SSTIs) in Pediatrics</td>
</tr>
<tr>
<td>2361</td>
<td>Factors Associated with Sepsis Development in Cellulitis. A Prospective Analysis of 606 Episodes in Adult Patients</td>
</tr>
<tr>
<td>2362</td>
<td>Emergency Department Resource Utilization after Implementation of a Dalbavancin Pathway for Skin and Soft Tissue Infections</td>
</tr>
<tr>
<td>2363</td>
<td>Identification of Risk Factors to Predict <em>Pseudomonas aeruginosa</em> and Methicillin Resistant <em>Staphyloccocus aureus</em> in Patients with Infected Chronic Foot Ulcers</td>
</tr>
<tr>
<td>2364</td>
<td>Evaluation of Renal Function Changes in Patients with Prolonged Telavancin Therapy (&gt;21 days): Results from the Telavancin Observational Use Registry (TOUR™)</td>
</tr>
<tr>
<td>2365</td>
<td>Post-Operative Vertebral Osteomyelitis—a Disease with Distinct Clinical and Microbiological Characteristics</td>
</tr>
<tr>
<td>2366</td>
<td>Treatment Characteristics and Predictors of Mortality in Patients with Infected Chronic Pressure Ulcers in Detroit</td>
</tr>
<tr>
<td>2367</td>
<td>Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)</td>
</tr>
<tr>
<td>2368</td>
<td>Cellulitis in Adult Patients: A Large, Multicenter, Observational, Prospective Study of 606 Episodes and Analysis of the Factors Related to the Response to Treatment</td>
</tr>
<tr>
<td>2369</td>
<td>Clinical Experience with Telavancin for Treatment of Patients with Monomicrobial <em>S. aureus</em> Infections (Vancomycin MIC ≥1 μg/mL) from TOUR™</td>
</tr>
<tr>
<td>2370</td>
<td>Dalbavancin Use in Emergency Department and Observation Unit to Prevent Inpatient Admission for Acute Bacterial Skin and Skin Structure Infection (ABSSI)</td>
</tr>
<tr>
<td>2371</td>
<td>Monomicrobial Gram-Negative Necrotizing Fasciitis: An Uncommon But Fatal Syndrome</td>
</tr>
</tbody>
</table>
Poster Abstract Sessions (continued)

2372 Multidisciplinary Care Teams to Reduce Major Amputations for Patients with Diabetic Foot Ulcers: A Systematic Review
2373 Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates
2374 Genomic Characteristics of Recurrent Staphylococcus aureus Skin and Soft Tissue Infection among U.S. Army Trainees
2375 Skin and Soft Tissue Infections in Patients with Obesity or Heart Failure
2376 In Vitro Activities of Ceftaroline and Comparator Agents against Bacterial Pathogens Collected from Patients with Skin and Skin Structure Infections in Latin America: AWARE Surveillance Program 2017
2377 Outcomes in Patients with History of Cardiac or Vascular Disease (CV) During Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) with Delafloxacin (DLX) vs Vancomycin/Aztreonam (VAN/AZ)
2378 Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) with Delafloxacin (DLX) IV/Oral Therapy

250. Poster Abstract Session
Treatment of AMR Infections
Saturday, 12:30 - 1:45 p.m.

2379 Multicenter Evaluation of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
2380 Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers (POICs)
2381 Ceftolozane/tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Resistance
2382 Ceftolozane/tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study
2384 Multidrug-Resistant Gram-Negative Infections Treated with Ceftolozane-Tazobactam: Impact of Delayed Initiation
2385 Ceftazidime-Avibactam in Combination with Fosfomycin: A Novel Therapeutic Strategy against Multidrug-Resistant Pseudomonas aeruginosa
2386 Efficacy of Lefamulin (LEF) Versus (vs) Moxifloxacin (MOX) Against Common Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Results from the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
2387 Selecting Clostridium difficile Infection (CDI) Outcome Measures Relevant to Public Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2 Trial
2388 Efficacy of Humanized Cefiderocol Exposures over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
2389 Effect of Rezafungin on QT Interval in Healthy Subjects
2390 Avibactam Sensitizes NDM Klebsiella pneumoniae to Innate Immune Killing by Human Cathelicidin LL-37, Serum, Neutrophils, and Platelets
2391 Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms
2392 Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade
2393 Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis
2394 Different Clostridiodes difficile Ribotypes among Patients with Colonization, Initial Clinical Disease, and Recurrent Clinical Disease
2395 Mechanism-Based-Susceptibility Testing (MBST) using Disc Diffusion Assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug Resistant Pseudomonas aeruginosa (MDR-XDR-Pa) in a Cystic Fibrosis (CF) Lung Transplant Recipient; Are We Ready for Combination Therapy vs. MDR-XDR-Pa?
2396 Fosfomycin Resistance among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
2397 Comparing Predictive Performance of INCREMENT Scores on Mortality Among Patients with Carbapenem-Non-Susceptible (CNS) Klebsiella pneumoniae (Kp) and Enterobacter cloacae Complex (Ecc) Bloodstream Infections (BSI) in the Veterans Health Administration (VHA)
2398 Utilization Practices of Ceftazidime-Avibactam at Academic Medical Centers in the United States
2399 Beta-Lactam Therapy for Potential AmpC-Producing Organisms: A Cohort Study and an Updated Systematic Review and Meta-analysis
2400 Activity of a Long-Acting Echinocandin, Rezafungin, Tested against Invasive Fungal Isolates Collected Worldwide
2401 Risk Factors for Antimicrobial Resistance in Invasive Pneumococcal Disease (IPD) in Toronto, Canada, 2012-2017
2402 Daptomycin Pulmonary Eosinophilia: Review of Cases and New Hyperacute Syndromic Presentation
2403 Comparison of Daptomycin Combination Therapy with Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
2404 Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
2405 In Vitro Synergistic Activity of Sitafloxacin in Combination with Colistin Against Clinical Isolates of Multidrug-Resistant Acinetobacter baumannii in Thailand
2406 “Real World” Treatment of Multidrug-Resistant (MDR) or Extensively-drug Resistant (XDR) P. aeruginosa Infections with Ceftolozane/Tazobactam (C/T) versus a Polymyxin or Aminoglycoside (Poly/AG) Based Regimen: A Multicenter Comparative Effectiveness Study
2407 Emerging Piperacillin/Tazobactam Resistance in *Escherichia coli* and *Klebsiella sp.*

2408 Delayed Appropriate Antimicrobial Therapy Does Not Affect the Clinical Outcome of Patients with Acute Pyelonephritis by Extended-spectrum β-lactamase-producing *Enterobacteriaceae*

2409 Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients treated with Aztreonam and Ceftazidime

2410 Clinical Outcomes Associated with Various Treatment Options for Infections Caused by Carbapenem-Resistant *Enterobacteriaceae*

2411 Expanded Susceptibility and Resistance Mechanism Testing among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017

2412 Our Experience with IV Fosfomycin

2413 The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug, and Pandrug Resistant *Acinetobacter baumannii*: A Systematic Review of Clinical Evidence

2414 Real-World Evaluation of Patient Characteristics and Outcomes of Patients Treated with Ceftolozane/Tazobactam Across 253 U.S. Hospitals

2415 Comparison of Minocycline MIC's Obtained by Etest to Those Obtained by Broth Microdilution in a Bank of Isolates of Acinetobacter Baumannii Collected in Southeastern Michigan

2416 Risk Factors and Outcomes of Bacteremia Caused by Carbapenem Resistant Enterobacteriaceae Compared to Carbapenem Susceptible Enterobacteriaceae

2417 Risk Factors, Response to Empiric Therapy, and Healthcare Utilization among Children with UTI Due to Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae

2418 Management of Carbapenem-Resistant Enterobacteriaceae Infections in a Long-Term Acute Care Hospital

2419 Standard vs Alternative Therapy for *Stenotrophomonas maltophilia* Infections: Focus on Trimethoprim-Sulfamethoxazole, Minocycline, and Moxifloxacin Monotherapy

2420 A Real-World Perspective on the Efficacy of Fosfomycin for Treatment of Multidrug-Resistant Pathogens Causing Urinary Tract Infections

2421 Tedizolid is Well-Tolerated Among Patients Receiving Prolonged Treatment Courses

2422 Efficacy of Ceftoxin for the Treatment of Urinary Tract Infection (UTI) due to ESBL-Producing *E. coli* and *K. pneumoniae* Isolates

2423 Effectiveness and Safety of Ceftolozane/Tazobactam (TOL/TAZ) Use for Carbapenem-Resistant Pseudomonas Infections in Children

2424 Review of Antimicrobial Susceptibility Profile of Different *Nocardia* Species: A Tertiary Center Experience

2425 Clinical and Microbiologic Outcomes Among Patients with Monomicrobial *Stenotrophomonas maltophilia* Infections

2426 Ceftaroline-Associated Neutropenia: Retrospective Study and Systematic Review of Incidence, Risk Factors, and Outcomes

2427 Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam *In Vitro* Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers (2017)

2428 Lower Rates of Antibiotic Treatment of Vancomycin Resistant Compared to Vancomycin Susceptible Enterococcal Bacteriuria

2429 The Epidemiology and Outcomes of *Enterobacter cloacae* Bloodstream Infections in Children

2430 Impact of USCAST Proposed Breakpoint Changes to Aminoglycosides, Cyclines, and Levofloxacin on Carbapenem-Resistant *Enterobacteriaceae* at a U.S. Tertiary Referral Academic Medical Center

2431 Evaluation of Clinical Outcomes in Bacteremia Due to AmpC β-lactamase Producing Organisms Stratified by Treatment

2432 Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit

2433 Evaluation of Meropenem (MEM) in Combination with Colistin (COL) Against Colistin Resistant Extensively Drug Resistant (XRD) Gram-Negative Bacteria

2434 Review of Linezolid (LZD) Use and Onset of Toxicity in 4 Belgian Hospital Centers: A Retrospective Study

2435 Clinical Outcomes with Ceftolozane-Tazobactam in Patients with Multidrug-Resistant (MDR) *Pseudomonas aeruginosa* Bloodstream Infections: A Multi-Center Study

2436 Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections due to *Serratia*, *Citrobacter*, or *Enterobacter*

2437 Colistin Usage: Do We Need to Worry About its Toxicity Among Children with Cancer?

2438 Ceftolozane/Tazobactam (C/T) against Multidrug-Resistant *Pseudomonas aeruginosa* (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance

2439 Outcomes of Minocycline Use on Gram-Negative Infections and Implications of MIC

2440 Weight-Adjusted Piperacillin-Tazobactam (PIP/TAZ) Therapy in Obese Patients versus Optimized Doses in Non-obese Patients: A Retrospective Cohort Study

2441 Outcomes of Patients with Vancomycin-Resistant *Enterococcus* Bloodstream Infections (BSI) Treated with Daptomycin

2442 Outcomes in ESBL Bacteremia Empirically Treated with Piperacillin/Tazobactam or Carbapenems

2443 Searching for the Optimal Treatment Regimen for Metallo-β-Lactamase Producing *Enterobacteriaceae*: Aztreonam plus Ceftazidine-Avibactam vs. Aztreonam plus Meropenem-Vaborbactam

2444 Incidence of Daptomycin Toxicity Among Patients with Vancomycin-resistant *Enterococcus* Bloodstream Infections

2445 Efficacy and Tolerability of Linezolid for Treatment of Infectious Spondylitis

2446 Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem Resistant Enterobacteriaceae

2447 Eratapenem and Faropenem for the Treatment of Drug-Resistant Tuberculosis

2449 Validation of *In vitro* Activity of Aminoglycosides Against Recently Isolated *Helicobacter pylori* for Commercialization of Gentamicin-intercalated Smectite Hybrid as a New Therapeutic Agent

2450 Antibiotic Treatment for Carbapenem-Resistant Enterobacteriaceae (CRE) and Outcomes in Veterans with Spinal Cord Injury/Disorder (SCI/D)

2451 Synergistic Activity of Ceftazidime-Avibactam in Combination with Polymyxin B against Carbapenem-Resistant *Klebsiella pneumoniae*

2452 Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections

2453 Repeated Exposures to Minocycline/Rifampin and + Chlorhexidine Combination Used to Coat Catheters Fails to Induce Antimicrobial Resistance

251. Poster Abstract Session

**Adolescent Vaccines**

Saturday, 12:30 - 1:45 p.m.

2454 Pertussis Vaccine Effectiveness and Waning Immunity in Alberta, Canada: 2004-2015

2455 Is Category B Working? Uptake Patterns of Meningococcal Group B Vaccine among U.S. Adolescents and Young Adults

2456 Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4-6 Years after Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy U.S. Adolescents and Adults

2457 Multivariate Analyses of Socio-Economic Inequities in Parental Awareness and Utilization of Meningococcal Serogroup B Vaccines

2458 Disparities in Healthcare Providers’ Interpretation and Implementation of ACIP’s Meningococcal Vaccine Recommendations

2459 Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the U.S.: How Compliant Are We with the Advisory Committee on Immunization Practices (ACIP) Recommendations?

2460 Factors Associated with Uptake of Meningococcal B Vaccine After an ACIP Category B Recommendation

2461 Safety of Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid-Conjugate Vaccine in Adolescents

2462 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Individuals 56 Years of Age and Older

2463 Post-Licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014-2017

2464 A Significant Portion of College Students are Not Aware of HPV Disease and HPV Vaccine Recommendations

2465 A Pilot Program to Improve Human Papillomavirus Vaccination Status of Adolescents at a School-Based Health Center

252. Poster Abstract Session

**Vaccine Policy and Hesitancy**

Saturday, 12:30 - 1:45 p.m.

2466 Evaluation of Immunization on the Neonatal Intensive Care Unit at British Columbia Women’s Hospital

2467 Timeliness of Childhood Vaccination with the Combination Measles-Mumps-Rubella-Varicella Vaccine versus the Separate Measles-Mumps-Rubella and Varicella Vaccines in the United States

2468 Impact of a Herd Immunity Educational Intervention on Parental Concern About Measles

2469 Knowledge, Attitudes, Confidence, and Hesitancy Towards Vaccines among Residents in Pediatric and Family Practice Programs

2470 The Effect of Information—Motivation—Behavioral Skills Model-Based Continuing Medical Education on Pediatric Influenza Immunization Uptake: A Randomized, Controlled Trial

2471 The State of Cost-utility Analyses in Vaccines: A Systematic Review

2472 The Impact of State Medicaid Policies on Adult Vaccination Post Affordable Care Act Implementation

2473 How Does Acquiring a Vaccine-Preventable Disease Impact Parental and Physician Responses to Vaccine Hesitancy?

2474 Early Feedback from a Pilot of a Cognitive Computing System to Analyze Immunization Data

2475 Hepatitis B Vaccination Coverage Among Asian-American Adults: A Population-Based Study of the Role of Race and Gender

253. Poster Abstract Session

**Vaccines for Herpes Zoster Virus**

Saturday, 12:30 - 1:45 p.m.

2476 Impact of the Vaccination Strategy on Varicella Burden Disease in Argentina

2477 Impact of Varicella Vaccination in the United States (U.S.): a Dynamic Model-Based Analysis

2478 Impact of 20 Years of Varicella Vaccination on the Epidemiology of Herpes Zoster in the United States: An Interrupted Time Series Analysis

2479 Varicella Zoster Immune Globulin Is Effective up to 10 Days Following Varicella Exposure in Pregnant Women, Immunocompromised Patients, and Infants: Results from a Large, Open-Label Expanded-Access Program

2480 Real-World Effectiveness of the Live Zoster Vaccine in Preventing Herpes Zoster: A Systematic Review

2481 Impact of Sex And Race/Ethnicity on The Effectiveness of Live Zoster Vaccine
254. Poster Abstract Session  
**Vaccines for the Elderly and Immune Compromised**  
Saturday, 12:30 - 1:45 p.m.

2484 Pre-Transplant Vaccination Adherence in Pediatric Solid Organ Transplant Patients at a Large Academic Medical Center

2485 Circulating T Follicular Helper Cells and Immune Response Induced by Influenza Vaccine in Children with Acute Lymphoblastic Leukemia During Maintenance Therapy

2486 The Effectiveness of High-Dose Hepatitis B Vaccination in Patients Receiving Immunomodulatory Therapy

2487 Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand?

2488 The Impact of Reactogenicity after Administration of the Recombinant Zoster Vaccine upon the Physical Functioning and Quality of Life of Older Adults

2490 A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥ 65 Years of Age

255. Poster Abstract Session  
**Virology Potpourri**  
Saturday, 12:30 - 1:45 p.m.

2491 Post-Exposure Prophylaxis with Ribavirin Plus Lopinavir/Ritonavir for Middle East Respiratory Syndrome in Healthcare Workers

2492 Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of U.S. Patients

2493 Marburg Virus Disease: Virulence of Angola Versus Musoke Strain in Cynomolgus Macaques

2494 Influenza B Hospitalizations are Associated with Mortality in Children, FluSurv-NET, 2011-2017

2495 Real-World Burden of Transmission and Care Seeking among Family Members with a Primary Influenza Infection

2496 A Comparative Evaluation of the Burden of Disease Caused by Influenza A and Influenza B During the 2011/2012, 2012/2013, and 2013/2014 Influenza Seasons in Canada

2497 Acute Flaccid Paralysis: 17-Year’s Active Epidemiological Surveillance in a Pediatric Hospital in Argentina

2498 Association of Increasing Age with Hospitalization Rates, Clinical Presentation, and Outcomes among Older Adults Hospitalized with Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET)

2499 Burden of Influenza Like Illness (ILI) among Congregate Military Populations

2500 Incidence of Herpes Zoster in the Pre and Post Vaccine Era: Do Trends Differ Between Blacks and Whites?

2501 Impact of Influenza A and B Infection on Stem Cell Transplant Patients During the 2017-2018 Season at a Single Center

2502 Host Susceptibility to Andes Hantavirus Infection Associates to a Single Nucleotide Polymorphism at the αβ3 Integrin

2503 Assessment of State-Level Influenza Season Severity, Utah, 2017–2018

2504 Influenza Surveillance and Outbreaks in the U.S. Department of Veterans Affairs (VA): 2017-2018 Season

2505 A Novel Mobile Phone Application for Remote Research Data Collection is Effective in Monitoring Chronic Sequelae after Acute Viral Infections

2506 Reactivation of Latent Cytomegalovirus Infection Following Major Surgery: Risk Factors and Outcomes

2507 Active Norovirus Surveillance in Children Under 5 years with Diarrhea following Rotavirus Vaccine Introduction in Argentina

2508 Absolute Lymphocyte Count and Adenovirus-specific CD8+ T-Cell Immunity as Immunological Predictors of Severe Adenovirus Disease after Kidney Transplantation

2509 High-Risk Human Papillomavirus Infection and the Risk of Cardiovascular Disease: A Cohort Study

2510 Epidemiological Change of Cytomegalovirus Diseases in the Developed Country with High Cytomegalovirus-Seropositive Rate: Nationwide, Whole Population-based Study

2511 Estimating Numbers of Influenza Excess Deaths and Hospitalizations at the State-Level


2513 The Utility of Next Generation Sequencing for Detection of Causative Viruses in Sera of Patients with Acute Myocarditis

2514 Pediatric Medically Attended Shingles in Alberta, Canada, 2016: Preliminary Results

2515 Impact of Human Parainfluenza Virus Type 4 in Hospitalized Children in Korea

2516 Predictors of Zika Virus Disease Severity within Veterans Affairs (VA)

2517 Seasonal Influenza 2017-2018: Epidemiological Review and Experience at a Veterans Affairs Medical Center in New York

2518 The Role of Non-Influenza Viruses in the Seasonal Viral Respiratory Illness: A Epidemiologic study from October 2016 - March 2017

2519 The Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Crimean-Congo Haemorrhagic Fever

2520 Epidemiology, Clinical Manifestations, and Outcomes of the 2017-2018 Influenza Season among Hospitalized Patients at a Tertiary Care Center

2521 The Potential Rise in the Incidence of Rotavirus G3P[8] in Kuwait
IDSA Board of Directors

Paul G. Auwaerter, MD, FIDSA, President, Johns Hopkins University School of Medicine, Baltimore, MD
Cynthia L. Sears, MD, FIDSA, President-Elect, Johns Hopkins University School of Medicine, Baltimore, MD
Thomas File, Jr., MD, FIDSA, Vice President, Summa Health, Akron, OH
Larry K. Pickering, MD, FIDSA, Secretary, Emory University School of Medicine, Atlanta, GA
Helen W. Boucher, MD, FIDSA, Treasurer, Tufts University School of Medicine, Boston, MA
William G. Powderly, MD, FIDSA, Immediate Past President, Washington University School of Medicine, St. Louis, MO
Angela M. Caliendo, MD, FIDSA, Brown University/Rhode Island Hospital, Providence, RI
Henry F. Chambers, MD, FIDSA, University of California, San Francisco, San Francisco, CA
Susan J. Rehm, MD, FIDSA, Cleveland Clinic, Cleveland, OH
Tina Q. Tan, MD, FIDSA, Northwestern University, Chicago, IL
Victoria J. Fraser, MD, FIDSA, FSHEA, Washington University School of Medicine, St. Louis, MO
Daniel P. McQuillen, MD, FIDSA, Lahey Hospital & Medical Center, Burlington, MA
Thomas A. Moore, MD, FIDSA, IDC of Kansas, Wichita, KS
Trish M. Perl, MD, MSc, FIDSA, FSHEA, UT Southwestern Medical Center, Dallas, TX
Ighowerha Ofotokun, MD, MSc, FIDSA, HIVMA Representative, Emory University School of Medicine, Atlanta, GA
Janet Gilsdorf, MD, PIDS Liaison, University of Michigan Medical Center, Ann Arbor, MI
Hilary M. Babcock, MD, MPH, SHEA Liaison, Washington University School of Medicine, St. Louis, MO
Chris Busky, CAE, CEO, Infectious Diseases Society of America, Arlington, VA

SHEA Board of Trustees

Keith Kaye, MD, MPH, FIDSA, FSHEA, President, University of Michigan Medical School, Ann Arbor, MI
Hillary Babcock, MD, MPH, President-Elect, Washington University School of Medicine, St. Louis, MO
David K Henderson, MD, FIDSA, FSHEA, Vice President, Bethesda, MD
Grace Lee, MD, MPH, FPIDS, Secretary, Stanford University, Stanford, CA
Elia Perencevich, MD, MPH, FIDSA, FSHEA, Treasurer, University of Iowa Carver College of Medicine, Iowa City, IA
Sara E. Cosgrove, MD, MS, FIDSA, FSHEA, Past President, Johns Hopkins University School of Medicine, Baltimore, MD
Gonzalo Bearman, MD, MPH, FIDSA, FSHEA, Virginia Commonwealth University, Richmond, VA
Kristina Bryant, MD, FPIDS, PIDS Liaison, University of Louisville, Louisville, KY
Mirian Dal Ben, MD, MSc, Hospital Sírio Libanês, São Paulo, Brazil
Aaron Milstone, MD, FIDSA, FSHEA, Johns Hopkins University, Baltimore, MD
Dan Morgan, MD, MS, FIDSA, FSHEA, University of Maryland School of Medicine, Baltimore, MD
Roger Scott Stienecker, MD, FIDSA, FSHEA, Community-Based Healthcare Epidemiologist Liaison, Parkview Health, Ft. Wayne, IN
David J. Weber, MD, MPH, FIDSA, FSHEA, University of North Carolina at Chapel Hill, Chapel Hill, NC
Eve Humphreys, MBA, CAE Executive Director, The Society for Healthcare Epidemiology of America, Arlington, VA

HIVMA Board of Directors

Melanie Thompson, MD, Chair, AIDS Research Consortium of Atlanta, Atlanta, GA
W. David Hardy, MD, Chair-Elect, Whitman Walker Health, Washington, DC
Judith Feinberg, MD, Vice Chair, West Virginia School of Medicine, Morgantown, WV
Wendy Armstrong, MD, FIDSA, Immediate Past Chair, Emory University, Atlanta, GA
Igho Ofotokun, MD, MSc, FIDSA, IDSA Representative, Emory University, Atlanta, GA
Michelle S. Csepedes, MD, MS, Icahn School of Medicine at Mount Sinai, New York, NY
Michelle Collins Ogle, MD, PIDS Liaison, Warren-Vance Community Health Center, Henderson, NC
Demetre Daskalakis, MD, MPH, NYC Department of Health and Mental Hygiene, Gotham Center, Queens, NY
Donna Futterman, MD, Albert Einstein College of Medicine, Bronx, NY
Marwan S. Haddad, MD, MPH, Community Health Center, Inc., New Haven, CT
Colleen F. Kelley, MD, MPH, Emory University, Atlanta, GA
Lynsay MacLaren, MPH, MPAS, PA-C, Whitman Walker Health, Washington, DC
James M. Josman, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI
Alice C. Thornton, MD, FIDSA, University of Kentucky School of Medicine, Lexington, KY
William Towner, MD, FIDSA, Kaiser Permanente, Los Angeles, CA
Rochelle Walensky, MD, MPH, FIDSA, Massachusetts General Hospital, Boston, MA
Ira Wilson, MD, MSc, Brown University School of Public Health, Providence, RI
Kimberly Scarsi, PharmD, MS, University of Nebraska Medical Center, College of Pharmacy, Omaha, NE
Andrea Weddle, MSW Executive Director, HIV Medicine Association, Arlington, VA

PIDS Board of Directors

Paul W. Spearman, MD, FIDSA, FPIDS, President, Cincinnati Children’s, Cincinnati, OH
Janet R. Gilsdorf, MD, FIDSA, FPIDS, Past President, University of Michigan Medical Center, Ann Arbor, MI
Kristina A. Bryant, MD, FPIDS, President-Elect, University of Louisville, Louisville, KY
C. Buddy Creech, MD, MS, FPIDS, Secretary-Treasurer, Vanderbilt University Medical Center, Nashville, TN
Susan E. Coffin, MD, FPIDS, FSHEA, Children’s Hospital of Philadelphia, Philadelphia, PA
Ravi Jhaveri, MD, FIDSA, FPIDS, University of North Carolina School of Medicine, Chapel Hill, NC
Grace Lee, MD, MPH, FPIDS, Stanford University, Stanford, CA
Yvonne A. Maldonado, MD, FPIDS, Stanford University, Stanford, CA
Jason Newland, MD, MEd, FPIDS, Baylor College of Medicine, Houston, TX
Jennifer S. Read, MD, MPH, DTMH, FIDSA, FPIDS, Boston, MA
Andi L. Shane, MD, MPH, MSc, FPIDS, Emory University School of Medicine, Atlanta, GA
William Steinbach, MD, FPIDS, Duke University Medical Center, Durham, NC
Terri Christene Phillips, MSA, Executive Director, Pediatric Infectious Diseases Society, Arlington, VA
See You Next Year!

October 2-6 • Washington, DC • www.idweek.org

IDWeek 2019
Advancing Science, Improving Care

The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

IDSA, in conjunction with ProCE, Inc., will provide continuing education (CE) for pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Visit our websites:
www.id society.org • www.shea-online.org • www.hivma.org • www.pids.org